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ABSTRACT 
 
Caroline Smith Hoffman 
Exposure to drinking water disinfection by-products and pregnancy health: Impacts on fetal 
growth and duration of gestation 
 
(Under the direction of Pauline Mendola, Ph.D., Andrew F. Olshan, Ph.D., and David A. 
Savitz. Ph.D.) 
 
Background: Previous studies suggest that elevated exposure to disinfection by-
products (DBPs) may lead to fetal growth restriction.  The association between DBP 
exposure and preterm birth is unclear.  This study examined the effects of trihalomethane 
(THM), haloacetic acid (HAA), and total organic halide (TOX) exposure on the probability 
of delivering a small-for-gestational age (SGA) infant, mean birth weight and preterm birth.  
Methods: Women were enrolled early in pregnancy (≤ 12 week’s gestation) or while 
planning a pregnancy from three U.S. communities from 2000-2004. Weekly (or biweekly) 
water samples were collected and analyzed for DBPs. Participant data were collected through 
interviews, an early ultrasound and birth records. Associations with total THM (TTHM), the 
sum of five HAAs (HAA5), and TOX were assessed using log-binomial regression for SGA 
(n=1,958) and preterm birth (n=2,039) and linear regression for term birth weight (n=1,854).  
A Bayesian analysis was conducted to examine associations between individual DBPs and 
fetal growth.  Discrete-time hazard analysis was used to model the conditional odds of 
delivery each week in relation to DBPs.  Results: HAA5 and TOX were not consistently 
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associated with SGA or term birth weight.  The risk ratio (95% confidence interval) 
associated with an average third trimester TTHM concentration above the regulatory 
standard (≥ 80 micrograms/liter) was 2.0 (1.1, 3.6).  Results of the Bayesian model did not 
support a consistent association between any particular DBP and fetal growth.  Conversely, 
average second trimester DBP levels were inversely associated with preterm birth: adjusted 
risk ratios (95% confidence interval) for preterm birth were 0.8 (0.5, 1.3), 0.9 (0.6, 1.4), 0.7 
(0.4, 1.1) and 0.5 (0.3, 0.9) for increasing TTHM concentrations and 1.1 (0.8, 1.7), 0.8 (0.5, 
1.2), 0.5 (0.3 0.8), and 0.7 (0.4, 1.1) for increasing HAA concentrations. The conditional 
odds of delivery each week also were decreased with elevated TTHM and HAA5 exposure 
for gestational weeks' 33-40. Conclusions: Results do not suggest an adverse effect of HAA 
or TOX exposure on fetal growth or an association with TTHM at average residential 
concentrations below the regulatory standard.  In addition, results clearly indicate the 
probability of preterm birth is not increased with elevated DBP exposure. 
 v
This dissertation is dedicated to my mother, Dr. Mary Deborah Smith Hoffman (June 11, 
1948 - June 18, 2006), who was a loving mother and wonderful role model.  Without her love 
and support, I could not have accomplished this work.  Thank you for always believing in 
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
 
1.1 Introduction 
Public heath concern over the potential health effects of drinking water disinfection 
first began in the 1970s after the discovery of chloroform and other trihalomethanes (THMs) 
in chlorinated drinking water 1.   While initial interest in drinking water disinfection 
byproduct (DBP) exposure focused on a possible association with cancer, particularly 
bladder, colon and rectal cancer 2-4, research that is more recent has focused attention on 
reproductive outcomes such as fetal growth restriction, preterm birth, stillbirth and birth 
defects 5-8.  Previous epidemiological studies of DBP exposure and restricted fetal growth 
generally have shown a moderate increased risk of delivering a small-for-gestational-age 
(SGA) infant among women exposed to elevated levels of total trihalomethanes (TTHM).  
Conversely, results of studies examining the impact of DBP exposure on preterm birth have 
been inconsistent and as a whole do not indicate an association between TTHM and preterm 
birth.  Limitations in exposure and outcome assessment may in part explain the null findings 
of prior preterm birth studies.   
The following analyses of the effects of DBP exposure on fetal growth restriction and 
preterm birth improve upon the methods used in previous work by utilizing weekly (or 
biweekly) water measures of several DBPs and incorporating information on individual 
water consumption and use.  Data come from Right from the Start (RFTS), a prospective 
cohort study of the effect of DBP exposure on pregnancy health.  As part of the RFTS, 
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approximately 3,000 women planning a pregnancy or newly pregnant (≤ 12 weeks’ 
gestation) were recruited from three geographic regions of the US.  Study sites were selected 
to provide a wide range of DBP exposure, including moderate levels of chlorinated and 
brominated DBPs and a low exposure site.  Data collection involved two primary 
components: 1) collection of information about RFTS participants and their pregnancies and 
2) collection of information on DBP levels in the water systems serving RFTS participants’ 
homes during their pregnancy.  Data on DBP exposure and birth outcomes (i.e., birth weight, 
date of birth, and infant sex) were available for 2,039 RFTS participants who delivered a live 
infant. The purpose of this study was to estimate the effect of exposure to a variety of THM 
and haloacetic acid (HAA) species during pregnancy on fetal growth restriction (specific aim 
1) and preterm birth (specific aim 2).  For specific aim 1, logistic regression was used to 
estimate the effect of exposure to specific DBP measures during pregnancy on the probability 
of delivering an SGA infant and linear regression was used to estimate the mean difference in 
term birth weight in grams associated with increased DBP exposure.  For specific aim 2, 
discrete-time hazard analysis was used to model the odds of delivery during each week 
conditional on a woman not having delivered in a prior week for specific intervals of 
pregnancy (i.e., ≤ 32 weeks’, 32-36 weeks’, 37-40 weeks’ and ≥ 41 weeks’) while allowing 
DBP exposure to change over the course of pregnancy.  Residential concentrations and 
personal exposure to total trihalomethanes (TTHM), the regulated sum of haloacetic acids 
(HAA5), and total organic halides (TOX) were the main exposures of interest for both fetal 
growth and duration of gestation analyses.     
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1.2 Specific aim 1 
Specific aim 1 of this study was to estimate the effect of drinking DBP exposure 
during pregnancy on restricted fetal growth.  As previously mentioned, elevated exposure to 
TTHM has been linked to a moderate increased risk of delivering a SGA infant.  However, it 
is unknown whether TTHM itself, a constituent of TTHM (e.g., BDCM), or some other 
unmeasured DBP for which TTHM serves as a marker is the biologically active contaminant.  
Toxicological data suggests that brominated THMs and HAAs are more harmful to the fetus 
than chlorinated THMs.  However, few epidemiological studies have been published on 
individual THM or HAA exposure and restricted fetal growth, and results of these studies are 
inconsistent (see chapter 2, section 2.4 for more detail).  Given the large number of women 
exposed to DBPs, understanding the association between this environmental exposure and 
restricted fetal growth is of great public health importance.   
Specific aim 1 examined the associations between THM, HAA and TOX exposure 
and fetal growth as measured by the proportion of infants born SGA and term birth weight in 
grams.  The following research questions were addressed:  
• Are elevated residential concentrations of TTHM, HAA5 and/or TOX during 
pregnancy associated with increased risk of restricted fetal growth as evidenced by 
increased odds of delivering an SGA infant and/or a decrease in mean term birth 
weight? 
• Is elevated personal exposure to TTHM, HAA5 and/or TOX during pregnancy 
associated with increased risk of restricted fetal growth as evidenced by increased 
odds of SGA and/or a decrease in mean term birth weight? 
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• Is elevated exposure to any of the individual THM and HAA species associated with 
increased risk of fetal growth restriction?  Is there evidence to suggest that HAAs and 
brominated compounds show a stronger relationship with restricted fetal growth than 
THMs and chlorinated compounds? 
Details of the analytic strategy taken to address these research questions can be found 
in chapter 3, section 8.  Results of the analyses and conclusions are presented in manuscript 
#1 entitled “Drinking water disinfection by-product exposure and fetal growth” (chapter 5, 
section 1).    
       
1.2 Specific aim 2 
Specific aim 2 of this study was to estimate the effect of DBP exposure during 
pregnancy on duration of gestation.  Several epidemiological studies have examined the 
association between exposure to TTHM during pregnancy and preterm birth (defined as 
gestational age < 37 weeks).  As a whole, these studies do not indicate an association 
between TTHM and preterm birth.  However, these null findings may be biased due to 
limitations in exposure assessment and the inability to accurately date pregnancies, both of 
which could potentially obscure a true association.  Preliminary analyses from the RFTS, 
which used superior exposure assessment methods and improved pregnancy dating compared 
to previous studies, found a modest but consistent reduction in the probability of preterm 
birth in relation to elevated DBP exposure (i.e. an inverse effect).  Analyses herein build on 
those previous findings to determine whether the observed protective effect is still present 
using alternative analytic techniques.   
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Specific aim 2 examined the odds of delivery each week conditional on a woman not 
having delivered in a prior week using discrete-time hazard analysis with time interactions 
for ≤ 32 weeks, 33-36 weeks, 37-40 weeks and ≥ 41.  Gestational age at birth was derived 
from first trimester report of last menstrual period (LMP), which was corrected by ultrasound 
(also obtained during the first trimester) if the two estimates of gestational age differed by 
more than +/- 7 days.  The following research questions were addressed: 
• Are elevated residential concentrations of TTHM, HAA5 and/or TOX during 
pregnancy associated with increased odds of delivery each week during weeks 20-32, 
33-36, 37-40 and/or 41-44 of gestation? 
• Is elevated personal exposure to TTHM, HAA5 and/or TOX during pregnancy 
associated with increased odds of delivery each during weeks 20-32, 33-36, 37-40 
and/or 41-44 of gestation? 
Details of the analytic strategy taken to address these research questions can be found 
in chapter 3, section 8.  Results of the analyses and conclusions are presented in 
manuscript #2 entitled “Drinking water disinfection by-product exposure and duration of 
gestation” (chapter 5, section 2).  In addition, results of a methodological study conducted 
to compare estimation of gestational age based on first-trimester report of LMP versus 
first trimester ultrasound is presented in manuscript #3, entitled “Comparison of 
gestational age at birth based on last menstrual period and ultrasound during the first 
trimester” (chapter 5, section 3).
CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
 
2.1 Drinking water disinfection by-products 
Public heath concern over the potential health effects of drinking water disinfection 
first began in the 1970s after the discovery of chloroform and other trihalomethanes (THMs) 
in chlorinated drinking water 1.   While initial interest in drinking water disinfection by-
product (DBP) exposure focused on a possible association with cancer, particularly bladder, 
colon and rectal cancer 2-4, more recent research has focused attention on reproductive 
outcomes such as fetal growth restriction, preterm birth, stillbirth and birth defects 5-8.  A 
brief overview of the formation and regulation of DBPs and a discussion of factors that 
influence exposure during pregnancy are given below.   
 
2.1.1 Formation of DBPs in drinking water 
 
DBPs form when chemicals added to water for disinfection (e.g., chlorine) react with 
organic material in the water supplying a distribution system.  The formation and 
concentrations of byproducts in a water system are influenced by source water characteristics 
(e.g., nature and concentration of organic material in water, temperature, pH, bromine 
concentration), the type of disinfectant employed (e.g., chlorine alone, chloramine, chlorine 
dioxide, ozone or ultra-violet [UV] treatment), and the conditions under which the 
disinfectant is used (e.g., dose and location of disinfectant addition, residual disinfectant 
concentrations and contact time) 9.  For example, surface water has more organic material 
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than ground water, resulting in higher DBP levels.  Prolonged chlorine contact time generally 
results in higher, non-uniform THM concentrations in a system because residual chlorine 
continues to react with organic material in the water as it moves through the distribution 
system.  On the contrary, haloacetic acid (HAA) concentrations generally decrease with 
increasing residence time within a water system due to biodegradation 10.   
Chloramination (combined treatment with free chlorine and ammonia) results in 
decreased spatial variability and lower overall concentrations of both THM and HAA levels 
within a distribution system, and therefore, is considered to be a more stable disinfectant 
method with respect to DBP formation than chlorination alone 11.  DBPs also exhibit 
temporal variability.  In general, higher temperatures during warm seasons (and possibly 
differences in the nature of organic material present in source water) increase THM levels 
compared to colder seasons.  However, the magnitude of seasonal variation in DBP 
concentrations may vary from year to year, such that spring concentrations in one year could 
be comparable to summer concentrations in another year 12.  
 
2.1.2 Regulations of DBPs in drinking water  
 
Over 500 DBP subspecies have been reported in the literature 13.  THMs and HAAs 
are the most prevalent and routinely monitored 12.  As a result, the majority of toxicological 
and epidemiological research to date has focused on exposure to a few THM and HAA 
species 5-7.  Table 1 lists and describes DBPs regulated by the U.S. Environmental Protection 
Agency (US EPA) Stage 1 Disinfectants and Disinfection Byproducts Rule.  Total 
trihalomethane (also referred to as “TTHM” or “THM4”) is the sum of four THM sub-
species: chloroform, bromoform, dibromochloromethane (DBDM) and 
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bromodichloromethane (BCDM).  HAA5 is the sum of five HAA sub-species:  
dichloroacetic acid (DCAA), trichloroacetic acid (TCAA), monochloroacetic acid (MCAA), 
bromoacetic acid (BAA) and dibromoacetic acid (DBAA).   
Water systems servicing greater than 500 households are required to monitor and 
report levels of these DBPs on a quarterly schedule.  Compliance is currently based upon a 
running annual average of quarterly measures for TTHM and HAA5 over all monitoring sites 
within a system 14.  The US Environmental Protection Agency (EPA) is now (as of April 
2007) in the process of approving and implementing Stage 2 regulations that will require 
more stringent monitoring of currently regulated DBPs and improve analytic assessment of 
these contaminants.  For example, stage 2 regulations will require that the running annual 
average DBP concentration at each monitoring site be in compliance rather than the average 
of all monitoring sites.  This will help insure that monitoring points with high concentrations 
are not obscured by low concentrations at other points monitored within a water system.   
Maximum contaminant level (MCL) values presented in table 1 were derived based 
upon cancer risk assessments and do not take into account potential adverse reproductive 
outcomes associated with DBP exposure.  Epidemiological studies have shown associations 
between adverse pregnancy outcomes such as restricted fetal growth, stillbirth and birth 
defects at TTHM levels within the allowable limit set forth by these standards 5-7, suggesting 
current regulations may not fully protect against adverse pregnancy outcomes.  On the other 
hand, many water distribution systems have already converted from using chlorination to 
chloramination or another disinfection method to comply with regulatory requirements.  Use 
of these alternative disinfection methods can increase the relative proportion of highly toxic 
DBPs in drinking water (e.g., iodated DBPs, haloacetamides, halonitromethanes) as THM 
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and HAA levels decrease 15,16.  Therefore, continued research of the potential adverse 
reproductive health effects of THM and HAA exposure is necessary to insure regulatory 
decision making results in adequate protection of the public health.  
     
Table 1. Drinking water disinfection by-products currently regulated by the US EPA 
under the Stage 1 Disinfectants and Disinfection By-products Rule 
Disinfection Byproduct 
MCLa 
(μg/liter) Individual DBPs contributing to measure 
Bromate 10  
Chlorite 1000  
Haloacetic acid (HAA5)b 60 
Dichloroacetic acid (DCAA) 
Trichloroacetic acid (TCAA)  
Monochloroacetic acid (MCAA)  
Bromoacetic acid (BAA) 
Dibromoacetic acid (DBAA) 
Total Trihalomethane (TTHM)c 80 
Chloroform 
Bromoform  
Dibromochloromethane (DBDM)  
Bromodichloromethane (BCDM) 
a Maximum contaminant level (MCL)=highest level of contaminant allowed in drinking water; compliance based on annual 
system-wide running average for bromate, HAA5 and TTHM, and monthly average for chlorite; b HAA5 is the sum of five 
haloacetic acids; c TTHM is the sum of four trihalomethanes  
 
 
 
2.1.3 Routes of DBP exposure 
 
DBP exposure occurs through multiple routes.  Primary sources of exposure include 
ingestion of contaminated water and inhalation and dermal absorption of DBPs during 
activities such as showering, bathing and swimming 12. Consequently, an individual’s DBP 
exposure depends not only on the DBP concentrations in tap water but also on water intake 
and use.  Table 2 lists the most common uses of water by route of exposure.  The relative 
contribution of each of these exposure sources to an individual’s overall exposure varies by 
type of DBP.   
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Volatile DBPs (e.g., THM) easily aerosolize and can be inhaled or absorbed through 
the skin.  Therefore, the frequency and duration of activities such as showering and bathing, 
swimming, and other household chores common among pregnant women (e.g., bathing 
children, washing dishes and clothes, boiling water) have the largest impact on personal 
exposure.  Conversely, exposure to non-volatile DBPs (e.g., HAA) mainly occurs through 
intake of tap water and tap-water-based beverages and foods 17.  Several factors influence 
DBP ingestion, including the volume of water consumed, whether water is bottled, boiled or 
filtered and the efficacy of filtration 18.    
 
Table 2. List of common sources of water exposure by route of exposure 
Ingestion Dermal and Inhalation Inhalation 
Consumption of tap water directly 
Consumption of tap water-based   
beverages and foods  
Washing dishes 
Bathing 
Showering 
Swimming 
Dishwasher 
Boiling water/cooking 
Washing Machine 
Humidifier 
 
 
2.1.4 Exposure to tap water during pregnancy 
 
Published estimates for the frequency and duration of personal washing (i.e., 
showering and bathing) during pregnancy vary considerably between studies.  Overall, 
studies indicate that pregnant women are more likely to shower (76.9-97.2%) than take baths 
(23-70.6%) but spend less time showering (7.8-13.9 minutes/day) than bathing (7.8-28.8 
minutes/day) 19-21.  Estimates for the average daily amount of water consumed by pregnant 
women also varies widely between studies, ranging from 0.8-3.4 liters of tap water per week 
19-24.  Differences may in part be due to differences in the study period, location and 
demographic make-up of study populations.  For example, it has been shown that average 
tap-water consumption varies slightly by region of the US (highest in the south and west, 
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intermediate in the mid-west and lowest in the north), urbanicity (higher in rural areas 
compared to urban/suburban areas), race (higher among non-white, non-black women 
compared to white or black women) and season (highest in the summer, intermediate in the 
winter and lowest in the spring and autumn) 23,24.  Average self-reported tap water intake 
during pregnancy among Right from the Start (RFTS) participants ranged from 1.3-2.1 
liters/day across study sites.  In addition, 18% of women in the RFTS study reported bottled 
water as their primary water source and 30% reported using home filtration devices 18.   
 
2.1.5 Exposure to tap water at work 
 
Given that approximately 70% of women are employed at some point during the 12 
months prior to giving birth 25, DBP exposure at work can be an important contributor to 
overall exposure.  Distinguishing between tap-water ingestion at home and work is important 
because both DBP concentrations in tap water and patterns of tap-water exposure (e.g., 
amount of water consumed, use of filtration systems) may vary between work and home.  For 
example, 8.3% of RFTS participants reported employment at a location outside the service 
area of the water system serving their residences.  The amount of DBP that a participant was 
exposed to at work may be different from her exposure level at home.  In addition, RFTS 
participants reported consuming more cold tap-water at home than at work (1.0 liter/day 
versus 0.6 liter/day, respectively) but approximately the same amount of hot tap-water at 
both locations (0.08 and 0.07 liter/day, respectively) 26.      
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2.1.6 Uptake and metabolism of DBPs 
 
Uptake of DBPs can be estimated by measuring the concentration of THMs in the 
blood or exhaled breath and concentration of HAAs in urine 12.  Using these biomarkers, it 
has been shown that the internal dose of chloroform due to inhalation and dermal absorption 
during a 10-minute shower or a half-hour bath is approximately equal to ingesting two liters 
of tap-water 27.  However, most DBP species have relatively short biological half-lives (e.g., 
the biological half-life of chloroform in blood is approximately 30 minutes), so biologic 
markers only reflect recent DBP exposure 12.  Given that these markers are highly sensitive to 
time since last exposure, their utility in epidemiological studies interested in estimating 
average DBP exposure over an extended period of time, such as months or years, is less 
clear.  Furthermore, little is known about genetic variation in metabolism of DBPs. 
 
2.1.7 Conclusions 
 
Potential adverse reproductive health effects of DBPs are an important public health 
concern given the potential widespread exposure of pregnant women to these contaminants.  
Current regulatory standards are based upon cancer risk assessments and may not be 
sufficient to protect against adverse pregnancy outcomes.  An individual’s DBP exposure is 
dependent on many factors: DBP concentrations in tap water, the uptake of DBPs by 
ingestion, inhalation and dermal absorption and exposure to other DBP sources, such as 
swimming.  Furthermore, hundreds of DBPs have been identified in drinking water and it is 
unclear which DBP species are most harmful.  Exposure assessment in research studies must 
be multifaceted to adequately address these aforementioned issues.  The RFTS study, which 
included the collection of weekly (or bi-weekly) measurements of DBP concentrations in tap 
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water and information on individual tap-water intake and use, is an example of such a study, 
and thus, provides an excellent opportunity to examine the association between exposure to 
DBPs during pregnancy and adverse pregnancy outcomes.      
 
2.2 Fetal growth restriction 
Fetal growth restriction (FGR) describes a decrease in fetal growth rate that prevents 
an infant from reaching his/her growth potential at a given age.  Growth-restricted fetuses are 
at increased risk of several perinatal complications, including increased fetal morbidity and 
mortality, prematurity, fetal compromise during labor, and need for induced labor or cesarean 
delivery 28-31.  FGR has also been linked to reduced postnatal growth, neurological and 
developmental disabilities in childhood 32 and several chronic adulthood diseases, such as 
cardiovascular disease, hypertension and diabetes mellitus 33,34.  Given the life-long adverse 
health impacts of FGR, prevention of this adverse pregnancy outcome is of great public 
health concern.    
 
2.2.1 Prevalence of FGR 
 
The prevalence of FGR is generally estimated to be 5% to 7% of pregnancies but can 
be up to 15% depending on how FGR is defined 35.  Small-for-gestational-age (SGA) is 
commonly used as a surrogate measure of FGR in epidemiological research studies.  The 
overall prevalence of newborns who were SGA in the Third National Health and Nutrition 
Examination Survey (NHANES III) was 8.6% of all live births 36.  Infants are categorized as 
SGA if their birth weight falls below a certain cut-point value derived from standardized 
birth weight curves (e.g., below the 10th percentile of birth weight according to gestational 
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age, sex, race and parity-specific birth weight curves derived from US birth certificate data).  
By definition, FGR implies a pathological process resulting in reduced fetal growth but does 
not imply an infant will necessarily be SGA.  Along those same lines, SGA infants include 
infants that are small due to growth restriction as well as infants who are small simply due to 
constitutional factors determined by maternal ethnicity, parity, weight or height.  
Furthermore, SGA is just one way of assessing the theoretical concept of FGR.  Nonetheless, 
these two terms are often used interchangeably in the literature and both have been associated 
with increased perinatal morbidity and mortality.  
 
2.2.2 Classification of infants as SGA 
 
Definitions employed to classify infants as SGA vary widely in the literature.  First, 
the percentile cut-point employed (e.g., 5th percentile or 10th percentile) may differ between 
studies.  While it is generally accepted that using a lower percentile cut-point, such as 5%, is 
more specific for identifying growth-restricted infants, use of lower cut-points is often 
prohibited by inadequate sample size.  Another complication of classifying infants as SGA is 
that values for percentile cut points can vary up to several hundred grams depending on the 
geographic location and composition of the population used to derive standard curves, the 
source of data (hospital or population-based), how gestational age was measured, subject 
exclusion criteria, and whether standards are controlled for maternal race, parity, and infant 
sex 37.  Therefore, use of a single national standard for defining SGA has been recommended, 
presuming that the standard is applicable to the study population at hand 37. 
In 1995, Zhang and Bowes published smoothed birth-weight-for-gestational-age 
curves derived from birth certificates data on the entire US population in 1989 for 
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combinations of race (black/white), gender (male/female), and parity 
(primiparous/multiparous) 38.  Gestational age was based on the date of the last menstrual 
period (LMP) unless the gestational age derived from LMP was < 36 weeks and birth weight 
for gestational age was greater than expected under the assumption of a normal birth weight 
distribution.  Under the later scenario, the clinical estimate provided on the birth certificate 
was used.  Zhang and Bowes noted that there were marked differences between the curves 
they derived and previously published curves in which the gestational age was based on 
ultrasound estimation 39,40.  A limitation of the Zhang et al. paper is that it does not provide 
birth weight curves for infants born to women of Hispanic origin, whom comprised 22% of 
live births in the US in 2003 41.  Application of these standards to Hispanic infants may result 
in misclassification of SGA status such that the prevalence of SGA is underestimated for 
preterm infants and overestimated for term and post-term infants 42.  Since 1995, two 
standardized birth weight curves have been published for infants of Hispanic ethnicity.  One 
of these papers failed to separate infants by parity 42.  The other focuses specifically on 
Mexican-American infants, and thus, is only appropriate for use in Hispanic populations that 
are predominately Mexican-American 43.    
 
2.2.3 Risk factors for fetal growth restriction 
 
Fetal growth depends on four principle variables: genetically predetermined growth 
potential, fetal health, maternal health, and placental function 44.  Restricted fetal growth may 
occur if any of the later three factors are impaired.  Table 3 outlines risk factors associated 
with fetal growth by fetal, maternal and placental factors.  Major maternal factors affecting 
growth include age, parity, medical conditions (e.g., hypertension), malnutrition, alcohol 
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abuse and cigarette smoking.  Fetal chromosomal abnormalities and congenital 
malformations are also highly associated with restricted fetal growth, as well multiple 
gestations and intrauterine infection.  Furthermore, any “mismatch” between placental 
perfusion and fetal oxygenation and nutrition needs can result in growth restriction 45,46.    
 
Table 3. Risk factors for restricted fetal growth 
Fetal Factors  Maternal Factors Placental Factors 
Chromosomal abnormalities 
Congenital malformations 
Multiple gestations 
Intrauterine Infectiona 
Race/ethnicity 
Young maternal age 
Parity 
Intrauterine Infectiona 
Undernutrition 
Low prepregnancy weight 
Low pregnancy weight gain  
Maternal complicationsb 
Uterine malformation or masses 
Emotional and physical stress 
Cigarette smoking 
Alcohol intake 
Illicit or therapeutic drug use 
Previous stillbirth, spontaneous abortion, SGA 
infant or preterm birth 
Family history of FGR 
Abnormal trophoblastic 
invasion 
Multiple placental infarctions 
Umbilical-placental vascular 
anomalies 
Abnormal cord insertion 
Placenta previa 
Circumvallate placenta 
Chorioangiomata 
Abbreviations: SGA= small-for-gestational-age, FGR=restricted fetal growth 
a Intrauterine infections includes malaria, parvovirus, cytomegalovirus, rubella, toxoplasmosis, herpes virus and human 
immunodeficiency virus (HIV) 
b Maternal complications include vascular disorders (hypertension, preeclampsia, diabetes mellitus, renal disease, collagen vascular 
disease), hypercoagulable states (thrombophilia, antiphospholipid antibody syndrome) and persistent hypoxia (residence in high 
altitude, pulmonary or cardiac disease, severe anemia) 
Adapted from Brodsky and Christou (2004), Baschat (2004), and Lin and Santolaya-Forgas (1998) 35,44,47 
 
 
2.2.4 Environmental exposures and fetal growth restriction 
 
Given that maternal toxicants such as cigarette smoking and alcohol use can 
contribute to the development of a growth-restricted fetus 35, it seems plausible that maternal 
exposure to environmental contaminants might also result in fetal growth restriction.  While 
there are many studies that have examined the association between environmental pollutants 
and low birth weight, relatively few studies have specifically focused on restricted fetal 
growth.  The major problem with studying low birth weight (LBW) alone is that it does not 
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distinguish between whether an infant is small because it was growth restricted or it was born 
preterm.  Environmental exposures that have been examined in relation to fetal growth 
include in utero exposure to air pollution 48,49, polyhalogenated aromatic hydrocarbons 
(PHAHs) such as dichloro-diphenyl-trichloroethane (DDT) and polychlorinated biphenyls 
(PCBs) 50,51, pesticides 52, and DBPs 5-7.  Most of these studies have shown a null effect, 
report inconsistent results, or are too few in number to make any conclusions.  However, 
epidemiological studies of DBP exposure and FGR have shown a moderate increased risk of 
delivering a SGA infant among women exposed to high levels of TTHM (see chapter 2, 
section 4.2).  The RFTS study serves as an excellent opportunity to examine this association 
further with superior exposure assessment compared to previous studies.           
 
2.3 Preterm birth 
Preterm birth, commonly defined as birth before 37 weeks’ gestational age, is 
associated with a number of adverse health outcomes, including physical, cognitive and 
psychosocial abnormalities, and is the second leading cause of perinatal mortality in the US 
53,54.  The high rate of morbidity and mortality following preterm birth, along with the 
associated high healthcare burden and cost, make preterm birth a very important public 
health issue 55.  Considerable research efforts have been made to uncover the causes of 
preterm birth so that women at high risk of delivering preterm can be identified and early 
delivery can be prevented.  However, few modifiable risk factors have been discovered. 
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2.3.1 Preterm birth proportions and trends 
 
The overall proportion of preterm births in the US has been steadily increasing over 
the past two decades 41,56, although the trend varies among race/ethnicity groups.  A recent 
report estimated that 12.3% of all live births in the US in 2003 were preterm, representing a 
16% increase since 1990 (from 10.6%) and more than 30% increase since 1981 (from 9.4%).  
Preterm birth increased from 8.5% of live births in 1990 to 11.3% in 2003 among non-
Hispanic whites (32.9% relative increase) and from 11.0% to 11.9% among Hispanics during 
this same time period (8.2% relative increase).  Conversely, preterm birth among blacks 
decreased from 18.9% in 1990 to 17.8% in 2003 (5.8% relative decrease) 41.  Nonetheless, 
the proportion of preterm birth among non-Hispanic blacks remains considerably higher than 
those of other race/ethnicity groups.  A possible explanation for the increase in preterm birth 
proportions among whites is an increase in births to older women and women receiving 
infertility treatment 41, as both older maternal age and assisted reproductive technology 
(ART) have been associated with increased risk of preterm birth 57.  The decrease in 
proportion of preterm birth among blacks may in part be due to improvements in prenatal 
care and management of other risk factors (e.g., cigarette smoking) but the specific factors 
associated with this decrease remain unclear 58.     
 
2.3.2 Classification of preterm birth 
  
Preterm births can be classified into one of three separate categories according to 
clinical presentation: 1) idiopathic preterm labor--  labor starting without apparent reason 
before rupture of the membranes, resulting in preterm delivery, 2) preterm premature rupture 
of membranes (PPROM)-- spontaneous rupture of the membranes at any time before onset of 
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labor, resulting in preterm birth and 3) iatrogenic preterm birth-- medically induced preterm 
delivery (induced labor or cesarean section) due to complications of pregnancy (e.g., fetal 
distress, maternal bleeding, severe preeclampsia).  Some researchers have argued that these 
categories may represent distinct etiological pathways to preterm birth, particularly 
spontaneous versus iatrogenic indications, and thus should be considered separately in 
analyses to avoid attenuation of results due to outcome misclassification 59,60.  Others have 
argued that the apparent clinical presentation of preterm birth are more likely a function of 
varying access to medical care and have proposed other classification schemes to separate 
preterm births into more etiologically homogenous groups for study 61.  In reality, adequate 
information to classify preterm births by indication and examine groups separately is often 
not available (e.g., in studies based on vital records).  
 
2.3.3 Estimation of gestational age 
 
Another methodological issue when studying preterm birth is how to most accurately 
estimate gestational age.  Most often gestational age at delivery is calculated using the self-
reported date of a woman’s last menstrual period (LMP) as an estimated date of conception.  
However, there are many reasons why LMP may be unreliable: recall of dates may not be 
accurate, occurrence of post-conception bleeding may be misinterpreted as normal menses, 
or women with irregular menstrual cycles or delayed ovulation may not have the presumed 
15-day interval between menstruation and ovulation 57,62.  An alternative method of 
estimating gestational age is the use of early ultrasound dating.  Because there is generally 
little variation in fetal growth up to mid-pregnancy, knowing the size of the baby is generally 
equivalent to knowing the gestational age.  However, this assumption may not hold in the 
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case of early growth restriction, which can occur due to chromosomal abnormalities, 
congenital malformations, infection or early onset pre-eclampsia 63.  Therefore, early 
ultrasound dating is often used to correct LMP assignments when the two measurements 
deviate substantially from each other or the LMP date deviates substantially from that 
expected given the birth weight of the infant.                        
 
2.3.4 Risk factors for preterm birth 
 
Table 4 lists factors that have been associated with preterm birth, including 
demographic characteristics, other maternal factors and exposures, aspects of the current 
pregnancy and prior pregnancy history.  The strongest predictor of preterm birth is a history 
of delivering a previous low birth weight or preterm infant 64.  Other common factors that 
have been consistently associated with a considerable increase in the risk of preterm birth are 
black race, single marital status, low socio-economic status as measured through education, 
occupation and family income, inadequate prenatal care, maternal cigarette smoking, use of 
ART, multiple gestations, gestational bleeding, and cervical and uterine anomalies. 
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Table 4. Risk factors for preterm birth 
Pregnancy history Maternal 
demographics 
Other maternal factors/ 
exposures Current Prior 
Black race 
Single marital 
status 
Low SES status 
Younger or older 
maternal age 
 
 
Cervical/uterine anomalies 
In utero DES exposure 
Cigarette smoking 
Cocaine use 
Poor nutrition 
High stress 
Alcohol intake 
High caffeine intake 
Low pre-pregnancy weight  
Conceived with ART 
Multiple gestations 
Placental abnormalities 
Gestational bleeding 
Urogenital infection 
Inadequate prenatal care 
Conception during 
summer/fall 
Male infant  
Maternal complicationsa 
Fetal complicationsb 
Low weight gain  
Previous LBW/preterm delivery 
Multi 2nd trimester miscarriages 
Parity 
Abbreviations: SES= socioeconomic status, DES= diethylstilbestrol, ART= assisted reproductive technology, LBW = low birth weight; 
a Maternal complications include placenta previa, abruptio placentae, cervical incompetence, hypertensive disorders, diabetes, asthma, 
epilepsy, and hyperthyroidism; b Fetal complications include congenital malformations and growth restriction; Table adapted from 
Berkowitz and Papiernik (1993) 57 
 
 
Several studies have suggested seasonal variation in the occurrence of preterm birth 
57.  For example, an analysis using vital records data from Minnesota between 1967-1973 
found the proportion of pregnancies delivered preterm during late summer and fall (59 per 
1,000 births) was slightly higher than the proportion of pregnancies delivered preterm spring 
months (55 per 1,000 births) 65.  Similar seasonal patterns were found in the Collaborative 
Perinatal Project 66 and a study conducted in Japan between 1979-1983 67.  The seasonal 
trend in preterm birth may in part be explained by seasonal changes in the rate of maternal 
infection and maternal nutritional status.  Another explanation may be seasonal variation in 
maternal exposure to environmental toxicants 57. 
 
2.3.5 Environmental exposures and preterm birth 
 
Several studies have been conducted to examine the association between exposure to 
air pollution and preterm birth.  Collectively, these studies suggest a moderate association 
between ambient levels of particulate matter ≤ 10 micrometers (PM10) and sulfur dioxide 
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(SO2) and preterm birth 48,68-71.  Increased risk of preterm birth has also been associated with 
exposure to environmental tobacco smoke 72 and DDT 50.  Studies examining the effect of 
DBP exposure during pregnancy and adverse pregnancy outcomes to date do not indicate an 
association between TTHM and preterm birth; however, these studies may be biased by poor 
exposure and outcome assessment (see chapter 2, section 4.2).  The RFTS study serves as an 
excellent opportunity to examine this association further using superior exposure assessment 
compared to previous studies. 
 
2.4 Exposure to DBPs in drinking water and adverse pregnancy outcomes  
Over the past decade, many animal and human studies have been published indicating 
an association between DBP exposure and several adverse pregnancy outcomes such as 
LBW, FGR, birth defects and stillbirth 5-7.  The mechanism by which DBP exposure may 
lead to these adverse pregnancy outcomes is not well understood 7.  Rather, it is evidence 
from in vitro and animal research and a few key epidemiological research studies implicating 
DBPs as reproductive toxicants that have fostered continued interest in the research area.  
Furthermore, there appears to be some consistency across the adverse pregnancy outcomes 
that have been associated with DBP exposure.  For example, birth defects and fetal growth 
restriction are both risk factors for stillbirth 73-75, and all three of these outcomes have been 
linked with DBP exposure.  The following section summarizes toxicological and 
epidemiological research on this topic. 
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2.4.1 Toxicological research  
 
Toxicological studies of the potential adverse effects of DBPs on reproduction have 
examined a wide range of outcomes in animals, including developmental disability, structural 
congenital malformations, growth retardation and fetal loss 7.  Reductions in body weight and 
pregnancy loss have been the most consistently found adverse effects of exposure.  
Chlorinated THMs (e.g., chloroform) have generally shown no direct evidence of 
teratogenicity.  However, toxicological data do suggest that brominated THM and HAA 
exposure may be harmful to the fetus.  For example, studies have found an increase in fetal 
resorption (i.e., fetal loss) in rats after exposure to BDCM 76-78, which may be mediated 
through alteration of luteinizing hormone (LH) levels 79.  Studies of HAA exposure have also 
found associations between DCAA and TCAA and craniofacial and cardiovascular 
malformations 80-82.  More recently, in vitro studies have shown that BDCM may inhibit 
human placental trophoblast differentiation 83,84.  As previously mentioned, abnormal 
trophoblast invasion may lead to reduced fetal growth. 
 
2.4.2 Epidemiological research 
 
Exposure assessment is arguably the most difficult aspect of studying the effect of 
DBP exposure on human health and is clearly the greatest limitation of epidemiological 
studies conducted to date.  The following sections discuss the design, results and limitations 
of epidemiological studies that have examined the association between THM and HAA 
exposure and reduced birth weight, SGA and/or preterm birth.  Although fetal growth 
restriction and preterm birth are the primary focus of this dissertation, previous studies of 
DBP exposure on birth weight are also relevant for review given that both fetal growth 
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restriction and preterm birth result in reduced birth weight.  Sections are divided by exposure 
assessment method and study outcome. 
 
Studies using type of water treatment as an exposure index 
Table 5 lists human studies that are based on the comparison of water treatment 
methods as a surrogate measure of DBP exposure 85-88.  These studies looked at a wide range 
of outcomes, including preterm birth (<37 weeks gestational age), very preterm birth (<32 
weeks gestational age), low birth weight (<2,500 grams), very low birth weight (<1,500 
grams) and SGA.  Study populations consisted of births that occurred in the late 1980s 
through the mid-1990s from several different countries.  All but one study identified births 
from birth registries, and all studies ascertained exposure by linking maternal address 
obtained from birth records with information on the type of water treatment employed by the 
utility plant servicing her residence.  Adjustment for covariates was similar across studies 
and included maternal age, education, smoking and alcohol intake, infant sex, year of birth, 
and urbanicity of residence.  Collectively, these studies do not indicate a strong association 
between type of water treatment and adverse live birth outcomes.  However, exposure 
assessment in these studies has several limitations: 
• Use of a contextual ecological variable to characterize DBP exposure, like type of 
water treatment, does not take spatial and temporal variation in DBP concentrations 
into consideration and provides little information on the types and concentrations of 
DBPs that may be present.  
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• Pregnant women often work and/or change residences during pregnancy, so water 
treatment status determined by maternal residence at birth may not be representative 
of exposure over the entire pregnancy. 
• Modification of exposure through individual variation in uptake of DBPs through the 
three routes of exposure (consumption, inhalation and dermal absorption) or use of 
private wells were not considered.  
These limitations likely resulted in exposure misclassification and attenuation of the 
estimated effect.  Therefore, it is difficult to make any conclusions about the association 
between THM and HAA exposure and adverse pregnancy outcomes in the context of these 
studies.    
 
Studies using routinely collected DBP measurements  
Tables 6, 7 and 8 summarize studies that have examined the association between birth 
weight, SGA, and preterm birth, respectively, using routinely collected DBP measurements 
89-101.  Many of these studies looked at more than one birth outcome, and therefore appear in 
more than one table.  For the convenience of the reader, basic study characteristics are 
repeated in each table.  Study results are discussed separately by outcome. 
 
Study characteristics 
A total of 13 studies have been conducted to date in the United States (Iowa, New 
Jersey, North Carolina, Denver, Massachusetts, Arizona and Maryland), Canada (Novia-
Scotia and Montreal) and the United Kingdom.  The majority of studies employed a 
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population-based cohort or case-control design in which births were identified from birth 
records or local hospitals.  For exposure estimation, maternal residence at the time of birth 
was linked with municipal water DBP measurements, which generally provided quarterly 
estimates of monitored DBP concentrations in the systems serving women’s residences.  
Because routine collection of HAAs did not begin until the late 1990s, early studies were 
only able to examine the association between THM exposures (most often TTHM) and birth 
outcomes.  
A little over half of the studies attempted to estimate pregnancy window-specific 
exposure, either focusing solely on third trimester exposure or calculating exposure for 
multiple windows (e.g., first, second and third trimesters).  In addition, several of the more 
recent studies incorporated various regression modeling techniques to estimate monthly 
residential DBP concentrations.  Only two studies incorporated information on individual 
water use to estimate personal DBP exposure: Savitz et al. (1995) combined residential DBP 
concentrations with self-reported consumption of water to estimate “THM dose” 92, and 
Infante-Rivard (2004) combined information on both maternal water consumption and 
showering to estimate personal exposure 94.  Adjustment covariates were similar across 
studies.   
 
Results for birth weight  
Previous studies have examined the effect of DBP exposure on birth weight using 
several birth weight measures, including mean change in birth weight in grams, the 
probability of a low birth weight infant (< 2,500 grams) and the probability of a very low 
birth weight infant (<1,500 grams) (table 6).  In general, these studies show a moderate yet 
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consistent decrease in continuous birth weight (-1 to -70 grams) with increasing exposure to 
TTHM.  Only one study examined the association between birth weight in grams and 
individual THM species (e.g., chloroform and BDCM); the decrease in birth weight 
associated with exposure was similar across THM measures 89.  No association between 
HAA exposure and birth weight in grams was indicated in the one study that looked at this 
association 89.  In addition, the association between low birth weight and very low birth and 
TTHM exposure was much less consistent across studies than the association with a 
continuous measure of birth weight in grams.        
 
Results for SGA  
Of the birth outcomes studied to date, studies of the reproductive health effects of 
DBPs provide the greatest support for increased risk of SGA associated with higher exposure 
(table 7).  Reported relative risk estimates in the literature range from 1.0-1.5 for residential 
TTHM exposure, depending on how categories of TTHM exposure were defined.  Of note, 
studies that have examined exposure to individual THM species (e.g., BDCM) have been 
much less consistent, and overall do not implicate any particular component of TTHM as 
responsible for the observed association found with the aggregate THM measure 89,93-95,101.  
Results for HAA exposure are also inconsistent, although two out of three studies did find an 
increased probability of delivering an SGA infant with increased residential HAA5 
concentrations, perhaps being driven by DCAA and TCAA concentrations 89,95,101.   
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Results for preterm birth 
Previous studies examining the association between TTHM and preterm birth have 
generally indicated no association, with estimated relative risks for preterm birth ranging 
between 0.7-1.2 and showing no notable dose-response trends (table 8).  To date, two studies 
have examined the association between preterm birth and individual TTHM components and 
both suggest no effects 89,93.  Only one previous study by Wright et al. (2004) has examined 
the association between HAA exposure and preterm birth and that study did not find an 
association 89.  Conversely, a moderate yet consistent inverse association between THM 
residential water concentrations and preterm birth was found in preliminary analyses of the 
RFTS study and in a recent study by Lewis et al. (2007)100.     
  
Strengths and limitations of previous studies 
Previous studies have several strengths.  First, most studies were population-based.  
Collectively, the studies cover a wide range of geographic locations and demographic 
characteristics.  Second, most studies are large, with several studies involving more than 
50,000 births.  However, there are also many limitations to previous studies.  Most studies 
relied on birth record data to obtain information on birth outcomes and covariates.  US birth 
certificate data is believed to provide poor information on gestational age among births dated 
< 37 weeks 102 and underreport exposures such as cigarette smoking and alcohol intake 
during pregnancy 103, which likely resulted in misclassification of preterm birth and residual 
confounding by smoking and alcohol use.  Furthermore, despite the large overall sample size 
of most studies, the number of cases in the highest categories of DBP exposure often was still 
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low, leading to unstable effect estimates.  Finally, studies had several limitations with respect 
to exposure assessment: 
• Variation in individual DBP uptake through ingestion, inhalation and dermal 
absorption, use of bottled water and treatment of water before consumption (filtering 
or boiling water) was not taken into account in most studies.  In the studies that did 
estimate personal exposure, information on changes in water intake and use over 
pregnancy was not used. 
• Exposure to DBPs at work was not taken into account 
• Exposure assessment was limited to DBP species that are routinely measured 
(TTHM). 
• Exposure window-specific estimates (e.g., 1st, 2nd 3rd trimester exposure) could not be 
estimated for some studies. 
Each of these limitations likely contributed to substantial error in exposure assessment 
and could have biased study results either to or away from the null.  Clearly, further research 
that addresses the limitations outlined above is warranted.   
The RFTS study improved upon previous studies in several ways.  First, concentrations 
of several THM and HAA species were collected prospectively, including some HAA 
species that are not routinely monitored.  In addition, weekly (or bi-weekly) DBP 
measurements were taken to capture the temporal variability in DBP concentrations and 
allow estimation of window-specific exposures, and pregnant women were prospectively 
followed, allowing collection of individual-level data during a baseline interview, follow-up 
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interview at 20 weeks gestation and medical record abstraction.  Finally, detailed information 
on water consumption and use during the perinatal period was collected. 
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Table 5. Summary of epidemiological studies using contextual surrogates of disinfection by-product exposure and adverse live birth 
outcomesa 
Author (year) 
Study 
location Study Population Outcome (n) Exposure Assessment Adjustment Covariates 
Main Results 
[OR(95% CI)] 
Kanitz et al. 
(1996) 
Genoa and 
Chiavarti, Italy 
 
 
Deliveries at two local 
hospitals between 1988 
and 1989 (N=676) 
PTB (50) 
LBW (20) 
Maternal residence used to 
ascertain type of water 
source (Chlorine dioxide, 
hypochlorite or both 
treatments vs. no treatment)  
Maternal age, education, 
smoking and alcohol 
intake 
Sex of infant 
 
Chlorine dioxide vs. none 
Na-hypochlorite vs. none 
Both vs. none 
PTB  
1.8 (0.7,4.7) 
1.1 (0.3,3.7) 
1.8 (0.6,5.0) 
 
LBW       
5.9 (0.8,14.9) 
6.0 (0.6,12.6) 
6.6 (0.9,14.6) 
Kallen and Robert 
(2000) 
Sweden Registered births 
occurring between 1985 
and 1994 in municipalities 
for which disinfection 
method remained the 
same over relevant 
exposure time (N= 74324) 
EPTB b 
PTB b 
VLBW b 
LBW b 
SGA b 
Maternal residence used to 
ascertain type of water 
source (Chlorine dioxide, 
hypochlorite or both 
treatments vs. no treatment) 
Maternal age, parity, 
education and smoking 
Year of birth 
County of residence 
 
Chlorine dioxide vs. none 
 Na-hypochlorite vs. none  
 
EPTB 
0.95 (0.75,1.09) 
1.22 (1.00,1.48) 
 
PTB 
0.96 (0.88,1.04) 
1.09 (1.01,1.17) 
 
VLBW 
0.84 (0.65,1.09) 
1.11 (0.90,1.36) 
 
LBW 
0.93 (0.84,1.03) 
1.15 (1.05,1.26) 
 
SGA  
0.95 (0.84,1.07) 
1.07 (0.96,1.19) 
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Jaakkola et al. 
(2001) 
Norway Registered births between 
1993-1995 (N=137145) 
PTB (7886) 
LBW (6249) 
SGA b 
Maternal residence used to 
ascertain disinfection status 
(chlorinated vs. non-  
chlorinated) and organic 
content (low color 
vs. high color) of water 
source 
 
Maternal age and parity 
Place of birth  
Urbanicity of 
municipality 
 
No CL,high vs. No CL,Low  
CL,low vs. No CL,Low 
CL,high vs. No CL,low  
 
PTB 
0.92 (0.83,1.03) 
0.95 (0.88,1.03) 
0.91 (0.84,0.99) 
 
LBW       
1.02 (0.91,1.14) 
0.99 (0.90,1.09) 
0.97 (0.89,1.06) 
 
SGA        
1.02 (0.89,1.14) 
1.00 (0.91,1.11) 
1.00 (0.91,1.10) 
Yang 
(2004) 
Taiwan Registered births in 310 
municipalities between 
1994 and 1996 (N= 
182796) 
PTB (8251) 
LBW (8225) 
Maternal residence used to 
ascertain disinfection status 
(chlorinated vs. non-  
chlorinated) of water source 
Maternal age, marital 
status and education 
Sex of infant 
Urbanicity of 
Municipality 
CL vs. No CL  
 
PTB  
1.05 (0.94,1.18) 
 
LBW  
1.37 (1.20,1.56) 
 
*All studies are cross-sectional in design, b Missing (n) value indicates the number of cases was not specified in article,Abbreviations: PTB= preterm birth (infants < 37 weeks gestational age at birth), 
EPTB = early preterm birth (infants < 32 weeks gestational age at birth), LBW = low birth weight (Infants weighing <2,500 grams at birth), VLBW = very low birth weight (Infants weighing <1,500 
grams at birth), SGA= Small for gestational age, OR = Odds Ratio, 95% CI= 95 percent Confidence Interval, CL = chlorine 
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Table 6. Summary of epidemiological studies examining the association between THM  exposure and  birth weight 
Author 
(year) Study details 
THM Exposure 
Assessment 
Adjustment 
Covariates 
Mean ∆ in Birth weight 
(grams) (95% CI) 
LBWa or VLBW 
OR (95% CI) 
Kramer et al. 
(1992) 
Design: Population-based 
case-control  
Location: Iowa, USA 
Population: All low birth 
weight cases delivered 
between 1989 and 1990 
identified from vital records 
along with five normal 
weight controls 
Sample Size: 159 preterm 
births and 795 term births  
Maternal residence at 
time of birth was linked 
with municipal water 
THM measurements for 
1987 
 
Measurements available 
for chloroform, 
bromoform, BDCM, 
DBCM and TTHM 
 
Non-specific time 
window of exposure 
Maternal age, parity, 
martial status, 
education and 
smoking during 
pregnancy 
Adequacy of prenatal 
care 
 
-- 
Chloroform: 1-9, ≥10 μ/liter vs. ND  
1.1 (0.7, 1.6), 1.3 (0.8,2.2) 
 
BDCM: 1-9, 10 μ/liter vs. ND 
1.0 (0.5, 1.9), 1.1 (0.7,1.5) 
 
DBCM: 1-3, 4 μ/liter vs. ND 
0.7 (0.5, 1.1), 0.8 (0.4,1.4) 
 
Bromoform: Detectable vs. ND 
0.9 (0.6,1.5) 
Bove et al. 
(1995) 
Design: Population-based 
cohort  
Location: New Jersey, USA 
Population: All live births 
and fetal deaths identified 
from vital records that were 
delivered in 1 of 75 NJ  
towns between 1985 and 
1988  
Sample Size: 1853 LBW 
infants, 905 VLBW infants 
and 52334 live, normal 
weight and gestational age 
comparison births 
Maternal residence at 
time of birth was linked 
with municipal water 
TTHM measurements for 
1984-1988 
 
Monthly estimates were 
averaged over entire 
pregnancy period 
Maternal age, race, 
education, parity, 
history of stillbirth or 
miscarriage 
Sex of infant 
Adequacy of prenatal 
care 
A-280 contaminantsb 
 
TTHM: 20-40, 40-60, 60-80, 
80-100, >100 ppb vs. ND  
 
34.8 (58.2,11.4)c 
-51.2 (-38.6,-63.8)c 
-26.6 (-11.9,-41.3)c 
-54.9 (-33.0,-76.8)c 
-70.4 (-23.8,-117.0)c 
 
TTHM: >100 ppb vs. ND  
1.42 (1.22,1.65)d  
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Savitz et al. 
(1995) 
Design: Population-based 
case-control  
Location: North Carolina, 
USA Population: Low birth 
weight cases 
identified from local 
hospitals between 1988 and 
1989 in 2 NC counties and 
1988 to 1991 in a third 
county; controls selected 
from term, normal weight 
births immediately following 
preterm birth matched to 
cases on race and hospital 
Sample Size: 178 LBW 
infants and 333 controls  
Maternal residence at 
time of birth was linked 
with municipal THM 
measurements  
 
THM measure nearest to 
the 28th week of 
pregnancy was used to 
assign residential THM 
level  
 
Also estimated “THM 
dose” by combining self-
reported data on maternal 
water consumption and 
residential THM levels:  
THM dose = (ppb X 
glasses/day)  
Maternal age, race, 
education, marital 
status, poverty level, 
smoking, alcohol 
consumption and 
employment 
Delivery hospital 
 
-- 
THM: 63.4-82.7, 82.8-168.8 vs. 40.8-
63.3 ppb 
1.5 (1.0,2.3), 1.3 (0.8,2.1) 
 
Per 50 ppb change in THM 
0.9 (0.6, 1.4) 
 
THM dose: 170.0-330.8, 330.9-1171.0 
vs. 44.0-169.9 units 
1.0 (0.6,1.5), 0.8 (0.5,1.3) 
 
Per 250 unit change in THM dose 
1.0 (0.8, 1.2) 
 
Gallagher et 
al. (1998) 
Design: population-based 
cohort  
Location: Denver, CO, USA 
Population: Births between 
1990 and 1993 to mothers 
residing in census blocks 
served by one of two water  
systems identified from vital 
records 
Sample Size: 1244 total 
births, including 72 LBW 
infants and 29 term LBW 
infants  
Maternal residence at 
time of birth was linked 
with municipal THM 
measurements for 1990-
1993 
 
Residential TTHM levels 
estimated using 
hydraulic modeling 
 
Focused analyses on third 
trimester exposure 
Maternal smoking, 
age, parity, education, 
marital status, 
employment during 
pregnancy 
 
-- 
TTHM: 21-40, 41-60,  ≥ 61 vs. 40.8-
63.3 ppb 
 
LBW 
1 (0.6,1.8) 
0.8 (0.3,1.7) 
2.1 (1.0,4.8) 
 
Term LBW 
1.3 (0.5,3.3) 
1.2 (0.4,4.0) 
5.9 (2.0,17.0) 
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Dodds et al. 
(1999) 
Design: Population-based 
cohort 
Location: Nova Scotia, 
Canada Population: All live 
born and stillborn infants 
>500 gm born between 1988 
and 1995 identified from 
nation-wide perinatal and 
fetal anomaly databases 
Sample Size: 50755 total 
births, including 2392 LBW 
infants and 342 VLBW  
Maternal residence at 
time of birth was linked 
with municipal THM 
measurements between 
1987 and 1995 
 
Third trimester TTHM 
exposure was estimated 
from linear regression 
model including terms 
for year, month and 
facility 
 
Maternal age, parity, 
smoking, attendance 
at perinatal classes 
Neighborhood family 
income 
Sex of infant 
 -- 
TTHM: 50-74, 75-99, >100 vs. 40.8-
63.3 μ/liter  
LBW 
1.07 (0.97,1.19) 
1.11 (0.97,1.26) 
1.04 (0.92,1.18) 
VLBW 
1.03 (0.80,1.33) 
0.93 (0.65,1.32) 
0.89 (0.64,1.23) 
Wright, 
Schwartz and 
Dockery 
(2003) 
Design: Population-based 
Cross-sectional  
Location: Massachusetts, 
USA 
Population: Births to women 
residing in communities that 
routinely monitored THMs in 
1990 identified from birth 
records and hospital 
worksheets 
Sample Size: 56513 total 
births, including 1325 term 
LBW infants 
Maternal residence at 
time of birth was linked 
with municipal TTHM 
measurements;  
City-specific aggregate 
TTHM concentrations 
where used to assign 
TTHM exposure 
 
Examined 1st, 2nd and 
3rd trimester and 
pregnancy average 
exposure   
Maternal age, race, 
education, parity, 
smoking, household 
income, pregnancy 
history, medical 
history 
Gestational age 
Sex of infant 
Adequacy of prenatal 
care 
 
1st trimester TTHM: 
60-80, >80 vs. 0-60 μ/liter 
-4 (-18, 9), -17 (-31,-3) 
 
2nd trimester TTHM: 
60-80, >80 vs. 0-60 μ/liter 
-5 (-19, 9), -23 (-36,-10) 
 
3rd trimester TTHM: 
60-80, >80 vs. 0-60 μ/liter 
-9 (-22, 4), -11 (-24, 2) 
 
Pregnancy average TTHM: 
60-80, >80 vs. 0-60 μ/liter 
-1 (-12, 11), -32 (-47, -18) 
1st trimester TTHM: 
60-80, >80 vs. 0-60 μ/liter 
1.13 (0.93,1.38), 0.98 (0.79,1.21) 
 
2nd trimester TTHM: 
60-80, >80 vs. 0-60 μ/liter 
0.93 (0.75,1.15), 1.14 (0.95,1.38) 
 
3rd trimester TTHM: 
60-80, >80 vs. 0-60 μ/liter 
1.08 (0.90,1.31), 1.09 (0.91,1.31) 
 
Pregnancy average TTHM: 
60-80, >80 vs. 0-60 μ/liter 
0.97 (0.81, 1.26), 1.05 (0.85, 1.29) 
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Wright, 
Schwartz and 
Dockery 
(2004) 
Design: Population-based 
cohort 
Location: Massachusetts, 
USA 
Population: Births to women 
residing in towns with 
population >10,000 between 
1995 and 1998 
identified from birth records 
(109 towns included in THM 
analyses and 17 towns 
included in HAA analyses) 
Sample Size: 196000 total 
births 
 
Maternal residence at 
time of birth was linked 
with municipal THM 
(TTHM, chloroform and 
BDCM) and HAA 
(HAA5, trichloroacetic 
acid, dichloroacetic acid) 
measurements 
 
City-specific aggregate 
DBP concentrations 
where used to assign 
third trimester DBP 
exposure 
 
   
Maternal age, race, 
education, parity, 
smoking, household 
income, pregnancy 
history, medical 
history 
Gestational age 
Sex of infant 
Adequacy of prenatal 
care 
 
TTHM: 33-74, 74-163 vs. 0-33 
μ/liter 
-12 (-16,-7), -18 (-26,-10) 
 
Chloroform: 26-63, 63-135 vs. 
0-26 μ/liter  
-14 (-19,-9), -18 (-26,-10) 
 
BDCM: 5-13, 13-46 vs. 0-5 
μ/liter 
-12 (-17,-8), -12 (-2,-3) 
 
HAA: 30-49, 49-58 vs. 4-30 
μ/liter 25 (9, 40), 7 (-25, 39) 
 
TCAA: 18-27, 27-37 vs. 0-
18μ/liter 
21 (9, 40), -4 (-35, 27) 
 
DCAA: 15-22, 22-24 vs. 2-
15μ/liter  
15 (-4, 34), 12 (-14, 38) 
-- 
Toledano et 
al. 
(2005) 
Design: Population-based 
cohort 
Location: United Kingdom 
Population: Births identified 
from birth registry born to 
women residing in area 
served by one of three water 
companies over specific 
periods for which water zone 
boundary 
information was available: 
1997 for Northumbrian, 
1992-1997 for United 
Utilities, 1993-1998 for 
Severn Trent 
Sample Size: 481255 total 
live births, including 30572 
LBW and 4686 VLBW 
infants 
Maternal residence at 
birth was linked with 
water zone data 
 
Quarterly, zone-specific 
TTHM levels were 
estimated using Bayesian 
modeling with terms for 
year, month and facility 
 
Estimated exposure for 
last 93 days of pregnancy 
(i.e., third trimester for 
full term infants) 
Maternal age 
Sex of infant 
Socioeconomic 
deprivation (measured 
at small-area level) 
 
-- 
TTHM: 30-59, ≥60 vs. <30 μ/liter  
 
LBW 
1.05 (0.96,1.15) 
1.09 (0.93,1.27) 
 
VLBW 
1.03 (0.96,1.10) 
1.05 (0.82,1.34) 
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Hinckley et 
al. 
(2005) 
Design: Population-based 
cohort Location: Arizona, 
USA  
Population: All live births 
and fetal deaths for women 
whose residence was 
provided water by one of 
three facilities from 1998-
2002 identified from birth 
records 
Sample Size: 48119 total 
births, including 1010 LBW 
infants and 564 VLBW 
infants   
 
Maternal residence at 
birth was linked with 
utility data by zip 
Code 
 
Quarterly THM and 
HAA5 measurements 
were available   
for 1998-2002 and  
supplemented with 
monthly  
and biweekly measures 
for some facilities in 
2001and 2002 
(HAA data only available 
prior to 2000 for one 
facility) 
 
Monthly DBP levels were 
imputed when missing 
using spline regression 
 
Third trimester exposure 
and window-specific 
exposure (25-28, 29-32, 
33-36, 37-40 and 41-44 
weeks) was estimated 
Maternal age, race, 
ethnicity, education, 
parity and smoking 
Adequacy of prenatal 
care (Kessner Index) 
 
-- 
TTHM: 40-53, ≥ 53 vs. ≤ 40 μ/liter   
1.06 (0.89, 1.25), 1.11 (0.94, 1.31) 
  
Chloroform: 10-16, ≥ 16 vs. ≤ 10 
μ/liter   
1.18 (1.00, 1.39), 1.04 (0.88, 1.23) 
 
BDCM: 13-18, ≥ 18 vs. ≤ 13 μ/liter   
1.05 (0.89, 1.24), 1.04 (0.88, 1.23) 
 
DBCM: 12-16, ≥ 16 vs. ≤ 12 μ/liter    
1.0 (0.84, 1.18), 1.05 (0.89, 1.24) 
 
 
HAA5: 15-19, ≥ 19 vs. ≤ 15 μ/liter    
1.26 (0.96, 1.65), 1.25 (0.96, 1.64) 
 
DBAA: 4-5, ≥ 5 vs. ≤ 4 μ/liter   
1.01 (0.72, 1.41), 1.49 (1.09, 2.04) 
 
DCAA: 6-8, ≥ 8 vs. ≤ 6 μ/liter    
1.04 (0.75, 1.43), 1.1 (0.80, 1.50) 
 
TCAA 4-6, ≥ 6 vs. ≤ 4 μ/liter    
0.94 (0.68, 1.30), 1.0 (0.73, 1.37) 
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Lewis, Suffet 
and Ritz 
(2006) 
Design: Population-based 
cohort  
Location: Massachusetts, 
USA 
Population: Births to women 
residing in 27 communities 
between August 1991 and 
December 2001 identified 
from birth records 
Sample Size: 36,529  total 
term births, including 780 
TLBW infants 
Maternal residence at 
time of birth was linked 
with weekly municipal 
TTHM measurements;  
 
Examined 1st, 2nd and 
3rd trimester and 
pregnancy average 
exposure   
 
Assessed OR-
modification by maternal 
race/ethnicity (Caucasian 
vs. Non-Caucasian) 
Maternal age, 
race/ethnicity, 
education, marital 
status, parity, 
smoking, household 
income, pregnancy 
history, medical 
history 
Gestational age 
Sex of infant 
Adequacy of prenatal 
care 
Season of conception 
Birth season 
TTHM exposure level 
in previous trimester 
-- 
1st trimester TTHM: 
40-50, 50-60, 60-70, >70 vs. <40 
μ/liter 
0.82 (0.66,1.03), 0.84 (0.66,1.08), 0.88 
(0.66,1.17), 0.87 (0.89,1.04) 
 
2nd trimester TTHM: 
40-50, 50-60, 60-70, >70 vs. <40 
μ/liter 
1.10 (0.81,1.49), 1.08 (0.79,1.49), 1.24 
(0.92,1.67), 1.50 (1.07,2.10) 
 
3rd trimester TTHM: 
40-50, 50-60, 60-70, >70 vs. <40 
μ/liter 
0.87 (0.60,1.26), 0.79 (0.56,1.12), 0.84 
(0.58,1.21), 0.74 (0.44,1.22) 
 
Pregnancy average TTHM: 
40-50, 50-60, 60-70, >70 vs. <40 
μ/liter 
1.07 (0.81,1.42), 0.95 (0.75,1.20), 1.23 
(0.92,1.64), N/A 
a “A-280 contaminants” are contaminants monitored by the New Jersey Bureau of Safe Drinking Water, including trichloroethylene, tetrachloroethylene, total dichloroethylenes, 1,1,1-trichloroethane, 
carbon tetrachloride, 1,2-dihcloroethane, and benzene Low birth weight among all births unless otherwise specified;   
b Analysis restricted to term birth and 99% Confidence Interval presented 
c 50% confidence interval  
Abbreviations: ∆= change, LBW= Low birth weight, VLBW= Very low birth weight, THM=  Trihalomethane,  BDCM = Dichlorobromomethane, DBCM= Dibromochloromethane, TTHM= Total 
trihalomethane, HAA5 = Haloacetic acid 5 (sum of CAA, DCAA, TCAA, BAA and DBAA), CAA = monochloroacetic acid, DCAA= dichloroacetic acid, TCAA= trichloroacetic acid, BAA= 
monobromoacetic acid, DBAA= dibromoacetic acid, OR= Odds ratio, 95% CI= 95 percent Confidence Interval, ND= non-detectable, N/A = not available  
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Table 7. Summary of epidemiological studies examining the association between THM exposure and SGA infant 
Author 
(year) Study details 
THM Exposure 
Assessment 
Adjustment 
Covariates 
Main results 
(OR [95% CI]) 
Kramer et al. 
(1992) 
Design: Population-based case-
control  
Location: Iowa, USA 
Population: All low birth weight 
cases delivered between 1989 
and 1990 identified from vital 
records along with five normal 
weight controls 
Sample Size: 187 SGA infants 
and 795 non-SGA controls  
Maternal residence at time of 
birth was linked with 
municipal water THM 
measurements for 1987 
 
Measurements available for 
chloroform, bromoform, 
BDCM, DBCM and TTHM 
 
Non-specific exposure 
window  
Maternal age, parity, 
martial status, 
education and 
smoking during 
pregnancy 
Adequacy of prenatal 
care 
 
Chloroform: 1-9, ≥ 10 μ/liter vs. ND  
1.3 (0.9, 1.8), 1.8 (1.1,2.9 
 
BDCM: 1-9, 10 μ/liter vs. ND 
1.2 (0.8, 1.7), 1.7 (0.9,2.9) 
 
DBCM: 1-3, 4 μ/liter vs. ND 
1.0 (0.7, 1.5), 0.9 (0.1,8.6) 
 
Bromoform: Detectable vs. ND 
1.1 (0.7,1.6) 
Bove et al. 
(1995) 
Design: Population-based cohort  
Location: New Jersey, USA 
Population: All live births and 
fetal deaths identified from vital 
records that were delivered in 1 
of 75 NJ  towns between 1985 
and 1988  
Sample Size: 4082 SGA infants 
and 52334 live, normal weight 
and gestational age births 
Maternal residence at time of 
birth was linked with 
municipal water TTHM 
measurements for 1984-1988 
 
Monthly estimates were 
averaged over entire 
pregnancy period 
Maternal age, race, 
education, parity, 
history of stillbirth or 
miscarriage 
Sex of infant 
Adequacy of prenatal 
care 
A-280 contaminants 
 
TTHM: 20-40, 40-60, 60-80, 80-100, >100 ppb vs. ND  
0.98 (0.79,1.20)c 
1.33 (1.20,1.47) c  
1.11 (0.98,1.25) c 
1.22 (1.02,1.45) c 
1.5 (1.04,2.09) c 
 
Dodds et al. 
(1999) 
Design: Population-based cohort 
Location: Nova Scotia, Canada 
Population: All live born and 
stillborn infants >500 gm born 
between 1988 and 1995 
identified from nation-wide 
perinatal and fetal anomaly 
databases 
Sample Size: 50755 total births, 
including 4673 SGA infants 
Maternal residence at time of 
birth was linked with 
municipal THM 
measurements between 1987 
and 1995 
 
Third trimester TTHM 
exposure was estimated from 
linear regression model 
including terms for year, 
month and facility 
Maternal age, parity, 
smoking, attendance 
at perinatal classes 
Neighborhood family 
income 
Sex of infant 
 
TTHM: 50-74, 75-99, >100 vs. 40.8-63.3 μ/liter  
1.04 (0.97,1.11) 
1.01 (0.92,1.11) 
1.08 (0.99,1.18) 
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Wright, 
Schwartz and 
Dockery 
(2003) 
Design: Population-based Cross-
sectional  
Location: Massachusetts, USA 
Population: Births to women 
residing in communities that 
routinely monitored THMs in 
1990 identified from birth 
records and hospital worksheets 
Sample Size: 56513 total births, 
including 5310 term LBW 
infants 
Maternal residence at time of 
birth was linked with 
municipal TTHM 
measurements 
 
City-specific aggregate 
TTHM concentrations where 
used to assign TTHM 
exposure 
 
First, second and third 
trimester and pregnancy 
average exposure were 
considered   
Maternal age, race, 
education, parity, 
smoking, household 
income, pregnancy 
history, medical 
history 
Gestational age 
Sex of infant 
Adequacy of prenatal 
care 
 
1st trimester TTHM:  60-80, >80 vs. 0-60 μ/liter 
1.00 (0.89,1.10), 1.09 (0.98,1.21) 
 
2nd trimester TTHM:  60-80, >80 vs. 0-60 μ/liter 
0.99 (0.89,1.10), 1.13 (1.03,1.14) 
 
3rd trimester TTHM:  60-80, >80 vs. 0-60 μ/liter 
0.98 (0.89, 1.09), 1.03 (0.94, 1.14) 
 
Pregnancy average TTHM:  60-80, >80 vs. 0-60 μ/liter 
1.00 (0.92,1.09), 1.14 (1.02,1.26) 
 
Wright, 
Schwartz and 
Dockery 
(2004) 
Design: Population-based cohort 
Location: Massachusetts, USA 
Population: Births to women 
residing in towns with 
population >10,000 between 
1995 and 1998 
identified from birth records 
(109 towns included in THM 
analyses and 17 towns 
included in HAA analyses) 
Sample Size: 196000 total births, 
including 17359 term SGA 
infants 
Maternal residence at time of 
birth was linked with 
municipal THM (TTHM, 
chloroform and BDCM) and 
HAA (HAA5, trichloroacetic 
acid, dichloroacetic acid) 
measurements 
 
City-specific aggregate DBP 
concentrations where used to 
assign third trimester DBP 
exposure 
Maternal age, race, 
education, parity, 
smoking, household 
income, pregnancy 
history, medical 
history 
Gestational age 
Sex of infant 
Adequacy of prenatal 
care 
 
TTHM: 33-74, 74-163 vs. 0-33 μ/liter 
1.06 (1.02,1.10), 1.13 (1.07,1.20) 
 
Chloroform: 26-63, 63-135 vs. 0-26 μ/liter  
1.05 (1.02,1.09), 1.11 (1.04,1.17) 
 
BDCM: 5-13, 13-46 vs. 0-5 μ/liter 
1.1 (1.07,1.14), 1.15 (1.08,1.22) 
 
HAA: 30-49, 49-58 vs. 4-30 μ/liter  
0.9 (0.81,1.01), 0.97 (0.77,1.23) 
 
TCAA: 18-27, 27-37 vs. 0-18 μ/liter 
0.87 (0.76,0.99), 0.95 (0.76,1.19) 
 
DCAA: 15-22, 22-24 vs. 2-15 μ/liter  
0.86 (0.75,0.99), 0.9 (0.75,1.09) 
 41
Infante-
Rivard 
(2004) 
Design: Hospital-based case-
control  
Location: Montreal, Canada 
Population: Cases and controls    
were recruited from one hospital 
between 1998 and 2000, and 
matched on gestational week, 
sex, race and date of birth 
(usually within 1 week window) 
Sample Size: 493 SGA cases and 
472 non-SGA controls 
Maternal residence during 
each trimester of pregnancy 
was linked with municipal 
THM (chloroform, 
bromoform, BDCM, DBCM, 
TTHM) measurements 
 
Residential THM 
concentrations were combined 
with self-reported data on 
maternal consumption and 
showering to estimate average 
personal exposure over the 
course of pregnancy 
Maternal race, 
weight gain during 
pregnancy, pre-
pregnancy BMI, 
parity, pregnancy 
history, parity, 
smoking during 
pregnancy 
Sex of infant 
Gestational age 
 
 
Chloroform: >23.7 vs. ≤23.7 μ/liter 
1.06 (0.63,1.79) 
 
Bromoform: >1.22 vs. ≤ 1.22 μ/liter 
2.44 (0.19,31.10) 
 
BDCM: >6.3 vs. ≤6.3 μ/liter 
0.84 (0.50,1.43) 
 
DBCM: >3.9 vs. ≤3.9 μ/liter 
0.62 (0.27,1.44) 
 
TTHM: >29.4 vs. ≤ 29.4 μ/liter 
0.97 (0.57,1.62) 
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Porter et al. 
(2005)b 
 
Design: Population-based cohort 
Location: Maryland county; 
USA Population: Births 
identified from birth records 
born to mothers whose resided in 
zip codes corresponding to a 
water 
utility's point measurements 
(four sampling points total) 
between 1998 to 2002 
Sample Size: 1114 SGA births 
and 14201 non-SGA births  
 
 
Maternal residence at birth 
was linked with utility 
company water data; monthly 
measurements were available 
for TTHM (bromoform, 
chloroform, BDCM, DBCM, 
TTHM) between 1997-2002 
and HAA5 (CAA, DCAA, 
TCAA, BAA, DBAA, HAA5) 
between 1999-2002 
 
Trimester-specific and 
pregnancy average DBP 
exposure was estimated   
 
 
Maternal age, weight 
gain, marital status, 
tobacco use, alcohol 
use, region of 
residence   
Child's race/ethnicity 
Adequacy of prenatal 
care 
 
 
THM:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
1.18 (0.97,1.44), 1.2 (0.99,1.46), 1.05 (0.86,1.26), 1.17 (0.96,1.24) 
 
Chloroform:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
1.02 (0.84,1.24), 0.96 (0.79,1.16), 0.98 (0.81,1.19), 1.07 
(0.88,1.29) 
 
Bromoform:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
1.14 (0.94,1.38), 1 (0.82,1.23), 1.2 (0.99,1.46), 1.01 (0.83,1.23) 
 
DBCM:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
0.95 (0.79,1.15), 0.84 (0.69,1.02), 0.92 (0.76,1.12), 0.9 (0.74,1.09) 
 
BDCM:  2nd, 3rd, 4th, 5th  vs. 1st quintile 
0.92 (0.76,1.12), 1.04 (0.86,1.25), 0.92 (0.76,1.12), 0.98 
(0.81,1.19) 
 
HAA5:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
1.29 (1.01,1.66), 1.41 (1.11,1.814), 1.15 (0.89,1.49), 1.34 
(1.04,1.71) 
 
CAA:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
0.83 (0.65,1.06), 0.94 (0.75,1.19), 0.95 (0.75,1.20), 1 (0.79,1.26) 
 
DCAA:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
1.14 (0.89,1.46), 1.29 (1.02,1.64), 1.06 (0.83,1.37), 1.27 
(0.99,1.61) 
 
TCAA:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
1.3 (1.01,1.65), 1.34 (1.05,1.71), 1.21 (0.94,1.55), 1.2 (0.94,1.54) 
 
BAA:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
0.87 (0.68,1.10), 0.97 (0.77,1.23), 0.95 (0.75,1.21), 1.07 
(0.85,1.35) 
 
DBAA:  2nd, 3rd, 4th, 5th  vs. 1st quintile  
0.87 (0.68,1.11), 0.99 (0.78,1.26), 1.1 (0.87,1.39), 1.05 (0.83,1.33) 
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Hinckley et 
al. 
(2005) 
Design: Population-based cohort 
Location: Arizona, USA  
Population: All live births and 
fetal deaths for women whose 
residence was provided water by 
one of three facilities from 1998-
2002 identified from birth 
records 
Sample Size: 48119 total births, 
including 4346 SGA infants   
 
Maternal residence at birth 
was linked with utility data by 
zip 
Code 
 
Quarterly THM and HAA5 
measurements were available   
for 1998-2002 and  
supplemented with monthly  
and biweekly measures for 
some facilities in 2001and 
2002 
(HAA data only available 
prior to 2000 for one facility) 
 
Monthly DBP levels were 
imputed when missing using 
spline regression 
 
Third trimester exposure and 
window-specific exposure 
(25-28, 29-32, 33-36, 37-40 
and 41-44 weeks) were 
estimated 
Maternal age, race, 
ethnicity, education, 
parity and smoking 
Adequacy of prenatal 
care (Kessner Index) 
 
TTHM: 40-53, ≥ 53 vs. ≤ 40 μ/liter 
0.98 (0.90, 1.07), 1.09 (1.00, 1.18) 
 
Chloroform: 10-16, ≥ 16 vs. ≤ 10 μ/liter   
1.02 (0.94, 1.11), 1.01 (0.93, 1.10) 
 
BDCM: 13-18, ≥ 18 vs. ≤ 13 μ/liter 
0.93 (0.85, 1.01), 1.03 (0.95, 1.12) 
 
DBCM: 12-16, ≥ 16 vs. ≤ 12 μ/liter 
0.96 (0.89, 1.05), 1.01 (0.94, 1.10) 
 
 
HAA5: 15-19, ≥ 19 vs. ≤ 15 μ/liter 
1.00 (0.87, 1.15), 1.08 (0.94, 1.23) 
 
DBAA: 4-5, ≥ 5 vs. ≤ 4 μ/liter  
1.04 (0.88, 1.23), 1.12 (0.95, 1.32) 
 
DCAA: 6-8, ≥ 8 vs. ≤ 6 μ/liter    
1.15 (0.97, 1.36), 1.28 (1.08, 1.51) 
 
TCAA 4-6, ≥ 6 vs. ≤ 4 μ/liter    
1 (0.84, 1.18), 1.19 (1.01, 1.41) 
* 99% Confidence Interval, bQuintile cut-points were not reported, main results presented for third trimester exposure  
Abbreviations:  LBW= Low birth weight, VLBW= Very low birth weight, THM=  Trihalomethane,  BDCM = Dichlorobromomethane, DBCM= Dibromochloromethane, TTHM= Total trihalomethane, 
HAA5 = Haloacetic acid 5 (sum of CAA, DCAA, TCAA, BAA and DBAA), CAA = monochloroacetic acid, DCAA= dichloroacetic acid, TCAA= trichloroacetic acid, BAA= monobromoacetic acid, 
DBAA= dibromoacetic acid, OR= Odds ratio, 95% CI= 95 percent Confidence Interval 
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Table 8. Summary of epidemiological studies examining the association between THM exposure and preterm birth 
Author (year) Study details THM Exposure Assessment Adjustment Covariates Main Results [OR(95% CI)] 
Kramer et al. 
(1992) 
Design: Population-based 
case-control  
Location: Iowa, USA 
Population: All preterm birth 
cases delivered between 1989 
and 1990 identified from vital 
records along with five term 
birth controls 
Sample Size: 342 preterm 
births and 1710 term births  
Maternal residence at time of birth 
was linked with municipal water 
THM measurements for 1987 
 
Measurements available for 
chloroform, bromoform, BDCM, 
DBCM and TTHM 
 
Non-specific time window of 
exposure 
Maternal age, parity, 
martial status, education 
and smoking during 
pregnancy 
Adequacy of prenatal care 
 
Chloroform: 1-9, ≥ 10 μ/liter vs. ND  
1.1 (0.8,1.4), 1.1 (0.7, 1.6) 
 
BDCM: 1-9, ≥ 10 μ/liter vs. ND 
1.1 (0.9,1.5), 1.0 (0.6, 1.5) 
 
DBCM: 1-3, ≥ 4 μ/liter vs. ND 
1.1 (0.7, 1.4), undefined-no cases 
 
Bromoform: Detectable vs. ND 
1.1 (0.8,1.4) 
Bove et al. 
(1995) 
Design: Population-based 
cohort  
Location: New Jersey, USA 
Population: All live births and 
fetal deaths identified from 
vital records that were 
delivered in 1 of 75 NJ  towns 
between 1985 and 1988  
Sample Size: 7167 preterm 
births and 52334 live, normal 
weight and gestational age 
comparison births 
Maternal residence at time of birth 
was linked with municipal water 
TTHM measurements for 1984-1988 
 
Monthly estimates were averaged 
over entire pregnancy period 
Maternal age, race, 
education, parity, history 
of stillbirth or miscarriage 
Sex of infant 
Adequacy of prenatal care 
A-280 contaminants 
 
Exact values were not specified but can infer all OR 
estimates < 1.5 because only estimated ORs ≥ 1.5 were 
reported in tables and no THM-preterm birth results 
were presented.   
Savitz et al. 
(1995) 
Design: Population-based 
case-control  
Location: North Carolina, 
USA Population: Preterm 
birth cases identified from 
local hospitals between 1988 
and 1989 in 2 NC counties and 
1988 to 1991 in a third county; 
controls selected from term, 
normal weight births 
immediately following 
preterm birth matched to cases 
on race and hospital 
Sample Size: 244 preterm 
births and 333 controls  
Maternal residence at time of birth 
was linked with municipal THM 
measurements  
 
THM measure nearest to the 28th 
week of pregnancy was used to 
assign residential THM level  
 
Also estimated “THM dose” by 
combining self-reported data on 
maternal water consumption and 
residential THM levels:  
THM dose = (ppb X glasses/day)  
 
Maternal age, race, 
education, marital status, 
poverty level, smoking, 
alcohol consumption and 
employment 
Delivery hospital 
 
THM: 63.4-82.7, 82.8-168.8 vs. 40.8-63.3 ppb 
1.2 (0.8,1.8), 0.9 (0.6,1.5) 
 
Per 50 ppb change in THM 
0.8 (0.6, 1.2) 
 
THM dose: 170.0-330.8, 330.9-1171.0 vs. 44.0-169.9 
units 
1.2 (0.8,1.7), 0.9 (0.6,1.3) 
 
Per 250 unit change in THM dose 
0.9 (0.8-1.1) 
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Gallagher et al. 
(1998) 
Design: population-based 
cohort  
Location: Denver, CO, USA 
Population: Births between 
1990 and 1993 to mothers 
residing in census blocks 
served by one of two water  
systems identified from vital 
records 
Sample Size: 1244 total births, 
including 68 preterm births  
Maternal residence at time of birth 
was linked with municipal THM 
measurements for 1990-1993 
 
Residential TTHM levels estimated 
using hydraulic modeling 
 
Focused analyses on third trimester 
exposure 
Maternal smoking, age, 
parity, education, marital 
status, employment 
during pregnancy 
 
TTHM: 21-40, 41-60,  ≥ 61 vs. 40.8-63.3 ppb 
1.0 (0.6,1.7), 0.7 (0.3,1.6), 1.0 (0.3,2.8) 
 
Dodds et al. 
(1999) 
Design: Population-based 
cohort 
Location: Nova Scotia, 
Canada Population: All live 
born and stillborn infants 
>500 gm born between 1988 
and 1995 identified from 
nation-wide perinatal and fetal 
anomaly databases 
Sample Size: 50755 total 
births, including 2689 preterm 
births  
Maternal residence at time of birth 
was linked with municipal THM 
measurements between 1987 and 
1995 
 
Third trimester TTHM exposure was 
estimated from linear regression 
model including terms for year, 
month and facility 
 
Maternal age, parity, 
smoking, attendance at 
perinatal classes 
Neighborhood family 
income 
Sex of infant 
 
TTHM: 50-74, 75-99, >100 vs. 40.8-63.3 μ/liter  
0.96 (0.88,1.06), 0.99 (0.88,1.12), 0.97 (0.87,1.09) 
 
Wright, 
Schwartz and 
Dockery 
(2003) 
Design: Population-based 
Cross-sectional  
Location: Massachusetts, 
USA 
Population: Births to women 
residing in communities that 
routinely monitored THMs in 
1990 identified from birth 
records and hospital 
worksheets 
Sample Size: 56513 total 
births, including 3173 preterm 
births 
Maternal residence at time of birth 
was linked with municipal TTHM 
measurements 
 
City-specific aggregate TTHM 
concentrations where used to assign 
TTHM exposure 
 
First, second and third trimester and 
pregnancy average exposure were 
considered  
Maternal age, race, 
education, parity, 
smoking, household 
income, pregnancy 
history, medical history 
Gestational age 
Sex of infant 
Adequacy of prenatal care 
1st trimester TTHM:  60-80, >80 vs. 0-60 μ/liter 
0.96 (0.84,1.10), 1.01 (0.88,1.16) 
 
2nd trimester TTHM:  60-80, >80 vs. 0-60 μ/liter 
1.02 (0.89,1.16), 0.9 (0.79,1.03) 
 
3rd trimester TTHM:  60-80, >80 vs. 0-60 μ/liter 
0.99 (0.87, 1.13), 0.97 (0.85, 1.11) 
 
Pregnancy average TTHM:  60-80, >80 vs. 0-60 μ/liter 
1.00 (0.89,1.12), 0.9 (0.77,1.04) 
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Wright, 
Schwartz and 
Dockery 
(2004) 
Design: Population-based 
cohort 
Location: Massachusetts, 
USA 
Population: Births to women 
residing in towns with 
population >10,000 between 
1995 and 1998 identified from 
birth records (109 towns 
included in THM analyses and 
17 towns included in HAA 
analyses) 
Sample Size: 196000 total 
births, including 11580 
preterm births 
Maternal residence at time of birth 
was linked with municipal THM 
(TTHM, chloroform and BDCM) and 
HAA (HAA5, trichloroacetic acid, 
dichloroacetic acid) measurements 
 
City-specific aggregate DBP 
concentrations where used to assign 
third trimester DBP exposure 
 
   
 
Maternal age, race, 
education, parity, 
smoking, household 
income, pregnancy 
history, medical history 
Gestational age 
Sex of infant 
Adequacy of prenatal care 
 
TTHM: 33-74, 74-163 vs. 0-33 μ/liter  
0.95 (0.91,0.99), 0.88 (0.81,0.94) 
 
Chloroform: 26-63, 63-135 vs. 0-26 μ/liter  
0.95 (0.91,0.99), 0.9 (0.84,0.97) 
 
BDCM: 5-13, 13-46  vs. 0-5 μ/liter  
0.89 (0.85,0.93), 0.92 (0.85,0.99) 
 
 
HAA: 30-49, 49-58 vs. 4-30 μ/liter  
0.95 (0.83,1.10), 1.03 (0.77,1.39) 
 
TCAA: 18-27, 27-31 vs. 0-18 μ/liter  
0.91 (0.77,1.07), 1.07 (0.81,1.42) 
 
DCAA: 15-22, 22-24 vs. 2-15 μ/liter  
0.85 (0.71,1.01), 0.99 (0.79,1.23) 
Lewis, Suffet 
and Ritz 
(2007) 
Design: Population-based 
cohort  
Location: Massachusetts, 
USA 
Population: Births to women 
residing in 27 communities 
between August 1991 and 
December 2001 identified 
from birth records 
Sample Size: 37,498  total 
births, including  2,813 
preterm infants 
Maternal residence at time of birth 
was linked with weekly municipal 
TTHM measurements;  
 
Examined 1st, 2nd and 3rd trimester 
and pregnancy average exposure   
 
Assessed OR-modification by 
maternal race/ethnicity (Caucasian 
vs. Non-Caucasian) 
Maternal age, 
race/ethnicity, education, 
marital status, parity, 
smoking, household 
income, pregnancy 
history, medical history 
Gestational age 
Sex of infant 
Adequacy of prenatal care 
Season of conception 
Birth season 
TTHM exposure level in 
previous trimester 
1st trimester TTHM: 
40-<60, ≥ 60 vs.<40 μ/liter 
1.02 (0.92,1.13), 1.00 (0.88,1.14) 
  
2nd trimester TTHM: 
40-<60, ≥ 60 vs.<40 μ/liter 
0.87 (0.77,1.99), 0.82 (0.71,0.94)  
 
3rd trimester TTHM: 
40-<60, ≥ 60 vs.<40 μ/liter 
1.00 (0.87,1.15), 1.13 (0.95,1.35) 
  
Pregnancy average TTHM: 
40-<60, ≥ 60 vs.<40 μ/liter 
0.92 (0.81,1.02), 0.85 (0.74,0.97) 
Abbreviations: THM=  Trihalomethane,  BDCM = Dichlorobromomethane, DBCM= Dibromochloromethane, TTHM= Total trihalomethane, HAA = Haloacetic acid, OR= Odds ratio, 95% CI= 95 
percent Confidence Interval 
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2.5 Public health significance 
Public health interest in the potential adverse health effects due to water DBP 
exposure is a legitimate concern.  Several recent studies have indicated an increased risk of 
fetal growth restriction among pregnant women exposed to high levels of DBPs.  Limitations 
in exposure assessment may in part explain the inconsistent findings of studies of birth 
weight and null findings of preterm birth studies.  Given the long-term consequences of fetal 
growth restriction and preterm birth and the fact that most pregnant women are exposed to 
some amount of DBPs during pregnancy, even a small effect of exposure could have a 
substantial impact on a population level.  Further examination of this association with 
improved DBP exposure estimation is clearly needed.  This proposed analysis of DBP 
exposure, fetal growth restriction and preterm birth improves upon the methods used in 
previous work by utilizing weekly (or biweekly) water measures of several DBPs and 
incorporating information on individual water consumption and use.  The author expected to 
find a stronger estimated effect of DBP exposure (presuming a causal association) than in 
previous studies given these improvements in exposure assessment.  
CHAPTER 3: MATERIAL AND METHODS 
3.1 Overview 
This study involved analyses of data collected from Phase I of Right from the Start 
(RFTS), a community-based prospective cohort study conducted from 2000-2004 to examine 
the effect of drinking water disinfection by-product (DBP) exposure on pregnancy health.  As 
part of the RFTS study, women trying to conceive or newly pregnant (≤ 12 weeks’ gestation) 
were recruited from three geographic locations in the US selected to provide a broad 
exposure range: moderate levels of predominately chlorinated DBPs (hereafter referred to as 
the “chlorinated DBP site”), moderate levels of predominately brominated DBPs (the 
“brominated DBP site”), and low levels of all DBPs (the “low DBP site”).  In addition, 
moderate DBP sites were selected because they used chloramination for terminal disinfection 
rather than free chlorine to insure that spatial variability in DBP concentrations within a site 
would be minimal.  
Approximately 3,000 women were enrolled across all study sites.  Data collection 
involved two primary components: 1) collection of information about RFTS participants and 
their pregnancy obtained through interviews, an early pregnancy ultrasound, medical record 
abstraction and vital records matching, and 2) collection of information on DBP levels in the 
water systems serving RFTS participants’ homes during their pregnancy obtained through 
weekly (or biweekly) sampling of water systems and testing for concentrations of 
trihalomethanes (THMs), haloacetic acids (HAAs) and total organic halide (TOX).  
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Information on infant date of birth, birth weight and sex was obtained by medical record 
abstraction, vital records matching and self-report for 2,039 RFTS participants who delivered 
a live infant.          
The purpose of this study was to estimate the effect of exposure to a variety of THM 
and HAA species during pregnancy on fetal growth restriction (specific aim 1) and preterm 
birth (specific aim 2).  To address specific aim 1, logistic regression was used to estimate the 
effect of exposure to specific DBP measures during pregnancy on the probability of 
delivering an SGA infant and linear regression was used to estimate the mean difference in 
term birth weight in grams associated with increased DBP exposure.  To address specific aim 
2, discrete-time hazard analysis was used to model the odds of delivery during each week 
conditional on a woman not having delivered in a prior week for specific intervals of 
pregnancy (i.e., ≤ 32 weeks’, 32-36 weeks’, 37-40 weeks’, ≥ 41 weeks’) while allowing DBP 
exposure to change over the course of pregnancy.  The associations with residential 
concentrations and personal exposure to total trihalomethane (TTHM), the sum of the 
regulated haloacetic acids (HAA5), and TOX were examined using traditional maximum 
likelihood estimation (MLE).  In addition, Bayesian methods were used to examine the 
associations between fetal growth outcomes and individual THMs and HAAs, which are 
highly correlated.   
The following sections give a detailed description of participant recruitment, 
enrollment and follow-up in the RFTS study as well as RFTS data collection methods.  In 
addition, methods for outcome assessment, exposure assessment and data analyses are 
outlined.        
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3.2 Selection of RFTS study sites 
The three geographic locations studied for RFTS were chosen based upon attributes 
of the water systems serving the area.  The chlorinated DBP site had moderate levels of 
predominantly chlorinated THMs and HAAs in the water (e.g., chloroform, dichloroacetic 
acid [DCAA], and trichloroacetic acid [TCAA]).  The brominated DBP site had similar total 
THM and HAA concentrations but speciation was dominated by brominated by-products due 
to the relatively high concentrations of bromide in the source water (e.g., 
bromodichloromethane [BDCM], dibromochloromethane [DBCM], bromoacetic acid 
[BAA], and dibromoacetic acid [DBAA]).  The low DBP site had relatively low overall DBP 
concentrations because source water for the water system comes from deep wells with low 
organic material concentration.  An additional consideration for the two moderate DBP sites 
(i.e., the chlorinated and brominated DBP sites) was that they used chloramination as a 
terminal disinfectant, which minimizes spatial variation in DBP concentrations, to facilitate 
the characterization of THM and HAA exposure.  The low DBP site used free chlorine but 
spatial variation was not a concern because of low DBP levels overall 26. 
 
3.3 Study population 
3.3.1 Recruitment and enrollment  
 
As part of the RFTS study, pregnant women ≤ 12 weeks’ gestation in pregnancy and 
women trying to become pregnant were recruited from private and public prenatal care 
venues, the community at large (e.g., via informational posters and brochures posted in drug 
stores, bookstores, childcare facilities, coffee shops, fitness centers, retail stores, grocery 
stores, libraries, beauty salons, worksites, and churches; advertisements placed in 
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community, worksite, and church publications) and by targeted mailings sent to new home 
owners and women who had delivered a child within the past three years.  Overall, the 
majority of participants (62%) were enrolled from private and public obstetric practices; 
however, the relative success of recruitment sources varied by site (e.g., approximately 70% 
of subjects were recruited from prenatal care practices in the chlorinated and low DBP sites 
versus only 26% in the brominated DBP site).   
Women interested in participating in the study were identified by RFTS staff in 
different ways.  Most commonly, interested women phoned RFTS using the study’s 
advertised 1-800-telephone number.  In addition, some prenatal clinics collected contact 
information for interested subjects and faxed it to the RFTS study office, or forwarded 
patient calls directly to the study office if women were interested in learning more about the 
study.  Once identified, women were screened over the phone to determine their eligibility to 
participate.  Eligibility criteria were as follows: 
• Less than or at 12 weeks’ gestation in pregnancy with a positive pregnancy test, or 
trying to conceive but had not been trying for more than 6 months. (These women 
were pre-enrolled and followed for a maximum of 6 months). 
• Maternal age ≥ 18 years if already pregnant or age 18 to 45 if trying to conceive. 
• Residence in the geographic study area served by city water and no intention to move 
out of the area prior to delivery. 
• No assisted reproductive technology used to conceive. 
• Intention to carry pregnancy to term. 
• Ability to speak, read, and write English or Spanish. 
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Table 9 gives the enrollment period and water sampling period for each study site.  Of 
note, enrollment and water sampling began much earlier in the chlorinated DBP site than the 
other study sites.  Recruitment at the brominated and low DBP sites was delayed for several 
reasons.  First, a functional protocol was developed at the chlorinated DBP site before 
attempting to scale up to multiple sites.  Additional delays incurred in the process of setting 
up subcontracts and in obtaining the needed Institutional Review Board (IRB) approvals.  
Finally, recruitment had to be delayed at brominated DBP site to accommodate the expansion 
of the water distribution system serving this study site. 
 
 
 
 
 
 
 
 
 
3.3.2 Participant follow-up 
 
The following sections outline RFTS participant attrition from screening through 
those eligible for the proposed analyses.  Follow-up is first discussed separately for 
participant interviews and collection of birth outcome information.  Then analysis-specific 
exclusions are given to produce the final sample size for each set of analyses.  Finally, select 
characteristics of women enrolled in the RFTS study are compared to characteristics of both 
the general population of women giving birth in the three study sites and characteristics of 
RFTS participants eligible to be included in analyses.     
 
Table 9. Enrollment and water sampling time frames 
Site Enrollment period 
Length of recruitment 
period (years) Water sampling period 
Chlorinated 12/2000–2/29/2004 3.3 10/10/2000–2/29/2004 
Low 6/2002–3/31/2004 1.8 7/30/2001–8/1/2004 
Brominated 9/2002–4/30/2004 1.7 6/3/2002–9/5/2004 
Adapted from Savitz et al. (2005) AWWARF report  
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Participant interviews 
Figure 1 is a flow chart outlining study participation from screening through follow-
up interview.  A total of 4,066 women were screened for inclusion.  Of those, 3,125 women 
(2,514 pregnant and 611 trying to conceive at screening) met the inclusion criteria listed 
above and were enrolled or pre-enrolled into the study.  Study participants who were 
pregnant at screening or converted to pregnant within 6 months after pre-enrollment (252 
women were formally enrolled after conceiving) were eligible to complete a baseline 
interview.  Of those eligible women, 2,418 (87%) completed the full baseline interview.  An 
additional 89 (3%) women completed the modified baseline interview (administered to 
women who reported a pregnancy loss at the beginning of the baseline interview).  Women 
who completed the full baseline interview were re-contacted later in pregnancy to participate 
in a follow-up interview.  Of these women, 2,066 (85%) completed the full follow-up 
interview and 196 (8%) completed the modified follow-up interview (administered to women 
who reported a loss).    
Women were excluded from the study after initial enrollment primarily because they 
did not become pregnant within 6 months of trying to conceive (n=359). Other participants 
were excluded because their estimated gestational age at enrollment based on ultrasound was 
>12 weeks, study staff were unable to reach the participant by telephone for >7 weeks, or the 
participant moved out of the study area.  Participants withdrew from the study for a variety of 
reasons including not wanting to have the study ultrasound, concerns about their pregnancy 
or having had a pregnancy loss, lack of time and other life events, or their partner’s concern 
about their participation in the study.  Some women also decided that the questions asked in 
the interview were too personal.  Table 10 shows exclusions and dropouts by site. 
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Table 10. Withdrawals and exclusions by Study Site 
n(%) 
All Sites 
(n=3125) 
Chlorinated 
(n=1393) 
Low 
(n=1178) 
Brominated 
(n=554) 
Excluded 499 (16.0) 204 (14.6) 209 (17.7) 86 (15.5) 
Withdrew 85 (2.7) 38 (2.7) 35 (3.0) 12 (2.2) 
Adapted from Savitz et al. (2005) AWWARF report  
  
 
 
Figure 1. Flow-chart of study participation in the RFTS study 
   a Modified interviews are completed by participants who reported a pregnancy loss 
   b A total of 2,507 women completed the full or modified baseline interview  
   Figure adapted from Savitz et al. (2005) AWWARF report 
Total Women Screened (n= 4066) 
Chlorinated DBP site (n=1923) 
Low DBP site (n=1479) 
Bromainetd DBP site (n=664) 
Unknown Pregnancy Status   
Total (n=7) 
  Chlorinated DBP site (n=5) 
  Low DBP site (n=2) 
Pregnancy at Screening (n=2514) 
  Chlorinated DBP site (n=1068) 
  Low DBP site (n=961) 
  Brominated DBP site (n=485) 
Trying to Become Pregnant 
(n=611) 
  Chlorinated site (n=325) 
  Low DBP site (n=217) 
Brominated DBP site (n=69)
Eligible for Interview 
(n =2766) 
Converted to Pregnancy (n=252) 
  Chlorinated DBP sire (n=164) 
  Low DBP site (n=70) 
  Brominated DBP site (n=18) 
Completed Modifieda,b 
Baseline Interview (n=89) 
Completed Baseline Interview 
(n=2418)b 
Completed Modifieda Follow-
Up Interview (n=196) 
 
Completed Follow-Up 
Interview (n=2066) 
Enrolled at Screening (n=3132) 
  Chlorinated DBP site (n=1398) 
  Low DBP site (n=1180) 
  Brominated DBP site (n=554) 
Others: 
Declined Interview (n=70) 
Contact Window Closed (n=44) 
Excluded (n=113) 
Others: 
Declined Interview (n=18) 
Contact Window Closed (n=129) 
Excluded (n=9) 
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Collection of birth outcome information  
Table 11 summarizes documented pregnancy outcomes of women who completed the 
full or modified baseline interview (n=2,507) shown in the highlighted boxes of figure 1.   
Among these women, 347 (13.8%) had pregnancies that ended in a loss (i.e., spontaneous 
abortions, induced abortions, stillbirth, or ectopic, tubal or molar pregnancies) and 2,070 
(82.6%) had pregnancies that ended in a live birth.  The outcome status of 90 pregnancies 
(3.6%) could not be determined because medical records for the participant could not be 
located or were not released to RFTS study staff, the participant could not be matched with 
vital records and RFTS staff were not able to re-contact the participant by mail or phone to 
inquire about the pregnancy outcome directly from the participant.   
Table 11. Pregnancy outcome for women completing baseline interview by study site 
n (%) All Sites Site 1 Site 2 Site 3 
Spontaneous Abortiona  306 (12.2) 143 (12.4) 100 (10.9) 63 (14.5) 
Induced Abortion  19 (0.8) 9 (0.9) 5 (0.5) 5 (1.2) 
Stillbirthb  12 (0.5) 7 (0.6) 4 (0.4) 1 (0.2) 
Ectopic, tubal or molar 
pregnancy 
10 (0.4) 1 (0.1) 5 (0.5) 4 (0.9) 
Live birth 2070 (82.6) 947 (82.3) 768 (83.5) 355 (81.4) 
Missing  90 (3.6) 44 (3.8) 38 (4.1) 8 (1.8) 
a defined as pregnancy loss at <20 weeks gestation; b defined as pregnancy loss at ≥20 weeks gestation 
Adapted from Savitz et al. (2005) AWWARF report  
 
 
Other exclusions  
Figures 2, 3, and 4 outline specific exclusions made for the duration of gestation 
analyses (specific aim 2, presented in manuscript #2), fetal growth analyses (specific aim 1, 
presented in manuscript #1), and gestational age comparison analysis (presented in 
manuscript #3), respectfully.  For fetal growth and duration of gestation analyses, 
pregnancies were excluded if missing information on infant’s date of birth (DOB) or birth 
weight (n=7), reducing the sample to 2,063 (99.7% of 2,070 documented live births with 
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complete baseline interview).  This information was obtained from medical records for 886 
pregnancies (42.9%), vital records for 1,167 pregnancies (56.6%), and self-reports for 10 
pregnancies (0.5%).  Among the 2,063 pregnancies, eight multigestional pregnancies (i.e., 
twins) were excluded.  In addition, 56 of the remaining 2,055 pregnancies were repeat 
pregnancies to women who re-enrolled in the RFTS study.  Forty of these pregnancies were 
to women whose first RFTS pregnancy ended in a loss or had missing outcome information 
(i.e., not included in the 2,055 live births detailed above) and were retained in the live birth 
analyses.  The remaining 16 pregnancies are a second live birth to a RFTS participant and 
excluded to retain independence of observations, resulting in a final sample of 2,039 for 
duration of gestation analyses (figure 2).   
 
Figure 2. Flow-chart of exclusions for duration of gestation analyses 
 
 
 
Documented live birth with  
baseline interview (n= 2070) 
Missing information on 
birth date or weight (n=7) 
Repeat live birth to a RFTS 
participant (n=16) 
Multi-gestational pregnancy 
(n=8) 
Singleton live births with complete baseline 
interview and birth outcome data (n=2039)a 
a 5 women missing data on showering and bathing (and thus, missing first and second 
trimester average TTHM personal exposure), 4 women missing data on tap water 
consumption (and thus, missing first and second trimester personal HAA5 and TOX 
exposure), 65 women missing DBP measurements during third trimester (and thus, 65 
missing third trimester average TTHM, HAA5 and TOX residential concentrations) and 
one additional woman missing follow-up data on bathing and showering and tap water 
consumption (and thus, 66 missing third trimester average TTHM, HAA5 and TOX 
personal exposure)      
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Figure 3. Flow-chart of exclusions for fetal growth restriction analyses 
 
 
 
In addition to exclusions outlined above to obtain a group of singleton live births with 
complete baseline interview and birth outcome data for duration of gestation analyses, SGA 
status could not be assigned for three births missing information on maternal race, 73 births 
with a reported maternal race of “Indian”, “Asian/Pacific islander”, or “Other”, and five 
births with an estimated gestational age at birth <25 or > 42 weeks’ gestation, reducing the 
final sample size for SGA models to 1,958 births (figure 3).  Term mean birth weight models 
Documented live births with  
baseline interview (n= 2070) 
Missing information on birth date 
or birth weight (n=7) 
Repeat live birth to a RFTS participant 
(n=16)
Multi-gestational pregnancy (n=8) 
Singleton live births with complete baseline 
interview and birth outcome data  
(n=2039) 
a 5 women missing data on showering and bathing (and thus, missing first and second trimester average 
TTHM personal exposure), 4 women missing data on tap water consumption (and thus, missing first and 
second trimester personal HAA5 and TOX exposure), 54 women missing DBP measurements during third 
trimester (and thus, 54 missing third trimester average TTHM, HAA5 and TOX residential concentrations 
and personal exposure) 
 
b 5 women missing data on showering and bathing (and thus, missing first and second trimester average 
TTHM personal exposure), 4 women missing data on tap water consumption (and thus, missing first and 
second trimester personal HAA5 and TOX exposure), 64 women missing DBP measurements during third 
trimester (and thus, 64 missing third trimester average TTHM, HAA5 and TOX residential concentrations) 
plus one additional woman missing data on bathing and showering and tap water consumption (and thus, 
65 missing third trimester average TTHM, HAA5 and TOX personal exposure)      
Term birth (born at > 37 weeks’ gestation) 
(n=1854)a 
Estimated gestational age at birth  
< 25 or > 42 weeks’ (n=5)
Missing maternal race (n=3) 
“Other” maternal race (n =73) 
Able to classify as SGA or Non-SGA 
(n=1958)b 
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were restricted to 1,854 of the 2,039 singleton live births with complete baseline interview 
and birth outcome data that were born at ≥ 37 weeks’.  
The analysis comparing gestational age at birth based on last menstrual period (LMP) 
versus first trimester ultrasound included 1,867 singleton live births with complete baseline 
interview, LMP (month and day of month) and ultrasound data (figure 4).  Again, 347 (12.5 
%) pregnancies that ended in a loss, 90 (3.3 %) pregnancies lost to follow-up, eight (0.3 %) 
multi-gestational pregnancies, 16 (0.6 %) repeat live births to a RFTS participant, and three 
(0.07 %) pregnancies missing infant birth date (0.07 %) were excluded. Additional 
exclusions were made for pregnancies with incomplete LMP date (n=18; 0.6 %) and 
pregnancies with no ultrasound data (n=158; 5.7 %). 
 
Figure 4. Flow-chart of exclusions for gestational age estimates comparison analysis 
 
  
Documented live births with  
baseline interview (n= 2070) 
Missing information on birth date 
(n=3) 
Repeat live birth to a RFTS participant 
(n=16)
Multi-gestational pregnancy (n=8)
Singleton live births with complete baseline 
interview and date of birth 
(n=2043) 
Abbreviations: LMP = last menstrual period 
Missing first trimester ultrasound   
(n=158) 
Missing day of month for LMP (n=18) 
LMP and ultrasound-based estimate of GA available  
(n=1867) 
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3.3.3 Comparison of general, study, and analysis populations  
 
Although RFTS attempted to recruit a cross-section of women from the participating 
geographic areas, the population that agreed to join the study was not random and likely not 
representative of the general population.  Therefore, RFTS obtained and analyzed vital 
records from the state health departments of study sites to assess the degree to which 
participating women differ from their counterparts who lived in the area and gave birth over 
the same time period as the study (table 12).  Participants from chlorinated DBP site were 
similar to the total population with respect to age, but more highly educated, more likely to 
be non-Hispanic White and less likely to be Hispanic, and more likely to be nulliparous.  
Participants from low DBP site were slightly less likely to be 18 or 19 years old at the start of 
pregnancy, more likely to be non-Hispanic White than Black or Hispanic, more likely to be 
nulliparous, and more highly educated than the total population of the area.  Participants from 
the brominated DBP site were more likely to be Hispanic and less likely to be non-Hispanic 
White or Black, and more likely to be nulliparous than the total population, but similar with 
respect to education and age.  Participants from low DBP site were slightly less likely to be 
18 or 19 years old at the start of pregnancy, more likely to be non-Hispanic White than Black 
or Hispanic, more likely to be nulliparous, and more highly educated than the total 
population of the area 26.   
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Table 12. Demographic characteristics of RFTS participants and the general population 
Maternal 
Characteristics 
Chlorinated DBP sire: 
 n (percent) 
Brominated DBP site: 
n (percent) 
Low DBP site: 
n (percent) 
 General 
population 
RFTS study 
population 
General 
population 
RFTS study 
population 
General 
population 
RFTS study 
population 
Age at pregnancy 
start 
      
18 – 19 years 354 (6.2) 52 (4.77) 366 (10.9) 40 (9.46) 1474 (11.5) 57 (6.34) 
20 – 34 years  4623 (80.5) 890 (81.58) 2663 (79.3) 349 (82.51) 10204 (79.3) 743 (82.65) 
> 35 years 764 (13.3) 149 (13.66) 329 (9.8) 34 (8.04) 1187 (9.2) 99 (11.01) 
Race/ethnicity       
White,  
non-Hispanic 2669 (46.6) 718 (65.81) 1760 (52.7) 153 (36.26) 4412 (34.3) 477 (53.12) 
Black,  
non-Hispanic 1658 (29.0) 290 (26.58) 607(18.2) 100 (23.70) 7144 (55.6) 375 (41.76) 
Hispanic 1113 (19.4) 30 (2.75) 848 (25.4) 158 (37.44) 890 (6.9) 21 (2.34) 
Other,  
non-Hispanic 287 (5.0) 53 (4.86) 123 (3.7) 11 (2.61) 410 (3.2) 25 (2.78) 
Parity       
Nulliparous 2388 (41.6) 586 (53.71) 1129 (34.3) 184 (43.50) 4432 (34.5) 423 (47.05) 
Parous 3348 (58.4) 505 (46.29) 2160 (65.7) 239 (56.5) 8411 (65.5) 476 (52.95) 
Education       
< 12 years 2128 (37.1) 201 (18.42) 1834 (54.8) 232 (54.85) 6276 (50.5) 282 (31.4) 
13 – 15 years 1049 (18.3) 200 (18.33) 704 (21.0) 107 (25.3) 2855 (23.0) 211 (23.5) 
> 16 years 2564 (44.7) 690 (63.24) 811 (24.2) 84 (19.86) 3287 (26.5) 405 (45.1) 
Adapted from Savitz et al. (2005) AWWARF report  
 
 
Table 13 presents demographic characteristics of women enrolled in RFTS compared 
to women eligible for duration of gestation analyses.  These two groups are similar with 
respect to maternal age at enrollment, estimated gestational age and parity.  Both groups are 
ethnically diverse.  However, White women were more likely and Black women were less 
likely to be retained in the analysis populations.  In addition, women included in analyses are 
more highly educated than women originally enrolled into the RFTS.  As noted earlier, 
women originally enrolled into the RFTS study sample were excluded from analysis for 
multiple reasons: 1) women were excluded or withdrew from the study after initial 
enrollment (including enrolled while trying to conceive that never became pregnant), 2) 
pregnancy ended in a loss or pregnancy outcome status is missing, 4) complete information 
on infant DOB and birth weight was not obtained or 5) pregnancy was multigestational. 
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Table 13. Demographics of women enrolled in RFTS and women included in 
duration of gestation analyses 
Characteristic 
Enrolled women 
(n = 3,132) 
Women in analysis 
(n=2,039) 
Mean age at enrollment (years) 28.34 28.2 
Mean estimated gestational age 
at enrollment (days) 56.26 55.2 
Race/ethnicity, n (%)   
African-American 1,102 (35.19) 614 (30.14) 
White 1,732 (55.30) 1,229 (60.33) 
Asian/Pacific Islander 58 (1.85) 43 (2.11) 
Other 228 (7.28) 151 (7.41) 
Hispanic origin 276 (8.81) 185 (9.08) 
Education, n (%)   
≤ 12 years 1,014 (32.38) 573 (28.12) 
13-15 years 679 (21.68) 440 (21.59) 
≥ 16 years 1,439 (45.95) 1,025 (50.29) 
Parity, n (%)   
0 1,425 (45.51) 991 (48.60) 
1 1,067 (34.07) 673 (33.01) 
≥ 2 640 (20.42) 375 (18.39) 
Adapted from Savitz et al. (2005) AWWARF report  
 
 
3.4 Data collection 
Data collection in RFTS involved two primary components: 1) collection of 
individual level information about RFTS participants and their pregnancy obtained through 
interviews, an early pregnancy ultrasound, medical record abstraction and vital records 
matching, and 2) collection of information on DBP concentrations in the water distribution 
systems serving the three study sites while RFTS participants were pregnant.  The following 
sections discuss these components in detail. 
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3.4.1 Collection of individual information on RFTS participants 
 
Figure 2 summarizes the sources and timing of individual level data collection over 
the course of RFTS, beginning with the screening interview through collection of birth 
outcome information.  These sources of data are described in detail below.      
 
  Figure 5. Flow diagram of data collection     
 
 
 
Screening interview 
A 5-minute telephone screening interview was conducted with interested women, at 
which time information necessary to establish eligibility was collected (e.g., maternal date of 
birth, residential address, and LMP).  In addition, if a woman was found eligible and agreed 
to enroll in the RFTS study, staff completed a 5 to 10-minute interview at screening to collect 
personal information about the participant.  This included information on race/ethnicity, 
marital status, and education level.  
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First trimester ultrasound 
First trimester endovaginal ultrasounds were conducted by clinical sonographers 
required to have ARDMS® certification, use state-of-the-art equipment as assessed by a 
study investigator (KH), conduct and document manufacturer recommended machine 
calibration, and have three or more years experience in pelvic and obstetric diagnostic 
sonography. In addition, sonographers participated in study-specific training. Measurements 
of the gestational sac, yolk sac, fetal pole, and fetal heart rate were fully comparable with 
those required for clinical pregnancy dating. A still image was reviewed by trained staff prior 
to entry of ultrasound data, and a 20% quality sample was reviewed by a clinician skilled in 
first trimester sonography (KH). All ultrasounds were performed at or before 13 weeks’ 
completed gestation (mean= 9 weeks, median = 8 weeks).           
 
Baseline telephone interview 
The baseline telephone interview was completed 1 to 2 weeks after enrollment and no 
later than 16 completed weeks’ gestation.  A contract research organization (Battelle) 
conducted the baseline interviews.  The baseline interview took on average 45 minutes to 
complete.  Phone numbers and best times to call were obtained during the screening 
interview and provided to Battelle.  The interview covered the following topics:  
• Demographic information: social, household, and income information 
• Recent/Current employment 
• Health behaviors 
• Water exposure 
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• Menstrual history 
• Previous pregnancy history, time to conception, current pregnancy history 
• Physical and sexual abuse 
• Vitamin and mineral supplement use 
If a participant had a pregnancy loss prior to completing the baseline interview, she 
completed a modified version of the baseline interview.  If a participant did not complete the 
baseline interview by 16 completed weeks’ gestation, she was not contacted to complete the 
follow-up interview 26. 
 
Follow-up telephone interview 
The follow-up interview was completed with participants starting at 20 weeks’ 
gestation.  RFTS attempted to complete the follow-up interview during week 20 when 
possible, and all follow-up interviews were completed no later than 25 weeks’ gestation.  
Battelle also conducted the follow-up interview, which lasted 30 minutes on average. This 
interview covered the following topics:  
• Changes in water use habits and health behaviors 
• More information on previous pregnancy history and current pregnancy history, 
including pregnancy-related symptoms and information on prenatal care/delivery 
choices 
• Maternal medical history 
• Paternal characteristics 
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A participant completed the modified follow-up interview if she had a pregnancy loss 
before she was called to complete the follow-up interview 26.  
 
Collection of live birth outcome information 
Information on birth outcomes was collected from three sources: medical records, 
vital records and participant self-report.  For pregnancies ending in a live birth between 2001 
and 2003, RFTS staff first attempted to obtain key information on pregnancy outcome from 
vital records (i.e., date of delivery, birth weight and infant sex).  For those women who gave 
birth in 2004 and for whom vital records could not be successfully matched, RFTS requested 
hospital discharge summaries and prenatal care records to abstract birth outcome 
information.  Information abstracted from medical records included: 
• Infant date of birth (DOB), birth weight and gender 
• Apgar scores at 1 and 5 minutes 
• Congenital anomalies 
• Delivery methods 
• Indication for preterm birthFinally, self-reported information on live birth outcomes 
was also obtained verbally from some participants during a follow-up telephone call or from 
a short 1-page questionnaire mailed to participants, which the participant then completed and 
mailed back to the RFTS office.  Of note, outcome information is available from multiple 
sources for some participants (e.g., medical records and self-report).  In this case, information 
was taken from medical records first, vital records second and participant self-report last. 
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3.4.2 Collection of data on DBP concentrations 
 
The following section describes how data on DBP concentrations was collected and 
analyzed.  In addition, results are presented from a small validation study to confirm the lack 
of spatial variation in THM and HAA concentrations at the chlorinated and brominated DBP 
sites. 
 
Determining sampling points 
Utility companies were visited by a RFTS team member at the beginning of the study 
to review the water treatment facilities (including the method of terminal disinfection), 
analyze the service area and distribution system, select possible sampling locations, and 
collect samples at a number of locations for DBP analysis.  Using information collected from 
the initial sampling trip, a representative sampling location was chosen for each utility for the 
remainder of the study.  Because Site 3 had several booster chlorination stations serving a 
large portion of its population, two sampling locations were chosen at the brominated DBP 
site: 1) the treatment plant point of entry (POE) to the distribution system and 2) a second 
location on the downstream side of a booster station.  The amount of chlorine applied at the 
booster station was relatively minor (0.3 to 0.5 mg/liter), so it was expected that the added 
free chlorine would be converted by residual free ammonia in the water to combined chlorine 
with little additional formation of DBPs 26. 
Collection of water samples 
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As part of the RFTS study, weekly water samples were collected at the representative 
locations for the chlorinated and brominated DBP site.  Samples were collected every other 
week at the low DBP site.  Residual chlorine concentrations and temperature were also 
measured at the time of DBP sample collection.  The chlorinated DBP site utility system 
switched from combined chlorine to free chlorine for one month each year (March) to control 
potential microbial re-growth and biofilm problems.  To account for the anticipated spatial 
variation in DBP levels during the one-month conversion, samples for DBP analysis were 
collected weekly at up to 10 locations in the distribution system.  The brominated DBP sire 
utility also converted to free chlorine for a period of several weeks during October 2003.  
Again, samples were collected weekly at a number of locations in the distribution system 
including the representative sample locations to account for the anticipated spatial variation 
in DBP levels 26. 
Collection of water samples was performed by field personnel in accordance with a 
specified protocol.  Key features of the protocol are listed below:  
• Sample collection vials were washed, labeled, and reagents added prior to shipment to 
study sites. 
• Identification labels indicating the sampling location, target analyte, reagents added 
were placed on all vials; samplers also recorded the date/time of sample collection 
and their initials on the label. 
• Chain of Custody documentation and return overnight shipping labels were included 
with each shipment of vials.  
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• Weekly THM and HAA samples at moderate DBP sites and bi-weekly sample at the 
low DBP site were collected in quadruplicate in order to provide duplicate samples 
for analysis and for matrix spike analyses. 
• Samples were collected near mid-day on Thursday at the chlorinated DBP site, 
Tuesday at the low DBP site, and Wednesday at the brominated DBP site from a 
cold-water tap that had been run for at least five minutes prior to sample collection.   
• The samples were returned by overnight delivery to the Drinking Water Research 
Center laboratories of UNC where they were inspected and stored in a refrigerator at 
4oC. 
• A tracking database which included information on sampling date, target analyte, 
outgoing shipment date, date received back at UNC, extraction date, instrument 
analysis date, quantification date, and quality control review status was kept at the 
University of North Carolina.   
Please see appendix 1, “Water Sampling Methodology” excerpted from Savitz et al. 
(2005) for the full protocol. 
 
Analysis of THM concentrations 
THM samples were analyzed within a 14-day holding time of the sample collection 
date using a 5890 series II gas chromatograph (Agilent Technologies, Palo Alto, CA) 
equipped with an electron capture detector.  A modified version of EPA Method 551.1 104 
was utilized to extract each of the THM4 species from the aqueous samples (see appendix 1 
for full details).  The practical quantification limit (PQL) for all THMs was 0.1 
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micrograms/liter.  Linear calibration for each THM species was in the range of 1.0-150 
micrograms/liter.  The acceptable relative percent difference for THM analysis duplicates 
was <10% and the matrix spike recovery had to be in the range 80-120%.  Any samples not 
meeting these criteria were flagged and examined further for analytical or instrumentation 
errors 26.   
 
Analysis of HAA concentrations 
HAA samples were analyzed within a 21-day holding time using a 5890 series II gas 
chromatograph (Agilent Technologies, Palo Alto, CA) equipped with an electron capture 
detector.  The method used for extraction of all nine HAA species was developed by Brophy 
et al. 105 and based upon EPA method 552 106 and Standard Method 6251B 107 (see appendix 
1 for full details).  The coefficient of variation (% CV) was calculated for the surrogate area 
counts of all analytical samples.  The PQL was 1.0 or 2.0 micrograms/liter, depending on the 
HAA, and the maximum calibration standard utilized was 150 micrograms/liter.  Analysis 
and quantification of the calibration standards and aqueous samples was based on replicate 
precision of duplicate samples having a relative percent difference of less than 25 percent 26.  
 
 
Analysis of TOX concentrations 
TOX analysis was performed using a model AD-2000 Adsorption Module and TOX 
Analyzer (Tekmar Dohrmann, Cincinnati, Ohio).  Samples of 250 milliliters were acidified to 
pH < 2 with 2 milliliters of concentrated sulfuric acid (H2SO4), loaded into an adsorption 
module, dispensed through two granular activated carbon columns, and subsequently rinsed 
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with potassium nitrate to remove retained inorganic chloride. The carbon was then 
combusted at 850°C to volatilize organic halogens, which were then analyzed by micro-
coulometric detection. Preceding and following each batch of samples, a “nitrate blank” was 
also analyzed to determine the contribution of background organic halogen from the 
reagents, carbon, and carrier gases.  TOX concentrations (in micrograms chlorine/liter) were 
calculated by adding organic halogen for the combustion of top and bottom columns of 
samples (in micrograms chlorine), subtracting the average of nitrate blank concentrations, 
and then dividing by volume (in milliliters) of sample absorbed. 
 
Table 14. Distributions of DBP concentrations by study site 
DBP concentration (µg/liter) 
Location n Mean Median Maximum Minimum 
Chlorinated DBP Site      
THM4 177 63.3 60.7 149 24.7 
CHCl3 177 45.6 43.5 124 14.7 
CHBrCl2 177 13.8 12.5 33.3 6.8 
THM-Br 177 17.8 16.2 43.5 9.0 
HAA5 177 33.2 31.9 62.2 12.1 
HAA9 177 43.2 41.5 78.9 15.4 
HAA-Br 177 10.8 10.2 28.7 1.9 
Brominated DBP site      
THM4 108 58.9 57.8 165.0 26.6 
CHCl3 108 11.5 10.0 52.7 3.0 
CHBrCl2 108 19.0 18.3 51.7 7.1 
THM-Br 108 47.4 44.9 112.3 21.4 
HAA5 108 21.5 20.1 53.1 13.2 
HAA9 108 45.8 44.7 98.9 30.4 
HAA-Br 108 32.0 31.4 55.7 20.4 
Low DBP site      
THM4 157 4.2 3.6 15.9 1.4 
CHCl3 157 BMRL BMRL 2.4 BMRL 
CHBrCl2 157 1.5 1.1 6.5 BMRL 
THM-Br 157 3.9 3.4 13.5 1.4 
HAA5 157 BMRL BMRL 3.1 BMRL 
HAA9 157 3.5 3.3 6.5 BMRL 
HAA-Br 157 BMRL BMRL 6.4 BMRL 
BMRL=below the minimum reporting level (i.e., “non-detects”) 
Table adapted from Savitz et al. 2005 AWWARF report 
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Measured THM and HAA concentrations 
Table 14 presents the mean, median, maximum and minimum concentrations of select 
THM and HAA species over the respective periods when water sampling was conducted at 
each site.  Overall concentrations of TTHM and HAA5 were similar at the chlorinated and 
brominated DBP sites; however, relative concentrations of chlorinated and brominated THM 
and HAA species varied markedly between.  THM and HAA concentrations were much 
lower at the low DBP site than at moderate DBP sites.  Of note, marked seasonal variation in 
THM levels was observed in the chlorinated DBP site and to a lesser extent at the brominated 
DBP site, with peak concentrations occurring in summer months and lower concentrations in 
winter months 26.  
 
 
Validation of sampling strategy 
 
The proposed sampling strategy described above was confirmed by validation studies 
conducted at chlorinated and brominated DBP sites.  Water samples were collected from six 
sampling locations within each water distribution system on the same day.  Apart from 
concentrations at the point of entry (POE) to the distribution system, measurements of 
TTHMs at the chlorinated DBP site were all similar, ranging from 51 to 57 micrograms/liter 
(figure 3).  The POE value (labeled HRT = 0 in figure 3) is lower than the others because the 
sample was taken before the ammonia was fully mixed into the finished water.  TTHM levels 
were also similar at the brominated DBP site, ranging 89 to 99 micrograms/liter (figure 4).  
These results, which were repeated on two other occasions at the chlorinated DBP site and 
one other occasion for the brominated DBP site, confirm that there was very little spatial 
variation in THM concentrations in the water distribution systems serving the moderate DBP 
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sites.  Similar consistency in HAA concentrations was found on multiple occasions at the 
moderate DBP sites (results not shown) 26.     
 
 
Figure 6. Spatial variability of THM species at the chlorinated DBP site, February 2003 
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Figure 7. Spatial variability of THM species at the brominated DBP site, June 2003 
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Abbreviations: Conc = concentrations, HRT = hydraulic residence time 
Adapted from Savtiz et al. (2005) AWWARF report  
Abbreviations: Conc = concentrations 
Adapted from Savtiz et al. (2005) AWWARF report  
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3.5 Outcome assessment 
The following sections describe how fetal growth restriction (specific aim 1) and 
duration of gestation (specific aim 2) were assessed for analyses.  The method used to date 
pregnancies is given and justified.  Definitions for SGA, term birth weight and gestational 
age also are presented. 
 
3.5.1 Estimation of gestational age 
 
Infant DOB is available from medical records, vital records and participant self-report 
and was combined with LMP estimates to calculate estimated gestational age (EGA) at 
delivery (i.e., EGA at delivery in days = DOB - LMP).  Two sources for estimating date of 
conception were available: 1) participant-reported LMP collected during a screening 
interview conducted at or before 12 weeks’ gestation and 2) early ultrasound dating 
conducted before 14 weeks’ gestation (assumes LMP occurred 14 days prior to date of 
conception).  Given that both estimates of conception were collected early in pregnancy, the 
concordance between gestational age estimates derived from these two sources (henceforth 
referred to as LMP-based and ultrasound-based estimates) should be high, particularly among 
pregnancies ending in a live birth.  As previously outlined in section 3.3.2, a total of 1,867 
documented singleton live birth were available with complete information on self-reported 
LMP, a first trimester ultrasound, and date of birth.  The mean difference in number of days 
between LMP and ultrasound-based estimates of gestational age is -0.9 ± 7.7 days (mean ± 
standard deviation), with a median discrepancy of 0 days.  Eighty-eight percent of births have 
an estimated gestational age from ultrasound within 1 week (i.e., plus or minus 7 days) of the 
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estimate derived from LMP.  Additional results are provided in manuscript #3 (chapter 5, 
section 3).   
Given that use of self-reported LMP was found to be an accurate method of 
estimating gestational age for most births, LMP-based estimates were used when LMP and 
ultrasound-based estimates were within +/- 7 days or if ultrasound data was missing.  This 
was done to help preserve comparability with previous DBP studies and maintain 
compatibility with birth weight percentile cut-points used for SGA classification (see section 
3.5.2 below. 
 
 
3.5.2 Assessment of restricted fetal growth 
 
Two outcomes were used to assess the impact of THM and HAA exposure during 
pregnancy on restricted fetal growth (specific aim 1): small for gestational age (SGA) and 
term birth weight in grams.  SGA was chosen because it is a conventional measure for 
identifying more severe growth restriction and has been consistently associated with DBP 
exposure in the literature.  Main analyses included all infants (both preterm and term births).  
In addition, analyses were run restricting to term births, which are often viewed as a 
“cleaner” group for assessing effects on fetal growth, to assess whether the inclusion of 
preterm SGA infants substantially influenced results. 
Term birth weight was chosen because it allows examination of the effect of DBP 
exposure on birth weight as a continuum while minimizing variation in birth weight due to 
differences in gestational age at birth.  Low birth weight (LBW) was also considered as an 
alternative measure; however, use of LBW is complicated by the relationship between 
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growth restriction and preterm delivery, both of which contribute to low birth weight.  Thus, 
LBW was not examined.   
 
Categorization of infants as SGA 
An SGA infant was defined as an infant with a birth weight below the tenth percentile 
according to gestational age (in weeks, ranging from 25 to 42 weeks), infant gender, maternal 
race/ethnicity (non-Hispanic White, Non-Hispanic Black, or Hispanic), and parity 
(primiparous or mulitparous) specific birth weight curves.  Tenth percentile cut-point values 
were obtained from standardized birth weight curves derived by Zhang and Bowes (1995) for 
non-Hispanic Black women 38 and by Overpeck et al (1999) for non-Hispanic White women 
and Hispanic women 43.  Estimated gestational age was converted from days into weeks of 
gestation using the calculation:  EGA (weeks) = integer [(EGA in days - 1) /7].  Information 
on infant gender, maternal race/ethnicity and parity was obtained from interviews.  All 
women included in analyses had complete information on infant gender and parity.   Subjects 
missing complete information on maternal race/ethnicity (n=3), a maternal race of “Indian”, 
“Asian/Pacific islander”, or “Other” (n=73) or estimated gestational age < 25 or > 42 weeks’ 
gestation (n=5) were excluded from SGA analyses (figure 3).  
 
Assigning term birth weight 
Term birth weight analyses were restricted to infants born ≥ 37 weeks completed 
gestational age (n=1854), and birth weight was coded continuously in grams.  Infant birth 
weight was obtained from medical records, vital records and/or participant self-report.  Birth 
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weight information was taken from the medical record first, vital records second and 
participant self-report last if more than one source of information was available for a 
participant.  Birth weight was converted to grams if reported in pounds (lbs) and ounces (oz).    
 
3.5.3 Assessment of reduced duration of gestation  
Time from LMP until delivery (gestational age in weeks) was used to assess the 
impact of THM and HAA exposure during pregnancy on duration of gestation (specific aim 
2) using a discrete hazard model.  This measure was chosen because it allows estimation of 
odds ratios for delivery during multiple intervals of pregnancy (e.g., ≤ 32 weeks, 33-36 
weeks, 37-40 weeks and ≥ 41 weeks) in one model so that a spectrum of preterm severity can 
be considered simultaneously.  The intervals ≤ 32 weeks, 32-36 weeks, 37-40 weeks and ≥ 
41 were chosen because they roughly represent very preterm, moderately preterm, term and 
post-term births, respectively.  Another option would be to dichotomize births into preterm 
and non-preterm (e.g., <37 weeks versus ≥ 37 weeks).  This measure is not ideal because it 
masks variability in severity of prematurity among infants categorized as preterm while over-
emphasizing a difference between deliveries occurring shortly before and after 37 weeks’ 
gestation.  However, preterm birth was examined in an ancillary analysis for manuscript #3 
to help in the interpretation of discrete hazard analyses and comparison with previous studies.   
 
3.6 Exposure assessment 
Several approaches can be taken to assign DBP exposure.  Incorporation of available 
information on personal water consumption and use may lead to more accurate estimation of 
 77
an individual’s exposure.  However, it also requires the assumptions that behavioral 
information is accurately reported and is correctly integrated into exposure assessment.  Two 
exposure metrics were examine in this study to address this concern: 1) average DBP 
concentrations for a study site over specific windows of pregnancy, henceforth referred to as 
“residential DBP concentrations” and 2) estimated personal DBP exposure (described in 
detail below in section 3.6.3) over the same time windows of pregnancy.  The first metric 
estimates DBP concentrations in tap water serving a woman’s home (and possibly her 
workplace if employed at a location within the study site) during pregnancy and ignores 
modification in exposure due to individual variation in water consumption and use.  The 
second metric estimates a woman’s individual DBP exposure during pregnancy given 
residential DBP concentrations and her personal water exposure patterns (specifically water 
consumption, filtering and boiling; showering and bathing).  These two exposure metrics 
were estimated for several different THM and HAA species and for several different 
exposure windows of interest.  The following sections described exposure assessment in 
more detail. 
 
3.6.1. Selection of main exposures to be examined 
 
THM and HAA species examined in this study are listed below in table 15.  The 
association between aggregate DBP measures (TTHM, HAA5, and TOX) and pregnancy 
outcomes (SGA, term birth weight, and duration of gestation) were assessed using traditional 
maximum likelihood estimation (MLE) methods. These THM and HAA aggregate measures 
were chosen because they represent DBP measures currently regulated, and TOX provides a 
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crude measure of overall DBP exposure.  The association between fetal growth outcomes and 
individual THMs and HAAs were examined simultaneously using a Bayesian approach.   
 
Table 15. THM and HAA species to be considered in analyses 
Maximum Likelihood Estimation Bayesian Analyses 
Chloroform   CAA BCAA BAA 
BDCM          DCAA BDCAA DBAA 
DBCM          TCAA DBCAA TBAA 
TTHM 
HAA5 
TOX 
 Bromoform      
Abbreviations: TTHM=total trihalomethanes, BDCM=bromodichloromethane, DBCM= dibromochloromethane, HAA5= sum of five 
regulated haloacetic acids, CAA= chloroacetic acid, DCAA= dichloroacetic acid, TCAA= trichloroacetic acid, BCAA = 
bromochloroacetic acid, BDCAA = bromodichloroacetic acid, DBCAA = dibromochloroacetic acid, BAA= bromoacetic acid, DBAA= 
dibromoacetic acid, TBAA = tribromoacetic acid, and TOX = total organic halide 
 
 
3.6.2 Calculation of window-specific residential DBP concentrations 
 
The most relevant time period for a potential adverse effect of DBPs on pregnancy 
health is unclear.  Possible exposure windows for restricted fetal growth analysis include the 
first, second and third trimester and the entire period of pregnancy.  Third trimester exposure 
(exposure during the latter part of pregnancy) was initially examined given that window-
specific averages are highly correlated and examining third trimester exposure would 
preserve comparability with several recent studies that only reported results for third 
trimester exposure.  However, after further considerations, first and second trimester average 
exposures were examined as an ancillary analysis for manuscript #2. 
Weekly exposure and average exposure over a 6-week running period (both allowing 
exposure to change) were examined in duration of gestation analyses as well as second 
trimester average exposure (exposure fixed).  Use of weekly exposure allowed examination 
of the effect of concurrent exposure on timing of delivery. Conversely, the 6-week running 
average exposure (i.e., average level over the current week and 5 proceeding weeks of 
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pregnancy) and second-trimester average exposure allowed examination of a more delayed 
effect of DBP exposure on duration of gestation.  The last 6-week running average exposure 
also was used assessment of the impact of average DBP exposure near the end of pregnancy 
but avoid bias that could be introduced by examining third trimester or total pregnancy 
exposure 108.  
The mean DBP concentration of all weekly measurements covered by each time 
window of interest was used to estimate window-specific residential DBP concentrations.  
Weekly DBP measurements below the PQL (i.e., below 0.1 µg/liter for THMs and 1.0 or 2.0 
µg/liter for HAAs) were set to zero.  Exposure windows were defined by gestational weeks 
relative to LMP: third trimester = 27 weeks’ gestation until birth, and second trimester = 13 
to 26 weeks’ gestation.  Window-specific residential DBP concentrations were then used to 
estimate window-specific personal DBP exposure as described below. 
 
3.6.3 Calculation of personal DBP exposure 
 
Information on individual water use was collected during the baseline interview and 
follow-up interview as part of the RFTS study and was integrated with residential DBP 
concentrations to estimate personal DBP exposure.  The estimation of integrated personal 
DBP exposure from residential DBP concentrations and self-reported water exposure was 
implemented in three main steps: 1) adjustment of residential THM and HAA concentrations 
for water treatment, 2) estimation of the amount of HAAs ingested daily, 3) estimation of the 
amount of THMs inhaled/absorbed through the skin daily.  Of note, only exposure through 
ingestion were considered for HAAs (steps 1 and 2), as exposure to HAAs primarily occurs 
through intake of tap water and tap-water-based beverages 17.  Conversely, only step 3 was 
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considered for THMs, as exposure to parent THM compounds primarily occurs through 
inhalation and dermal absorption.  Steps 1 through 3 are explained in detail below. 
 
Step 1- adjusting THM and HAA residential concentrations for heating and filtration  
Two main water treatment activities that can alter DBP concentrations in tap water 
before ingestion were considered: thermal treatment (e.g., heating water in the microwave or 
a kettle) and point of use filtration (e.g., filtering water using a home filtration system or 
filtration pitcher).  As part of the RFTS study, a series of experiments was conducted to 
calculate correction factors to adjust residential DBP levels if a woman reported boiling 
and/or filtering her water 26.  Thermal correction factors for individual THM and HAA 
species in chlorinated and chloraminated water are also available from a study by Krasner 
and Wright 109.  These correction factors were applied to residential DBP concentrations to 
estimate the amount of DBPs ingested under eight different combinations of heating 
(cold/hot) and filtration (no filtration/faucet filtration/pitcher filtration/filtration of unknown 
type).  A table of conversions factors by treatment and DBP exposure can be found in 
appendix 2.     
 
Step 2- estimate amount of HAA exposure due to ingestion 
Women were asked about their typical tap water consumption in detail during 
baseline and follow-up interviews.  Briefly, information was collected at baseline on the 
number of glasses of tap water (or tap water-based drinks) typically consumed per day, the 
usual size of glasses, whether frequency of consumption had changed over the past 4 months, 
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and if so, how many glasses were previously consumed per day and when consumption 
changed.  All women were asked these questions separately for cold and hot tap water 
consumption.  These questions were also asked separately for home and work if a woman 
reported working at a location outside of the study site.  In addition, information was 
collected on the frequency and type of water filtration system a woman used to treat water 
before consumption.  At follow-up interview, women were again asked about the typical 
number and size of glasses of cold and hot tap water they consumed per day at work and 
home.  Please see appendix 3 and 4 for the complete sequence of questions asked at baseline 
and follow-up interview, respectively. 
To estimate the average daily amount of DBPs ingested (ounces per day), adjusted 
DBP concentrations estimated in step 1 were combined with interview information to 
estimate the amount of DBP ingested under each of the eight different water treatment 
scenarios.  The following assumptions were made: 
• The volume of cold/hot water contained in small, medium and large glasses/cups was 
equal to the mid-range of ounces given to describe size categories during interview. 
• Self-reports of filtering “all or nearly all”, “most”, “some”, “very little” and “none” of 
water corresponded to filtering 100%, 75%, 40%, 20% and 0%, respectively, of all 
cold and hot water that was ingested. 
Treatment-specific values were then summed to derive daily ingested amounts in units of 
“micrograms/day”.  If a woman reports a change in tap-water ingestion over the period of 
pregnancy, a time-weighted average was calculated for all periods during which a change 
was reported to have occurred.  For changes reported between baseline and follow-up 
interview, that change was assumed to have occurred halfway through the period between 
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interviews.  If no change was reported, this value was simply the reported average daily 
amount.  Also, bottled water was assumed to have no DBP content and did not contribute to 
the estimated amount of DBPs ingested, which is supported by a small study conducted by 
RFTS researchers that found most brands of bottled water contain little to no DBP 
contaminants 26.   
 
Step 3- estimate amount of THM exposure due to showering and bathing 
To quantify exposure through absorption and inhalation from showering and bathing, 
data on residential THM levels was integrated with self-reported information on the average 
duration and frequency of showering and bathing using an uptake factor that links duration 
and water concentration into an absorbed dose.  Information on the frequency and length of 
time typically spent showering and bathing was collected at baseline and follow-up interview 
and was converted to the average minutes per day engaged in each.  Uptake factors of 
0.001538 micrograms and 0.001321 micrograms of THMs in blood per minute per 
microgram were used for showering and bathing, respectively.  These uptake factor values 
were obtained from previous studies that measured blood THMs in relation to known 
duration of bathing and showering in water of known THM concentration 26,110.   
Of note, inhalation and absorption of THMs also occurs through swimming, washing 
dishes and clothes, bathing children, and other activities such as washing hands and flushing 
the toilet.  Furthermore, the amount of THM exposure via inhalation is influenced by home 
ventilation.  However, incorporating all of these DBP sources into exposure assessment is not 
feasible, as exposure pathways are very complex and toxicokinetic studies of exposure routes 
are either non-existent or do not provide results that can be easily incorporated into exposure 
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assessment.  Therefore, only showering and bathing were considered in estimating exposure 
through inhalation and dermal absorption.    
 
3.7 Covariate assessment  
Covariate information is available from RFTS telephone interviews, medical record 
abstraction and vital record matching.  Potential confounders were defined as moderate to 
strong risk factors for restricted fetal growth and/or preterm birth according to the literature 
that may also be associated with DBP exposure (e.g., demographic variables that vary in 
distribution by study site or are potentially associated with water exposure) but are not 
thought to be on the causal pathway between exposure and outcome.  Covariates are listed 
below in table 16 along with coding schemes used in analyses.  In addition to confounder 
assessment, maternal age, race/ethnicity and swimming during pregnancy (yes/no) were 
assessed as potential effect measure modifiers in both the fetal growth and gestational age 
analyses.  Of note, most coding schemes outlined in table 16 were previously implemented in 
preliminary analyses conducted for the RFTS end-of-grant report 26 and used in this study to 
preserve uniformity across publications.  The appropriateness of coding schemes was 
confirmed in univariate analyses.    
Several studies have shown that the proportion of births delivered preterm is higher 
during late summer and fall compared to spring months 65-67.  Likewise, DBP concentrations 
are generally higher during warm seasons compared to colder seasons 12.  Seasonal variation 
in preterm birth could in part reflect seasonal variation in DBP concentrations assuming a 
casual association.  On the other hand, an erroneous association between DBP exposure and 
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preterm birth may arise due to parallel temporal variability in the prevalence of preterm birth 
and DBP concentrations, making adjustment for season of conception necessary.   
 
Table 16. Covariates to be considered as potential confounders in analyses. 
Covariate description Coding  
Maternal Age  
(range: 18 to 45) 
Categorical variables grouped into 5 year increments 
(<25, 25-30, 30-35 or >=35) and/or a continuous 
variable using quadratic term 
Race/ethnicity 
 
Categorical variable (white non-Hispanic, black non-
Hispanic, Hispanic or other) 
Marital status Dichotomous variable (unmarried or married) 
Highest attained education level Categorical variable (high school only, high school plus 
some college or college degree +)  
Annual Household Income 
(range:≤ $5,000/year to >$ 80,000/year) 
Categorical variable (cut points will be chosen based 
upon distribution among study subjects)  
Employment Dichotomous variable (unemployed or employed) 
Body mass index (BMI) Categorical variable (underweight, normal weight, 
overweight, obese) 
Smoking during pregnancy Dichotomous variable (non-smoker, <10 cigarettes per 
day or ≥10 cigarettes per day) 
Alcohol use during pregnancy Dichotomous variable (yes/no) 
Caffeine consumptiona Categorical variable (0, 1-150, 151-300, or >300 
mg/day) 
Number of previous live births (parity) Dichotomous variable (nulliparous/multiparous) 
Infant Sexb Dichotomous variable (male/female) 
a Only included in gestational age analyses (specific aim 2) 
b Only included in term birth weight analyses (specific aim 1) 
 
To assess whether adjustment for season in aim #2 analyses was needed, the ability of 
season of LMP or season of birth to predict the proportion of infants born preterm (i.e., 
before 37 weeks’ completed gestation) was tested.  Season was coded into four groups: 
winter (January, February and March), spring (April, May and June), summer (July, August 
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and September) and fall (October, November December), and entered into the model using 
indicator variable coding.  For both season of LMP and season of birth, none of the 
individual indicator terms for season were statistically significant at an alpha level = 0.05 nor 
were Wald Chi-square tests significant for an overall seasonal effect.  Accordingly, it was 
decided not to control for season in duration of gestation analyses. 
Because study sites were selected based upon having distinct distributions of DBP 
concentrations in the water, any risk factor for adverse pregnancy outcome that varies in 
distribution between sites may confound the association between DBP exposure and that 
outcome.  These risk factors may extend beyond what can be adequately controlled for by the 
list of covariates above in table 16.  Furthermore, THM and HAA levels may serve as 
markers for other unmeasured, toxic DBPs rather than increasing risk themselves.  The 
occurrence of unmeasured DBPs relative to measured DBPs likely varies by site.  Therefore, 
residual confounding and/or effect modification by study site is of significant concern.  To 
address this issue, site-specific analyses were run to examine the extent to which results vary 
by study site.  Women from the low DBP site have a small range of low exposure levels, 
making analyses restricted to these women of less interest.  Relatively few women were 
recruited from the brominated DBP site (total number live births = 320, number of SGA 
infants = 28, number of preterm infants = 48), so effect estimates estimated from an analyses 
restricted to these women would be highly imprecise. Therefore, two sets of MLE analyses 
were conducted: one using all women and one restricted to women from the chlorinated DBP 
site.       
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3.8 Data analysis 
3.8.1 Univariate analysis 
  
The univariate distribution of all variables included in analyses was examined, 
including variables involved in constructing outcome measures, exposure variables and 
covariates of interest.  For categorical variables, the frequency and percent of observations at 
each level of the covariate was calculated, including missing values.  For continuous 
variables, descriptive statistics (e.g., mean, median, standard deviation and percentile values) 
were calculated and the frequency and percent of observations with missing values was 
assessed.   
Out-of-range values that are known to be impossible were set to missing.  In 
particular, gestational age and birth weight values were examined individually and jointly to 
check for implausible values.  A gestational age at birth outside the range of 20 to 45 weeks 
or birth weight outside the range of 125 to 6,000 grams was considered implausible and 
resulted in exclusion of that observation.  In addition, an “expert opinion” rule developed by 
Alexander et al. (1996) was employed to identify and exclude live births with implausible 
values of birth weight for gestational age 111.  While several rules are available, this particular 
rule was chosen because it is the least conservative with respect to excluding live births too 
small for gestational age (i.e., least likely to exclude questionable infants with low birth 
weights given their gestational age) and is relatively simple to implement 112.  Constructed 
variables (e.g., SGA status, first trimester personal TTHM exposure) were created after data 
cleaning was complete.  Exposure variables and covariates that did not exhibit sufficient 
variability to support multivariate analysis (i.e., maternal alcohol use and smoking) were 
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dropped from subsequent modeling.  Participants missing information on the outcome, 
exposure or important covariates were also excluded from those specific analyses.         
 
3.8.2 Bivariate analysis 
  
Pairwise associations between outcomes, exposures and covariates of interest were 
examined prior to regression modeling.  The following bivariate analyses were conducted: 
• Cross-tabulations of SGA status with quantiles of exposure (collapsed over and 
stratified by covariate categories). 
• Cross-tabulations of SGA status with covariates. 
• Calculation of descriptive statistics for term birth weight and gestational age at 
delivery (i.e., mean, median, and standard deviation) by exposure quantiles (collapsed 
over and stratified by covariate categories).  
• Calculation of descriptive statistics for term birth weight and gestational age at 
delivery by covariate categories. 
• Cross-tabulations of exposure quantiles with covariate categories and calculation of 
descriptive statistics for exposure by covariate levels. 
In addition, correlation coefficients between residential concentrations of different DBP 
species, exposure metric estimates (residential versus personal) and exposure window 
estimates were examined.  Graphical techniques such as side-by-side histograms and scatter 
plots were employed when warranted to get a visual impression of pairwise associations.   
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3.8.3 Analytic plan for specific aim #1: 
 
Traditional MLE analyses 
 
To estimate the effect of drinking water DBP exposure during pregnancy on restricted 
fetal growth, logistic regression was used to estimate the effect of exposure to specific DBP 
measures during pregnancy on the probability of delivering an SGA infant.  Linear regression 
was used to estimate the difference in mean term birth weight (in grams) associated with 
exposure to DBP measures during pregnancy.  As outlined in section 3.6, aggregate DBP 
measures (TTHM, HAA5, and TOX) were examined in MLE analyses.  Two exposure 
metrics (residential DBP concentrations and personal DBP exposure) and three exposure 
windows (1st trimester, 2nd trimester, 3rd trimester) were considered for each DBP measure.   
 Multiple coding schemes for DBP exposures could be employed given that DBP 
exposures will be estimated on a continuous scale.  Exposure could be coded categorically 
using quantiles of exposure (the conventional coding scheme) or coded continuously using 
flexible splines.  While categorizing exposure produces more easily interpretable results and 
facilitates comparison with previous studies, splines can give a better idea of the dose-
response relationship between DBP exposure and fetal growth.  Therefore, residential DBP 
concentrations were initially coded continuously using restricted quadratic splines with knots 
at quantile values.  Model estimates were then used to plot the predicted outcome response 
(i.e., probability of delivering a small-for-gestational-age [SGA] infant, mean birth weight or 
probability of delivery by pregnancy intervals) by residential DBP concentration to get a 
visual impression of the dose-response relationship.  Since spline-based dose-response plots 
did not strongly oppose coding residential DBP concentrations into quantiles (i.e., the plots 
do not show substantial change in predicted risk within quantile categories), models using 
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quantile categories of exposure, with the low exposure site used as the referent, were run to 
produce more easily interpretable results and facilitate comparison with previous studies.  
The amount of error introduced into exposure assessment while estimating personal 
DBP exposure is unknown, and it is unclear how much confidence should be given to the 
exact numeric value estimated for personal exposure.  Nonetheless, the author felt confident 
that proposed algorithm for estimating personal DBP exposure would roughly sort women 
into those with relatively “high”, “intermediate” or “low” exposure.  Therefore, the 
association between personal DBP exposure estimates and adverse pregnancy outcomes were 
examined using quantile coding only.   
For SGA models, the number of quantile levels (two or three) that exposures at the 
moderate exposure sites were chosen so that approximately 20 cases were in each index 
exposure category.  Quartiles were used in term birth weight models.  In addition, residential 
TTHM levels were examined at the current maximum contaminant limit (MCL) (i.e., 
residential TTHMs ≥ 80 vs. < 80 micrograms/liter).  The MCL for HAA5 could not be 
assessed because too few RFTS participants were exposed to levels ≥ 60 micrograms/liter. 
 
Bayesian analyses 
As expected, individual THM and HAA levels were highly correlated in this study.  
Modeling each exposure in a separate risk model could lead to spurious associations due to 
confounding by other correlated DBPs, so a single model that controls for all individual 
THMs and HAAs is desirable.  However, adjustment for multiple DBP exposures using 
standard MLE may fail to provide plausible estimates given that exposures are highly 
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correlated 113.   Alternatively, Bayesian analytic techniques allow simultaneous modeling of 
highly correlated exposures in a single model.  In addition, prior distributions can be 
specified to “borrow” information across sets of individual DBPs that may have a common 
underlying biologic mechanism (e.g., HAAs or brominated DBP compounds)113.   
    A fully Bayesian analysis was conducted to examine the association between fetal 
growth measures and third trimester average residential concentrations of individual THMs 
and HAAs.  Logistic and linear regression models were constructed for SGA and term birth 
weight, respectively, and DBP concentrations were entered into the model using quantile 
categories.  DBP exposures were coded categorically as described above for MLE analyses.  
In addition, like the conventional MLE analyses, generalized linear models were constructed 
for SGA (link=logit) and term birth weight (link=identity).  
The generalized structure of the model can be written as follows: 
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Here, the response of subject i  ( iy ; i = 1 to n, where n is the number of study 
subjects) is conditional on her DBP exposure values ( ijx ) and the effect of DBP exposures 
( jβ ; j =1 to p, where p is the number of DBP exposures).  The prior distribution for jβ  is 
specified as a normal distribution with prior mean = ∑
=
p
l
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covariates representing substantive information that may in part explain the effect of the DBP 
exposure j  (e.g., DBP class, number of brominated halogens) and corresponding coefficients 
which may have their own specified prior distribution = lθ  ~ ),( 2llN ωμ 113.  The variance of 
the normal distribution prior for jβ is specified as 2jφ . In a fully-Bayesian approach, which 
was used herein, a prior distribution is also placed on 2jφ . Recently, Bayesian statisticians 
have turned away from using an inverse gamma distribution as a non-informative prior for 2jφ  
(or on the precision parameter τ = 1 / 2jφ ), and instead, place priors on the standard deviation 
of jβ  , represented by jφ .  
For this study, two scenarios were considered for the specification of the prior mean: 
1) no effect of DBP exposures (i.e., μj=0 for all j) and 2) the effect of an individual DBP 
compound is a function of DBP class and bromination status (i.e., μj= μk, where μk ~N(0,10) 
and represents the mean of the combined effect of DBP class and bromination status).  This 
latter prior specification of the mean results in shrinkage of the effect for non-brominated 
THMs (i.e., chloroform), non-brominated HAAs, brominated THMs, and brominated HAAs 
towards each other, to the extent that the data support a similar effect within groups, and 
allows “borrowing” of information within groups.  For prior specification of the variance of 
effects of DBP exposures, R was set at 0.70 for the SGA analysis (mean value of φ = 0.35) 
and 100 (mean value of φ = 50) for the term birth weight analysis.  In a semi-Bayesian 
approach with fixed R, these mean values would corresponds to a 95% range in risk ratios 
(RR) for SGA of 0.5 to 2.0 and 95% range in mean difference in birth weight of -100 to 100 
grams, respectively.   
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Marchov Chain Monte Carlo (MCMC) was implemented to obtain posterior 
distributions, including the mean effect for each DBP category and an associated 95% 
posterior interval (PI), which can be interpreted as an interval that has a high probability 
(95%) of containing the unknown quantity of interest 114.  Three chains were simulated, with 
5,000 iterations run for each chain.  The first 2,500 iterations of each chain were discarded as 
“burn-in”, and the remaining iterations were thinned by keeping every 7th simulation drawn 
to avoid dependence of iterations from the same chain114, resulting in a total of 1,074 
simulations saved.   
For simplicity, the above model does not explicitly show adjustment for confounding 
variables but these variables were taken into consideration in Bayesian analyses. Three sets 
of Bayesian analyses were conducted: one using all women, one restricted to women from 
the chlorinated DBP site and one restricted to women from the brominated DBP site.  Unlike 
the MLE analyses, the Bayesian analyses could be restricted to the brominated DBP site and 
still provide reasonably stable results.    
  
Assessing effect measure modification 
Maternal age, race/ethnicity and swimming during pregnancy were evaluated as 
potential effect measure modifiers.  Maternal age and race/ethnicity were chosen because it 
seems biologically plausible that the effect of DBP exposure may vary by age of the mother 
and/or across race and ethnicity groups.  Modification by swimming during pregnancy is of 
interest as one might hypothesis that exposure to DBPs (particularly chlorinated THMs) 
while swimming in a chlorinated pool would far surpass exposure incurred through tap water 
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alone, making an observable effect of DBP exposure via tap-water exposure alone less likely 
among swimming mothers.   
The presence of odds ratio modification was assessed by both visual inspection and 
statistical testing.  Stratum-specific effect estimates for each potential effect measure 
modifier were calculated and graphed to get a visual impression of interaction. Statistical 
significance of modification was assessed by constructing DBP-covariate interaction terms 
and retaining the terms if the p- value for the joint effect of all terms was < 0.10.   The set of 
interaction terms for each potential effect modifier were assessed separately to avoid over-
specification of the model. 
 
Assessing confounding  
Covariates identified from the literature as potential confounders are listed in table 16 
(section 4.7).  Confounding was first examined using a backwards elimination approach 
starting with a full model that included all covariates and the DBP exposure of interest.  
Covariates that resulted in < 10 percent change in one or more of the estimates for DBP 
exposure were then dropped from the model until a final reduced model was obtained.  Very 
few covariates were retained in the model as “confounders” according to this method of 
confounder selection.  Nonetheless, full models were not notably less precise than the 
reduced models.  Given that impacts on precision were minimal but residual confounding by 
study site was a great concern, it was ultimately decided to adjust for all risk factors 
identified from the literature as risk factors for fetal growth restriction that may be 
independently associated with DBP exposure but not on the causal pathway between 
exposure and disease according to directed acyclic graph analysis115.  All variables in table 
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16 met this criterion except maternal alcohol use and smoking, which were infrequently 
reported across sites, and infant birth weight.  In addition, site-specific analyses were re-run 
to assess the potential for residual confounding by site.   
 
Power calculations for SGA analyses 
Table 17 presents results of preliminary power calculations conducted to determine 
the power of this study to detect odds ratios of varying magnitude for SGA.  A sample size of 
450 participants per DBP exposure quartile (or, a total of 900 women for each exposure 
contrast) was assumed for the comparison of women in an “exposed” quartile (e.g., ≥ 75th 
percentile) to women in the referent quartile (i.e., < 25th percentile).  Similarly, samples sizes 
of 600 and 360 were used for tertile and quintile contrasts, respectively.  For comparing 
women exposed to residential THM4 concentrations ≥ 80 versus < 80 micrograms/liter, it 
was assumed that approximately 260 women would be “exposed” and 1540 would be 
“unexposed”.  In all calculations, it was assumed the “unexposed” prevalence of SGA infant 
was 0.06, which was the prevalence of SGA infant found among all RFTS births in 
preliminary analyses.   
Table 17. Power calculations for SGA analysis a  
 Power (%) for contrast 
OR Quartiles Tertiles Quintiles 
TTHM MCL  
 (80 μg/liter) 
1.2 11 11 8 13 
1.4 29 30 20 33 
1.6 52 56 37 58 
1.8 75 78 56 78 
1.9 83 86 65 85 
2.0 90 92 73 90 
2.2 97 98 86 97 
a Alpha = 0.05, Prevalence of SGA infant among “unexposed” = 0.06  
b total sample size of 900 for contrast between an “exposed” quartile (2nd, 3rd, or 4th quartile) and the lower, “unexposed” 
quartile (1st quartile), 1200 for tertile contrast and 720 for quintile contrast. 
c total sample size of 1800 for contrast between THM4 ≥ 80 versus < 80 μg/liter 
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According to preliminary power calculations, there was adequate power (≥ 80%) to 
detect an OR ≥ 1.9 for all exposure contrasts of interest except when using quintiles.  The 
study was underpowered to detect ORs of ≤ 1.5, which is approximately the range of OR 
estimates reported by previous studies.  However, there were several issues to consider when 
interpreting these preliminary calculations: 
• An overall sample size of 1800 births was assumed in power calculations to account 
for the fact that some observations may be dropped due to incomplete information on 
outcome, exposure or covariates.  It was proposed that the final complete case sample 
size might actually be greater, which would improve power.  This was not the case. 
• Power calculations did not take into account adjustment for confounding or 
stratification by effect measure modifiers, which may influence power. 
• A constant probability of SGA infants was assumed across study sites to simplify 
calculations but probabilities in fact varied slightly between sites. 
• A stronger estimated effect of DBP exposure than that found in previous studies was 
expected (if causal) given the improvements in proposed exposure methods. 
• Power would be higher for modeling DBP exposure continuously. 
Post-hoc assessment of power via examination of estimated 95% confidence intervals 
(see chapter 4, section 4.1) indicate that power was less than ideal in this study but within the 
range predicted by preliminary power calculations.  As such, the inability to detect moderate 
effects of DBP exposure on the probability of delivering an SGA infant must be taken into 
account when interpreting results.  
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Power calculations for term birth weight analyses 
 
Table 18 presents preliminary power calculations for detecting a difference in mean 
term birth weight when comparing women with a DBP exposure in an upper quintiles of 
exposure (e.g., ≥ 80th percentile) to women with an exposure level in the lowest quintile 
(<20th percentile).  A sample size of 670 infants was used to calculate power for the quintile 
contrast.  This number was derived by multiplying the expected number of term infants in the 
study sample (n=1675) by the percentage of term infants expected to fall within the two 
exposure quintiles being compared (40%).  In addition, the standard deviation (SD) for DBP 
exposure category (coded 0 or 1) was set at 0.5 and root mean square error (RMSE) at 455 
for all calculations (derived from preliminary analyses).   
Table 18. Power calculations for difference in mean term birth weight a,b  
Absolute difference in mean birth weight Power(%) 
10 5 
25 10 
50 29 
80 62 
100 81 
150 98 
200 99 
a Alpha = 0.05, σ(x) = 0.5 and σ(y.x) =455 ; b total sample size fixed at 670 term infants for each exposure 
contrast, assuming 40% of subjects fall into “exposed” (2nd, 3rd, 4th or 5th quintile) or “unexposed” (1st 
quintile) category for comparison at hand. 
 
According to preliminary power calculations, there was adequate power (≥ 80%) to detect 
a mean difference in term birth weight of approximately 100 grams or greater.  However, the 
study was underpowered to detect differences of -1 to -70 grams, which is the range of 
differences found for residential TTHM exposure in previous studies.  It is also important to 
note that these power calculations did not take into account adjustment for confounding or 
stratification by effect measure modifiers.  Ultimately, Post-hoc assessment of power via 
examination of estimated 95% confidence intervals (see chapter 4, section 4.3) indicate that 
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power was less than ideal in this study but within the range predicted by preliminary power 
calculations.  As such, the inability to detect moderate effects of DBP exposure on the 
distribution of birth weight among term infants must be taken into account when interpreting 
results.  
  
3.8.4 Analytic plan for specific aim #2 
 
Discrete hazard regression with a logit link and time interactions was used to estimate 
the effect of DBP exposure during pregnancy on duration of gestation by modeling the effect 
of DBP exposure on the odds of delivery each week conditional on a woman not having 
delivered in a prior week 116.  This model is analogous to a partially unconstrained 
continuation log odds model because categorical time interactions between DBP exposure 
and pregnancy intervals of ≤ 32 weeks’, 32-36 weeks’, 37-40 weeks’, ≥ 41 weeks’  will be 
included in the model.  This model can be written as follows: 
logit(h(tij)) = zij'α+xij'βK 
 
 
In this model, h(tij) = Pr(Ti = j | Ti ≥ j, xij) is the probability that the week of pregnancy 
delivery for subject i (indicated by Ti) is equal to week j, given that subject i did not deliver 
in a week preceding week j.  The logit(h(tij)) is the log odds of that probability (i.e., a discrete 
hazard model using a logit link).  The vector xij represents a DBP concentration summary 
(e.g., vector of indicator variables for quantile categories of the DBP exposure of interest) for 
subject i at pregnancy week j.  The βk’s describe the association between DBP exposure and 
the log odds of delivery during pregnancy intervals k=1,2 3, and 4 (≤ 32 weeks, 32-36 weeks, 
37-40 weeks, and ≥ 41 weeks, respectively.  The vector product zij'α represents week-specific 
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intercepts, which will account for the varying baseline probability of delivery as pregnancy 
progresses, and the association between potential confounders of interest and the log odds of 
delivery.    
The partially unconstrained continuation log odds model has several advantages.  
First, it avoids having to dichotomize infants into preterm and term births (e.g., <37 weeks 
vs. ≥ 37 weeks).  Second, the model allows estimation of an odds ratio for the effect of 
exposure during each pregnancy interval (i.e., allows the effect of exposure to vary over the 
course of pregnancy).  As a result, an effect of exposure early in gestation, when there are 
fewer births, is not dominated by the effect of exposure at later weeks, when the number of 
births is greater.  Finally, this model facilitates easy incorporation of time-varying exposures.  
Gestational intervals ≤ 32 weeks, 32-36 weeks, 37-40 weeks and ≥ 41 weeks were chosen 
because these intervals represent meaningful groups (very preterm, moderately preterm, term 
and post-term births, respectively) and there are a reasonable number of births during each 
interval to support statistical analyses.         
 
Coding of DBP exposures and assessment of  effect modification and confounding  
As outlined in section 3.6, aggregate DBP measures examined in duration of gestation 
analyses were TTHM, HAA5 and TOX.  Two exposure metrics (residential DBP 
concentrations and personal DBP exposure) and three exposure “windows” (second 
trimester, weekly, and 6-week sliding average exposure) were considered for each DBP 
measure.  Coding of DBP exposures was identical to that outlined for specific aim 1.  
Assessment of effect measure modification and confounding was the same as that outlined 
for specific aim 1.      
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 Power calculations  
Table 19 presents preliminary power calculations for duration of gestation analyses.  
Because there is no computer software program available to calculate power for a discrete 
hazard analysis, the power to detect ORs of varying magnitude for each gestational interval 
(≤ 32 weeks, 32-36 weeks, 37-40 weeks and ≥ 41 weeks) was approximated using power 
calculation software for traditional time-to-event methods (specifically, a two group test of 
equal exponential survival with no dropouts).  These calculations assumed a constant 
exponential rate of birth over the period of follow-up, which is a reasonable assumption 
within the pregnancy intervals examined.  For the first pregnancy interval, a sample size of 
450 participants was assumed at the beginning of the interval in each DBP exposure quartile 
and a 2% probability of delivery among the “unexposed”.  For the second, third and last 
pregnancy interval, initial sample sizes of 440, 405 and 60 participants were assumed per 
DBP exposure quartile and interval-specific delivery probabilities of 8%, 85% and 100% 
among the unexposed.   
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Table 19. Power calculations for duration of gestation analysesa,b,c 
Pregnancy Interval 
≤ 32 weeks 33-36 weeks 37-40 weeks ≥ 41 weeks 
OR Power (%) OR Power (%) OR Power (%) OR Power (%) 
1.5 15 1.5 45 1.1 24 1.5 49 
2.0 40 1.8 79 1.2 67 1.8 81 
2.5 65 1.9 86 1.3 93 1.9 87 
3.0 82 2.0 91 1.4 99 2.0 92 
3.5 91 2.2 97 1.5 99 2.2 97 
a Alpha = 0.05. 
b Contrast between an “exposed” quartile (2nd, 3rd, or 4th quartile) and the  referent quartile (1st quartile), 
1200 for tertile contrast and 720 for quintile contrast. 
c Initial sample sizes per quartile for the first, second, third and last pregnancy interval were set at 450, 440, 
405 and 60 participants.  
 
 
According to preliminary power calculations, there was adequate power (≥ 80%) to 
detect an odds ratio for delivery of 1.3 or higher for the pregnancy interval 37-40 weeks, an 
odds ratio of 1.8 or higher for the pregnancy intervals 33-36 and ≥ 41 weeks, and an odds 
ratio of 3.0 or higher for the interval ≤ 32 weeks.  Of note, the initial sample sizes for 
subsequent pregnancy intervals were calculated under the simplifying assumption that an 
equal number of births would occur in each exposure category in the proceeding interval; 
however, this would not be the case if exposure influences the probability of delivery in the 
preceding interval.  Furthermore, these power calculations did not take into account 
adjustment for confounding or stratification by effect measure modifiers.  Post-hoc 
assessment of power via examination of estimated 95% confidence intervals (see chapter 4, 
section 5.1) indicate that power was better than predicted by preliminary power calculations.   
 
3.9 Software use 
 Data cleaning was conducted using SAS 8.2 (SAS Institute, Inc., Cary, NC) and Stata 
9.2 (Statcorp, College Station, TX).  Univariate, bivariate and MLE analyses were conducted 
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using Stata.  Bayesian analyses were conducted using R (R Development Core Team, 
Vienna, Austria)117 and WinBUGS 1.4.2 (2007 MRC Biostatistics Unit, Cambridge, UK)118.  
 
3.10 Required Approvals 
 The Public Health IRB at the University of North Carolina at Chapel Hill determined 
that this dissertation does not constitute human subjects research as defined under federal 
regulations, and therefore does not require IRB approval (Study #: 06-0082). 
CHAPTER 4: GENERAL RESULTS 
 
4.1 Study population characteristics 
Table 20 presents the distributions of maternal demographic and health behavior 
variables, pregnancy-related variables, and tap water exposure variables for women included 
in duration of gestation analyses (n=2,039).   General descriptive statistics were calculated 
among this group of women because they also serve as the base for women included in SGA 
and term birth weight analyses.  The description “women eligible for inclusion in live birth 
analyses” is used to refer to this group of women in subsequent text, tables and figures.   
A considerably higher number of women were missing data on annual household 
income (number missing = 82) and body mass index (BMI) (number missing = 51) compared 
to other covariates, but the percentage of missing data for all variables was still under 5%.  In 
addition, a number of women did not report information on swimming in a pool and/or 
Jacuzzi use at follow-up interview (n= 169).  For these women, pool or Jacuzzi use at follow-
up was assumed to be the same as that reported at baseline when creating the final indicator 
variable for pool or Jacuzzi use anytime during gestation (yes/no) shown below in table 20.  
Very few women (< 5%) reported alcohol use or smoking during pregnancy or reported 
“Other” maternal race/ethnicity (i.e., “Indian”, “Asian/Pacific islander”, or “Other”).    
 
 
 103
Table 20. Descriptive statistics describing the distribution of variables to be used in live birth 
analyses among women eligible for inclusion in live birth analyses, 2000-2004 (n=2,039) 
 Categorical coding Continuous coding 
    Percentile Values Range 
Variable N 
(n missing) % Mean SD 25% 50% 75% Min Max 
MATERNAL 
DEMOGRAPHICS          
Reported household 
Income ($/year)          
   <5,000 64 3.3 
  5,001-10,000 108 5.5 
  10,001-15,000 141 7.2 
  15,001-20,000 143 7.3 
  20,001-30,000 181 9.2 
  30,001-40,000 188 9.6 
  40,001-60,000 347 17.7 
  60,001-80,000 321 16.4 
  > 80,000 465 23.8 
NA 
  Missing (81)         
Annual Household 
Income Category 
($/year)  
        
  <30,000 637 32.5 
  30,001-60,000 535 27.3 
  60,001-80,000 321 16.4 
  >80,000 465 23.8 
NA 
  Missing (81)         
Body Mass Index 
(kg/m2)          
  < 19.8 232 11.7 
  19.8-25.9 1,016 51.1 
  26.0-29.9 333 16.8 
  > 29.9 407 20.5 
25.8 6.4 21.3 24.1 28.5 15.1 64.0 
  Missing (51)         
Caffeine intake 
(mg/day)          
   0 519 25.5 
   1-150 468 23.0 
  151-300 387 19.0 
  > 300 665 32.6 
301.1 429.9 0 153.8 396.1 0 4801.1 
Employment           
   Employed 608 29.8 
  Unemployed 1,430 70.2 NA 
  Missing (1)         
Maternal Age 
(years)          
  < 25 599 29.4 
  25-59 657 32.2 
  30-35 564 27.7 
  >= 35 219 10.7 
28.2 5.3 24.1 28.3 32.1 17.8 44.7 
Maternal alcohol 
use          
  Yes 2,007 98.4 
  No 32 1.6 NA 
Maternal education 
level          
  ≤ HS 573 28.1 
  Some college 440 21.6 
  4+ years college 1,025 50.3 
14.6 2.6 12.0 16.0 16.0 3.0 22.0 
  Missing (1)         
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Self-reported 
marital status          
  Single 588 28.9 
  Married 1,390 68.2 
  Separated 33 1.6 
  Divorced 26 1.3 
  Widowed 1 0.1 
NA 
  Missing (1)         
Maternal marital 
status          
  married 1,390 68.2 
  not married 648 31.8 NA 
  Missing (1)         
Maternal race          
  White 1,229 60.3 
  Black 614 30.1 
  Indian 5 0.3 
  Asian 43 2.1 
NA 
  Other 146 7.2        
  Missing (2)         
Hispanic ethnicity          
  Yes 1,853 90.9 
  No 185 9.1 NA 
  Missing (1)         
Maternal 
Race/ethnicity          
Non-Hispanic White 1,169 57.4 
Non-Hispanic Black 609 29.9 
   Hispanic 185 9.1 
   Other 73 3.6 
NA 
   Missing (3)         
Maternal Smoking          
  Smoker 1,940 95.1 
  Non-smoker 99 4.9 NA 
Study Site          
  Chlorinated 929 45.6 
  Brominated 349 17.1 
  Low 791 37.3 
NA 
PREGNANCY 
RELATED 
VARIABLES 
         
Self-reported LMP 2021 NA 11/21/02 NA    10/20/00 3/18/04 
  Missing (18)         
Certainty in LMP          
   very sure 1,368 68.6 
   pretty sure 398 20.0 
   somewhat sure 156 7.8 
   very uncertain 72 3.6 
NA 
   Missing (45)         
Estimated 
Gestational age at 
delivery 
         
LMP 2021 
(18) NA 274.1 15.4 269 276 283 152 315 
Ultrasound 1881 
(158) NA 273.5 13.7 269 276 281 155 307 
 LMP corrected by 
ultrasound 2039 NA 273.4 13.9 269 276 282 152 310 
          
Infant Birth 
Weight 2,039 NA 3380.4 589.4 3085.7 3400.0 3742.9 428.6 5228.6 
          
 105
Infant sex          
   female 994 49.0 
   male 1045 51.0 NA 
Number of 
previous live 
births (parity) 
         
   0 993 48.6 
   1 674 33.0 
   ≥ 2 375 18.4 
0.8 1.0 0 1 1 0 9 
VARIABLES 
RELATED TO 
PERSONAL DBP 
EXPOSURE 
(baseline) 
         
Reported 
swimming in pool 
or Jacuzzi 
currently at 
baseline 
         
  No 1402 68.8 
  Yes 637 31.2 NA 
Portion of water 
filtered at home          
  None 144 70.9 
  Some 26 1.3 
  half 69 3.4 
  most 93 4.6 
  all 406 19.9 
NA 
  missing (1)         
Portion of water 
filtered at work          
  None 1493 73.2 
  Some 234 11.5 
  half 153 7.5 
  most 65 3.2 
  all 94 4.6 
NA 
          
Consumption of 
cold tap water at 
home 
(ounces/day) 
2037 
(2) NA 43.7 39.8 13.4 35.3 64.0 0.0 336.0 
          
Consumption of 
hot tap water at 
home 
(ounces/day) 
2039 NA 3.8 8.7 0.0 0.0 3.6 0.0 91.0 
          
Total consumption 
of tap water at 
home 
(ounces/day) 
2037 
(2) NA 47.5 41.6 16.0 40.3 66.0 0.0 336.0 
          
Consumption of 
cold tap water at 
work (ounces/day) 
2038 
(1) NA 13.2 18.8 0.0 2.6 23.7 0.0 188.2 
          
Consumption of 
hot tap water at 
work (ounces/day) 
2038 
(1) NA 1.5 4.5 0.0 0.0 0.0 0.0 74.9 
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Total consumption 
of tap water at 
work (ounces/day) 
2037 
(2) NA 14.8 20.1 0.0 5.2 24.0 0.0 188.2 
          
Total consumption 
of cold tap water 
(ounces/day) 
2037 
(2) NA 57.0 48.4 16.0 48.0 80.0 0.0 336.0 
          
Total consumption 
of hot tap water 
(ounces/day) 
2038 
(1) NA 5.3 11.4 0.0 0.0 7.0 0.0 156.0 
          
Total tap water 
consumption 
(ounces/day) 
2036 
(1) NA 62.3 50.3 21.0 56.0 91.0 0.0 340.0 
          
          
Total time spent 
showering 
(minutes/day) at 
baseline 
2038 
(1) NA 16.7 15.7 10.0 15.0 20.0 0 270.0 
          
Total time spent 
bathing 
(minutes/day) at 
baseline 
2036 
(3) NA 5.8 15.4 0 0 5.7 0 270.0 
          
Total time spent 
showering 
(minutes/day) at 
follow-up 
2039 NA 14.2 13.5 8.0 10.0 17.1 0 180.0 
          
Total time spent 
bathing 
(minutes/week) at 
follow-up 
2038 
(1) NA 5.2 14.0 0 0 4.3 0 190.0 
          
Abbreviations: DOB= date of birth, HS = high  school, LMP= last menstrual period, NA= not applicable 
 
 
  
Table 21 presents the distributions of study population characteristics (i.e., final 
“cleaned” variables used in regression models as confounders and/ or effect measure 
modifiers) by study site.  Women from the brominated disinfection by-product (DBP) site 
were more likely to be Hispanic, overweight, and parous, less likely to be employed during 
pregnancy or married, and tended to be younger, less educated, and have a lower income than 
women from the chlorinated and low DBP sites.  Although women from the chlorinated and 
low DBP sites were much more similar, women from the chlorinated site were still slightly 
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older, more educated, had higher income and were more likely to be non-Hispanic White 
than those from the low DBP site.  In addition, women at the chlorinated site were more 
likely to report swimming in a pool or Jacuzzi during pregnancy than women from the 
brominated or low sites.  The distribution of daily caffeine intake was similar across sites.      
   
Table 21. Participant characteristics by site among women eligible for inclusion in live 
birth analyses, 2000-2004 
Chlorinated DBP site 
(n=929) 
Brominated DBP site 
(n=349) 
Low DBP site 
(n=761) 
Covariate N Col % N Col % N Col % 
Maternal Age (years)       
< 25 195 21.0 168 48.1 236 31.0 
25-29 294 31.7 114 32.7 249 32.7 
30-35 321 34.6 47 13.5 196 25.8 
≥ 35 119 12.8 20 5.7 80 10.5 
Maternal Race/ethnicity       
Non-Hispanic White 623 67.1 125 35.9 421.0 55.5 
Non-Hispanic Black 234 25.2 78 22.4 297.0 39.1 
Hispanic 29 3.1 138 39.7 18 2.4 
Other 43 4.6 7 2.0 23 3.0 
Missing 0  1  2  
Highest education level 
obtained       
High school or less 157 16.9 186 53.3 230 30.3 
Some college 172 18.5 95 27.2 173 22.8 
College degree or more 600 64.6 68 19.5 357 47.0 
Missing 0  0  1  
Annual household income ($)       
<30,000 200 22.3 200 60.2 237 32.5 
30,001-60,000 263 29.4 73 22.0 199 27.3 
60,001-80,000 162 18.1 31 9.3 128 17.5 
>80,000 271 30.3 28 8.4 166 22.7 
Missing 33  17  31  
Employed during pregnancy       
Non-employed 262 28.2 131 37.5 215 28.3 
Employed 667 71.8 218 62.5 545 71.7 
Missing 0  0  1  
Marital status       
Married 696 74.9 185 53.2 509 66.9 
Not married 233 25.1 163 46.8 252 33.1 
Missing 0  1  0  
Pre-pregnancy BMI (kg/m2)       
<19.8 122 13.4 27 8.3 83 11.1 
19.8-25.9 500 54.7 151 46.3 365 48.8 
26.0-29.9 139 15.2 59 18.1 135 18.1 
>29.9 153 16.7 89 27.3 165 22.1 
Missing 15  23  13  
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Daily caffeine intake (mg/day)       
0 256 27.6 81 23.2 182 23.9 
1-150 198 21.3 79 22.6 191 25.1 
151-300 154 16.6 76 21.8 157 20.6 
>300 321 34.6 113 32.4 231 30.4 
Parity       
Nulliparous 493 53.1 148 42.4 350 46.0 
Parous 436 46.9 201 57.6 411 54.0 
Pool or Jacuzzi use       
No 605 65.1 257 73.6 540 71.0 
Yes 324 34.9 92 26.4 221 29.0 
Abbreviations: BMI = body mass index, DBP= disinfection by-product 
 
 
4.2 Distributions of birth outcomes 
 Among all participants eligible for outcome-specific analyses, 5.8 % (113 out of 
1,854 included in SGA analyses) delivered an infant that was small-for-gestational-age 
(SGA) and 9.1% (185 of 2,039 included in preterm birth analyses) delivered preterm.  The 
mean birth weight among term births (n= 1854) was 3480.1 grams (standard deviation = 
470.4).   Table 22 presents the proportion of SGA infants, term mean birth weight, and 
proportion of preterm infants by study site and other maternal characteristics.   The 
proportion of SGA infants was higher at the brominated DBP site (8.2%) compared to the 
chlorinated and low DBP sites (4.8% and 5.9%, respectively).  Mean birth weight among 
term births was higher at the chlorinated site compared to the brominated and low DBP sites.   
The proportions of births born preterm also varied by site (6.1% at the chlorinated DBP site, 
12.6% at the brominated DBP site, and 11.0% at the low DBP site).  The breakdown of live 
birth outcomes by other maternal characteristics followed expected patterns of association.  
Crude associations between birth outcomes and DBP exposures are provided in section 4.4. 
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Table 22. Distribution of live birth outcomes by maternal characteristics among women 
eligible for inclusion in analyses of live birth outcomes, 2000-2004 
Women included in  
SGA analyses 
(n=1,958) 
Women included in term birth 
weight analyses 
(n=1,854) 
Women included in 
preterm birth analyses
(n=2,039) 
Covariate N % SGA N Mean birth weight N % preterm 
Study site       
Chlorinated DBP site 883 4.8 872 3530.5 929 6.1 
Brominated DBP site 340 8.2 305 3406.3 349 12.6 
Low DBP site 735 5.9 677 3448.3 761 11.0 
Maternal Age (years)       
< 25 579 7.4 534 3361.9 599 10.9 
25-29 631 5.7 603 3480.9 657 8.2 
30-35 543 4.1 523 3567.0 564 7.3 
≥ 35 205 5.9 194 3568.3 219 11.4 
Maternal Race/ethnicity       
Non-Hispanic White 1168 4.9 1082 3560.4 1169 7.4 
Non-Hispanic Black 605 7.4 533 3316.4 609 12.5 
Hispanic 185 5.9 169 3499.1 185 8.6 
Other 0 . 68 3444.7 73 6.8 
Highest education level 
obtained       
High school or less 561 8.9 500 3366.5 573 12.7 
Some college 423 5.4 398 3454.8 440 9.5 
College degree or more 973 4.1 955 3550.1 1025 6.8 
Annual household income ($)       
<30,000 610 6.9 561 3385.8 637 11.9 
30,001-60,000 511 6.7 497 3505.8 535 7.1 
60,001-80,000 310 4.8 303 3495.6 321 5.6 
>80,000 450 3.1 428 3593.0 465 8.0 
Employed during pregnancy       
Non-employed 580 6.6 551 3514.1 608 9.4 
Employed 1377 5.4 1303 3465.6 1430 8.9 
Marital status       
Married 1334 4.7 1290 3534.6 1390 7.2 
Not married 623 8.0 563 3353.5 648 13.1 
Pre-pregnancy BMI (kg/m2)       
<19.8 220 8.6 214 3362.9 232 7.8 
19.8-25.9 978 5.1 934 3487.9 1016 8.1 
26.0-29.9 317 5.7 311 3490.1 333 6.6 
>29.9 398 4.8 349 3539.1 407 14.3 
Daily caffeine intake (mg/day)       
0 496 4.4 472 3514.2 519 9.1 
1-150 453 5.1 430 3471.4 468 8.1 
151-300 371 5.9 346 3453.1 387 10.6 
>300 638 7.2 606 3475.0 665 8.9 
Parity       
Nulliparous 947 7.1 890 3429.0 991 10.2 
Parous 1011 4.5 964 3527.2 1048 8.0 
Pool or Jacuzzi use       
No 1339 5.5 1260 3467.1 1402 10.1 
Yes 619 6.3 594 3507.6 637 6.8 
Abbreviations: BMI = body mass index, DBP= disinfection by-product, SGA= small-for-gestational-age 
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4.3 Distributions of disinfection by-product exposures 
 
4.3.1 Residential DBP concentrations 
 
Table 23 presents the mean and standard deviation of second trimester average 
concentrations for aggregate and individual DBP measures by study site.  As expected, total 
trihalomethane (TTHM) concentrations were similar between the chlorinated and brominated 
DBP sites.  While concentrations of the sum of five haloacetic acids (HAA5) and total 
organic halides (TOX) were elevated at both of the moderate exposure sites, the chlorinated 
site had slightly higher concentrations of HAA5 and slightly lower concentrations of TOX 
compared to the brominated DBP site (table 2).  In addition, the brominated DBP site had 
much higher concentrations of the brominated DBP compounds and much lower 
concentrations of non-brominated compounds compared to the chlorinated DBP site, with the 
exception of bromodichloromethane (BDCM), chloroacetic acid (CAA), bromochloroacetic 
acid (BCAA) and bromodichloroacetic (BDCAA), which were found in relatively 
comparable concentrations between the two moderate exposure sites.  Over all, DBP 
concentrations at the low exposure site were much less than concentrations found at the two 
moderate exposure sites.  Means and standard deviations for DBP concentrations were 
essentially the same when restricted to births included in the SGA analyses alone and term 
births alone and when examining first and third trimester average DBP concentrations. 
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Table 23. Second trimester average residential DBP concentrationsa, b across study 
sites among women eligible for inclusion in live birth analyses, 2000-2004    
DBP (μg/liter) 
Chlorinated DBP site 
(n=929) 
Brominated DBP site 
(n=349) 
Low DBP site 
(n=761) 
Trihalomethanes    
Chloroform 46.7 (13.3) 13.7 (3.3) 0.2 (0.2) 
BDCM 15.1 (4.4) 21.1 (2.9) 1 (0.2) 
DBCM 4.4 (2.1) 23.1 (6.5) 1.4 (0.2) 
Bromoform 0.2 (0.2) 5.7 (3.9) 0.7 (0.1) 
TTHMc 66.4 (15.8) 63.6 (11.8) 3.3 (0.6) 
Haloacetic Acids    
CAA 2.8 (1.1) 1.7 (0.9) 0 (0.1) 
DCAA 18.7 (3.5) 7.1 (1.8) 0 (0) 
TCAA 13.6 (5) 5.3 (1.8) 0 (0.1) 
BCAA 4.6 (1.3) 8.9 (1.3) 0.8 (0.7) 
BDCAA 4.6 (1.4) 8.2 (0.7) 0 (0) 
DBCAA 1.2 (0.6) 5.6 (1.2) 0.4 (0.6) 
BAA 0.1 (0.1) 0.7 (0.5) 0 (0) 
DBAA 0.7 (0.5) 6.2 (2.6) 0 (0.1) 
TBAA 0.2 (0.3) 2.7 (0.9) 0.2 (0.4) 
HAA5d 35.9 (8.6) 21.1 (2.5) 0.08 (0.1) 
TOX 173.8 (16.3) 195.3 (16.7) 17.7 (2.0) 
a Mean (standard deviation) 
b Weekly DBP concentrations below the practical quantitation limit (PQL) were set to zero for 
calculation of second trimester average residential DBP concentrations 
Abbreviations: DBP= disinfection by-product, BDCM= bromodichloromethane, DBCM = 
dibromochloromethane, TTHM = total trihalomethane, CAA= chloroacetic acid, 
DCAA=dichloroacetic acid, TCAA=trichloroacetic acid, BCAA= bromochloroacetic acid, 
BDCAA= bromodichloroacetic acid, DBCAA= dibromochloroacetic acetic acid, BAA= 
bromoacetic acid, DBAA= dibromoacetic acid, TBAA= tribromoacetic acid, HAA5 = sum of five 
haloacetic acids, TOX= total organic halides. 
c TTHM is the sum of chloroform, BDCM, DBCM and bromoform 
d HAA5 is the sum of CAA, DCAA, TCAA, BAA, DBAA 
 
  Figures 5, 6 and 7 are plots of weekly TTHM, HAA5 and TOX concentrations, 
respectively, from gestational week 20 until birth (or until water sampling ended) for 30 
women randomly selected from the three study sites (10 women from each site).  As in table 
23, TTHM concentrations are comparable between the two moderate exposure sites, but 
HAA5 concentrations are lower at the brominated DBP site compared to the chlorinated site.  
Furthermore, TTHM and HAA5 concentrations appear to be less stable overtime at the 
brominated DBP, at least among this particular sample of women.  For each site, variability 
in aggregate DBP exposures between and within women overtime appears similar.            
 112
Figure 8. Weekly residential concentrations of total trihalomethane (TTHM) from gestational 
week 20 until birth among 30 women randomly selected from the group of women eligible 
for inclusion in live birth outcome analyses.  
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Figure 9. Weekly residential concentrations of the sum of five haloacetic acids (HAA5) from 
gestational week 20 until birth among 30 women randomly selected from the group of 
women eligible for inclusion in live birth outcome.   
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Figure 10. Weekly residential concentrations of total organic halide (TOX) from gestational 
week 20 until birth among 30 women randomly selected from the group of women eligible 
for inclusion in live birth outcome analyses.  
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4.3.2 Personal DBP exposure  
 
 Table 24 present the percentage of women falling within categories of personal 
TTHM, HAA5 and TOX exposure by trimester (first, second and third) and study site.  Cut-
points for exposure categorization were derived from second trimester average exposure 
estimates among all women eligible for live birth outcome analyses (i.e., combined over 
study sites).  Overall, personal TTHM exposure appeared to go down slightly over gestation 
where as personal exposure to HAA5 and TOX appeared to go up across study sites.  
Personal TTHM exposure distributions were similar at the chlorinated and brominated DBP 
sites, but the low exposure site remained the predominant “low exposure” referent TTHM 
group.  Conversely, there was much more overlap in HAA5 and TOX personal exposure 
Chlorinated DBP site 
Brominated DBP site 
Low DBP site
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distributions across study sites at the lower end of exposure ranges but few or no women 
from the low exposure site in the highest category of exposures.  This would suggest that 
residential and personal metrics for TTHM rank women more similarly than residential and 
personal metrics for HAA5 and TOX when examining the total population of women eligible 
for analyses.  None-the-less, the major factor influencing variability in personal DBP 
exposure across study sites continues to be residential DBP concentrations.      
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Table 3. Distribution of second trimester average personal TTHM, HAA5, and TOX 
exposure by study site among women eligible for inclusion in live birth analyses, 2000-2004 
 
Chlorinated DBP sitea 
(n=929) 
Brominated DBP siteb 
(n=349) 
Low DBP sitec 
(n=761) 
 Trimester (col. %) Trimester (col. %) Trimester (col. %) 
 First  Second Third First Second Third First  Second Third 
TTHM exposure through showering & 
bathing (μg absorbed /day)          
0.02-0.09 0.1 0.3 2.3 0 0 8.6 64.69 66.5 69.8 
0.1-0.8 19.8 22.5 23.4 15.9 14 10.4 35.05 33.2 30 
0.9-1.5 39.9 43.1 41.8 32 31 31.1 0.26 0.3 0.27 
1.6-27.1 40.2 34.1 32.4 52.2 55 50 0 0.0 0 
(Missing) (1) (1) (28) (2) (2) (11) (2) (2) (27) 
HAA5 exposure through tap-water 
consumption (μg consumed /day)          
0 10.78 5.9 8.56 32.7 20 28.6 58.84 63.1 84.1 
0.01-16.1 9.05 9.6 7.67 19.8 32 23.3 39.58 36.7 15.9 
16.2-54.4 38.9 38 36.56 35.8 34 35.7 1.19 0.1 0 
54.7-369.1 41.27 46 47.22 11.8 14 12.4 0.4 0.1 0 
(Missing) (1) (1) (29) (0) (0) (10) (3) (3) (27) 
TOX exposure through tap-water intake 
(μg/day)          
0-25.8 12.07 8.6 10.33 33 26 28.9 50.26 44.9 43.3 
25.9-75 9.59 9.8 7.78 10.3 11 6.5 44.2 49.7 48.8 
75.1-253.5 40.19 39 39.56 27.2 30 28.6 5.54 5.4 7.9 
253.6-1827 38.15 42 42.33 29.5 33 36 0 0.0 0 
(Missing) (1) (1) (29) (0) (0) (10) (3) (3) (27) 
Abbreviations: TTHM = trihalomethane, HAA5 = sum of five haloacetic acids, TOX = total organic halides 
a 1 woman from the chlorinated DBP site was missing data on showering and bathing needed to assign first and second 
trimester average TTHM personal exposure; 1 woman was missing data on tap water consumption needed to assign first, 
second and third trimester average HAA5 and TOX personal exposure; and an additional 28 women were missing 
residential DBP concentrations during third trimester needed to assign third trimester average TTHM, HAA5 and TOX 
personal exposure  
b 2 women from the brominated DBP site were missing data on showering and bathing needed to assign first and second 
trimester average TTHM personal exposure; one of those women was also missing data on showering and bathing needed to 
assign third trimester average TTHM personal exposure; and an additional 10 women were missing residential DBP 
concentrations during third trimester needed to assign third trimester average TTHM, HAA5 and TOX personal exposure  
c 2 women from the low DBP site were missing data on showering and bathing needed to assign first and second trimester 
average TTHM personal exposure; 3 women were missing data on tap water consumption needed to assign first and second 
trimester average HAA5 and TOX personal exposure; and an additional 27 women were missing residential DBP 
concentrations during third trimester needed to assign third trimester average TTHM, HAA5 and TOX personal exposure     
 
4.4 Results of fetal growth analyses  
Results of SGA and term birth weight analyses, addressing specific aim #1 of this 
dissertation, are summarized in tables below.  A brief description precedes each table or 
figure and any notable findings are highlighted.  For all analyses, results for the total study 
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population are presented first and then followed by the analogous results restricted to the 
chlorinated site alone. 
 
4.4.1 Associations between DBPs and SGA for all sites 
 
 Tables 24-26 present results from SGA models for TTHM, HAA5 and TOX, 
respectively, combined over study sites.  Models were run separately for each trimester and 
exposure metric (residential versus personal).  In addition, models were re-run restricting to 
infants born after 37 week’s gestation (“term SGA”).  Overall, estimated RRs comparing 
quartiles of moderate DBP exposure to the low exposure group did not suggest a consistent 
association with TTHM, HAA5, or TOX residential levels or personal exposure estimates for 
any trimester.  However, the estimated probability of delivering an SGA infant among 
women with an average third trimester residential TTHM concentration ≥ 80 
micrograms/liter was twice as high as the probability of delivering an SGA infant among 
women with an average concentration < 80 micrograms/liter (RR [95% confidence interval] 
= 2.0 [1.1, 3.6]).  Similar results were found when results were restricted to term births.  
Effect measure modification by maternal age, race/ethnicity or swimming during pregnancy 
was not found (p-values for the joint effect of interaction terms ranged from 0.3-0.9).   
Dose-response curves for the probability of delivering an SGA infant by third 
trimester average residential concentrations of TTHM, HAA5 and TOX also did not indicate 
any consistent pattern of associations (figures 7, 8, and 9, respectively).  Similar curves were 
found when linear spline, restricted quadratic spline and categorical coding of residential 
concentrations were used.    
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Table 24. Association between TTHM exposure and the probability of delivering an SGA infant among all women included in 
SGA analyses from all study sites, 2000-2004 
 SGA (n=1,958) Term SGA only (n=1,780) 
Residential TTHM 
Concentration (μg/liter) 
#  
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
#  
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
1st-trimester average         
2.2-4.6 43 692 1. 1. 31 623 1. 1. 
33.1-55 21 339 1.00 (0.60,1.65) 1.14 (0.67, 1.97) 15 305 0.99 (0.54,1.81) 1.20 (0.63, 2.26) 
55-66.3 16 256 1.01 (0.58,1.75) 1.19 (0.67, 2.12) 16 234 1.35 (0.75,2.42) 1.62 (0.88, 2.99) 
66.4-74.8 18 239 1.20 (0.70,2.04) 1.21 (0.67, 2.16) 16 225 1.40 (0.78,2.51) 1.49 (0.79, 2.79) 
74.9-108.8 15 319 0.77 (0.43,1.36) 0.82 (0.44, 1.52) 14 301 0.94 (0.51,1.74) 1.05 (0.54, 2.04) 
p for trend testc   0.8 0.9   0.6 0.3 
≥ 80 vs. <80d 9/104 202/1,643 0.72 (0.37,1.39) 0.65 (0.31,1.37) 9/83 195/1,493 0.84 (0.43, 1.64) 0.77 (0.36, 1.63) 
2nd-trimester average         
1.4-5.4 43 692 1. 1. 31 623 1. 1. 
24.7-54.8 17 290 0.95 (0.55,1.63) 1.01 (0.55, 1.84) 15 265 1.13 (0.62,2.06) 1.25 (0.64, 2.44) 
55.1-65.4 20 289 1.11 (0.66,1.85) 1.26 (0.74, 2.16) 16 264 1.21 (0.67,2.17) 1.35 (0.73, 2.49) 
66.6-74.6 15 289 0.84 (0.48,1.49) 0.82 (0.43, 1.55) 13 269 0.97 (0.52,1.83) 1.04 (0.52, 2.06) 
74.9-165 18 285 1.02 (0.60,1.73) 1.20 (0.69, 2.08) 17 267 1.26 (0.71,2.24) 1.61 (0.90, 2.90) 
p for trend testc   0.9 0.7   0.6 0.2 
≥ 80 vs. <80d 8/105 166/1,679 0.78 (0.39,1.58) 0.83 (0.40,1.73) 7/85 158/1,530 0.81 (0.38, 1.71) 0.98 (0.47, 2.06) 
3rd-trimester average         
2.1-5.3 41 667 1. 1. 30 602 1. 1. 
28.8-54.8 19 258 1.18 (0.70,2.00) 1.22 (0.69, 2.16) 19 245 1.52 (0.87,2.64) 1.61 (0.89, 2.93) 
55.1-66.3 15 330 0.75 (0.42,1.34) 0.80 (0.43, 1.50) 11 308 0.73 (0.37,1.43) 0.83 (0.41, 1.70) 
66.4-74.7 16 256 1.01 (0.58,1.78) 1.22 (0.68, 2.19) 13 233 1.11 (0.59,2.10) 1.46 (0.76, 2.78) 
75.1-133.2 18 274 1.06 (0.62,1.82) 1.28 (0.73, 2.26) 16 250 1.27 (0.70,2.29) 1.51 (0.81, 2.80) 
Missing 4 60   3 50   
p for trend testc   0.9 0.5   0.7 0.3 
≥ 80 vs. <80d 12/97 108/1,677 1.83 (1.03,3.24) 2.00 (1.09,3.61) 11/78 100/1,538 2.05 (1.13, 3.75) 2.09 (1.11, 3.94) 
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TTHM exposure through 
showering and bathing 
(μg/day)   
 
     
1st-trimester average         
0-0.09 25 446 1. 1. 16 404 1. 1. 
0.1-0.8 24 467 0.92 (0.53,1.59) 0.87 (0.49, 1.56) 21 426 1.23 (0.65,2.33) 1.23 (0.62, 2.42) 
0.9-1.5 26 438 1.06 (0.62,1.80) 1.00 (0.55, 1.79) 22 414 1.32 (0.71,2.49) 1.33 (0.68, 2.61) 
1.6-31.2 37 490 1.32 (0.81,2.16) 1.27 (0.75, 2.15) 32 440 1.78 (0.99,3.20) 1.83 (0.98, 3.41) 
Missing 1 4   1 4   
2nd-trimester average         
0.1-0.09 25 466 1. 1. 18 424 1. 1. 
0.1-0.8 29 460 1.16 (0.69,1.96) 1.10 (0.62, 1.92) 22 414 1.24 (0.67,2.28) 1.21 (0.63, 2.33) 
0.9-1.5 24 465 0.96 (0.56,1.66) 0.98 (0.55, 1.76) 22 439 1.17 (0.64,2.15) 1.17 (0.61, 2.22) 
1.6-27.1 34 450 1.38 (0.84,2.28) 1.35 (0.79, 2.32) 29 407 1.63 (0.92,2.90) 1.73 (0.95, 3.18) 
Missing 1 4   1 4   
3rd-trimester average         
0-0.09 30 511 1. 1. 20 458 1. 1. 
0.1-0.8 28 419 1.13 (0.69,1.86) 1.24 (0.71, 2.16) 24 384 1.41 (0.79,2.51) 1.57 (0.83, 2.97) 
0.9-1.5 18 444 0.70 (0.40,1.24) 0.99 (0.55, 1.80) 16 420 0.88 (0.46,1.67) 1.19 (0.61, 2.31) 
1.6-24.5 33 410 1.34 (0.83,2.17) 1.63 (0.98, 2.73) 29 375 1.72 (0.99,2.99) 2.03 (1.13, 3.67) 
Missing 4 61   3 51   
a Unadjusted model. 
b Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term); p-value rounded to 1 significant figure 
d # SGA and non-SGA presented as number ≥ 80 μg/liter over number < 80 μg/liter. 
Abbreviations: RR = risk ratio, CI= confidence interval  
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Table 25. Association between HAA5 exposure and the probability of delivering an SGA infant among all women included in 
SGA analyses from all study sites, 2000-2004 
 SGA (n=1,958) Term SGA only (n=1,780) 
Residential HAA5 
Concentration (μg/liter) 
# 
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
#  
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
1st-trimester average         
0-0.9 43 692 1. 1. 31 623 1. 1. 
17.9-22 17 267 1.02 (0.59,1.76) 1.23 (0.68, 2.21) 15 243 1.23 (0.67,2.23) 1.51 (0.79, 2.87) 
22.1-31.5 30 338 1.39 (0.89,2.18) 1.53 (0.94, 2.49) 25 305 1.60 (0.96,2.66) 1.94 (1.13, 3.34) 
31.6-40.4 11 272 0.66 (0.35,1.27) 0.80 (0.42, 1.55) 9 257 0.71 (0.34,1.48) 0.86 (0.41, 1.80) 
40.4-52.8 12 276 0.71 (0.38,1.33) 0.72 (0.36, 1.43) 12 260 0.93 (0.49,1.78) 0.98 (0.48, 2.00) 
p for trend testc   0.3 0.5   0.7 0.9 
2nd-trimester average         
0-1.5 43 692 1. 1. 31 623 1. 1. 
12.1-22 28 283 1.54 (0.97,2.43) 1.81 (1.09, 3.00) 23 251 1.77 (1.05,2.98) 2.21 (1.25, 3.91) 
22.1-31.5 14 289 0.79 (0.44,1.42) 0.86 (0.46, 1.63) 13 266 0.98 (0.52,1.85) 1.11 (0.56, 2.21) 
31.6-40.3 15 291 0.84 (0.47,1.49) 0.88 (0.48, 1.64) 13 275 0.95 (0.51,1.79) 1.13 (0.58, 2.20) 
40.7-62.2 13 290 0.73 (0.40,1.34) 0.88 (0.48, 1.62) 12 273 0.89 (0.46,1.70) 1.05 (0.54, 2.02) 
p for trend testc   0.2 0.6   0.6 0.9 
3rd-trimester average         
0-0.6 41 667 1. 1. 30 602 1. 1. 
16-21.8 30 366 1.31 (0.83,2.06) 1.35 (0.80, 2.25) 26 331 1.53 (0.92,2.55) 1.71 (0.97, 3.02) 
22.1-31.5 12 192 1.01 (0.54,1.90) 1.28 (0.67, 2.45) 11 179 1.22 (0.62,2.39) 1.60 (0.80, 3.22) 
31.6-40.3 12 234 0.84 (0.45,1.58) 0.94 (0.49, 1.82) 9 220 0.83 (0.40,1.72) 1.00 (0.48, 2.09) 
40.6-56.4 14 326 0.71 (0.39,1.29) 0.90 (0.49, 1.65) 13 306 0.86 (0.45,1.62) 1.08 (0.57, 2.06) 
Missing 4 60   3 50   
p for trend testc   0.2 0.8   0.6 0.8 
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HAA5 exposure through tap-
water intake (μg/day)   
 
     
1st-trimester average         
0 35 597 1. 1. 28 541 1. 1. 
0.01-16.1 31 408 1.28 (0.80,2.04) 1.53 (0.92, 2.53) 21 369 1.09 (0.63,1.90) 1.35 (0.75, 2.45) 
16.2-54.4 30 446 1.14 (0.71,1.83) 1.47 (0.88, 2.47) 27 409 1.26 (0.75,2.10) 1.76 (1.00, 3.08) 
54.7-369.1 17 390 0.75 (0.43,1.33) 0.94 (0.51, 1.70) 16 365 0.85 (0.47,1.56) 1.08 (0.57, 2.05) 
Missing 0 4   0 4   
2nd-trimester average         
0 43 538 1. 1. 34 486 1. 1. 
0.2-16.1 22 436 0.65 (0.39,1.07) 0.58 (0.33, 1.01) 15 391 0.57 (0.31,1.02) 0.54 (0.28, 1.05) 
16.1-54.7 30 427 0.89 (0.57,1.39) 0.99 (0.61, 1.60) 27 391 0.99 (0.61,1.61) 1.18 (0.70, 1.98) 
54.7-511.4 18 440 0.53 (0.31,0.91) 0.61 (0.35, 1.06) 16 416 0.57 (0.32,1.01) 0.70 (0.38, 1.26) 
Missing 0 4   0 4   
3rd-trimester average         
0 48 712 1. 1. 36 639 1. 1. 
0.2-16.1 16 240 0.99 (0.57,1.71) 1.10 (0.61, 1.99) 13 222 1.04 (0.56,1.92) 1.26 (0.66, 2.42) 
16.1-54.7 26 402 0.96 (0.61,1.53) 1.08 (0.65, 1.77) 25 370 1.19 (0.72,1.95) 1.41 (0.83, 2.39) 
54.7-511.4 19 430 0.67 (0.40,1.12) 0.82 (0.48, 1.40) 15 406 0.67 (0.37,1.21) 0.86 (0.47, 1.57) 
Missing 4 61   3 51   
a Unadjusted model. 
b Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term) ; p-value rounded to 1 significant figure 
Abbreviations: RR = risk ratio, CI= confidence interval  
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Table 26. Association between TOX exposure and the probability of delivering an SGA infant among all women included in 
SGA analyses from all study sites, 2000-2004 
 SGA (n=1,958) Term SGA only (n=1,780) 
Residential TOX 
Concentration (μg/liter) 
# 
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b # SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
1st-trimester average         
14.3-22.4 43 692 1. 1. 31 623 1. 1. 
136.7-169.6 18 338 0.86 (0.51,1.48) 0.97 (0.55, 1.72) 14 311 0.91 (0.49,1.68) 1.08 (0.57, 2.07) 
169.6-177.7 18 315 0.92 (0.54,1.58) 1.10 (0.63, 1.92) 15 285 1.05 (0.58,1.92) 1.24 (0.66, 2.33) 
177.7-192.6 18 261 1.10 (0.65,1.88) 1.12 (0.62, 2.00) 17 247 1.36 (0.77,2.41) 1.53 (0.83, 2.83) 
192.8-235.2 16 239 1.07 (0.62,1.87) 1.17 (0.64, 2.14) 15 222 1.34 (0.73,2.43) 1.54 (0.80, 2.94) 
p for trend testc   1.0 0.7   0.4 0.2 
2nd-trimester average         
9-28 43 692 1. 1. 31 623 1. 1. 
104-169 13 290 0.73 (0.40,1.34) 0.74 (0.38, 1.43) 12 272 0.89 (0.46,1.71) 0.90 (0.44, 1.83) 
170-177 23 286 1.27 (0.78,2.07) 1.52 (0.91, 2.55) 21 267 1.54 (0.90,2.63) 1.87 (1.06, 3.31) 
178-192 13 293 0.73 (0.40,1.33) 0.77 (0.40, 1.49) 11 272 0.82 (0.42,1.61) 0.98 (0.48, 2.00) 
192.8-290 21 284 1.18 (0.71,1.95) 1.34 (0.78, 2.30) 17 254 1.32 (0.75,2.35) 1.62 (0.89, 2.98) 
p for trend testc   1.0 0.6   0.7 0.2 
3rd-trimester average         
10.9-25.5 41 667 1. 1. 30 602 1. 1. 
121.7-169.5 16 302 0.87 (0.50,1.52) 0.95 (0.52, 1.74) 15 287 1.05 (0.57,1.91) 1.17 (0.62, 2.23) 
170-177.5 16 250 1.04 (0.59,1.82) 1.28 (0.71, 2.31) 13 237 1.10 (0.58,2.07) 1.46 (0.76, 2.81) 
177.8-192.5 13 288 0.75 (0.41,1.37) 0.78 (0.40, 1.52) 11 265 0.84 (0.43,1.65) 0.95 (0.46, 1.93) 
192.7-250.2 23 278 1.32 (0.81,2.16) 1.49 (0.87, 2.53) 20 247 1.58 (0.91,2.73) 1.83 (1.02, 3.30) 
Missing 4 60   3 50   
p for trend testc   0.8 0.4   0.4 0.1 
 122
 
TOX exposure through tap-
water intake (μg/day)   
 
     
1st-trimester average         
0-25.8 44 541 1. 1. 33 490 1. 1. 
25.9-75 15 426 0.45 (0.26,0.80) 0.48 (0.26, 0.90) 10 387 0.40 (0.20,0.80) 0.44 (0.21, 0.93) 
75.1-252.9 27 466 0.73 (0.46,1.16) 0.95 (0.58, 1.56) 24 429 0.84 (0.50,1.40) 1.14 (0.66, 1.95) 
253.6-1302.9 27 408 0.83 (0.52,1.31) 0.93 (0.57, 1.52) 25 378 0.98 (0.59,1.63) 1.15 (0.67, 1.97) 
Missing 0 4   0 4   
2nd-trimester average         
0-25.8 34 456 1. 1. 26 412 1. 1. 
25.9-75 28 460 0.83 (0.51,1.34) 0.84 (0.50, 1.43) 21 414 0.81 (0.46,1.42) 0.92 (0.50, 1.70) 
75.1-253.5 26 462 0.77 (0.47,1.26) 0.90 (0.53, 1.53) 24 428 0.89 (0.52,1.53) 1.15 (0.64, 2.06) 
253.6-1827 25 463 0.74 (0.45,1.22) 0.84 (0.49, 1.43) 21 430 0.78 (0.45,1.37) 0.99 (0.54, 1.81) 
Missing 0 4   0 4   
3rd-trimester average         
0-25.8 33 453 1. 1. 25 410 1. 1. 
25.9-75 25 407 0.85 (0.52,1.41) 0.82 (0.48, 1.42) 18 372 0.80 (0.45,1.45) 0.87 (0.46, 1.65) 
75.1-253.6 27 464 0.81 (0.49,1.33) 0.91 (0.53, 1.54) 26 431 0.99 (0.58,1.69) 1.17 (0.66, 2.08) 
253.6-1827 24 460 0.73 (0.44,1.22) 0.83 (0.48, 1.41) 20 424 0.78 (0.44,1.39) 0.96 (0.52, 1.77) 
Missing 4 61   3 51   
a Unadjusted model. 
b Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term); p-value rounded to 1 significant figure. 
Abbreviations: RR = risk ratio, CI= confidence interval  
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Figure 11. Predicted risk of term SGA by average residential TTHM concentration during the third trimester of pregnancy among all 
women included in SGA analyses from all study sites, 2000-2004 
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Figure 12.  Predicted risk of term SGA by average residential HAA5 concentration during the third trimester of pregnancy among all 
women included in SGA analyses from all study sites, 2000-2004 
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Figure 13.  Predicted risk of term SGA by average residential TOX concentration during the third trimester of 
pregnancy among all women included in SGA analyses from all study sites, 2000-2004 
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4.4.2 Associations between DBPs and SGA at the chlorinated DBP site 
 
Tables 27-29 present results from SGA models for TTHM, HAA5 and TOX, 
respectively, restricted to the chlorinated DBP site. Again, models were run separately for 
each trimester and exposure metric (residential versus personal), and with and without 
restricting to infants born after 37 week’s gestation (“term SGA”).   Findings were similar to 
those found when examining all study sites combined, except for personal exposure to HAA5 
and TOX, which showed an inverse trend.  However, when residential concentrations of 
HAA5 were examined stratified by women who reported consuming ≥ 5 glasses of tap water 
per day (the median number of glasses of tap water consumed per day reported among all 
women) versus < 5 glasses per day, no modification of the effect of HAA5 residential 
concentrations was found.  It is possible that women who reported drinking greater amounts 
of bottled water and filtered water (and thus, have lower HAA5 and TOX personal exposure 
estimates) also tend to engage in other healthy behaviors and have better pregnancy 
outcomes.  If so, this could explain the inverse association found when examining personal 
exposure metrics for HAA5 and TOX.      
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Table 27. Association between TTHM exposure and the probability of delivering an SGA infant among women included in 
SGA analyses from the chlorinated DBP site, 2000-2004 
 SGA (n= 883) Term SGA (n=828) 
Residential TTHM 
Concentration (μg/liter) 
# 
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
#  
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
1st trimester average         
33.9-60.2 16 277 1. 1. 13 255 1. 1. 
60.3-73.7 13 251 0.90 (0.44,1.84) 0.90 (0.42, 1.93) 11 235 0.92 (0.42,2.02) 1.05 (0.46, 2.38) 
74-111.3 13 313 0.73 (0.36,1.49) 0.65 (0.30, 1.42) 13 301 0.85 (0.40,1.81) 0.82 (0.36, 1.86) 
p-value for trendc    0.4 0.2   0.6 0.5 
≥ 80 vs. <80d 6/36 174/667 0.65 (0.28, 1.52) 0.58 (0.23, 1.45)   0.72 (0.30, 1.69) 0.64 (0.25, 1.62) 
2nd trimester average         
33.1-60.2 14 282 1. 1. 12 263 1. 1. 
60.4-73.9 16 281 1.14 (0.57,2.29) 1.26 (0.60, 2.63) 14 267 1.14 (0.54,2.42) 1.26 (0.56, 2.81) 
74-108.8 12 278 0.87 (0.41,1.86) 0.94 (0.42, 2.06) 11 261 0.93 (0.42,2.06) 1.10 (0.48, 2.52) 
p-value for trendc 7/35 143/698 0.7 1.0   0.7 0.8 
≥ 80 vs. <80d   0.98 (0.44, 2.16) 0.97 (0.41, 2.28)   0.92 (0.39, 2.16) 1.11 (0.47, 2.60) 
3rd trimester average         
31.9-60.2 17 317 1. 1. 15 307 1. 1. 
60.3-73.7 10 273 0.69 (0.32,1.49) 0.72 (0.32, 1.61) 8 256 0.65 (0.28,1.51) 0.71 (0.30, 1.67) 
74-114.8 13 226 1.07 (0.53,2.16) 1.25 (0.60, 2.62) 12 207 1.18 (0.56,2.46) 1.32 (0.61, 2.86) 
Missing 2 25   2 21   
p-value for trendc 8/32 93/723 0.9 0.7   0.7 1.0 
≥ 80 vs. <80d   1.87 (0.89, 3.94) 1.91 (0.87, 4.16)   1.91 (0.86, 4.26) 1.76 (0.76, 4.08) 
 128
 
TTHM exposure through 
showering and bathing 
(μg/liter)         
1st trimester average         
0-0.9 8 235 1. 1. 8 225 1. 1. 
1-1.5 12 286 1.22 (0.51,2.94) 1.29 (0.51, 3.25) 9 271 0.94 (0.37,2.39) 1.07 (0.41, 2.80) 
1.6-31.2 22 319 1.96 (0.89,4.33) 1.86 (0.76, 4.56) 20 294 1.86 (0.83,4.14) 1.61 (0.65, 3.99) 
Missing 0 1   0 1   
 2nd trimester average         
0.1-0.9 9 286 1. 1. 8 272 1. 1. 
1-1.5 19 278 2.10 (0.96,4.56) 2.32 (0.97, 5.54) 17 265 2.11 (0.93,4.81) 1.87 (0.77, 4.55) 
1.6-27.1 14 276 1.58 (0.70,3.60) 1.69 (0.65, 4.39) 12 253 1.58 (0.66,3.82) 1.33 (0.50, 3.58) 
Missing 0 1   0 1   
3rd trimester average         
0-0.9 14 306 1. 1. 13 293 1. 1. 
1-1.5 8 257 0.69 (0.29,1.62) 0.78 (0.33, 1.88) 6 241 0.57 (0.22,1.48) 0.55 (0.21, 1.45) 
1.6-16.1 18 253 1.52 (0.77,3.00) 1.74 (0.83, 3.65) 16 236 1.49 (0.73,3.05) 1.41 (0.66, 3.01) 
Missing 2 25   2 21   
a Unadjusted model. 
b Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term); p-value rounded to 1 significant figure. 
d # SGA and non-SGA presented as number ≥ 80 μg/liter over number < 80 μg/liter. 
Abbreviations: RR = risk ratio, CI= confidence interval  
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Table 28. Association between HAA5 exposure and the probability of delivering an SGA infant among women included in 
SGA analyses from the chlorinated DBP site, 2000-2004 
 SGA (n= 883) Term SGA (n=828) 
Residential HAA5 
Concentration (μg/liter) 
# 
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
#  
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
1st trimester average         
17.5-32.4 21 311 1. 1. 18 292 1. 1. 
32.5-40.7 10 268 0.57 (0.27,1.19) 0.57 (0.26, 1.24) 8 253 0.53 (0.23,1.19) 0.51 (0.21, 1.21) 
40.8-53.2 11 262 0.64 (0.31,1.30) 0.64 (0.31, 1.35) 11 246 0.74 (0.35,1.53) 0.74 (0.35, 1.57) 
p-value for trendc   0.3 0.3   0.5 0.6 
 2nd trimester average         
18.7-32.4 16 276 1. 1. 13 259 1. 1. 
32.5-40.7 13 286 0.79 (0.39,1.62) 0.71 (0.32, 1.54) 12 270 0.89 (0.41,1.92) 0.89 (0.39, 2.04) 
40.8-52.8 13 279 0.81 (0.40,1.66) 0.90 (0.43, 1.87) 12 262 0.92 (0.43,1.97) 1.06 (0.48, 2.35) 
p-value for trendc   0.4 0.6   0.5 0.8 
3rd trimester average         
17.6-32.4 14 267 1. 1. 13 253 1. 1. 
32.6-40.7 13 236 1.05 (0.50,2.19) 1.07 (0.49, 2.35) 10 222 0.88 (0.39,1.97) 0.92 (0.40, 2.13) 
40.8-53.9 13 313 0.80 (0.38,1.67) 0.91 (0.42, 1.97) 12 295 0.80 (0.37,1.72) 0.91 (0.41, 2.02) 
Missing 2 25   2 21   
p-value for trendc   0.3 0.6   0.3 0.7 
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HAA5 exposure through 
tap-water intake (μg/liter)         
1st trimester average         
0-35.2 17 323 1. 1. 14 299 1. 1. 
35.5-69.2 16 259 1.16 (0.60,2.26) 1.19 (0.59, 2.42) 14 248 1.19 (0.58,2.46) 1.17 (0.55, 2.50) 
69.8-349.5 9 258 0.67 (0.31,1.49) 0.64 (0.27, 1.51) 9 243 0.80 (0.35,1.81) 0.75 (0.31, 1.81) 
Missing 0 1   0 1   
2nd trimester average         
0-35.2 21 270 1. 1. 19 251 1. 1. 
35.4-69.7 12 282 0.57 (0.28,1.13) 0.46 (0.22, 0.96) 10 267 0.51 (0.24,1.08) 0.37 (0.17, 0.81) 
69.8-369.1 9 288 0.42 (0.20,0.90) 0.35 (0.16, 0.77) 8 272 0.41 (0.18,0.91) 0.33 (0.14, 0.74) 
Missing 0 1   0 1   
3rd trimester         
0-35.2 19 267 1. 1. 17 250 1. 1. 
35.6-69.5 10 255 0.57 (0.27,1.20) 0.59 (0.27, 1.28) 9 241 0.57 (0.26,1.24) 0.53 (0.24, 1.19) 
69.8-418.4 11 293 0.54 (0.26,1.12) 0.52 (0.24, 1.10) 9 278 0.49 (0.22,1.09) 0.45 (0.20, 1.03) 
Missing 2 26   2 22   
a Unadjusted model. 
b Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term); p-value rounded to 1 significant figure. 
Abbreviations: RR = risk ratio, CI= confidence interval  
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Table 29. Association between TOX exposure and the probability of delivering an SGA infant among women included in 
SGA analyses from the chlorinated DBP site, 2000-2004 
 SGA (n= 883) Term SGA (n=828) 
Residential TOX 
Concentration (μg/liter) 
# 
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
#  
SGA 
# 
Non-SGA 
Unadjusted 
RR (95% CI)a 
Adjusted 
RR (95% CI)b 
1st trimester average         
136.8-169.2 17 307 1. 1. 13 284 1. 1. 
169.4-178.3 14 266 0.95 (0.48,1.90) 1.07 (0.53, 2.18) 13 246 1.15 (0.54,2.43) 1.26 (0.59, 2.70) 
178.6-223 11 268 0.75 (0.36,1.58) 0.65 (0.29, 1.46) 11 261 0.92 (0.42,2.03) 0.78 (0.33, 1.82) 
p-value for trendc     0.7 0.5   1.0 0.9 
2nd trimester average         
136.7-169.1 13 280 1. 1. 12 262 1. 1. 
169.4-178.3 17 281 1.29 (0.64,2.60) 1.41 (0.66, 3.01) 15 265 1.22 (0.58,2.57) 1.32 (0.59, 2.96) 
178.5-220.5 12 280 0.93 (0.43,2.00) 1.01 (0.45, 2.30) 10 264 0.83 (0.37,1.90) 1.02 (0.44, 2.39) 
p-value for trendc     0.4 0.5   0.5 0.8 
3rd trimester average         
134.1-169.2 15 295 1. 1. 14 281 1. 1. 
169.4-178.3 14 237 1.15 (0.57,2.34) 1.24 (0.59, 2.62) 11 226 0.98 (0.45,2.11) 1.10 (0.50, 2.42) 
178.5-224.8 11 284 0.77 (0.36,1.65) 0.87 (0.40, 1.89) 10 263 0.77 (0.35,1.71) 0.83 (0.37, 1.88) 
Missing 2 25   2 21   
p-value for trendc   0.2 0.6   0.2 0.5 
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TOX exposure through tap-
water intake (μg/liter)         
1st trimester average         
0-143.8 19 322 1. 1. 16 299 1. 1. 
145.1-304.6 9 269 0.58 (0.27,1.26) 0.64 (0.29, 1.45) 8 255 0.60 (0.26,1.38) 0.63 (0.27, 1.50) 
307-1349.6 14 249 0.96 (0.49,1.87) 0.87 (0.42, 1.78) 13 236 1.03 (0.50,2.10) 0.89 (0.41, 1.91) 
Missing 0 1   0 1   
2nd trimester average         
0-143.9 20 270 1. 1. 18 250 1. 1. 
144.6-306.6 11 287 0.54 (0.26,1.10) 0.46 (0.22, 1.00) 10 272 0.53 (0.25,1.12) 0.41 (0.19, 0.91) 
307-1225.5 11 283 0.54 (0.26,1.11) 0.48 (0.23, 1.02) 9 268 0.48 (0.22,1.06) 0.42 (0.18, 0.94) 
Missing 0 1   0 1   
3rd trimester         
0-144.3 18 259 1. 1. 16 243 1. 1. 
144.7-306.2 12 270 0.65 (0.32,1.33) 0.58 (0.27, 1.22) 10 256 0.61 (0.28,1.32) 0.46 (0.21, 1.03) 
308.2-1370.8 10 286 0.52 (0.24,1.11) 0.45 (0.20, 0.98) 9 270 0.52 (0.23,1.16) 0.42 (0.19, 0.97) 
Missing 2 26   2 22   
a Unadjusted model. 
b Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term); p-value rounded to 1 significant figure. 
Abbreviations: RR = risk ratio, CI= confidence interval  
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4.4.3 Association between DBPs and term birth weight for all study sites 
 
  Tables 30-31 present results from term birth weight models for TTHM, HAA5 and 
TOX, respectively, combined over study sites.  Models were run separately for each trimester 
and exposure metric (residential versus personal).  Estimated changes in mean birth weight 
among term births associated with moderate DBP exposure compared to the low exposure 
group did not suggest a consistent association with TTHM, HAA5, or TOX residential levels 
or personal exposure estimates for any trimester.  The estimated decrease in term birth 
weight associated with an average third trimester residential TTHM concentration ≥ 80 
versus < 80 micrograms/liter (mean difference in grams = -55.5 [-143.7, 31.9]) was 
consistent but less pronounced than the association found for SGA.  Effect measure 
modification by maternal age, race/ethnicity or swimming during pregnancy was not found 
(p-values for the joint effect of interaction terms ranged from 0.1-0.9).  Dose-response curves 
for mean term birth weight by third trimester average residential concentrations of TTHM, 
HAA5 and TOX also did not indicate any consistent pattern of associations (figures 10, 11, 
and 12, respectively).   
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Table 30. Association between TTHM exposure and mean term birth weight among women 
included in term birth weight analyses, 2000-2004 
 Term Birth Weight (grams) 
Residential TTHM Concentration 
(μg/liter) 
N 
(n= 1,854) 
Unadjusted 
Mean change (95% CI)a 
Adjusted 
Mean change (95% CI)b 
1st-trimester average    
2.2-4.6 677 0. 0. 
33.1-55 334 30.1 (-31.5,  91.66) -10.0 (-72.3, 52.3) 
55-66.3 258 66.2 (-1.1,  133.62) 34.4 (-32.7, 101.5) 
66.4-74.8 253 6.5 (-61.4,  74.32) -21.3 (-88.6, 46.0) 
74.9-108.8 332 90.8 (29.1,  152.51) 58.6 (-3.0, 120.1) 
p for trend testc  0.01 0.2 
≥ 80 vs. <80d 214/1640 45.0 (-22.0,  112.1) 36.1 (-30.4,  102.5) 
2nd-trimester average    
1.4-5.4 677 0. 0. 
24.7-54.8 295 63.8 (-0.5,  128.11) 31.2 (-33.2, 95.5) 
55.1-65.4 288 65.0 (0.1,  129.87) 31.2 (-33.3, 95.8) 
66.6-74.6 294 46.1 (-18.3,  110.45) 29.7 (-35.2, 94.6) 
74.9-165 300 26.1 (-37.8,  90.08) -22.4 (-85.7, 40.9) 
p for trend testc  0.08 0.8 
≥ 80 vs. <80d 175/1679 -4.2 (-77.5,  69.1) -35.6 (-107.1,  35.9) 
3rd-trimester average    
2.1-5.3 655 0. 0. 
28.8-54.8 281 19.6 (-45.7,  84.96) -7.1 (-72.3, 58.0) 
55.1-66.3 335 90.2 (28.7,  151.74) 52.2 (-9.7, 114.1) 
66.4-74.7 255 64.3 (-3.4,  131.97) 33.1 (-35.1, 101.3) 
75.1-133.2 275 34.9 (-31.0,  100.72) 3.8 (-62.8, 70.4) 
Missing 53   
p for trend testc  0.04 0.5 
≥ 80 vs. <80d 117/1684 -43.9 (-132.1,  44.4) -55.9 (-143.7,  31.9) 
TTHM exposure through showering 
& bathing (μg/day)    
1st-trimester average    
0-0.09 439 0. 0. 
0.1-0.8 458 -80.8 (-142.3,  -19.4) -26.0 (-87.3, 35.2) 
0.9-1.5 455 16.6 (-45.0,  78.1) -4.6 (-65.6, 56.4) 
1.6-31.2 497 -59.5 (-119.7,  0.8) -7.0 (-68.8, 54.9) 
Missing 5   
2nd-trimester average    
0-0.09 458 0. 0. 
0.1-0.8 453 -25.3 (-86.4,  35.8) 13.7 (-46.8, 74.2) 
0.9-1.5 480 20.2 (-40.0,  80.5) 3.2 (-56.0, 62.5) 
1.6-27.1 458 -35.7 (-96.6,  25.3) 8.1 (-54.4, 70.7) 
Missing 5   
3rd-trimester average    
0-0.09 497 0. 0. 
0.1-0.8 425 -45.7 (-106.6,  15.2) -38.8 (-99.1, 21.6) 
0.9-1.5 457 53.7 (-6.0,  113.4) 7.2 (-51.9, 66.3) 
1.6-24.5 421 -14.2 (-75.2,  46.8) 4.8 (-57.0, 66.7) 
Missing 54   
a Unadjusted model. 
b Model adjusted for maternal age,   race/ethnicity,   income,   education,   employment status,   marital status,   pre-pregnancy BMI,   parity 
and caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single,   continuous residential DBP concentration term (i.e.,   linear term), p-value rounded to 1 
significant figure. 
d Numbers for N are number in exposure group ≥ 80 / number in exposure group < 80 μg/liter  
Abbreviations: RR = risk ratio,   CI= confidence interval  
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Table 31. Association between HAA5 exposure and mean term birth weight among women 
included in term birth weight analyses, 2000-2004  
 Term Birth Weight (grams) 
Residential HAA5 Concentration 
(μg/liter) 
N 
(n= 1,854) 
Unadjusted 
Mean change (95% CI)a 
Adjusted 
Mean change (95% CI)b 
1st-trimester average    
0-0.9 677 0. 0. 
17.9-22 268 -1.4 (-67.7, 64.81) -26.9 (-96.1, 42.3) 
22.1-31.5 345 -9.0 (-69.7, 51.71) -57.5 (-118.7, 3.6) 
31.6-40.4 280 120.7 (55.4, 185.87) 78.6 (14.0, 143.2) 
40.4-52.8 284 100.8 (35.9, 165.66) 72.3 (8.0, 136.5) 
p for trend testc  <0.001 0.02 
2nd-trimester average    
0-1.5 677 0. 0. 
12.1-22 282 -3.2 (-68.4, 62.08) -31.5 (-100.9, 37.8) 
22.1-31.5 294 35.6 (-28.7, 99.88) 4.4 (-59.9, 68.6) 
31.6-40.3 300 74.0 (10.1, 137.83) 33.4 (-30.5, 97.3) 
40.7-62.2 301 90.2 (26.5, 154.01) 48.4 (-14.7, 111.6) 
p for trend testc  0.001 0.08 
3rd-trimester average    
0-0.6 655 0. 0. 
16-21.8 367 -9.1 (-68.6, 50.52) -36.9 (-99.5, 25.7) 
22.1-31.5 205 98.6 (25.3, 171.85) 68.0 (-5.5, 141.5) 
31.6-40.3 244 54.2 (-14.5, 122.78) 12.0 (-56.5, 80.5) 
40.6-56.4 330 95.8 (34.1, 157.54) 59.0 (-2.9, 120.9) 
Missing 53   
p for trend testc  0.001 0.08 
HAA5 through tap-water consumption 
(μg/liter)    
1st-trimester average    
0 594 0. 0. 
0.01-16.1 402 -7.4 (-66.7, 52.0) -25.7 (-84.5, 33.1) 
16.2-54.4 454 51.4 (-5.9, 108.7) -7.6 (-65.0, 49.9) 
54.7-369.1 400 105.2 (45.8, 164.7) 57.3 (-2.4, 117.0) 
Missing 4   
2nd-trimester average    
0 539 0. 0. 
0.2-16.1 422 -26.9 (-86.6, 32.8) -31.7 (-90.7, 27.4) 
16.1-54.7 437 38.8 (-20.3, 98.0) 10.2 (-48.7, 69.1) 
54.7-511.4 452 96.0 (37.4, 154.6) 52.9 (-5.9, 111.8) 
Missing 4   
3rd-trimester average    
0 701 0. 0. 
0.2-16.1 243 -21.6 (-90.0, 46.9) -34.9 (-103.2, 33.4) 
16.1-54.7 417 30.3 (-26.6, 87.1) 10.1 (-46.2, 66.5) 
54.7-511.4 439 96.4 (40.5, 152.4) 61.9 (5.5, 118.4) 
Missing 54   
a Unadjusted model 
b Model adjusted for maternal age,  race/ethnicity,  income,  education,  employment status,  marital status,  pre-pregnancy BMI,  parity and 
caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single,  continuous residential DBP concentration term (i.e.,  linear term), p-value rounded to 1 
significant figure. 
d Numbers for N are number in exposure group ≥ 80 / number in exposure group < 80 μg/liter  
Abbreviations: RR = risk ratio,  CI= confidence interval  
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Table 32. Association between TOX exposure and mean term birth weight among women 
included in term birth weight analyses, 2000-2004 (n= 1,854). 
 Term Birth Weight (grams) 
Residential TOX Concentration 
(μg/liter) 
N 
(n= 1,854)
Unadjusted 
Mean change (95% CI)a 
Adjusted 
Mean change (95% CI)b 
1st-trimester average    
14.3-22.4 677 0. 0. 
136.7-169.6 340 57.1 (-4.2, 118.38) 18.8 (-42.2, 79.7) 
169.6-177.7 315 78.7 (15.8, 141.53) 34.9 (-27.6, 97.5) 
177.7-192.6 278 22.7 (-43.0, 88.33) -14.0 (-79.7, 51.7) 
192.8-235.2 244 34.5 (-34.3, 103.33) 25.6 (-44.3, 95.4) 
p for trend testc  0.04 0.5 
2nd-trimester average    
9-28 677 0. 0. 
104-169 300 93.5 (29.6, 157.40) 69.8 (6.5, 133.1) 
170-177 300 36.5 (-27.5, 100.36) -11.9 (-75.5, 51.8) 
178-192 295 42.5 (-21.8, 106.81) 17.3 (-47.0, 81.7) 
192.8-290 282 26.2 (-39.1, 91.51) -15.2 (-82.2, 51.9) 
p for trend testc  0.07 0.7 
3rd-trimester average    
10.9-25.5 655 0. 0. 
121.7-169.5 322 101.7 (39.5, 163.99) 62.1 (-0.1, 124.4) 
170-177.5 259 31.1 (-36.1, 98.27) -19.9 (-87.1, 47.3) 
177.8-192.5 292 78.7 (14.3, 143.04) 64.1 (-0.1, 128.4) 
192.7-250.2 273 -7.5 (-73.5, 58.37) -39.9 (-108.6, 28.9) 
Missing 53   
p for trend testc  0.07 0.6 
TOX exposure through tap-water 
consumption (μg/liter)    
1st-trimester average    
0-25.8 543 0. 0. 
25.9-75 414 12.3 (-47.8, 72.3) 0.5 (-59.0, 60.1) 
75.1-252.9 470 65.9 (7.9, 123.8) 14.8 (-43.4, 73.0) 
253.6-1302.9 423 81.7 (22.0, 141.4) 39.7 (-20.3, 99.6) 
Missing 4   
2nd-trimester average    
0-25.8 454 0. 0. 
25.9-75 453 33.9 (-27.2, 95.1) 19.7 (-40.7, 80.2) 
75.1-253.5 471 72.5 (12.0, 133.0) 33.7 (-26.7, 94.2) 
253.6-1827 472 98.2 (37.7, 158.6) 63.8 (2.7, 124.8) 
Missing 4   
3rd-trimester average    
0-25.8 455 0. 0. 
25.9-75 405 42.1 (-20.8, 105.0) 24.9 (-37.4, 87.2) 
75.1-253.6 477 50.5 (-9.8, 110.9) 19.7 (-40.5, 79.8) 
253.6-1827 463 86.2 (25.4, 147.0) 53.7 (-7.9, 115.3) 
Missing 54   
a Unadjusted model. 
b Model adjusted for maternal age,  race/ethnicity,  income,  education,  employment status,  marital status,  pre-pregnancy BMI,  parity and 
caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single,  continuous residential DBP concentration term (i.e.,  linear term), p-value rounded to 1 
significant figure. 
d Numbers for N are number in exposure group ≥ 80 / number in exposure group < 80 μg/liter  
Abbreviations: RR = risk ratio,  CI= confidence interval  
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Figure 14. Estimated mean birth weight among terms by average third trimester residential 
TTHM concentration among women included in term birth weight analyses, 2000-2004 
32
00
33
00
34
00
35
00
36
00
A
ve
ra
ge
 b
irt
h 
w
ei
gh
t
0 50 100 150
Residential TTHM concentration (microgram/L)  
 
Model adjusted for and averaged over gestational age at birth, maternal age, race/ethnicity, household income, employment 
status, education level, marital status, pre-pregnancy BMI and caffeine intake.  Third trimester average TTHM exposure was 
coded using restricted quadratic splines and missing for 53 of 1,854 term births.  Dashed line represents the 95% pointwise 
confidence interval.  Abbreviations: TTHM = total trihalomethane.    
 
 
Figure 15. Estimated mean birth weight among terms by average third trimester residential 
HAA5 concentration among women included in term birth weight analyses, 2000-2004 
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Model adjusted for and averaged over gestational age at birth, maternal age, race/ethnicity, household income, employment 
status, education level, marital status, pre-pregnancy BMI and caffeine intake.  Third trimester average HAA5 exposure was 
coded using restricted quadratic splines and missing for 53 of 1,854 term births. Dashed line represents the 95% pointwise 
confidence interval.  Abbreviations: HAA5= sum of five haloacetic acids.    
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Figure 16. Estimated mean birth weight among terms by average third trimester residential 
TOX concentration among women included in term birth weight analyses, 2000-2004 
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Model adjusted for and averaged over gestational age at birth, maternal age, race/ethnicity, household income, employment 
status, education level, marital status, pre-pregnancy BMI and caffeine intake.  Third trimester average TOX exposure was 
coded using restricted quadratic splines and missing for 53 of 1,854 term births. Dashed line represents the 95% pointwise 
confidence interval.  Abbreviations: TOX = total organic halide.    
 
 
4.4.4. Association between DBPs and term birth weight at the chlorinated DBP site 
 
  Tables 33-34 present results from term birth weight models for TTHM, HAA5 and 
TOX, respectively, restricted to the chlorinated DBP site.  Models were run separately for 
each trimester and exposure metric (residential versus personal).  Estimated changes in mean 
birth weight among term births associated with moderate DBP exposure compared to the low 
exposure group did not suggest a consistent association with TTHM, HAA5, or TOX 
residential levels or personal exposure estimates for any trimester.  The estimated decrease in 
term birth weight associated with an average third trimester residential TTHM concentration 
≥ 80 versus < 80 micrograms/liter (mean difference in grams = -96.9 [-198.5, 4.6]) was more 
pronounced than when examining all study sites combined.   
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Table 33. Association between TTHM exposure and mean term birth weight among women 
included in term birth analyses from the chlorinated DBP site, 2000-2004 
 Term Birth Weight (grams) 
Residential TTHM Concentration 
(μg/liter) 
N 
(n= 872) 
Unadjusted 
Mean change (95% CI)a 
Adjusted 
Mean change (95% CI)b 
1st-trimester average    
33.8-57.4 211 0. 0. 
57.5-66.5 208 49.5 (-43.0, 141.9) 52.4 (-40.0, 144.7) 
66.5-77 223 1.1 (-89.8, 92.0) -6.3 (-97.2, 84.5) 
77-111.3 230 53.5 (-36.7, 143.8) 66.6 (-24.1, 157.2) 
p for trend testc  0.4 0.3 
≥ 80 vs. <80d 185/687 20.9 (-57.5, 99.3) 36.8 (-41.5, 115.1) 
2nd-trimester average    
33.1-57.1 218 0. 0. 
57.4-66.5 215 11.6 (-79.4, 102.6) 2.3 (-88.2, 92.9) 
66.6-76.8 215 5.1 (-85.9, 96.1) 13.1 (-78.1, 104.3) 
77-108.8 224 -44.4 (-134.5, 45.7) -62.4 (-151.6, 26.7) 
p for trend testc  0.5 0.2 
≥ 80 vs. <80d 153/719 -53.0 (-137.2, 31.2) -70.3 (-153.6, 13.1) 
3rd-trimester average    
31.8-57.4 239 0. 0. 
57.5-66.5 259 23.0 (-61.8, 107.7) 16.0 (-68.0, 99.9) 
66.6-77 201 15.5 (-74.9, 105.9) 2.0 (-87.5, 91.5) 
77-114.8 150 -23.4 (-121.8, 75.0) -9.1 (-108.7, 90.5) 
Missing 23   
p for trend testc  0.6 0.5 
≥ 80 vs. <80d 99/750 -88.3 (-189.1, 12.4) -96.9 (-198.5, 4.6) 
TTHM exposure through 
showering & bathing (μg/day)    
1st-trimester average    
0-0.09 194 0. 0. 
0.1-0.8 181 46.4 (-50.7, 143.4) 33.0 (-64.0, 130.1) 
0.9-1.5 246 -38.4 (-128.5, 51.8) -45.6 (-136.8, 45.5) 
1.6-31.2 250 -133.9 (-223.7, -44.1) -66.0 (-160.9, 28.8) 
Missing 1   
2nd-trimester average    
0.1-0.09 220 0. 0. 
0.1-0.8 219 -38.6 (-128.5, 51.4) -28.9 (-118.7, 60.8) 
0.9-1.5 220 -57.0 (-146.9, 32.8) -57.1 (-147.0, 32.8) 
1.6-27.1 212 -138.8 (-229.5, -48.1) -48.5 (-147.7, 50.7) 
Missing 1   
3rd-trimester average    
0-0.09 245 0. 0. 
0.1-0.8 220 4.1 (-83.5, 91.6) -10.6 (-97.9, 76.8) 
0.9-1.5 189 25.6 (-65.7, 116.8) 11.3 (-79.3, 101.8) 
1.6-24.5 195 -73.1 (-163.6, 17.3) -3.0 (-98.4, 92.3) 
Missing 23   
a Unadjusted model. 
b Model adjusted for maternal age,  race/ethnicity,  income,  education,  employment status,  marital status,  pre-pregnancy BMI,  parity and 
caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single,  continuous residential DBP concentration term (i.e.,  linear term), p-value rounded to 1 
significant figure. 
Abbreviations: RR = risk ratio,  CI= confidence interval  
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Table 34. Association between HAA5 exposure and mean term birth weight among women 
included in term birth analyses from the chlorinated DBP site, 2000-2004 
 Term Birth Weight (grams) 
Residential HAA5 Concentration 
(μg/liter) 
N 
(n= 872) 
Unadjusted 
Mean change (95% CI)a 
Adjusted 
Mean change (95% CI)b 
1st-trimester average    
17.5-29.7 243 0. 0. 
29.8-37.8 249 11.3 (-74.1, 96.6) 6.4 (-79.1, 91.9) 
37.9-42.2 162 43.2 (-52.8, 139.2) 35.6 (-59.4, 130.7) 
42.2-53.2 218 67.8 (-20.5, 156.1) 75.5 (-12.5, 163.6) 
p for trend testc  0.08 0.05 
2nd-trimester average    
18.7-29.7 215 0. 0. 
29.7-37.9 218 -10.9 (-101.9, 80.2) -1.7 (-92.5, 89.1) 
37.9-42.2 223 13.5 (-77.1, 104.0) 5.8 (-85.0, 96.6) 
42.2-52.8 216 10.9 (-80.4, 102.2) 0.7 (-90.0, 91.3) 
p for trend testc  0.6 0.7 
3rd-trimester average    
17.6-29.7 237 0. 0. 
29.8-37.9 181 -37.7 (-131.0, 55.5) -60.1 (-152.5, 32.4) 
37.9-42.2 172 -41.8 (-136.4, 52.8) -50.2 (-143.6, 43.2) 
42.2-53.9 259 -5.1 (-89.9, 79.8) -7.0 (-91.8, 77.7) 
Missing 23   
p for trend testc  0.9 0.8 
HAA5 through tap-water consumption 
(μg/liter)    
1st-trimester average    
0-0 261 0. 0. 
2.1-35.3 212 79.0 (-8.2, 166.2) 75.1 (-42.5, 192.6) 
35.4-69.3 211 98.1 (10.8, 185.5) 69.4 (-46.1, 184.9) 
69.7-349.6 187 95.6 (5.3, 186.0) 110.6 (-4.7, 225.9) 
Missing 1   
2nd-trimester average    
0-0 213 0. 0. 
0.1-35.3 219 68.7 (-22.2, 159.6) 40.5 (-109.9, 191.0) 
35.3-69.7 220 78.9 (-11.9, 169.7) 90.6 (-57.2, 238.3) 
69.7-369.1 219 85.8 (-5.1, 176.7) 120.8 (-27.6, 269.2) 
Missing 1   
3rd-trimester average    
0-0 224 0. 0. 
2.7-35.2 198 36.4 (-55.6, 128.3) 15.4 (-113.1, 143.9) 
35.5-69.5 189 54.1 (-39.0, 147.2) 54.5 (-71.5, 180.5) 
69.8-418.5 237 65.2 (-22.6, 153.1) 73.9 (-51.4, 199.2) 
Missing 24   
a Unadjusted model. 
b Model adjusted for maternal age,  race/ethnicity,  income,  education,  employment status,  marital status,  pre-pregnancy BMI,  parity and 
caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single,  continuous residential DBP concentration term (i.e.,  linear term), p-value rounded to 1 
significant figure. 
Abbreviations: RR = risk ratio,  CI= confidence interval  
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Table 35. Association between TOX exposure and mean term birth weight among women 
included in term birth analyses from the chlorinated DBP site, 2000-2004 
 Term Birth Weight (grams) 
Residential TOX Concentration 
(μg/liter) 
N 
(n= 872) 
Unadjusted 
Mean change (95% CI)a 
Adjusted 
Mean change (95% CI)b 
1st-trimester average    
136.7-165.6 224 0. 0. 
165.7-173.8 221 -61.3 (-151.0, 28.3) -57.5 (-147.1, 32.2) 
173.8-180.8 195 9.5 (-83.2, 102.2) -10.7 (-103.5, 82.0) 
180.9-223.1 232 9.2 (-79.4, 97.8) 21.2 (-67.7, 110.0) 
p for trend testc  0.3 0.2 
2nd-trimester average    
136.7-165.4 218 0. 0. 
165.7-173.8 213 15.0 (-76.3, 106.3) 9.0 (-82.2, 100.1) 
173.8-180.7 227 -16.4 (-106.3, 73.4) -16.0 (-105.2, 73.3) 
180.9-220.6 214 -4.3 (-95.5, 86.8) -21.0 (-111.5, 69.5) 
p for trend testc  0.9 0.8 
3rd-trimester average    
134.1-165.6 248 0. 0. 
165.7-173.8 174 -17.6 (-111.0, 75.8) -33.9 (-126.9, 59.0) 
173.9-180.9 211 -44.9 (-133.4, 43.5) -32.4 (-120.4, 55.7) 
180.9-224.8 216 0.2 (-87.7, 88.1) 8.5 (-79.6, 96.5) 
Missing 23   
p for trend testc  1.0 1.0 
TOX exposure through tap-water 
consumption (μg/liter)    
1st-trimester average    
0-108.5 268 0. 0. 
109.1-215.7 204 52.8 (-35.0, 140.7) 23.2 (-65.4, 111.9) 
216.2-369.7 209 33.0 (-54.3, 120.2) 27.9 (-60.2, 116.0) 
369.8-1349.7 190 71.5 (-18.2, 161.1) 71.6 (-19.4, 162.5) 
Missing 1   
2nd-trimester average    
0-108.3 216 0. 0. 
108.8-216.1 214 45.6 (-45.6, 136.8) 43.2 (-47.6, 134.0) 
216.2-369.7 221 37.2 (-53.3, 127.6) 42.1 (-49.3, 133.5) 
369.8-1225.5 220 71.8 (-18.8, 162.4) 91.7 (-1.5, 185.0) 
Missing 1   
3rd-trimester average    
0-108.5 216 0. 0. 
109-216 210 28.6 (-62.8, 120.0) 47.5 (-42.9, 137.9) 
217.3-369.4 203 7.4 (-84.8, 99.6) 15.1 (-77.8, 108.0) 
370.7-1370.8 219 52.9 (-37.5, 143.4) 88.2 (-4.0, 180.5) 
Missing 24   
a Unadjusted model. 
b Model adjusted for maternal age,  race/ethnicity,  income,  education,  employment status,  marital status,  pre-pregnancy BMI,  parity 
and caffeine intake. 
c Chi-square test (H0: βDBP = 0) for a single,  continuous residential DBP concentration term (i.e.,  linear term), p-value rounded to 1 
significant figure. 
Abbreviations: RR = risk ratio,  CI= confidence interval  
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4.4.5 Associations between individual DBPs and fetal growth measures 
 
Table 36 and 37 show estimated associations between individual trihalomethanes 
(THMs) and haloacetic acids (HAAs) with fetal growth outcomes (probability of SGA infant 
and term birth weight, respectively) among all study sites combined.  For each set of 
analyses, separate maximum likelihood estimation (MLE) models were created for each of 
the individual DBPs to serve as a reference when examining results from the fully adjusted 
Bayesian models.  Conversely, a single model including all individual THMs and HAAs 
were constructed for Bayesian analyses.  Results from both the Bayesian model specifying a 
vague prior mean and the model specifying shrinkage by DBP class and bromination 
categories are shown.  All models were adjusted for maternal characteristics. 
As previously discussed, distributions of the predominantly chlorinated (e.g., 
chloroform) and predominately brominated (e.g., bromoform) compounds overlapped very 
little (if at all) between the chlorinated and brominated DBP sites.   As such, comparisons of 
exposure categories for these individual DBPs are completely confounded by study site.  
Therefore, while several of the MLE estimates for the brominated THMs were elevated in 
analyses, it is unclear whether these associations truly reflect a relationship with brominated 
THMs or are simply an artifact of confounding by site.  Results of the Bayesian model 
specifying a vague prior mean did not implicate any particular DBP, and results of the 
Bayesian analyses with shrinkage by DBP class and bromination were contradictory to that 
found from MLE models.    
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Table 36. Associations between third trimester average exposure to residential 
concentrations of individual THMs and HAAs and the odds of delivering an SGA infant 
among women included in SGA analyses, 2000-2004a 
Bayesian Modelsc 
   MLE modelsb Model 1 Model 4 
DBP n SGA n Non-SGA OR (95% CI) OR (95% CI) OR (95% CI) 
Chloroform      
0-0.1 28 451 1 1 1 
0.1-16.5 33 442 1.4 (0.8,2.5) 1.1 (0.7,1.6) 1.6 (0.5,6.0) 
16.5-47.2 27 441 1.2 (0.6,2.1) 1.1 (0.7,1.8) 1.6 (0.4,7.4) 
>47.2 21 451 1.0 (0.5,1.8) 1.0 (0.7,1.6) 1.5 (0.4,6.7) 
BDCM      
0-1.1 28 448 1 1  
1.1-12.1 26 448 1.1 (0.6,2.1) 1.1 (0.8,1.8) 1.2 (0.6,2.2) 
12.1-17.8 18 448 0.8 (0.4,1.5) 1.0 (0.6,1.3) 1.1 (0.4,2.0) 
>17.8 37 441 1.8 (1.0,3.1) 1.1 (0.7,1.6) 1.3 (0.6,2.7) 
DBCM      
0-1.5 29 448 1 1  
1.5-3.2 22 453 1.0 (0.6,1.9) 1.1 (0.7,1.8) 1.2 (0.6,2.2) 
3.2-6.8 20 446 0.8 (0.4,1.6) 1.0 (0.6,1.5) 1.1 (0.4,1.8) 
>6.8 38 438 1.8 (1.0,3.1) 1.0 (0.7,1.6) 1.3 (0.5,2.7) 
Bromoform      
0-0.1 18 454 1 1  
0.1-0.6 31 436 1.9 (1.0,3.6) 1.2 (0.9,2.2) 1.5 (0.8,3.0) 
0.6-0.9 25 451 1.5 (0.8,2.9) 1.1 (0.7,1.6) 1.3 (0.7,2.7) 
>0.9 35 444 2.1 (1.1,4.1) 1.0 (0.7,1.5) 1.3 (0.6,2.7) 
CAA      
0 37 612 1 1  
>0-2.3 40 587 1.2 (0.7,2.1) 1.1 (0.7,1.8) 1.8 (0.8,4.1) 
>2.3 32 586 1.1 (0.6,1.9) 1.0 (0.7,1.8) 1.8 (0.7,4.1) 
DCAA      
0 41 667 1 1  
>0-17.5 39 557 1.1 (0.7,1.9) 0.9 (0.5,1.3) 1.2 (0.4,3.0) 
>17.5 29 561 1.1 (0.6,1.8) 1.1 (0.8,2.2) 2.0 (0.8,5.5) 
TCAA      
0 41 667 1 1  
>0-10.2 43 552 1.4 (0.8,2.3) 1.1 (0.8,2.0) 1.8 (0.8,5.0) 
>10.2 25 566 0.8 (0.5,1.5) 0.9 (0.5,1.2) 1.2 (0.4,3.0) 
BCAA      
0 41 667 1 1 1 
>0-5 24 567 0.8 (0.4,1.3) 1.0 (0.6,1.5) 0.6 (0.2,1.2) 
>5 44 551 1.5 (0.9,2.5) 1.1 (0.7,1.8) 0.7 (0.3,1.3) 
BDCAA      
0-1.3 33 443 1 1 1 
1.3-3.7 19 450 0.5 (0.3,1.0) 0.9 (0.5,1.2) 0.6 (0.3,1.0) 
3.7-6.2 19 453 0.7 (0.4,1.2) 1.0 (0.6,1.5) 0.6 (0.3,1.2) 
>6.2 38 439 1.4 (0.8,2.4) 1.1 (0.7,1.8) 0.8 (0.4,1.6) 
DBCAA      
0 37 439 1 1 1 
>0-1.4 26 679 0.5 (0.3,0.8) 0.8 (0.4,1.1) 0.5 (0.2,0.9) 
>1.4 46 667 0.9 (0.6,1.5) 1.0 (0.7,1.6) 0.7 (0.4,1.3) 
BAA      
0 67 1,297 1 1 1 
>0 42 488 1.7 (1.1,2.8) 1.1 (0.8,1.8) 0.8 (0.5,1.8) 
DBAA      
0 44 692 1 1 1 
>0-1 21 552 0.7 (0.4,1.2) 0.9 (0.6,1.2) 0.7 (0.3,1.1) 
>1 44 541 1.4 (0.9,2.4) 1.0 (0.7,1.6) 0.7 (0.3,1.5) 
TBAA      
0 53 815 1 1 1 
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>0-0.6 22 487 0.7 (0.4,1.3) 0.9 (0.5,1.2) 0.7 (0.4,1.1) 
>0.6 34 483 1.1 (0.6,1.8) 1.0 (0.6,1.3) 0.7 (0.4,1.1) 
a N= 1,894; seven births born before 27 weeks’ gestation and 57 births that were < 27 weeks’ in gestation when water sampling ended (64 
births total) are not included in third trimester average models 
b Maximum likelihood estimation models were constructed separately for each individual THM and HAA; all models were adjusted for 
maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake 
c Two fully-Bayesian models were constructed using different prior specifications for the effect of DBP exposures: model 1 specified 
βj~N(0,φ2), model 2 specified βj~N(μk,φk2) where k is an indictor for DBP class and bromination (non-brominated THM, non-brominated 
HAA, brominated TTHM, brominated HAA); models adjusted for all other DBPs listed in the table and maternal age, race/ethnicity, 
income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake   
Abbreviations: SGA, small-for-gestational-age, MLE = maximum likelihood estimation, OR= odds ratios, CI = confidence interval, DBP= 
disinfection by-product, BDCM= bromodichloromethane, DBCM = dichloromethane, CAA= chloroacetic acid, DCAA=dichloroacetic 
acid, TCAA=trichloroacetic acid, BCAA= bromochloroacetic acid, BDCAA= Bromochloroacetic acid, DBCAA= dibromochloroacetic 
acetic acid, BAA= bromoacetic acid, DBAA= dibromoacetic acid, TBAA= tribromoacetic acid 
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Table 37. Associations between third trimester average exposure to residential concentrations 
of individual THMs and HAAs and mean birth weight among term infants born to women 
included in the analysis of exposure to drinking water DBPs and term birth weight, 2000-
2004a 
Bayesian Modelsc 
  MLE modelsb Model 1 Model 2 
DBP n ∆ in grams  (95% CI) ∆ in grams  (95% CI) ∆ in grams  (95% CI) 
Chloroform     
0-0.1 438 0 0 0 
0.1-16.5 442 -64.8 (-127.5, -2.0) -13.0 (-54.0, 16.7) -25.4 (-91.0, 23.6) 
16.5-47.2 465 25.5 (-35.4, 86.5) 4.1 (-31.0, 38.1) 9.0 (-38.0, 83.5) 
>47.2 456 51.7 (-9.8, 113.1) 10.5 (-23.0, 55.0) 26.4 (-22.0, 111.4) 
BDCM     
0-1.1 437 0 0 0 
1.1-12.1 464 4.2 (-56.5, 64.9) -5.4 (-41.0, 23.3) -3.9 (-52.0, 24.7) 
12.1-17.8 461 41.0 (-20.6, 102.6) 2.9 (-36.0, 36.5) 0.6 (-39.0, 43.2) 
>17.8 439 -37.9 (-103.1, 27.3) 1.3 (-33.0, 51.3) 1.7 (-37.0, 61.3) 
DBCM     
0-1.5 438 0 0  
1.5-3.2 451 34.0 (-26.7, 94.7) 8.6 (-21.0, 47.9) 7.6 (-19.0, 73.2) 
3.2-6.8 476 51.7 (-8.9, 112.4) 8.5 (-21.0, 49.7) 4.3 (-27.0, 61.0) 
>6.8 436 -54.4 (-120.0, 11.2) -5.7 (-44.0, 33.4) -3.6 (-63.0, 45.0) 
Bromoform     
0-0.1 475 0 0 0 
0.1-0.6 445 -35.6 (-96.0, 24.7) 1.8 (-28.0, 33.6) 0.6 (-37.0, 37.7) 
0.6-0.9 449 -92.8 (-152.8, -32.7) -10.6 (-53.0, 17.3) -7.9 (-63.0, 18.8) 
>0.9 432 -99.1 (-164.8, -33.3) 2.0 (-30.0, 49.3) 2.7 (-37.0, 51.5) 
CAA     
0 604 0 0 0 
>0-2.3 584 -6.5 (-60.6, 47.6) -3.2 (-36.0, 27.2) -0.8 (-42.0, 37.0) 
>2.3 613 39.7 (-13.2, 92.7) 6.3 (-25.0, 42.0) 1.4 (-33.0, 60.3) 
DCAA     
0 655 0 0 0 
>0-17.5 563 -10.1 (-64.9, 44.6) 1.6 (-36.0, 42.3) 0.7 (-48.0, 51.0) 
>17.5 583 41.4 (-11.3, 94.1) 0.5 (-40.0, 38.2) -0.9 (-59.0, 39.2) 
TCAA     
0 655 0 0 0 
>0-10.2 563 -13.0 (-67.9, 41.9) -3.2 (-44.0, 31.8) -1.3 (-54.0, 37.8) 
>10.2 583 43.8 (-8.9, 96.5) 3.3 (-35.0, 39.9) 0.6 (-47.0, 45.0) 
BCAA     
0 655 0 0 0 
>0-5 587 63.1 (10.8, 115.4) 11.6 (-21.0, 48.7) 7.6 (-28.0, 59.8) 
>5 559 -38.4 (-93.8, 16.9) -10.3 (-50.0, 22.6) -8.4 (-64.0, 32.7) 
BDCAA     
0-1.3 441 0 0 0 
1.3-3.7 456 -1.0 (-61.7, 59.6) -2.2 (-37.0, 28.9) -2.3 (-57.0, 36.0) 
3.7-6.2 463 58.7 (-2.2, 119.5) 10.4 (-21.0, 50.6) 7.9 (-31.0, 61.7) 
>6.2 441 -89.1 (-153.6, -24.5) -18.6 (-69.0, 10.4) -20.3 (-100.0, 12.9) 
DBCAA     
0 442 0 0 0 
>0-1.4 693 27.1 (-28.6, 82.8) 4.0 (-27.0, 38.5) 4.3 (-26.0, 54.2) 
>1.4 666 19.6 (-37.8, 77.0) 4.5 (-29.0, 47.5) 4.5 (-33.0, 71.7) 
BAA     
0 1298 0 0 0 
>0 503 -75.5 (-127.1, -23.9) -8.6 (-46.0, 26.0) -8.0 (-59.0, 34.6) 
DBAA     
0 681 0 0 0 
>0-1 576 43.7 (-7.9, 95.3) 3.9 (-33.0, 35.1) 0.4 (-44.0, 41.9) 
>1 544 -51.7 (-107.2, 3.8) -12.7 (-60.0, 21.8) -12.2 (-79.0, 21.0) 
TBAA     
0 836 0 0 0 
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>0-0.6 497 19.5 (-31.9, 71.0) 4.1 (-31.0, 39.4) 2.5 (-33.0, 45.8) 
>0.6 468 -56.1 (-113.0, 0.9) -5.4 (-42.0, 30.0) -2.4 (-51.0, 38.4) 
a N=1801; 53 births that were < 27 weeks’ in gestation when water sampling ended are not included in third trimester average models 
b Maximum likelihood estimation models were constructed separately for each individual THM and HAA; all models were adjusted for 
maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake 
c Four fully-Bayesian models were constructed using different prior specifications for the effect of DBP exposures: model 1 specified 
βj~N(0,φ2), model 2 specified βj~N(μk,φk2) where k is an indictor for DBP class and bromination (non-brominated THM, non-brominated 
HAA, brominated TTHM, brominated HAA); models adjusted for all other DBPs listed in the table and maternal age, race/ethnicity, 
income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake   
Abbreviations: SGA, small-for-gestational-age, MLE = maximum likelihood estimation, ∆= change, CI = confidence interval, DBP= 
disinfection by-product, BDCM= bromodichloromethane, DBCM = dichloromethane, CAA= chloroacetic acid, DCAA=dichloroacetic 
acid, TCAA=trichloroacetic acid, BCAA= bromochloroacetic acid, BDCAA= Bromochloroacetic acid, DBCAA= dibromochloroacetic 
acetic acid, BAA= bromoacetic acid, DBAA= dibromoacetic acid, TBAA= tribromoacetic acid 
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Bayesian analyses also were run separately for the chlorinated (table 38) and 
brominated (table 39) DBP sites to avoid the potential for residual confounding by study site.  
Results of the MLE analyses restricted to the chlorinated DBP site suggested that elevated 
exposure to bromoform, dibromochloromethane (DBCM) and bromoacetic acid (BAA) was 
associated with increased probability of delivering an SGA infant.  Estimated associations for 
these DBPs from the Bayesian analysis were attenuated after adjustment for other DBPs and 
shrinking by DBP class and bromination status, and 95% CIs for all effect estimates included 
values below the null value, indicating that a null or protective effect of DBPs was within the 
probable range.  RRs for SGA from the Bayesian analysis using a vague prior were all within 
the range of 0.9.-1.2, with wide 95% CIs (data not shown).  A similar pattern of associations 
was found for term birth weight.  
In contrast, results of the MLE analyses restricted to the brominated DBP site 
suggested that elevated exposure to predominately chlorinated DBPs (i.e., chloroform, 
chloroacetic acid [CAA], dichloroacetic acid [DCAA], trichloroacetic acid [TCAA], and 
bromochloroacetic acid [BCAA]) was associated with increased probability of delivering an 
SGA infant and decreased term birth weight, albeit effect estimates were highly unstable 
given the small number of participants from this study site (table 38).  Estimated effects for 
CAA, DCAA and BCAA remained elevated in the Bayesian analysis for SGA, but a 
respective decrease in mean birth weight for the DBPs was not found.   Again, 95% CIs for 
all effect estimates included the null value, and results of Bayesian analysis using a vague 
prior did not indicate an association between either fetal growth measure and any individual 
THM or HAA.   
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Table 38. Estimated effects of third trimester average concentrations of individual THMs and 
HAAs on fetal growth measures among women included in the analysis of exposure to 
drinking water DBPs and fetal growth restriction from the chlorinated DBP site, 2000-
2004a,b 
   SGA Term birth weight (in grams) 
 
n  
SGA 
n  
Non-SGA 
MLE model  
OR (95% CI)c 
Bayesian Model 
OR (95% PI)d 
MLE model 
Mean ∆ (95% CI)c 
Bayesian Model 
Mean ∆ (95% PI)d 
Chloroform       
19.9-44.2 14 267 1 1 0 0 
44.3-49 14 274 1.4 (0.6, 3.1) 2.0 (0.5, 8.2) 41.6 (-40.3,  123.6) 11.8 (-29.5,  96.0) 
49.1-94.0 12 275 1.1 (0.5, 2.6) 1.8 (0.4, 8.2) 27.3 (-57.1,  111.6) 4.5 (-44.5,  75.0) 
BDCM       
8.2-11.8 14 274 1 1 0 0 
11.9-14.1 10 273 0.9 (0.4,2.2) 1.5 (0.7,3.0) 26.0 (-56.3, 108.3) 2.4 (-39.0, 56.0) 
14.2-28.5 16 269 1.5 (0.7,3.5) 1.3 (0.6,2.7) -43.6 (-126.7, 39.4) -3.3 (-72.7, 40.0) 
DBCM       
1.1-3.2 11 281 1 1 0 0 
3.3-4.4 11 269 0.8 (0.3,2.1) 1.5 (0.6,2.7) 4.1 (-77.7, 85.9) 3.9 (-30.8, 65.0) 
4.5-9.1 18 266 2.0 (0.9,4.4) 1.6 (0.8,3.7) -51.5 (-135.7, 32.8) -1.2 (-54.0, 53.0) 
Bromoform       
0.0-0 8 278 1 1 0 0 
0.1-0.2 13 275 1.5 (0.6,3.9) 1.5 (0.8,3.0) 41.7 (-40.4, 123.8) 5.7 (-26.0, 67.0) 
0.3-0.9 19 263 2.9 (1.2,7.0) 1.8 (0.9,4.1) -32.4 (-116.9, 52.1) -2.4 (-62.3, 46.0) 
CAA       
0.0-2.2 13 273 1 1 0 0 
2.3-3.2 11 273 1.1 (0.5,2.7) 0.9 (0.5,2.0) 11.3 (-70.8, 93.3) 0.1 (-42.1, 42.0) 
3.3-5.6 16 270 1.6 (0.7,3.7) 0.9 (0.4,1.8) -18.3 (-103.3, 66.7) -0.8 (-43.7, 39.0) 
DCAA       
10.2-17.3 15 269 1 1 0 0 
17.4-20.8 14 267 1.2 (0.5,2.7) 0.9 (0.5,2.0) 1.9 (-81.6, 85.4) -0.7 (-40.3, 37.0) 
20.9-26.9 11 280 0.9 (0.4,2.2) 0.9 (0.5,2.2) 23.2 (-59.8, 106.2) -0.6 (-45.7, 46.0) 
TCAA       
5.3-11 16 268 1 1 0 0 
11-17.2 14 272 0.9 (0.4,1.9) 0.7 (0.3,1.3) 4.0 (-80.7, 88.7) 1.5 (-33.4, 54.0) 
17.3-24.1 10 276 0.6 (0.3,1.5) 0.9 (0.4,1.8) 1.9 (-81.2, 84.9) -2.3 (-53.9, 35.0) 
BCAA       
0.4-3.7 16 274 1 1 0 0 
3.8-4.5 8 274 0.5 (0.2,1.2) 0.7 (0.3,1.5) 49.1 (-33.2, 131.5) 8.9 (-25.7, 75.0) 
4.6-11.7 16 268 1.2 (0.5,2.5) 0.9 (0.4,1.8) -27.8 (-110.8, 55.2) -4.3 (-62.3, 42.0) 
BDCAA       
1.6-3.7 13 270 1 1 0 0 
3.8-5 13 275 1.4 (0.6,3.3) 1.0 (0.5,2.2) 53.2 (-30.3, 136.6) 10.3 (-20.2, 76.0) 
5.1-7.5 14 271 1.3 (0.6,3.1) 0.9 (0.4,1.8) -33.5 (-116.2, 49.2) -8.5 (-67.9, 27.0) 
DBCAA       
0.0-0.8 11 270 1 1 0 0 
0.9-1.6 15 272 1.5 (0.6,3.5) 1.0 (0.5,2.2) 10.4 (-72.5, 93.3) 0.4 (-42.9, 50.0) 
1.7-2.4 14 274 1.6 (0.7,3.9) 1.2 (0.6,3.0) 33.9 (-49.9, 117.8) 3.0 (-35.0, 62.0) 
BAA       
0 25 621 1 1 0 0 
0.0-0.5 15 195 1.9 (0.9,3.9) 1.2 (0.6,2.7) -73.9 (-152.8, 4.9) -5.3 (-59.8, 33.0) 
DBAA       
0.0-0.3 16 274 1 1 0 0 
0.4-0.9 7 272 0.5 (0.2,1.2) 0.7 (0.3,1.5) 19.5 (-63.6, 102.7) 4.4 (-35.1, 61.0) 
1-2.1 17 270 1.1 (0.5,2.3) 0.9 (0.4,1.8) -37.0 (-121.3, 47.3) -4.2 (-55.5, 42.0) 
TBAA       
0 19 365 1 1 0 0 
0.0-1.8 21 451 1.0 (0.5,2.0) 0.8 (0.4,1.5) 25.8 (-42.6, 94.3) 4.0 (-33.4, 59.0) 
a N = 856 for SGA analysis; two births born before 27 weeks’ gestation and 25 births that were < 27 weeks’ in gestation when water 
sampling ended (27 births total)  are not included in third trimester average SGA models 
b N = 849 for term birth weight analysis; 23 births that were < 27 weeks’ in gestation when water sampling ended are not included in third 
trimester average term birth weight models 
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c Maximum likelihood estimation models were constructed separately for each individual THM and HAA; all models were adjusted for 
maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake 
d Fully-Bayesian models specified βj~N(μk,φ2) where k is an indictor for DBP class and bromination (non-brominated THM, non-
brominated HAA, brominated THM, brominated HAA); models adjusted for other DBPs listed in the table and maternal age, race/ethnicity, 
income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake.   
Abbreviations: SGA= small-for-gestational-age, MLE = maximum likelihood estimation, OR= odds ratios, CI = confidence interval, PI= 
posterior interval, DBP= disinfection by-product, BDCM= bromodichloromethane, DBCM = dibromochloromethane, CAA= chloroacetic 
acid, DCAA=dichloroacetic acid, TCAA=trichloroacetic acid, BCAA= bromochloroacetic acid, BDCAA= bromodichloroacetic acid, 
DBCAA= dibromochloroacetic acetic acid, BAA= bromoacetic acid, DBAA= dibromoacetic acid, TBAA= tribromoacetic acid 
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Table 39. Estimated effects of third trimester average concentrations of individual THMs 
and HAAs on fetal growth measures among women included in the analysis of exposure to 
drinking water DBPs and fetal growth restriction from the brominated DBP site, 2000-
2004a,b 
   SGA Term birth weight (in grams) 
 
n  
SGA 
n  
Non-SGA 
MLE model  
OR (95% CI)‡ 
Bayesian Model
OR (95% PI)§ 
MLE model 
Mean ∆ (95% CI) ‡ 
Bayesian Model 
Mean ∆ (95% PI)§ 
Chloroform       
6.4-11.5 4 104 1 1 0 0 
11.6-15.6 15 96 4.9 (1.5,15.8) 3.9 (0.6,24.8) -87.4 (-215.8, 41.1) -9.9 (-115.0, 61.0) 
15.7-22.1 9 102 2.4 (0.7,8.4) 3.5 (0.6,23.8) 59.3 (-70.8, 189.3) 11.7 (-64.0, 129.0) 
BDCM       
15.8-20.1 8 101 1 1 0 0 
20.2-22.9 8 103 1.0 (0.3,2.7) 0.8 (0.3,2.1) 55.1 (-74.3, 184.4) 8.4 (-62.0, 108.0) 
23-29.2 12 98 1.6 (0.6,4.1) 0.9 (0.4,2.5) 49.1 (-81.0, 179.1) -2.3 (-95.0, 73.0) 
DBCM       
15.2-19.3 14 95 1 1 0 0 
19.4-26 8 103 0.5 (0.2,1.2) 0.7 (0.3,1.6) 170.9 (42.5, 299.4) 32.6 (-28.0, 169.0) 
26.1-38.7 6 104 0.3 (0.1,0.9) 0.7 (0.3,1.8) 142.8 (14.3, 271.2) 7.3 (-62.0, 118.0) 
Bromoform       
0.8-2.4 12 98 1 1 0 0 
2.5-11.5 7 102 0.6 (0.2,1.6) 0.8 (0.3,2.0) 145.9 (16.4, 275.3) 18.5 (-45.0, 137.0) 
11.6-15.1 9 102 0.7 (0.3,1.7) 0.9 (0.3,2.4) 76.1 (-53.0, 205.2) -1.0 (-94.0, 83.0) 
CAA       
0.4-0.8 7 102 1 1 0 0 
0.9-1.8 9 101 1.3 (0.5,3.7) 1.1 (0.4,2.4) -134.0 (-265.2, -2.8) -15.4 (-124.0, 41.0) 
1.9-4.0 12 99 1.9 (0.7,5.3) 1.3 (0.5,3.6) -105.9 (-234.6, 22.8) 1.2 (-74.0, 84.0) 
DCAA       
2.7-6.5 6 103 1 1 0 0 
6.6-7.8 14 98 3.0 (1.1,8.3) 1.4 (0.6,3.2) -56.7 (-184.5, 71.2) -5.6 (-101.0, 64.0) 
7.9-10.3 8 101 1.5 (0.5,4.6) 1.1 (0.4,2.6) 49.7 (-82.6, 182.0) 13.5 (-46.0, 130.0) 
TCAA       
1.8-4 6 103 1 1 0 0 
4.1-5.7 10 101 1.8 (0.6,5.4) 1.2 (0.5,2.7) -39.7 (-170.1, 90.7) -2.4 (-92.0, 82.0) 
5.8-9.1 12 98 2.6 (0.9,7.4) 1.3 (0.5,3.5) -43.0 (-173.1, 87.0) -3.6 (-99.0, 67.0) 
BCAA       
7.0-7.8 6 103 1 1 0 0 
7.9-8.4 11 99 2.2 (0.8,6.3) 1.4 (0.7,3.4) -94.4 (-224.5, 35.8) -4.3 (-77.0, 44.0) 
8.5-9.9 11 100 2.0 (0.7,5.6) 1.4 (0.6,3.6) -67.2 (-198.3, 63.9) -1.1 (-76.0, 58.0) 
BDCAA       
6.1-7.8 7 102 1 1 0 0 
7.9-9.4 10 101 1.5 (0.5,4.1) 1.1 (0.4,2.5) 20.4 (-108.2, 148.9) 8.8 (-34.0, 99.0) 
9.5-11.5 11 99 1.7 (0.6,4.7) 1.4 (0.6,3.9) 34.5 (-97.3, 166.3) -4.5 (-78.0, 48.0) 
DBCAA       
2.5-4.3 10 99 1 1 0 0 
4.4-5.8 12 99 1.4 (0.5,3.4) 1.2 (0.5,2.9) 21.0 (-108.3, 150.3) 0.4 (-64.0, 69.0) 
5.9-8.2 6 104 0.5 (0.2,1.6) 1.2 (0.5,3.1) 71.6 (-58.0, 201.2) -0.3 (-61.0, 71.0) 
BAA       
0.0-0.4 12 99 1 1 0 0 
0.5-1.2 7 102 0.5 (0.2,1.4) 0.9 (0.4,1.8) -39.1 (-169.2, 91.1) -3.8 (-77.0, 50.0) 
1.3-2.1 9 101 0.7 (0.3,1.7) 1.7 (0.8,5.1) -12.5 (-143.6, 118.6) 0.5 (-70.0, 70.0) 
DBAA       
2.3-4.4 13 98 1 1 0 0 
4.5-7.2 10 100 0.8 (0.3,1.9) 1.3 (0.6,3.4) 12.3 (-117.7, 142.4) 0.2 (-56.0, 69.0) 
7.3-11.4 5 104 0.3 (0.1,0.9) 1.1 (0.4,2.6) 62.3 (-69.0, 193.6) 2.2 (-57.0, 73.0) 
TBAA       
1.5-2.6 8 102 1 1 0 0 
2.7-3 14 97 1.9 (0.7,4.8) 1.7 (0.6,4.8) -57.4 (-186.4, 71.6) -8.8 (-86.0, 36.0) 
3.1-5.2 6 103 0.7 (0.2,2.0) 1.3 (0.5,3.4) -14.3 (-145.0, 116.4) -3.4 (-95.0, 51.0) 
a N = 330 for SGA analysis; two births born before 27 weeks’ gestation and 8 births that were < 27 weeks’ in gestation when water 
sampling ended (10 births total)  are not included in third trimester average SGA models 
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b N = 297 for term birth weight analysis; eight births that were < 27 weeks’ in gestation when water sampling ended are not included in 
third trimester average term birth weight models 
c Maximum likelihood estimation models were constructed separately for each individual THM and HAA; all models were adjusted for 
maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake 
d Fully-Bayesian models specified βj~N(μk,φ2) where k is an indictor for DBP class and bromination (non-brominated THM, non-
brominated HAA, brominated THM, brominated HAA); models adjusted for other DBPs listed in the table and maternal age, 
race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake.   
Abbreviations: MLE = maximum likelihood estimation, OR= odds ratios, CI = confidence interval, CI = credible interval, DBP= 
disinfection by-product, BDCM= bromodichloromethane, DBCM = dibromochloromethane, CAA= chloroacetic acid, 
DCAA=dichloroacetic acid, TCAA=trichloroacetic acid, BCAA= bromochloroacetic acid, BDCAA= bromodichloroacetic acid, DBCAA= 
dibromochloroacetic acetic acid, BAA= bromoacetic acid, DBAA= dibromoacetic acid, TBAA= tribromoacetic acid 
 
 
4.5 Results of duration of gestation analyses 
Results of the time-to-birth analyses, addressing specific aim #2 of this dissertation, 
are summarized below.  A brief description precedes each table or figure and any notable 
findings are highlighted.  For all analyses, results for the total study population are presented 
first and then followed by the analogous results restricted to the chlorinated site alone.  
Additionally, supplementary tables of preterm birth results are provided in appendix 5. 
 
4.5.1 Associations between time-to-birth and DBP exposure for all study sites 
Tables 40-42 present estimated odds ratios for associations between aggregate DBP 
measures and the conditional odds of delivery each week stratified by gestational periods (≤ 
32, 33-36, 37-40 and ≥ 41 weeks).  Results are also presented graphically in figure 14.  The 
odds of delivery each week, conditional on not having delivered in a previous week, were 
decreased for women in the higher categories of average second trimester residential TTHM 
and HAA5 concentrations compared to women in the lowest group for gestational weeks 33-
40.  Odds ratios (ORs) over this period ranged from 0.5-0.9 for residential TTHM 
concentrations and 0.4 to 1.3 for residential HAA5 concentrations.   
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ORs for 20-32 weeks and 41-44 weeks were imprecise, as evidenced by wide 
confidence intervals, due to the small number of infants born during these periods.  Results 
suggest that the conditional probability of birth each week was increased with higher DBP 
exposure over the 41-44 weeks period (ORs ranged from 2.1-7.3); however, these findings 
should be interpreted with caution.  In addition to poor precision, the majority of births 
during the 41-44 weeks’ period occurred at 41 or 42 weeks’ (98%) and later births (at 43 or 
44 weeks’) are likely due to errors in gestational age estimation. 
Conditional ORs estimates for personal TTHM and HAA5 exposure showed a pattern 
of association similar to residential concentrations for 37-40 weeks and 41-44 weeks but 
were inconsistent for 33-36 weeks.  Estimated ORs from models examining 6-week sliding 
average exposure and weekly exposure did not differ substantially from those shown in 
figure 2.  Effect measure modification by maternal age, maternal race/ethnicity or swimming 
during pregnancy was not indicated (p-values for joint effect of interaction terms ranged 
form 0.1-0.7).   
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Table 40. Association between TTHM exposure and the conditional probability if delivery each week (gestational weeks 20 to 
44) stratified by gestational period among women included in duration of gestation analyses, 2000-2004. 
 Unadjusted Model Fully-adjusted Modela 
 Gestational Period (weeks’) Gestational Period (weeks’) 
 ≤ 32 33-36 37-40 ≥ 41 ≤ 32 33-36 37-40 ≥ 41 
Residential TTHM level 
(μg/liter) nb 
OR 
(95% CI) nb 
OR 
(95% CI) nb 
OR 
(95% CI) nb 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
2nd-trimester average              
2.2-4.6 15 1 69 1 636 1 41 1 1 1 1 1 
33.1-55 3 
0.47 
(0.14,1.63) 24 
0.80 
(0.50,1.29) 258 
0.74 
(0.61,0.90) 37 
2.31 
(0.78,6.84) 
0.38  
(0.09,1.68) 
0.92 
(0.56,1.50) 
0.73 
(0.59,0.89) 
2.31 
(0.77,6.96) 
55-66.3 6 
0.96 
(0.37,2.47) 24 
0.81 
(0.51,1.30) 252 
0.72 
(0.60,0.88) 36 
4.97 
(1.06,23.38) 
1.16  
(0.44,3.05) 
0.85 
(0.51,1.41) 
0.77 
(0.63,0.95) 
4.40 
(0.92,21.03) 
66.4-74.8 4 
0.64 
(0.21,1.92) 20 
0.67 
(0.40,1.11) 247 
0.71 
(0.58,0.87) 47 
4.40 
(1.19,16.28) 
0.78 
(0.26,2.41) 
0.65 
(0.37,1.14) 
0.75 
(0.61,0.92) 
4.28 
(1.14,16.11) 
74.9-108.8 5 
0.79 
(0.29,2.18) 15 
0.49 
(0.28,0.87) 254 
0.68 
(0.56,0.83) 46 
4.31 
(1.16,15.98) 
0.77 
(0.25,2.37) 
0.47 
(0.25,0.88) 
0.75 
(0.61,0.93) 
4.06 
(1.08,15.27) 
Weekly concentration             
1.4-5.4 15 1 69 1 636 1 41 1 1 1 1 1 
24.7-54.8 1 
0.15 
(0.45,1.15) 17 
0.48 
(0.28,0.83) 283 
0.68 
(0.56,0.82) 43 
3.38 
(0.98,11.67) 
0.18 
(0.02,1.43) 
0.55 
(0.31,0.97) 
0.72 
(0.58,0.88) 
3.09 
(0.88,10.82) 
55.1-65.4 7 
1.15 
(0.02,2.89) 21 
0.62 
(0.37,1.02) 247 
0.65 
(0.53,0.8) 49 
4.56 
(1.42,14.64) 
1.21 
(0.45,3.28) 
0.61 
(0.35,1.05) 
0.68 
(0.55,0.84) 
4.15 
(1.27,13.54) 
66.6-74.6 2 
0.52 
(0.46,2.33) 18 
0.99 
(0.58,1.69) 158 
0.76 
(0.60,0.97) 27 
2.96 
(0.75,11.62) 
0.65 
(0.14,2.95) 
1.16 
(0.67,2.01) 
0.79 
(0.62,1.02) 
2.77 
(0.70,11.04) 
74.9-165 7 
1.13 
(0.12,2.84) 22 
0.75 
(0.46,1.24) 219 
0.64 
(0.52,0.79) 38 
6.10 
(1.26,29.48) 
1.21 
(0.44,3.27) 
0.67 
(0.38,1.18) 
0.67 
(0.54,0.84) 
5.92 
(1.21,29.02) 
6-week average              
2.1-5.3 15 1 69 1 636 1 41 1 1 1 1 1 
28.8-54.8 1 
0.16 
(0.02,1.24) 16 
0.50 
(0.29,0.88) 265 
0.69 
(0.56,0.84) 38 
2.63 
(0.85,8.13) 
0.18 
(0.02,1.42) 
0.55 
(0.31,0.96) 
0.73 
(0.60,0.90) 
2.44 
(0.78,7.64) 
55.1-66.3 3 
0.53 
(0.15,1.88) 16 
0.5 
(0.29,0.88) 257 
0.68 
(0.56,0.83) 51 
5.78 
(1.54,21.75) 
0.60 
(0.17,2.13) 
0.53 
(0.30,0.93) 
0.70 
(0.57,0.87) 
5.52 
(1.45,21.08) 
66.4-74.7 4 
0.87 
(0.28,2.66) 26 
1.17 
(0.73,1.87) 158 
0.58 
(0.46,0.74) 29 
5.13 
(1.08,24.42) 
0.97 
(0.31,3.03) 
1.16 
(0.72,1.89) 
0.61 
(0.48,0.77) 
4.87 
(1.01,23.44) 
75.1-133.2 9 
1.43 
(1.61,3.34) 20 
0.65 
(0.39,1.08) 227 
0.73 
(0.59,0.89) 39 
4.19 
(1.08,16.27) 
1.60 
(0.67,3.81) 
0.60 
(0.35,1.03) 
0.76 
(0.61,0.94) 
4.34 
(1.10,17.11) 
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TTHM exposure through 
showering & bathing 
(μg/day)             
2nd-trimester average             
0.02-0.09 12 1 38 1 433 1 25 1 1 1 1 1 
0.1-0.8 6 
0.50 
(0.19,1.32) 50 
1.32 
(0.86,2.03) 406 
0.80 
(0.67,0.96) 47 
4.15 
(1.23,13.94) 
0.38 
(0.12,1.20) 
1.30 
(0.83,2.05) 
0.79 
(0.65,0.95) 
3.72 
(1.09,12.68) 
0.9-1.5 4 
0.33 
(0.11,1.03) 25 
0.63 
(0.38,1.05) 405 
0.70 
(0.58,0.84) 75 
4.38 
(1.52,12.63) 
0.38 
(0.12,1.21) 
0.73 
(0.43,1.23) 
0.74 
(0.61,0.89) 
4.00 
(1.36,11.74) 
1.6-27.1 11 
0.92 
(0.40,2.08) 39 
1.02 
(0.65,1.61) 398 
0.76 
(0.63,0.91) 60 
4.23 
(1.38,12.98) 
0.98 
(0.42,2.33) 
0.93 
(0.56,1.53) 
0.79 
(0.65,0.96) 
3.51 
(1.12,10.97) 
Weekly concentration             
0-0.09 8 1 41 1 354 1 21 1 1 1 1 1 
0.1-0.8 6 
0.73 
(0.25,2.12) 36 
0.80 
(0.51,1.26) 356 
0.84 
(0.69,1.02) 44 
9.25 
(1.84,46.63) 
0.52 
(0.16,1.72) 
0.80 
(0.49,1.30) 
0.87 
(0.71,1.07) 
8.61 
(1.69,43.84) 
0.9-1.5 7 
0.85 
(0.31,2.34) 23 
0.50 
(0.30,0.85) 346 
0.67 
(0.55,0.82) 58 
4.43 
(1.50,13.09) 
0.76 
(0.26,2.21) 
0.57 
(0.33,0.97) 
0.70 
(0.57,0.86) 
4.25 
(1.41,12.79) 
1.6-29.3 9 
1.11 
(0.43,2.87) 39 
0.89 
(0.57,1.39) 352 
0.76 
(0.62,0.92) 63 
5.75 
(1.84,17.98) 
1.07 
(0.40,2.85) 
0.82 
(0.50,1.34) 
0.79 
(0.64,0.97) 
5.17 
(1.62,16.47) 
6-week average             
0-0.09 9 1 40 1 362 1 26 1 1 1 1 1 
0.1-0.8 8 
0.92 
(0.35,2.38) 40 
0.97 
(0.62,1.52) 340 
0.76 
(0.62,0.93) 42 
8.66 
(1.79,41.87) 
0.61 
(0.20,1.82) 
0.91 
(0.57,1.47) 
0.77 
(0.63,0.95) 
8.28 
(1.70,40.42) 
0.9-1.5 3 
0.33 
(0.09,1.22) 22 
0.5 
(0.29,0.85) 372 
0.72 
(0.59,0.88) 59 
8.32 
(2.19,31.59) 
0.35 
(0.09,1.30) 
0.58 
(0.34,0.98) 
0.76 
(0.62,0.93) 
8.05 
(2.09,30.95) 
1.6-29.3 10 
1.11 
(0.45,2.74) 38 
0.91 
(0.58,1.43) 342 
0.71 
(0.58,0.87) 61 3.36 (1.28,8.84) 
1.08 
(0.43,2.73) 
0.81 
(0.49,1.33) 
0.73 
(0.59,0.90) 
3.00 
(1.12,8.06) 
a Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
b Number of births attributed to exposure category during the gestational period.  
Abbreviations: OR = conditional odds ratio, CI= confidence interval 
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Table 41. Association between HAA5 exposure and the conditional probability if delivery each week (gestational weeks 20 to 44) 
stratified by gestational period among women included in duration of gestation analyses, 2000-2004. 
 Unadjusted Model Fully-adjusted Modela 
 Gestational Period (weeks’) Gestational Period (weeks’) 
 ≤ 32 33-36 37-40 ≥ 41 ≤ 32 33-36 37-40 ≥ 41 
Residential HAA5 level 
(μg/liter) nb 
OR 
(95% CI) nb 
OR 
(95% CI) nb 
OR 
(95% CI) nb 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
2nd-trimester average              
0-0.9 15 1 69 1 636 1 41 1 1 1 1 1 
17.9-22 3 
0.47 
(0.14,1.63) 36 
1.24 
(0.82,1.87) 261 
1.03 
(0.84,1.25) 21 --
c 0.61 (0.17,2.14) 
1.32 
(0.84,2.07) 
1.08 
(0.87,1.35) --
c 
22.1-31.5 3 
0.48 
(0.14,1.65) 21 
0.7 
(0.43,1.16) 250 
0.66 
(0.54,0.80) 44 
2.38  
(0.87,6.51) 
0.39 
(0.09,1.73) 
0.81 
(0.49,1.36) 
0.71 
(0.58,0.87) 
2.13 
(0.76,5.96) 
31.6-40.4 4 
0.63 
(0.21,1.92) 14 
0.46 
(0.26,0.82) 251 
0.64 
(0.52,0.77) 49 
3.03 
 (1.04,8.89) 
0.58 
(0.17,2.04) 
0.43 
(0.23,0.83) 
0.67 
(0.55,0.83) 
2.83 
(0.95,8.47) 
40.4-52.8 8 
1.27 
(0.54,3.00) 12 
0.39 
(0.21,0.73) 249 
0.62 
(0.51,0.75) 52 
7.22 
(1.55,33.62) 
1.52 
(0.63,3.69) 
0.43 
(0.22,0.82) 
0.67 
(0.55,0.82) 
6.69 
(1.41,31.65) 
Weekly concentration             
0-1.5 15 1 69 1 636 1 41 1 1 1 1 1 
12.1-22 1 
0.14 
(0.02,1.09) 34 
0.95 
(0.62,1.45) 271 
0.82 
(0.67,1.00) 34 
5.3 
 (1.08,26.07) 
0.18 
(0.02,1.40) 
1.01 
(0.64,1.61) 
0.88 
(0.71,1.10) 
4.41 
(0.88,22.00) 
22.1-31.5 4 
0.88 
(0.29,2.69) 15 
0.65 
(0.37,1.15) 198 
0.72 
(0.57,0.89) 34 
3.03 
(0.91,10.12) 
0.80 
(0.22,2.88) 
0.73 
(0.40,1.32) 
0.75 
(0.59,0.94) 
3.01 
(0.89,10.20) 
31.6-40.3 2 
0.45 
(0.10,1.99) 12 
0.52 
(0.28,0.98) 176 
0.54 
(0.43,0.68) 40 
4.9  
(1.32,18.18) 
0.56 
(0.12,2.52) 
0.53 
(0.27,1.05) 
0.56 
(0.44,0.70) 
4.30 
(1.14,16.26) 
40.7-62.2 10 
1.50 
(0.66,3.43) 17 
0.49 
(0.28,0.84) 262 
0.62 
(0.51,0.76) 49 
4.03 
(1.19,13.62) 
1.67 
(0.69,4.04) 
0.48 
(0.27,0.88) 
0.67 
(0.54,0.83) 
3.90 
(1.14,13.35) 
6-week average             
0-0.6 15 1 69 1 636 1 41 1 1 1 1 1 
16-21.8 3 0.4 (0.11,1.4) 38 
0.98 
(0.65,1.49) 309 
0.86 
(0.71,1.05) 32 
5.35 
(1.11,25.83) 
0.46 
(0.13,1.65) 
1.01 
(0.66,1.55) 
0.95 
(0.77,1.17) 
4.49 
(0.92,21.96) 
22.1-31.5 1 
0.25 
(0.03,1.93) 10 
0.56 
(0.29,1.10) 142 
0.63 
(0.49,0.81) 31 
2.83 
 (0.85,9.43) 
0.29 
(0.04,2.26) 
0.54 
(0.27,1.10) 
0.64 
(0.49,0.82) 
2.80 
(0.83,9.51) 
31.6-40.3 5 
1.04 
(0.37,2.92) 18 
0.71 
(0.42,1.21) 175 
0.6 
(0.48,0.75) 37 
6.11 
(1.27,29.41) 
1.15 
(0.41,3.28) 
0.75 
(0.44,1.28) 
0.63 
(0.50,0.79) 
6.13 
(1.26,29.79) 
40.6-56.4 8 
1.24 
(0.51,3.01) 12 
0.34 
(0.18,0.64) 281 
0.59 
(0.48,0.71) 57 
3.95 
(1.30,11.99) 
1.39 
(0.57,3.41) 
0.36 
(0.19,0.67) 
0.62 
(0.51,0.75) 
3.78 
(1.23,11.69) 
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HAA5 exposure through 
tap-water consumption 
(μg/day)             
2nd-trimester average              
0 14 1 49 1 500 1 39 1 1 1 1 1 
0.01-16.1 7 
0.63 
(0.25,1.56) 49 
1.26 
(0.84,1.89) 390 
0.97 
(0.81,1.16) 32 
7.85 
(0.96,63.81) 
0.40 
(0.13,1.22) 
1.17 
(0.75,1.81) 
0.95 
(0.79,1.15) 
7.32 
(0.89,60.38) 
16.2-54.4 5 
0.45 
(0.16,1.24) 35 
0.88 
(0.56,1.36) 374 
0.78 
(0.65,0.94) 63 
4.15 
(1.28,13.47) 
0.50 
(0.18,1.41) 
0.99 
(0.62,1.57) 
0.81 
(0.67,0.98) 
3.95 
(1.19,13.09) 
54.7-369.1 7 
0.63 
(0.25,1.55) 19 
0.47 
(0.27,0.79) 380 
0.64 
(0.54,0.77) 72 
2.57 
 (1.02,6.47) 
0.71 
(0.28,1.77) 
0.53 
(0.30,0.92) 
0.65 
(0.54,0.79) 
2.41 
(0.93,6.26) 
Weekly concentration             
0 14 1 49 1 500 1 39 1 1 1 1 1 
0.2-16.1 7 
0.88 
(0.26,3.04) 49 
0.7 
(0.37,1.32) 390 
0.78 
(0.60,1.02) 32 
4.40 
 (0.53,36.4) 
0.76 
(0.17,3.39) 
0.64 
(0.30,1.34) 
0.84 
(0.64,1.11) 
3.64 
(0.43,30.81) 
16.1-54.7 5 
0.47 
(0.16,1.41) 35 
0.53 
(0.33,0.84) 374 
0.77 
(0.65,0.92) 63 
5.71 
(1.22,26.74) 
0.59 
(0.19,1.82) 
0.56 
(0.34,0.92) 
0.80 
(0.66,0.97) 
5.48 
(1.16,25.99) 
54.7-511.4 7 
0.82 
(0.34,1.99) 19 
0.54 
(0.34,0.85) 380 
0.62 
(0.52,0.74) 72 
2.08 
 (0.86,5.00) 
1.05 
(0.42,2.64) 
0.64 
(0.40,1.03) 
0.64 
(0.53,0.77) 
1.98 
(0.80,4.90) 
6-week average             
0 16 1 78 1 618 1 48 1 1 1 1 1 
0.2-16.1 3 
0.87 
(0.25,3.00) 13 
0.76 
(0.42,1.39) 118 
0.77 
(0.59,1.00) 19 
4.58 
(0.56,37.63) 
0.75 
(0.17,3.34) 
0.66 
(0.33,1.35) 
0.82 
(0.62,1.09) 
4.07 
(0.49,33.98) 
16.1-54.7 5 
0.58 
(0.21,1.60) 27 
0.62 
(0.40,0.97) 348 
0.85 
(0.72,1.02) 52 
6.4  
(1.39,29.41) 
0.74 
(0.26,2.08) 
0.73 
(0.46,1.16) 
0.89 
(0.74,1.07) 
6.36 
(1.37,29.53) 
54.7-511.4 6 
0.70 
(0.27,1.79) 22 
0.47 
(0.29,0.76) 333 
0.60 
(0.50,0.72) 68 
2.03 
 (0.85,4.90) 
0.90 
(0.34,2.36) 
0.54 
(0.32,0.89) 
0.62 
(0.51,0.75) 
1.85 
(0.75,4.58) 
a Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
b Number of births attributed to exposure category during the gestational period.  
c Non-estimable parameter (all 21 pregnancies in HAA5 category delivered at 41 weeks) 
Abbreviations: OR = conditional odds ratio, CI= confidence interval  
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Table 42. Association between TOX exposure and the conditional probability if delivery each week (gestational weeks 20 to 44) 
stratified by gestational period among women included in duration of gestation analyses, 2000-2004. 
 Unadjusted Model Fully-adjusted Modela 
 Gestational Period (weeks’) Gestational Period (weeks’) 
 ≤ 32 33-36 37-40 ≥ 41 ≤ 32 33-36 37-40 ≥ 41 
Residential TOX level 
(μg/liter) nb 
OR 
(95% CI) nb 
OR 
(95% CI) nb 
OR 
(95% CI) nb 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
2nd-trimester average             
14.3-22.4 15 1 69 1 636 1 41 1 1 1 1 1 
136.7-169.6 2 
0.32 
(0.07,1.38) 17
0.56 
(0.33,0.96) 258 
0.64 
(0.53,0.78) 42 2.61 (0.89,7.67) 
0.38 
(0.09,1.70) 
0.67 
(0.39,1.16) 
0.66 
(0.54,0.81) 
2.54 
(0.85,7.62) 
169.6-177.7 5 
0.79 
(0.29,2.18) 16
0.53 
(0.30,0.91) 245 
0.58 
(0.48,0.71) 55 7.42 (1.59,34.62) 
0.77 
(0.25,2.35) 
0.55 
(0.31,0.99) 
0.63 
(0.51,0.77) 
6.64 
(1.40,31.54) 
177.7-192.6 5 
0.80 
(0.29,2.19) 19
0.63 
(0.38,1.06) 250 
0.71 
(0.58,0.86) 45 2.76 (0.94,8.12) 
0.79 
(0.26,2.41) 
0.60 
(0.34,1.07) 
0.75 
(0.61,0.92) 
2.50 
(0.83,7.49) 
192.8-235.2 6 
0.95 
(0.37,2.46) 31
1.06 
(0.69,1.63) 258 
1.01 
(0.83,1.23) 24 6.55 (0.80,53.31) 
1.20 
(0.45,3.16) 
1.11 
(0.69,1.77) 
1.09 
(0.88,1.35) 
6.11 
(0.74,50.41) 
Weekly concentration             
9-28 15 1 69 1 636 1 41 1 1 1 1 1 
104-169 6 
0.69 
(0.26,1.83) 15
0.31 
(0.18,0.55) 350 
0.62 
(0.52,0.75) 75 6.27 (1.88,20.90) 
0.86 
(0.32,2.32) 
0.36 
(0.20,0.64) 
0.66 
(0.55,0.80) 
6.01 
(1.78,20.34) 
170-177 3 
1.38 
(0.39,4.85) 10
0.88 
(0.45,1.74) 100 
0.78 
(0.59,1.05) 17 5.73 (0.68,48.14) 
1.12 
(0.25,5.07) 
1.05 
(0.53,2.10) 
0.87 
(0.64,1.17) 
5.83 
(0.69,49.52) 
178-192 2 
0.47 
(0.10,2.07) 15
0.77 
(0.43,1.37) 171 
0.65 
(0.52,0.82) 29 5.26 (1.11,25.01) 
0.59 
(0.13,2.66) 
0.87 
(0.48,1.58) 
0.68 
(0.53,0.87) 
4.54 
(0.94,21.92) 
192.8-290 6 
0.79 
(0.30,2.07) 38
1.01 
(0.67,1.53) 286 
0.73 
(0.60,0.88) 36 2.21 (0.77,6.37) 
0.81 
(0.28,2.33) 
0.92 
(0.58,1.47) 
0.74 
(0.60,0.91) 
1.96 
(0.67,5.76) 
6-week average             
10.9-25.5 15 1 69 1 636 1 41 1 1 1 1 1 
121.7-169.5 2 
0.3 
(0.07,1.33) 17
0.48 
(0.28,0.82) 276 
0.62 
(0.51,0.75) 41 3.23 (0.94,11.14) 
0.34 
(0.08,1.53) 
0.52 
(0.30,0.90) 
0.65 
(0.53,0.79) 
3.03 
(0.86,10.62) 
170-177.5 4 
1.16 
(0.38,3.56) 10
0.59 
(0.30,1.17) 143 
0.64 
(0.50,0.81) 31 5.37 (1.13,25.57) 
1.31 
(0.42,4.07) 
0.62 
(0.31,1.22) 
0.68 
(0.53,0.87) 
5.23 
(1.08,25.27) 
177.8-192.5 4 
0.58 
(0.19,1.77) 23
0.66 
(0.40,1.07) 273 
0.69 
(0.56,0.84) 55 4.7 (1.43,15.47) 
0.66 
(0.21,2.04) 
0.64 
(0.39,1.06) 
0.72 
(0.59,0.88) 
4.35 
(1.31,14.52) 
192.7-250.2 7 
1.24 
(0.49,3.1) 28
0.96 
(0.61,1.51) 215 
0.77 
(0.62,0.95) 30 3.44 (0.89,13.21) 
1.38 
(0.54,3.52) 
0.94 
(0.59,1.51) 
0.80 
(0.64,1.00) 
3.38 
(0.87,13.17) 
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TOX exposure through 
tap-water consumption 
(μg/day)             
2nd-trimester average             
0-25.8 12 1 43 1 421 1 33 1 1 1 1 1 
25.9-75 8 
0.66 
(0.27,1.62) 47
1.08 
(0.71,1.65) 416 
0.91 
(0.76,1.10) 37 5.11 (1.07,24.4) 
0.53 
(0.19,1.43) 
0.93 
(0.59,1.47) 
0.92 
(0.76,1.11) 
4.66 
(0.95,22.76) 
75.1-252.9 5 
0.41 
(0.15,1.17) 33
0.74 
(0.46,1.17) 403 
0.72 
(0.59,0.86) 68 6.13 (1.63,23.12) 
0.37 
(0.12,1.16) 
0.68 
(0.41,1.12) 
0.75 
(0.62,0.91) 
6.33 
(1.64,24.36) 
253.6-1302.9 8 
0.66 
(0.27,1.62) 29
0.65 
(0.40,1.05) 404 
0.69 
(0.57,0.82) 68 2.36 (0.96,5.80) 
0.74 
(0.30,1.85) 
0.74 
(0.45,1.20) 
0.69 
(0.57,0.84) 
2.21 
(0.86,5.63) 
Weekly concentration             
0-25.8 13 1 42 1 364 1 31 1 1 1 1 1 
25.9-75 3 
0.28 
(0.08,0.97) 33
0.88 
(0.55,1.39) 312 
0.98 
(0.80,1.20) 28 4.22 (0.87,20.36) 
0.20 
(0.04,0.89) 
0.85 
(0.51,1.42) 
0.97 
(0.79,1.20) 
3.76 
(0.76,18.53) 
75.1-253.5 8 
0.62 
(0.26,1.50 ) 32
0.72 
(0.45,1.16) 353 
0.76 
(0.62,0.92) 66 9.19 (1.92,43.94) 
0.52 
(0.19,1.38) 
0.78 
(0.47,1.30) 
0.81 
(0.66,0.99) 
9.19 
(1.90,44.55) 
253.6-1827 6 
0.47 
(0.18,1.25) 32
0.71 
(0.44,1.13) 380 
0.74 
(0.61,0.90) 60 2.23 (0.90,5.53) 
0.54 
(0.20,1.44) 
0.83 
(0.51,1.37) 
0.74 
(0.60,0.91) 
2.10 
(0.82,5.38) 
6-week average             
0-25.8 13 1 45 1 376 1 35 1 1 1 1 1 
25.9-75 4 
0.36 
(0.12,1.11) 39
1.04 
(0.67,1.61) 321 
1.07 
(0.87,1.31) 30 4.73 (0.99,22.46) 
0.30 
(0.08,1.05) 
0.89 
(0.55,1.44) 
1.06 
(0.86,1.30) 
4.48 
(0.93,21.68) 
75.1-253.6 6 
0.49 
(0.19,1.29) 24
0.51 
(0.31,0.85) 351 
0.76 
(0.62,0.92) 61 
17.47 
(2.17,140.72) 
0.36 
(0.12,1.13) 
0.52 
(0.30,0.89) 
0.79 
(0.65,0.97) 
17.73 
(2.18,144.35) 
253.6-1827 7 
0.55 
(0.22,1.38) 32
0.69 
(0.43,1.09) 369 
0.73 
(0.60,0.88) 61 2.18 (0.92,5.12) 
0.62 
(0.24,1.59) 
0.75 
(0.46,1.22) 
0.72 
(0.59,0.88) 
2.07 
(0.85,5.03) 
a Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
b Number of births attributed to exposure category during the gestational period.  
Abbreviations: OR = conditional odds ratio, CI= confidence interval 
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Figure 17. Association between second trimester average drinking water disinfection by-
products (DBP) exposure and the conditional odds of delivery each week (gestational weeks’ 
20-44) stratified by gestational period among women included in the analysis of exposure to 
drinking water DBPs and duration of gestation, 2000-2004 
 
Residential concentrations of total trihalomethane (TTHM), the sum of five haloacetic acids (HAA5) and total 
organic halides presented in μg/liter; personal exposure to TTHM through showering and bathing presented in 
μg absorbed/day and to HAA5 through tap water consumption as μg consumed/day; models adjusted for 
maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity 
and caffeine intake; ** = non-estimable because all infants in exposure category delivered at 41 weeks’ 
gestation.  
 
 
4.5.2 Associations between time-to-birth and DBP exposure at the chlorinated DBP site 
Tables 43-45 present estimated odds ratios for associations between aggregate DBP 
measures and the conditional odds of delivery each week restricted to women from the 
chlorinated DBP site alone.  Time interactions were included for gestational periods ≤ 36 
weeks’, 37-40 weeks’, and ≥ 40 weeks’.  Findings were similar to those found for all study 
sites combined. 
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Table 43. Association between TTHM exposure and the conditional probability of delivery each week (gestational weeks’ 20 to 44) 
stratified by gestational period among women included in duration of gestation analyses from the chlorinated DBP site, 2000-2004. 
 Unadjusted Model Fully-adjusted Modela 
 Gestational Period (weeks’) Gestational Period (weeks’) 
 ≤ 36 37-40 ≥ 41 ≤ 36 37-40 ≥ 41 
Residential TTHM level (μg/liter) nb OR (95% CI) nb OR  (95% CI) nb OR (95% CI) OR  (95% CI) OR  (95% CI) OR  (95% CI) 
2nd-trimester average          
33.1-60.3 21 1 248 1 41 1 1 1 1 
60.4-74 16 0.80 (0.42,1.53) 236 0.87 (0.69,1.09) 58 2.61 (0.86,7.93) 0.84 (0.44, 1.61) 0.86 (0.67, 1.09) 2.25 (0.72, 7.02) 
74-108.8 17 0.91 (0.49,1.70) 241 0.98 (0.78,1.23) 48 3.42 (0.89,13.06) 0.73 (0.37, 1.44) 1.00 (0.78, 1.26) 2.91 (0.75, 11.38) 
Weekly concentration           
24.7-60.2 14 1 310 1 59 1 1 1 1 
60.7-73.4 20 2.11 (1.09,4.06) 190 1.09 (0.86,1.37) 46 1.84 (0.62,5.50) 2.25 (1.13, 4.48) 1.05 (0.82, 1.34) 1.57 (0.51, 4.85) 
75-148.6 18 1.90 (0.96,3.75) 173 1.02 (0.81,1.30) 36 3.17 (0.67,15.11) 1.94 (0.94, 4.00) 1.03 (0.81, 1.33) 3.15 (0.65, 15.30) 
6-week average          
28.8-60.2 10 1 263 1 54 1 1 1 1 
60.8-73.8 25 2.71 (1.33,5.51) 237 1.02 (0.82,1.28) 49 3.28 (0.86,12.43) 2.42 (1.17, 5.00) 0.99 (0.78, 1.26) 2.98 (0.77, 11.55) 
74.7-133.2 17 2.34 (1.10,4.97) 173 1.02 (0.80,1.31) 38 4.32 (0.93,20.22) 2.08 (0.96, 4.52) 1.02 (0.79, 1.32) 4.41 (0.92, 21.03) 
TTHM exposure through showering & 
bathing (μg/day)          
2nd-trimester average          
0.08-0.9 15  257  37     
1-1.5 15 1.01 (0.49,2.08) 236 0.88 (0.70,1.11) 58 3.13 (0.93,10.52) 1.12 (0.54, 2.33) 0.90 (0.71, 1.14) 3.33 (0.96, 11.59) 
1.6-27.1 27 1.88 (0.99,3.54) 231 0.87 (0.69,1.09) 52 2.38 (0.78,7.29) 1.87 (0.95, 3.67) 0.96 (0.74, 1.23) 2.40 (0.76, 7.62) 
Weekly concentration           
0-0.9 13  247  50     
1-1.5 18 1.77 (0.86,3.62) 205 0.98 (0.77,1.25) 37 1.85 (0.56,6.16) 1.97 (0.94, 4.11) 0.99 (0.78, 1.27) 1.74 (0.51, 5.98) 
1.6-20.6 24 2.17 (1.10,4.28) 218 0.99 (0.78,1.25) 54 2.22 (0.75,6.56) 2.17 (1.05, 4.49) 1.07 (0.83, 1.39) 2.33 (0.75, 7.19) 
6-week average          
0-0.9 13  241  49     
1-1.5 15 1.36 (0.64,2.87) 219 1.09 (0.86,1.37) 38 3.36 (0.70,16.16) 1.46 (0.68, 3.15) 1.09 (0.85, 1.39) 3.47 (0.70, 17.09) 
1.6-16.6 27 2.40 (1.23,4.67) 210 0.98 (0.77,1.24) 55 1.65 (0.62,4.41) 2.41 (1.19, 4.90) 1.04 (0.80, 1.34) 1.77 (0.64, 4.95) 
a Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
b Number of births attributed to exposure category during the gestational period.  
Abbreviations: OR = conditional odds ratio, CI= confidence interval 
 161
Table 44. Association between HAA5 exposure and the conditional probability of delivery each week (gestational weeks’ 20 to 44) 
stratified by gestational period among women included in duration of gestation analyses from the chlorinated DBP site, 2000-2004. 
 Unadjusted Model Fully-adjusted Modela 
 Gestational Period (weeks’) Gestational Period (weeks’) 
 ≤ 36 37-40 ≥ 41 ≤ 36 37-40 ≥ 41 
Residential HAA5 level (μg/liter) nb OR (95% CI) nb OR  (95% CI) nb OR (95% CI) OR  (95% CI) OR  (95% CI) OR  (95% CI) 
2nd-trimester average          
18.7-32.4 20 1 240 1 48 1 1 1 1 
32.5-40.7 16 0.83 (0.43,1.59) 242 0.99 (0.78,1.24) 52 2.32 (0.77,6.96) 0.61 (0.30, 1.23) 0.98 (0.77, 1.25) 1.93 (0.63, 5.92) 
40.7-52.8 18 0.99 (0.53,1.85) 243 1.06 (0.84,1.33) 47 4.61 (0.97,21.96) 0.90 (0.48, 1.70) 1.10 (0.86, 1.39) 3.94 (0.81, 19.17) 
Weekly concentration           
12.1-32.5 18 1 266 1 35 1 1 1 1 
32.6-40.7 10 0.97 (0.45,2.06) 161 0.96 (0.74,1.23) 48 2.91 (0.80,10.58) 0.78 (0.35, 1.74) 0.91 (0.70, 1.18) 2.58 (0.68, 9.82) 
40.8-62.2 24 1.44 (0.78,2.63) 246 1.01 (0.81,1.27)  1.96 (0.58,6.61) 1.27 (0.68, 2.36) 1.00 (0.79, 1.27) 1.77 (0.51, 6.10) 
6-week average          
16-32.4 13 1 223 1 48 1 1 1 1 
32.7-40.7 23 2.16 (1.10,4.24) 184 1.01 (0.79,1.3) 40 4.32 (0.92,20.36) 1.99 (1.00, 3.95) 1.00 (0.77, 1.29) 4.21 (0.88, 20.15) 
41-56.4 16 1.14 (0.55,2.36) 266 1.05 (0.84,1.32) 53 2.21 (0.73,6.75) 0.94 (0.44, 2.02) 1.04 (0.82, 1.32) 1.77 (0.57, 5.56) 
HAA5 exposure through tap-water 
consumption (μg/day)          
2nd-trimester average          
0-35.3 22 1 239 1 48 1 1 1 1 
35.3-69.7 16 0.74 (0.39,1.39) 243 0.96 (0.76,1.21) 48 4.18 (0.87,19.99) 0.87 (0.44, 1.70) 0.93 (0.73, 1.18) 4.32 (0.88, 21.18) 
69.7-369.1 16 0.73 (0.39,1.37) 242 0.89 (0.71,1.12) 51 1.58 (0.59,4.24) 0.91 (0.47, 1.76) 0.85 (0.66, 1.08) 1.43 (0.51, 4.03) 
Weekly concentration           
0-35.3 18 1 240 1 46 1 1 1 1 
35.3-69.7 14 0.75 (0.38,1.49) 197 0.99 (0.78,1.26) 41 2.29 (0.59,8.93) 0.72 (0.35, 1.49) 0.99 (0.77, 1.27) 2.32 (0.57, 9.38) 
69.7-511.4 20 0.91 (0.49,1.69) 233 0.91 (0.72,1.14) 54 1.68 (0.64,4.46) 1.01 (0.53, 1.92) 0.87 (0.68, 1.11) 1.46 (0.52, 4.09) 
6-week averages          
0-35.3 19 1 233 1 48 1 1 1 1 
35.3-69.7 16 0.97 (0.51,1.85) 199 0.91 (0.72,1.16) 44 3.71 0.77,17.8) 1.08 (0.55, 2.13) 0.92 (0.71, 1.18) 3.77 (0.77, 18.56) 
69.7-511.4 17 0.79 (0.41,1.50) 238 0.91 (0.72,1.15) 50 1.36 (0.53,3.49) 0.91 (0.46, 1.80) 0.88 (0.69, 1.13) 1.15 (0.42, 3.11) 
a Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
b Number of births attributed to exposure category during the gestational period.  
Abbreviations: OR = conditional odds ratio, CI= confidence interval 
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Table 13. Association between TOX exposure and the conditional probability of delivery each week (gestational weeks’ 20 to 44) stratified by gestational period among women 
included in duration of gestation analyses from the chlorinated DBP site, 2000-2004. 
 Unadjusted Model Fully-adjusted Modela 
 Gestational Period (weeks’) Gestational Period (weeks’) 
 ≤ 36 37-40 ≥ 41 ≤ 36 37-40 ≥ 41 
Residential TOX level (μg/liter) nb OR (95% CI) nb OR  (95% CI) nb OR (95% CI) OR  (95% CI) OR  (95% CI) OR  (95% CI) 
2nd-trimester average          
136.7-169.2 19 1 249 1 41 1 1 1 1 
169.3-178.4 16 0.93 (0.49,1.79) 240 0.87 (0.69,1.09) 55 4.15 (1.09,15.82) 0.78 (0.39, 1.54) 0.87 (0.68, 1.11) 3.34 (0.86, 13.06) 
178.4-220.6 19 1.06 (0.57,2.01) 236 1.03 (0.82,1.3) 51 3.04 (0.91,10.12) 0.93 (0.49, 1.79) 1.10 (0.86, 1.40) 2.72 (0.80, 9.23) 
Weekly concentration           
104-169 13 1 323 1 73 1 1 1 1 
170-178 8 2.51 (1.05,5.97) 73 1.04 (0.75,1.45) 18 3.34 (0.39,28.22) 2.30 (0.92, 5.76) 1.02 (0.72, 1.43) 3.52 (0.41, 30.45) 
179-269 31 2.52 (1.36,4.67) 277 0.92 (0.75,1.14) 50 1.2 (0.45,3.21) 2.40 (1.26, 4.57) 0.89 (0.72, 1.10) 1.03 (0.37, 2.87) 
6-week average          
121.7-169 14 1 257 1 38 1 1 1 1 
169.5-178.3 13 1.46 (0.7,3.05) 169 0.97 (0.75,1.24) 42 2.57 (0.77,8.53) 1.22 (0.57, 2.63) 0.96 (0.74, 1.25) 2.44 (0.71, 8.41) 
178.5-237.3 25 1.61 (0.85,3.05) 247 0.87 (0.7,1.09) 61 3.85 (1.2,12.39) 1.41 (0.73, 2.73) 0.84 (0.66, 1.07) 3.81 (1.15, 12.60) 
TOX exposure through tap-water 
consumption (μg/day)          
2nd-trimester average          
0-143.9 22 1 239 1 46 1 1 1 1 
144.6-306.7 15 0.65 (0.34,1.23) 242 0.99 (0.79,1.25) 52 3.04 (0.8,11.55) 0.78 (0.40, 1.54) 1.05 (0.82, 1.33) 3.25 (0.83, 12.71) 
307-1225.5 17 0.7 (0.37,1.3) 243 0.89 (0.7,1.12) 49 1.48 (0.55,3.98) 0.88 (0.46, 1.69) 0.87 (0.68, 1.11) 1.25 (0.44, 3.56) 
Weekly concentration           
0-144.6 16 1 227 1 50 1 1 1 1 
144.6-306.6 19 1.03 (0.54,1.96) 213 1 (0.78,1.27) 46 2.65 (0.7,10.05) 1.09 (0.55, 2.16) 1.04 (0.81, 1.34) 2.82 (0.72, 11.03) 
306.7-1823.4 17 0.89 (0.46,1.72) 230 0.88 (0.69,1.11) 45 1.34 (0.5,3.61) 0.99 (0.49, 1.97) 0.85 (0.66, 1.10) 1.12 (0.39, 3.16) 
6-week average          
0-144.6 19 1 222 1 45 1 1 1 1 
144.6-306.3 15 0.73 (0.38,1.42) 224 1.06 (0.83,1.34) 50 4.37 (0.91,20.94) 0.84 (0.42, 1.69) 1.10 (0.86, 1.41) 4.67 (0.95, 22.91) 
306.8-1823.4 18 0.81 (0.43,1.51) 224 0.87 (0.69,1.11) 47 1.35 (0.53,3.49) 0.94 (0.48, 1.82) 0.84 (0.65, 1.08) 1.15 (0.42, 3.13) 
a Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake. 
b Number of births attributed to exposure category during the gestational period.  
Abbreviations: OR = conditional odds ratio, CI= confidence interval 
CHAPTER 5: MANUSCRIPTS 
 
 
5.1 Manuscript 1: Drinking water disinfection by-product exposure and fetal growth. 
 
Abstract 
 Background: Previous studies suggest that elevated exposure to total 
trihalomethanes (TTHM) may lead to fetal growth restriction.  We examined the effects of 
exposure to trihalomethanes (THMs), haloacetic acids (HAAs) and total organic halide 
(TOX) on the probability of delivering a small-for-gestational-age (SGA) infant and term 
birth weight.   Methods: Women early in pregnancy (≤ 12 week’s gestation) or planning a 
pregnancy were enrolled into a prospective pregnancy study conducted in three U.S. 
communities from 2000-2004. Weekly water samples were collected and analyzed for DBPs. 
Participant data were collected through interviews, an early ultrasound and birth records. 
Associations between aggregate DBP measures (TTHM, HAAs, TOX) and fetal growth were 
assessed using log-binomial regression for SGA (n=1,958) and linear regression for term 
birth weight (n=1,854).  A fully-Bayesian analysis was conducted to examine joint 
associations between individual DBPs and fetal growth in a single model.  Results: HAAs 
and TOX were not associated with SGA or term birth weight.  The estimated probability of 
delivering an SGA infant for an average third trimester residential TTHM concentration ≥ 80 
micrograms/liter was twice as high as the probability for an average concentration < 80 
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micrograms/liter (Risk Ratio [95% confidence interval] = 2.0 [1.1, 3.6]).  Results of the 
Bayesian model did not support a consistent association between any particular THM or 
HAA and SGA or term birth weight.  Conclusions: Our results do not suggest an adverse 
effect of HAA or TOX exposure on fetal growth.  An association with TTHM was seen for 
average residential concentrations above the current regulatory standard. 
 
5.1.1 Introduction 
 
Over the past two decades, toxicological and epidemiological studies have suggested 
that drinking water disinfection by-product (DBP) exposure during pregnancy may increase 
the risk of adverse pregnancy outcomes such as pregnancy loss, birth defects, and fetal 
growth restriction5-7.  In particular, epidemiological studies have found a moderate increased 
risk of delivering a small-for-gestational-age (SGA) infant among women exposed to high 
levels of total trihalomethanes (TTHM) compared to women in the lowest exposure group, 
reporting relative risks in the range of 1.0-1.5 89,90,94,95,97,98,101.  TTHM also has been 
associated with decreased mean birth weight and an increased risk of delivering a low birth 
weight (LBW) infant 89-92,94-99.   
The mechanism by which TTHM exposure may lead to reduced fetal growth is not 
well understood 7.   TTHM is an aggregate measure of four individual trihalomethanes 
(THMs), chloroform, bromodichloromethane (BDCM), dibromochloromethane (DBCM) and 
bromoform, that is regulated by the US Environmental Protection Agency (EPA)14.  The 
concentration of TTHM within a distribution system is generally correlated with the 
concentrations of other DBPs, but the magnitude of correlation between DBPs may vary 
from system to system.  Therefore, it is unclear whether findings of previous epidemiological 
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studies indicate that THMs as a whole or a specific constituent of TTHM (e.g., BDCM) are 
biologically active, or alternatively, TTHM is serving as a marker for another drinking water 
contaminant.  Toxicological data suggests that brominated THMs and haloacetic acids 
(HAAs) are probably more harmful to the fetus than chlorinated THMs7, but relatively few 
epidemiological studies of DBPs and fetal growth restriction have examined individual 
THMs 89,93-95,101 or HAA exposure89,95,101.  Results of these studies as a whole have not 
implicated any particular constituent of TTHM as being more or less harmful and have been 
inconsistent for HAA exposure.  
Previous epidemiological studies of DBP exposure and pregnancy health are limited 
by poor exposure assessment.  The majority of these studies obtained information on DBP 
concentrations retrospectively from regulatory databases, which may not have provided 
sufficient data to capture spatial and/or temporal variability in DBP concentrations within the 
distribution systems serving the population under study 119,120.  Furthermore, most previous 
studies were not able to account for individual variation in tap water uptake through 
ingestion, inhalation and dermal absorption, which can influence an individual’s actual 
exposure to DBPs and lead to exposure assessment error 18,24,121.  
This study had two objectives.  The first was to examine the association between 
aggregate DBP measures and measures of fetal growth, specifically the proportion of infants 
born SGA and mean birth weight among term births, using improved exposure data that 
allow inter-individual variability to be estimated more accurately than in previous studies.  
The second was to examine the effect of exposure to individual THMs and HAAs on fetal 
growth measures simultaneously using Bayesian analytic techniques to account for the high 
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correlation between DBP concentrations.  To the authors’ knowledge, this is the most 
extensive study of DBP exposure and fetal growth that has been conducted to date. 
 
5.1.2 Material and Methods 
 
Study design and population 
Women from three US communities were recruited into a prospective cohort study 
early in pregnancy (≤ 12 weeks’ gestation) or while planning to become pregnant from 2000 
to 2004.  Communities were chosen to insure a wide range of DBP exposure across study 
sites: moderate levels of predominately chlorinated DBPs (hereafter referred to as the 
“chlorinated DBP site”), moderate levels of predominately brominated DBPs (the 
“brominated DBP site”), and low levels of all DBPs (the “low DBP site”).  Moderate DBP 
sites were also selected because they used chloramination for terminal disinfection rather 
than free chlorine, which minimizes spatial variability in DBP concentrations within a site 
122,123.  Additional details on study design and recruitment have been published elsewhere 
26,124,125.  
A total of 2,766 pregnancies (68% of all women screened) were enrolled.  For this 
study, 259 pregnancies with missing or incomplete baseline interviews, 237 pregnancies that 
ended in a loss, 90 pregnancies lost to follow-up, seven pregnancies missing information on 
date of birth or birth weight, eight multi-gestational pregnancies and 16 repeat live births to a 
study participant were excluded, resulting in a total of 2,039 pregnancies (74% of those 
enrolled) eligible for fetal growth analyses. In addition, SGA status could not be assigned for 
three births missing information on maternal race, 73 births with a reported maternal race of 
“Indian”, “Asian/Pacific islander”, or “Other”, and five births with an estimated gestational 
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age at birth <25 or > 42 weeks’ gestation, reducing the final sample size for SGA models to 
1,958 births.  Term mean birth weight models were restricted to 1,854 live births born at ≥ 37 
weeks’ gestation. Women eligible for fetal growth analyses were similar to all enrolled 
participants with respect to maternal age, estimated gestational age at enrollment, and parity, 
but were slightly more likely to be White and to have completed ≥ 16 years of education.  
 
Measurement of DBP concentrations 
Details of water sample collection, shipment and analysis have been published 
elsewhere26.  Briefly, weekly water samples were collected from each study site at a single 
location that was verified to accurately represent DBP concentrations throughout the water 
distribution system 26.  Additional samples were collected during one month each year when 
the chlorinated and brominated sites converted to free chlorine for system flushing and 
averaged to estimate system wide levels.  Concentrations of four individual THMs and nine 
HAAs (listed in table 2) and total organic halide (TOX) were measured in micrograms/liter 
using standard methods104-107.  Individual THMs were summed to calculate the concentration 
of TTHM.  In addition, the US EPA regulated sum of five HAAs was calculated (i.e., the 
sum of chloroacetic acid [CAA], dichloroacetic acid [DCAA], trichloroacetic acid [TCAA], 
bromoacetic acid [BAA], and dibromoacetic acid [DBAA] concentrations)14, henceforth 
referred to as “HAA5”.  DBP concentrations below the practical quantitation limit for each 
analytic method (i.e., 0.1 µg/liter for all four THM species and 1.0 or 2.0 µg/liter for HAA 
species) were set to zero.   
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Characterization of DBP exposure 
Two exposure metrics were considered for TTHM and HAA5: 1) residential 
concentrations (i.e., concentrations in the water distribution system serving a woman’s 
residence) and 2) personal exposure.  Personal TTHM and HAA5 were estimated by 
combining residential concentrations of TTHM and HAA5 with detailed information on tap 
water consumption, showering and bathing habits collected during telephone interviews 
conducted at baseline (by 16 weeks’ gestation) and follow-up (between 20-25 weeks’ 
gestation).  Algorithms used to estimate personal exposure have been previously published 
26,125.  Briefly, personal TTHM exposure was estimated by integrating residential THM 
concentrations and self-reported information on average duration and frequency of showering 
and bathing into an absorbed dose (µg/day) using uptake factors derived from toxicokinetic 
studies126,127.  Personal HAA exposure was estimated by first adjusting residential HAA 
concentrations for boiling and filtering 26,109 and then combining adjusted HAA 
concentrations with self-reported information on the number and size of glasses of cold/hot 
filtered/unfiltered tap water drinks typically consumed per day.  The personal HAA exposure 
estimate represents average daily intake of HAAs (µg/day).  Exposure to individual THMs 
and HAAs and TOX were examined using residential concentrations alone.          
 
Assessment of fetal growth parameters 
Data used for fetal growth assessment (i.e., infant date of birth, birth weight and 
gender) were obtained from medical records for 43.0% of live births, vital records for 56.5%, 
and participant self-report for only 0.5%.  SGA was defined as an infant with a birth weight 
below the tenth percentile for his or her gestational age at birth (between 25 to 42 weeks), 
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gender, maternal race/ethnicity (non-Hispanic White, Non-Hispanic Black, or Hispanic), and 
maternal parity (nulliparous or parous) based upon previously published standardized birth 
weight curves 38,43.  Maternal race/ethnicity and parity were self-reported at telephone 
interview.  Gestational age at birth was derived from first trimester report of last menstrual 
period (LMP), which was corrected by ultrasound (also obtained during the first trimester) if 
the two estimates of gestational age were different by more than 7 days.  
    
Statistical Analysis 
The association between aggregate DBP measures (TTHM, HAA5 and TOX) and the 
probability of delivering a SGA infant was examined using log binomial regression.  The 
association with average term birth weight was examined using linear regression, restricting 
to pregnancies born at ≥ 37 weeks’ gestation. Trimester-specific average DBP exposures 
(first, second and third) were estimated and considered in separate models.  First trimester 
was defined as 0 to 12 weeks, second trimester as 13 to 26 weeks, and third trimester as 27 
weeks until birth.  
Restricted quadratic splines were used to model the dose-response in probability of an 
SGA birth and mean term birth by residential DBP concentrations, which was then plotted 
and visually inspected to determine if quantile categorization of exposure was appropriate.  
Residential DBP concentrations among the moderate exposure sites also were divided into 
quartiles using cut-points derived from second-trimester average DBP distributions, and the 
low exposure site served as the referent. In addition, the US EPA regulatory standard for 
residential TTHM level (80 micrograms/liter) was examined.  Too few women had average 
HAA5 levels above the US EPA standard (60 micrograms/liter) to be examined.  Personal 
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DBP exposure estimates were examined using categorical coding only, as the authors believe 
this exposure metric is most useful for roughly separating women into “high”, “moderate” 
and “low” exposure groups when considering the amount of error potentially introduced 
through self-reported data on water use and consumption.   
Individual THM and HAA levels were highly correlated in this study.  Modeling each 
exposure in a separate risk model could lead to spurious associations due to confounding by 
other correlated DBPs, so a single model that controls for all individual THMs and HAAs is 
desirable.  However, adjustment for multiple DBP exposures using standard maximum 
likelihood estimation (MLE) may fail to provide plausible estimates given that exposures are 
highly correlated 113.   Alternatively, Bayesian analytic techniques allow simultaneous 
modeling of highly correlated exposures in a single model.  In addition, prior distributions 
can be specified to “borrow” information across sets of individual DBPs that may have a 
common underlying biologic mechanism (e.g., HAAs or brominated DBP compounds)113.  
A fully Bayesian analysis was conducted to examine the association between fetal 
growth measures and third trimester average residential concentrations of individual THMs 
and HAAs.  Logistic and linear regression models were constructed for SGA and term birth 
weight, respectively, and DBP concentrations were entered into the model using quantile 
categories.  Prior distributions were specified for the effect of DBP exposures (i.e., βj ~ 
Normal[μj,φ2], where j represents individual DBP compounds) and the variance of the effect 
of DBP exposures (i.e., the standard deviation was specified as φ ~ uniform[0,R]).  Two 
scenarios were considered for the specification of the prior mean: 1) no effect of DBP 
exposures (i.e., μj=0 for all j) and 2) the effect of an individual DBP compound is a function 
of DBP class and bromination status (i.e., μj= μk, where μk ~N(0,10) and represents the mean 
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of the combined effect of DBP class and bromination status).  This latter prior specification 
of the mean results in shrinkage of the effect for non-brominated THMs (i.e., chloroform), 
non-brominated HAAs, brominated THMs, and non-brominated HAAs towards each other, 
to the extent that the data support a similar effect within groups, and allows “borrowing” of 
information within groups.  For prior specification of the variance of effects of DBP 
exposures, the upper bound for the variance, R, was set at 0.70 for the SGA analysis (mean 
value of φ = 0.35) and 100 (mean value of φ = 50) for the term birth weight analysis.  In a 
semi-Bayesian approach with fixed R, these mean values would correspond to a 95% range 
in risk ratios (RR) for SGA of 0.5 to 2.0 and 95% range in mean difference in birth weight of 
-100 to 100 grams, respectively.  Markov chain Monte Carlo methods (MCMC) in the 
software package WinBUGS (2007 MRC Biostatistics Unit, Cambridge, UK) were used 
obtain posterior distributions, including the posterior mean for the effect for each DBP 
category and an associated 95% credible interval (CI), which can be interpreted as an interval 
that has a high probability (95%) of containing the unknown quantity of interest 114.  Three 
chains were simulated, with 5,000 iterations run for each chain.  The first 2,500 iterations of 
each chain were discarded as “burn-in”, and the remaining iterations were thinned by keeping 
every 7th simulation drawn to avoid dependence of iterations from the same chain114, 
resulting in a total of 1,074 simulations saved.  
For MLE and Bayesian models, confounders were identified from the literature as 
risk factors for fetal growth restriction that may be independently associated with DBP 
exposure but not on the causal pathway between exposure and disease according to directed 
acyclic graph analysis115. Effect measure modification by maternal age (< 25, 25-29, 30-35, ≥ 
35 years of age), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic and 
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other) and swimming during pregnancy (yes/no) was assessed in MLE models by 
constructing DBP-covariate interaction terms, which were retained if the p- value for the 
joint effect of all terms was < 0.10.  Variables identified as effect measure modifiers in MLE 
analyses, if any, were incorporated into Bayesian analyses.  MLE analyses were conducted 
using Stata (College Station, TX) and Bayesian analyses were conducted using R (Vienna, 
Austria)117 and WinBUGS software (Cambridge, England)118. 
 
5.1.3 Results 
  
Examining the descriptive statistics by site, the proportion of SGA infants was higher 
at the brominated DBP site (8.2%) compared to the chlorinated and low DBP sites (4.8% and 
5.9%, respectively).  Mean birth weight among term births was higher at the chlorinated site 
compared to the brominated and low DBP sites (table 45).  
TTHM concentrations were similar between the chlorinated and brominated DBP 
sites, but the chlorinated site had slightly higher concentrations of HAA5 and slightly lower 
concentrations of TOX compared to the brominated DBP site (table 46).  As expected, the 
brominated DBP site had much higher concentrations of the brominated DBP compounds 
and much lower concentrations of non-brominated compounds compared to the chlorinated 
DBP site, with the exception of BDCM, CAA, BCAA and BDCAA.  These DBPs were 
found in relatively comparable concentrations between the two moderate exposure sites.  
Overall, DBP concentrations at the low exposure site were much less than concentrations 
found at the two moderate exposure sites.  Means and standard deviations for DBP 
concentrations were essentially the same as those presented in table 46 when calculations 
were restricted strictly to women included in the SGA and term birth weight analyses.      
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Analyses of aggregate DBP measures 
Spline modeling of aggregate DBP measures did not suggest a dose-response in the 
probability of delivering an SGA infant in relation to TTHM, HAA5 or TOX residential 
concentrations (data not shown).  Although elevated effects for the lowest quartile of 
moderate residential HAA5 exposure during the second trimester and the highest quartile of 
personal THM exposure during the third trimester were found, estimated RRs for SGA 
comparing quartiles of moderate DBP exposure to the low exposure group overall did not 
suggest consistent patterns of association with increasing TTHM, HAA5, or TOX residential 
levels or increasing personal TTHM and HAA5 exposure (table 47).  The estimated 
probability of delivering an SGA infant among women with an average third trimester 
residential TTHM concentration ≥ 80 micrograms/liter was twice as high as the probability 
of delivering an SGA infant among women with an average concentration < 80 
micrograms/liter (RR [95% confidence interval] = 2.0 [1.1, 3.6]).  Effect measure 
modification by maternal age, race/ethnicity or swimming during pregnancy was not found.     
A dose-response in mean birth weight among term live births in relation to TTHM, 
HAA5, or TOX was not suggested by spline modeling of residential concentrations (data not 
shown) or by estimated changes in mean birth weight when comparing upper quartiles of 
DBP exposure to the low exposure group for residential concentrations and personal 
exposure estimates (table 48).  A few statistically significant increases and decreases in birth 
weight were observed, (e.g., first trimester HAA5 residential concentrations), but patterns of 
associations were not consistent. The estimated decrease in term birth weight associated with 
an average third trimester residential TTHM concentration ≥ 80 versus < 80 micrograms/liter 
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(mean difference in grams = -55.9 [-143.7, 31.9]) was less pronounced than the association 
found for SGA.  Effect measure modification by maternal age, race/ethnicity or swimming 
during pregnancy was not found. 
 
Analyses of individual DBPs  
As previously mentioned, examination of the distributions of individual DBPs by 
study site revealed that the range of concentrations at each site overlapped very little for most 
THMs and HAAs.  Therefore, Bayesian analyses were run separately for the chlorinated and 
brominated DBP sites to avoid the potential for residual confounding by study site.  MLE 
models were also constructed separately for each DBP to serve as a reference when 
examining results from the fully adjusted Bayesian models.   
Results of the MLE analyses restricted to the chlorinated DBP site suggested that 
elevated exposure to bromoform, DBCM and BAA was associated with increased probability 
of delivering an SGA infant (table 49).  Estimated associations for these DBPs from the 
Bayesian analysis were attenuated after adjustment for other DBPs and shrinking by DBP 
class and bromination status, and 95% CIs for all effect estimates included values below the 
null value, indicating that a null or protective effect of DBPs was within the probable range.  
RRs for SGA from the Bayesian analysis using a vague prior were all within the range of 
0.9.-1.2, with wide 95% CIs (data not shown).  A similar pattern of associations was found 
for term birth weight.   
In contrast, results of the MLE analyses restricted to the brominated DBP site 
suggested that elevated exposure to predominately chlorinated DBPs (i.e., chloroform, CAA, 
DCAA, TCAA, and BCAA) was associated with increased probability of delivering an SGA 
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infant and decreased term birth weight, albeit effect estimates were highly unstable given the 
small number of participants from this study site (table 50).  Estimated effects for chloroform 
remained elevated in the Bayesian analysis for SGA, but a respective decrease in mean birth 
weight for the DBPs was not found.   Again, 95% CIs for all effect estimates included the 
null value, and results of Bayesian analysis using a vague prior did not indicate an 
association between either fetal growth measure and any individual THM or HAA (data not 
shown).   
         
5.1.4 Discussion 
 
Findings of our study do not suggest an adverse effect of TTHM or HAA5 exposure 
on fetal growth at residential concentrations below the current regulatory standards or when 
examining estimated personal exposure to TTHM or HAA5.  We also did not find an 
association with TOX residential concentrations.  An increased probability of delivering an 
SGA infant was found when comparing women with average third trimester TTHM 
residential concentrations ≥ 80 micrograms/liter to women with average levels < 80 
micrograms/liter.  This finding suggests that the increased risk of fetal growth restriction 
associated with elevated residential TTHM concentrations occurs only at levels above the 
current US EPA regulatory standard, albeit very few women experienced average TTHM 
levels ≥ 80 micrograms/liter in our study.    
Findings for site-specific analyses of individual THMs and HAAs are less clear.  
Results from the chlorinated DBP site suggest that THMs, particularly the brominated 
species, may be associated with increased risk of delivering an SGA infant.  Conversely, 
results from the brominated DBP site suggest that chlorinated HAAs may be associated with 
 176
both increased risk of SGA and decreased mean birth weight among term births.  However, 
concentrations of the individual DBPs implicated at each site for the most part are not 
comparable to concentrations at the other site, except for CAA and BDCM.  In addition, 95% 
CI from the Bayesian analysis underscore that a null or protective effect of all THMs and 
HAAs in relation to fetal growth restriction is also probable given our prior assumptions and 
the data at hand.  Therefore, we do not feel our study provides strong support that any 
particular DBP (or set of DBPs) is associated with fetal growth restriction. 
Previous studies have examined the effect of TTHM exposure on fetal growth using 
several different outcome measures, including mean change in birth weight in grams, the 
probability of a LBW (< 2,500 grams) or very LBW (<1,500 grams) infant, and the 
probability of a SGA infant.  In general, these studies suggest that elevated TTHM levels in 
drinking water may be associated with a moderate decrease in continuous birth weight (-1 to 
-70 grams) and increased risk of SGA (RRs of 1.0-1.5).  Few studies have examined 
individual THM species or HAA exposure 89,93-95,101.  Findings of these studies have been 
much less consistent, and overall do not implicate any particular component of TTHM as 
responsible for the observed association found with this aggregate THM measure.  Results 
from studies examining HAA exposure have also been inconsistent.   
A major strength of our study is the concurrent measurement of DBP concentrations 
over the course of pregnancy, including some HAAs that are not routinely regulated by the 
US EPA.  Weekly DBP measurements (or bi-weekly at the low exposure site) were collected 
to capture the temporal variability in DBP concentrations and allowed estimation of window-
specific average exposures based on more measurements (generally 6-13) made at regular 
intervals rather than the typical case of one day of monitoring during a 3-month period.  
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Furthermore, our water sampling strategy was validated to accurately represent levels 
throughout the water distribution systems serving study participants’ homes 26.  As a result, 
assignment of trimester average residential DBP concentrations should be quite accurate.  
An additional strength of our study is that pregnant women were prospectively 
followed.  This allowed collection of self-reported data on maternal demographics and health 
behaviors that may confound the association between DBP exposure and fetal growth as well 
as the collection of a first trimester ultrasound and medical record abstraction to provide 
accurate information on gestational age and birth weight.  In addition, data on tap water 
consumption, showering and bathing, and other tap water use was collected and used to 
estimate personal DBP exposure and account for intra-individual variability in water 
exposure.  The majority of previous studies relied on birth certificate data to obtain 
information on pregnancy outcomes and potential confounders, and only two studies have 
incorporated information on individual water use to estimate personal DBP exposure 92,94, 
although like our study, personal exposure did not show a stronger association than 
residential concentration with respect to fetal growth outcomes.  
Given these improvements in exposure and outcome assessment and our ability to 
better control for known risk factors for fetal growth restriction, we expected to find stronger 
effects of TTHM exposure than previously reported if TTHM is truly associated with fetal 
growth restriction.  However, we did not find an association with TTHM at concentrations 
below the regulatory cut-point, as has been suggested by previous studies.  One possible 
explanation is differences in the population of women under study. Unlike previous studies, 
our study population represents a group of women who knew they were pregnant in the first 
trimester and volunteered to participate in a prospective pregnancy study. We compared 
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maternal characteristics of pregnancies enrolled in the RFTS study to all births identified 
from vital records in the same geographic location over the same time period in a previous 
report and found that our study participants were similar to the general population with 
respect to age but where more likely to be highly educated (≥ 16 years of education), non-
Hispanic White, and nulliparous when compared to the general population26.  In addition, the 
sample size of our study was considerably lower than most previous studies, which 
ultimately resulted in low precision of effect estimates, particularly when stratifying by study 
site.     
By selecting study sites with different distributions of DBP concentrations, we 
created a range of reliable DBP measures (high/literow, chlorinated/brominated) that would 
not be possible studying a single geographic region.  No other study of DBPs and 
reproductive health has examined such a broad range of DBP exposure.  However, the 
underlying population characteristics of our three study sites are very different, and factors 
associated with study participation (e.g., maternal age, race/ethnicity, education) also varied 
by site.  As a result, women who participated from each site have different demographic 
profiles and show an overall difference in the proportion of infants born SGA and mean birth 
weight.  We adjusted TTHM, HAA5 and TOX analyses for the major risk factors for fetal 
growth restriction that varied in distribution between sites to control for potential 
confounding between study sites, and only performed site-specific analyses for individual 
THMs and HAAs.  In addition, we ran aggregate DBP analyses stratifying by study site to 
confirm that the pattern of results were similar across study sites but less precise (data not 
shown). For example, RRs (95% CI) for SGA comparing average third trimester TTHM 
concentrations ≥ 80 micrograms/liter versus < 80 micrograms/liter) were 1.9 (1.0, 3.7) 
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excluding the low DBP site, 1.9 (0.9, 4.2) restricting to the chlorinated DBP site alone, and 
1.7 (0.6, 5.0) restricting to the brominated DBP site alone.  While the resiliency of this 
finding across study sites is impressive, it should be noted that there were few SGA cases in 
the high exposure group (eight at the chlorinated DBP site and four at the brominated DBP 
site), so these RR estimates are very unstable.   
Fetal growth restriction describes a decrease in fetal growth rate that prevents an 
infant from reaching his/her growth potential at a given age. We used SGA as a surrogate for 
fetal growth restriction because it is conventionally used to identify more severe growth 
restriction in epidemiological research and has been examined in previous DBP studies.  
However, not all infants that are “small” at birth are growth restricted and vice versa. 
Researchers often restrict SGA analyses to term infants to obtain a “cleaner” group of infants 
to assess fetal growth restriction.  We found similar results when we restricted analyses to 
infants born at ≥ 37 weeks’ completed gestation (data not shown).  
In conclusion, our study is the most extensive study of DBP exposure and fetal 
growth restriction conducted to date.  Our results do not suggest an adverse effect of 
residential TTHM or HAA5 levels within the regulatory limits on fetal growth, but we did 
find an increased probability of delivering an SGA infant at exposure levels above the 
regulatory standard for TTHM (≥ 80 micrograms), which was consistent across study sites.  
Although the brominated THMs (at the chlorinated DBP site) and non-brominated HAAs (at 
the chlorinated DBP site) showed a positive association with SGA in MLE analyses, none of 
the individual THMs or HAAs examined were associated with fetal growth restriction after 
adjustment for other DBPs.  
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5.1.5 References 
 
Table 45. Characteristics of women included in the analyses of exposure to 
drinking water DBPs and fetal growth restriction, 2000-2004 
 
SGA analysis 
(n=1,958) 
Tem birth weight analysis 
(n=1,854) 
 SGA (n=113) Non-SGA (n=1,845)  Birth weight (grams) 
 N Col. % Col. % N Mean (s.d.) 
Study site     
Chlorinated 883 45.6 37.2 305 3530 (482) 
Brominated 340 16.9 24.8 677 3406 (460) 
Low DBP site 735 37.5 38.1 874 3448 (453) 
Maternal Age      
< 25 575 38.1 29.1 531 3360 (446) 
25-29 625 31.9 32.2 597 3479 (470) 
30-35 538 19.5 28.2 517 3567 (471) 
≥ 35 205 10.6 10.6 194 3568 (466) 
Maternal      
Non-Hispanic 1168 50.4 60.2 1082 3560 (459) 
Non-Hispanic 605 39.8 30.4 535 3316 (460) 
Hispanic 185 9.7 9.4 169 3499 (456) 
Other --*   68 3445 (435) 
Missing --*   2  
Highest education      
High school or 561 44.3 27.7 502 3366 (481) 
Some college 423 20.4 21.7 398 3455 (462) 
College degree 973 35.4 50.6 955 3550 (456) 
Missing 1   1  
Annual household      
<30,000 610 40.0 32.0 562 3386 (450) 
30,001-60,000 511 32.4 26.9 497 3506 (476) 
60,001-80,000 310 14.3 16.6 303 3496 (472) 
>80,000 450 13.3 24.6 428 3593 (461) 
Missing 77   66  
Employed during      
Non-employed 580 33.6 29.4 552 3514 (476) 
Employed 1377 66.4 70.6 1304 3466 (467) 
Missing 1     
Marital status      
Married 1334 55.8 68.9 1290 3535 (461) 
Not married 623 44.3 31.1 565 3354 (466) 
Missing 1   1  
Pre-pregnancy BMI 
2
     
<19.8 220 17.9 11.1 214 3363 (457) 
19.8-25.9 978 47.2 51.4 936 3488 (464) 
26.0-29.9 317 17.0 16.6 311 3490 (456) 
>29.9 398 17.9 21.0 349 3539 (494) 
Missing 45   46  
Daily caffeine      
0 496 19.5 25.7 473 3514 (483) 
1-150 453 20.4 23.3 431 3471 (456) 
151-300 371 19.5 18.9 346 3453 (481) 
>300 638 40.7 32.1 606 3475 (464) 
Parity      
Nulliparous 947 59.3 47.7 892 3429 (475) 
Parous 1011 40.7 52.3 964 3527 (461) 
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* SGA could not be assigned for 3 births with missing maternal race or 73 births to women of “other” race. 
Abbreviations: SGA = small-for-gestational-age, s.d. = standard deviation, BMI = body mass index, DBP= 
disinfection by-product, SGA= small-for-gestational-age     
 
 
Table 46. Second trimester average residential DBP concentrations 
across study sites among women eligible for inclusion in the analyses of 
exposure to drinking water DBPs and fetal growth restriction, 2000-
2004 (n=2,039 women eligible for both SGA and term birth weight 
analyses)    
DBP (μg/liter)* 
Chlorinated DBP site 
(n=929) 
Brominated DBP site 
(n=349) 
Low DBP site 
(n=761) 
Trihalomethanes    
Chloroform 46.7 (13.3) 13.7 (3.3) 0.2 (0.2) 
BDCM 15.1 (4.4) 21.1 (2.9) 1 (0.2) 
DBCM 4.4 (2.1) 23.1 (6.5) 1.4 (0.2) 
Bromoform 0.2 (0.2) 5.7 (3.9) 0.7 (0.1) 
TTHM† 66.4 (15.8) 63.6 (11.8) 3.3 (0.6) 
 
Haloacetic Acids    
CAA 2.8 (1.1) 1.7 (0.9) 0 (0.1) 
DCAA 18.7 (3.5) 7.1 (1.8) 0 (0) 
TCAA 13.6 (5) 5.3 (1.8) 0 (0.1) 
BCAA 4.6 (1.3) 8.9 (1.3) 0.8 (0.7) 
BDCAA 4.6 (1.4) 8.2 (0.7) 0 (0) 
DBCAA 1.2 (0.6) 5.6 (1.2) 0.4 (0.6) 
BAA 0.1 (0.1) 0.7 (0.5) 0 (0) 
DBAA 0.7 (0.5) 6.2 (2.6) 0 (0.1) 
TBAA 0.2 (0.3) 2.7 (0.9) 0.2 (0.4) 
HAA5‡ 35.9 (8.6) 21.1 (2.5) 0.08 (0.1) 
 
TOX 173.8 (16.3) 195.3 (16.7) 17.7 (2.0) 
* Numbers in table are mean (standard deviation) 
† TTHM is the sum of chloroform, BDCM, DBCM and bromoform 
‡ HAA5 is the sum of CAA, DCAA, TCAA, BAA, DBAA  
Abbreviations: DBP= disinfection by-product, BDCM= bromodichloromethane, DBCM = 
dibromochloromethane, TTHM = total trihalomethane, CAA= chloroacetic acid, 
DCAA=dichloroacetic acid, TCAA=trichloroacetic acid, BCAA= bromodichloroacetic acid, 
BDCAA= bromodichloroacetic acid, DBCAA= dibromochloroacetic acetic acid, BAA= 
bromoacetic acid, DBAA= dibromoacetic acid, TBAA= tribromoacetic acid, HAA5 = sum of 
five haloacetic acids, TOX= total organic halides. 
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Table 47. Associations between trimester-specific average DBP exposure and probability of SGA among women 
included in the analyses of exposure to drinking water DBPs and SGA*, 2000-2004. 
 First trimester average Second trimester average Third trimester average 
 n SGA n Non-SGA RR (95% CI)† n SGA n Non-SGA RR (95% CI)† n SGA n Non-SGA RR (95% CI)† 
Residential TTHM concentration (μg/liter)          
2.2-4.6 43 692 1 43 692 1 43 667 1 
33.1-55 21 339 1.1 (0.7, 2.0) 17 290 1.0 (0.5, 1.8) 19 258 1.2 (0.7, 2.2) 
55-66.3 16 256 1.2 (0.7, 2.1) 20 289 1.3 (0.7, 2.2) 15 330 0.8 (0.4, 1.5) 
66.4-74.8 18 239 1.2 (0.7, 2.2) 15 289 0.8 (0.4, 1.5) 16 256 1.2 (0.7, 2.2) 
74.9-108.8 15 319 0.8 (0.4, 1.5) 18 285 1.2 (0.7, 2.1) 18 274 1.3 (0.7, 2.3) 
Missing 0 0  0 0  4 60  
≥ 80 vs. <80‡ 9/104 202/1,643 0.6 (0.3, 1.4) 8/105 166/1,679 0.8 (0.4, 1.7) 12/97 108/1,677 2.0 (1.1, 3.6) 
TTHM exposure through showering & bathing  
(μg absorbed /day)           
0.02-0.09 25 446 1 25 466 1 30 511 1 
0.1-0.8 24 467 0.9 (0.5, 1.6) 29 460 1.1 (0.6, 1.9) 28 419 1.2 (0.7, 2.2) 
0.9-1.5 26 438 1.0 (0.6, 1.8) 24 465 1.0 (0.5, 1.8) 18 444 1.0 (0.5, 1.8) 
1.6-27.1 37 490 1.3 (0.7, 2.1) 34 450 1.4 (0.8, 2.3) 33 410 1.6 (1.0, 2.7) 
Missing 1 4  1 4  4 61  
Residential HAA5 concentration (μg/liter)          
0-0.9 43 692 1 43 692 1 43 667 1 
17.9-22 17 267 1.2 (0.7, 2.2) 28 283 1.8 (1.1, 3.0) 30 366 1.3 (0.8, 2.2) 
22.1-31.5 30 338 1.5 (0.9, 2.5) 14 289 0.9 (0.5, 1.6) 12 192 1.3 (0.7, 2.4) 
31.6-40.4 11 272 0.8 (0.4, 1.5) 15 291 0.9 (0.5, 1.6) 12 234 0.9 (0.5, 1.8) 
40.4-52.8 12 276 0.7 (0.4, 1.4) 13 290 0.9 (0.5, 1.6) 14 326 0.9 (0.5, 1.6) 
Missing 0 0  0 0  4 60  
HAA5 exposure through tap-water consumption 
(μg consumed /day)          
0 35 597 1 43 538 1 48 712 1 
0.01-16.1 31 408 1.5 (0.9, 2.5) 22 436 0.6 (0.3, 1.0) 16 240 1.1 (0.6, 2.0) 
16.2-54.4 30 446 1.5 (0.9, 2.4) 30 427 1.0 (0.6, 1.6) 26 402 1.1 (0.6, 1.8) 
54.7-369.1 17 390 0.9 (0.5, 1.7) 18 440 0.6 (0.3, 1.1) 19 430 0.8 (0.5, 1.4) 
Missing 0 4  0 4  4 61  
Residential TOX concentration (μg/liter)          
14.3-22.4 43 692 1 43 692 1 43 667 1 
136.7-169.6 18 338 1.0 (0.5, 1.7) 13 290 0.7 (0.4, 1.4) 16 302 0.9 (0.5, 1.7) 
169.6-177.7 18 315 1.1 (0.6, 1.9) 23 286 1.5 (0.9, 2.5) 16 250 1.3 (0.7, 2.3) 
177.7-192.6 18 261 1.1 (0.6, 2.0) 13 293 0.8 (0.4, 1.5) 13 288 0.8 (0.4, 1.5) 
192.8-235.2 16 239 1.2 (0.6, 2.0) 21 284 1.3 (0.8, 2.3) 23 278 1.5 (0.9, 2.5) 
Missing 0 0  0 0  4 60  
*  Seven births born before 27 weeks’ gestation and 57 births that were < 27 weeks’ in gestation when water sampling ended are not included in third trimester average models; five 
women were missing information on showering and bathing needed to assign first and second trimester average personal TTHM exposure; four were women missing information on 
tap water consumption necessary to assign first and second trimester average HAA5 personal exposure; and one women was missing information on showering and bathing and tap 
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water consumption needed to assign third trimester average personal  TTHM and HAA5 exposure.  
†Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake 
‡ # SGA and # non-SGA are frequency of births with TTHM ≥ 80 μg/liter / frequency of births with TTHM < 80 μg/liter. 
Abbreviations: DBP = disinfection by-product, SGA = small-for-gestational-age, RR = risk ratio, CI= confidence interval, TTHM = trihalomethane, HAA5 = sum of five haloacetic 
acids, TOX = total organic halides 
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Table 48. Associations between trimester-specific average DBP exposure and average birth weight among term births to 
women included in the analyses of exposure to drinking water DBPs and term birth weight*, 2000-2004. 
 First trimester average Second trimester average Third trimester average 
 N 
Mean difference in grams  
(95% CI) N 
Mean difference in grams  
 (95% CI) N 
Mean difference in grams  
 (95% CI)* 
Residential TTHM concentration (μg/liter)       
2.2-4.6 677 0 677 0 655 0 
33.1-55 334 -10.0 (-72.3, 52.3) 295 31.2 (-33.2, 95.5) 281 -7.1 (-72.3, 58.0) 
55-66.3 258 34.4 (-32.7, 101.5) 288 31.2 (-33.3, 95.8) 335 52.2 (-9.7, 114.1) 
66.4-74.8 253 -21.3 (-88.6, 46.0) 294 29.7 (-35.2, 94.6) 255 33.1 (-35.1, 101.3) 
74.9-108.8 332 58.6 (-3.0, 120.1) 300 -22.4 (-85.7, 40.9) 275 3.8 (-62.8, 70.4) 
Missing 0  0  53  
≥ 80 vs. <80‡ 214/1640 36.1 (-30.4,  102.5) 175/1679 -35.6 (-107.1,  35.9) 117/1684 -55.9 (-143.7,  31.9) 
TTHM exposure through showering & bathing  
(μg absorbed /day)       
0.02-0.09 439 0 458 0 497 0 
0.1-0.8 458 -26.0 (-87.3, 35.2) 453 13.7 (-46.8, 74.2) 425 -38.8 (-99.1, 21.6) 
0.9-1.5 455 -4.6 (-65.6, 56.4) 480 3.2 (-56.0, 62.5) 457 7.2 (-51.9, 66.3) 
1.6-27.1 497 -7.0 (-68.8, 54.9) 458 8.1 (-54.4, 70.7) 421 4.8 (-57.0, 66.7) 
Missing 5  5  54  
Residential HAA5 concentration (μg/liter)       
0-0.9 677 0 677 0 655 0 
17.9-22 268 -26.9 (-96.1, 42.3) 282 -31.5 (-100.9, 37.8) 367 -36.9 (-99.5, 25.7) 
22.1-31.5 345 -57.5 (-118.7, 3.6) 294 4.4 (-59.9, 68.6) 205 68.0 (-5.5, 141.5) 
31.6-40.4 280 78.6 (14.0, 143.2) 300 33.4 (-30.5, 97.3) 244 12.0 (-56.5, 80.5) 
40.4-52.8 284 72.3 (8.0, 136.5) 301 48.4 (-14.7, 111.6) 330 59.0 (-2.9, 120.9) 
Missing 0  0  53  
HAA5 exposure through tap-water consumption  
(μg consumed /day)       
0 594 0 539 0 701 0 
0.01-16.1 402 -25.7 (-84.5, 33.1) 422 -31.7 (-90.7, 27.4) 243 -34.9 (-103.2, 33.4) 
16.2-54.4 454 -7.6 (-65.0, 49.9) 437 10.2 (-48.7, 69.1) 417 10.1 (-46.2, 66.5) 
54.7-369.1 400 57.3 (-2.4, 117.0) 452 52.9 (-5.9, 111.8) 439 61.9 (5.5, 118.4) 
Missing 4  4  54  
Residential TOX concentration (μg/liter)       
14.3-22.4 677 0 677 0 655 0 
136.7-169.6 340 18.8 (-42.2, 79.7) 300 69.8 (6.5, 133.1) 322 62.1 (-0.1, 124.4) 
169.6-177.7 315 34.9 (-27.6, 97.5) 300 -11.9 (-75.5, 51.8) 259 -19.9 (-87.1, 47.3) 
177.7-192.6 278 -14.0 (-79.7, 51.7) 295 17.3 (-47.0, 81.7) 292 64.1 (-0.1, 128.4) 
192.8-235.2 244 25.6 (-44.3, 95.4) 282 -15.2 (-82.2, 51.9) 273 -39.9 (-108.6, 28.9) 
Missing 0  0  53  
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*  53 births that were < 27 weeks’ in gestation when water sampling ended are not included in third trimester average models; five women were missing information on showering and 
bathing needed to assign first and second trimester average personal TTHM exposure; four women were missing information on tap water consumption necessary to assign first and 
second trimester average HAA5 personal exposure; and one women was missing information on showering and bathing and tap water consumption needed to assign third trimester 
average personal  TTHM and HAA5 exposure.  
† Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine intake 
‡ # preterm and # term are frequency of births with TTHM ≥ 80 μg/liter / frequency of births with TTHM < 80 μg/liter. 
Abbreviations: DBP = disinfection by-product, TTHM = trihalomethane, HAA5 = sum of five haloacetic acids, TOX = total organic halides 
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Table 49. Estimated effects of third trimester average concentrations of individual 
THMs and HAAs on fetal growth measures among women included in the 
analysis of exposure to drinking water DBPs and fetal growth restriction from the 
chlorinated DBP site, 2000-2004 
   SGA* Term birth weight (in grams)† 
 n SGA n Non-SGA 
MLE model  
OR (95% CI)‡ 
Bayesian Model
OR (95% PI)§ 
MLE model 
Mean ∆ (95% CI)‡ 
Bayesian Model 
Mean ∆ (95% PI)§ 
Chloroform       
19.9-44.2 14 267 1 1 0 0 
44.3-49 14 274 1.4 (0.6, 3.1) 2.0 (0.5, 8.2) 41.6 (-40.3, 123.6) 11.8 (-29.5, 96.0) 
49.1-94.0 12 275 1.1 (0.5, 2.6) 1.8 (0.4, 8.2) 27.3 (-57.1, 111.6) 4.5 (-44.5, 75.0) 
BDCM       
8.2-11.8 14 274 1 1 0 0 
11.9-14.1 10 273 0.9 (0.4,2.2) 1.5 (0.7,3.0) 26.0 (-56.3,108.3) 2.4 (-39.0,56.0) 
14.2-28.5 16 269 1.5 (0.7,3.5) 1.3 (0.6,2.7) -43.6 (-126.7,39.4) -3.3 (-72.7,40.0) 
DBCM       
1.1-3.2 11 281 1 1 0 0 
3.3-4.4 11 269 0.8 (0.3,2.1) 1.5 (0.6,2.7) 4.1 (-77.7,85.9) 3.9 (-30.8,65.0) 
4.5-9.1 18 266 2.0 (0.9,4.4) 1.6 (0.8,3.7) -51.5 (-135.7,32.8) -1.2 (-54.0,53.0) 
Bromoform       
0.0-0 8 278 1 1 0 0 
0.1-0.2 13 275 1.5 (0.6,3.9) 1.5 (0.8,3.0) 41.7 (-40.4,123.8) 5.7 (-26.0,67.0) 
0.3-0.9 19 263 2.9 (1.2,7.0) 1.8 (0.9,4.1) -32.4 (-116.9,52.1) -2.4 (-62.3,46.0) 
CAA       
0.0-2.2 13 273 1 1 0 0 
2.3-3.2 11 273 1.1 (0.5,2.7) 0.9 (0.5,2.0) 11.3 (-70.8,93.3) 0.1 (-42.1,42.0) 
3.3-5.6 16 270 1.6 (0.7,3.7) 0.9 (0.4,1.8) -18.3 (-103.3,66.7) -0.8 (-43.7,39.0) 
DCAA       
10.2-17.3 15 269 1 1 0 0 
17.4-20.8 14 267 1.2 (0.5,2.7) 0.9 (0.5,2.0) 1.9 (-81.6,85.4) -0.7 (-40.3,37.0) 
20.9-26.9 11 280 0.9 (0.4,2.2) 0.9 (0.5,2.2) 23.2 (-59.8,106.2) -0.6 (-45.7,46.0) 
TCAA       
5.3-11 16 268 1 1 0 0 
11-17.2 14 272 0.9 (0.4,1.9) 0.7 (0.3,1.3) 4.0 (-80.7,88.7) 1.5 (-33.4,54.0) 
17.3-24.1 10 276 0.6 (0.3,1.5) 0.9 (0.4,1.8) 1.9 (-81.2,84.9) -2.3 (-53.9,35.0) 
BCAA       
0.4-3.7 16 274 1 1 0 0 
3.8-4.5 8 274 0.5 (0.2,1.2) 0.7 (0.3,1.5) 49.1 (-33.2,131.5) 8.9 (-25.7,75.0) 
4.6-11.7 16 268 1.2 (0.5,2.5) 0.9 (0.4,1.8) -27.8 (-110.8,55.2) -4.3 (-62.3,42.0) 
BDCAA       
1.6-3.7 13 270 1 1 0 0 
3.8-5 13 275 1.4 (0.6,3.3) 1.0 (0.5,2.2) 53.2 (-30.3,136.6) 10.3 (-20.2,76.0) 
5.1-7.5 14 271 1.3 (0.6,3.1) 0.9 (0.4,1.8) -33.5 (-116.2,49.2) -8.5 (-67.9,27.0) 
DBCAA       
0.0-0.8 11 270 1 1 0 0 
0.9-1.6 15 272 1.5 (0.6,3.5) 1.0 (0.5,2.2) 10.4 (-72.5,93.3) 0.4 (-42.9,50.0) 
1.7-2.4 14 274 1.6 (0.7,3.9) 1.2 (0.6,3.0) 33.9 (-49.9,117.8) 3.0 (-35.0,62.0) 
BAA       
0 25 621 1 1 0 0 
0.0-0.5 15 195 1.9 (0.9,3.9) 1.2 (0.6,2.7) -73.9 (-152.8,4.9) -5.3 (-59.8,33.0) 
DBAA       
0.0-0.3 16 274 1 1 0 0 
0.4-0.9 7 272 0.5 (0.2,1.2) 0.7 (0.3,1.5) 19.5 (-63.6,102.7) 4.4 (-35.1,61.0) 
1-2.1 17 270 1.1 (0.5,2.3) 0.9 (0.4,1.8) -37.0 (-121.3,47.3) -4.2 (-55.5,42.0) 
TBAA       
0 19 365 1 1 0 0 
0.0-1.8 21 451 1.0 (0.5,2.0) 0.8 (0.4,1.5) 25.8 (-42.6,94.3) 4.0 (-33.4,59.0) 
* N = 856 for SGA analysis; two births born before 27 weeks’ gestation and 25 births that were < 27 weeks’ in gestation 
when water sampling ended (27 births total)  are not included in third trimester average SGA models 
† N = 849 for term birth weight analysis; 23 births that were < 27 weeks’ in gestation when water sampling ended are not 
included in third trimester average term birth weight models 
‡ Maximum likelihood estimation models were constructed separately for each individual THM and HAA; all models were 
adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity 
 187
and caffeine intake 
§ Fully-Bayesian models specified βj~N(μk,φ2) where k is an indictor for DBP class and bromination (non-brominated 
THM, non-brominated HAA, brominated THM, brominated HAA); models adjusted for other DBPs listed in the table and 
maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine 
intake.   
Abbreviations: SGA= small-for-gestational-age, MLE = maximum likelihood estimation, OR= odds ratios, CI = confidence 
interval, PI= posterior interval, DBP= disinfection by-product, BDCM= bromodichloromethane, DBCM = 
dibromochloromethane, CAA= chloroacetic acid, DCAA=dichloroacetic acid, TCAA=trichloroacetic acid, BCAA= 
bromochloroacetic acid, BDCAA= bromodichloroacetic acid, DBCAA= dibromochloroacetic acetic acid, BAA= 
bromoacetic acid, DBAA= dibromoacetic acid, TBAA= tribromoacetic acid 
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Table 50.  Estimated effects of third trimester average concentrations of individual 
THMs and HAAs on fetal growth measures among women included in the 
analysis of exposure to drinking water DBPs and fetal growth restriction from the 
brominated DBP site, 2000-2004 
   SGA* Term birth weight (in grams)† 
 n SGA n Non-SGA 
MLE model  
OR (95% CI)‡ 
Bayesian Model
OR (95% PI)§ 
MLE model 
Mean ∆ (95% CI)‡ 
Bayesian Model 
Mean ∆ (95% PI)§ 
Chloroform       
6.4-11.5 4 104 1 1 0 0 
11.6-15.6 15 96 4.9 (1.5,15.8) 3.9 (0.6,24.8) -87.4 (-215.8,41.1) -9.9 (-115.0,61.0) 
15.7-22.1 9 102 2.4 (0.7,8.4) 3.5 (0.6,23.8) 59.3 (-70.8,189.3) 11.7 (-64.0,129.0) 
BDCM       
15.8-20.1 8 101 1 1 0 0 
20.2-22.9 8 103 1.0 (0.3,2.7) 0.8 (0.3,2.1) 55.1 (-74.3,184.4) 8.4 (-62.0,108.0) 
23-29.2 12 98 1.6 (0.6,4.1) 0.9 (0.4,2.5) 49.1 (-81.0,179.1) -2.3 (-95.0,73.0) 
DBCM       
15.2-19.3 14 95 1 1 0 0 
19.4-26 8 103 0.5 (0.2,1.2) 0.7 (0.3,1.6) 170.9 (42.5,299.4) 32.6 (-28.0,169.0) 
26.1-38.7 6 104 0.3 (0.1,0.9) 0.7 (0.3,1.8) 142.8 (14.3,271.2) 7.3 (-62.0,118.0) 
Bromoform       
0.8-2.4 12 98 1 1 0 0 
2.5-11.5 7 102 0.6 (0.2,1.6) 0.8 (0.3,2.0) 145.9 (16.4,275.3) 18.5 (-45.0,137.0) 
11.6-15.1 9 102 0.7 (0.3,1.7) 0.9 (0.3,2.4) 76.1 (-53.0,205.2) -1.0 (-94.0,83.0) 
CAA       
0.4-0.8 7 102 1 1 0 0 
0.9-1.8 9 101 1.3 (0.5,3.7) 1.1 (0.4,2.4) -134.0 (-265.2,-2.8) -15.4 (-124.0,41.0) 
1.9-4.0 12 99 1.9 (0.7,5.3) 1.3 (0.5,3.6) -105.9 (-234.6,22.8) 1.2 (-74.0,84.0) 
DCAA       
2.7-6.5 6 103 1 1 0 0 
6.6-7.8 14 98 3.0 (1.1,8.3) 1.4 (0.6,3.2) -56.7 (-184.5,71.2) -5.6 (-101.0,64.0) 
7.9-10.3 8 101 1.5 (0.5,4.6) 1.1 (0.4,2.6) 49.7 (-82.6,182.0) 13.5 (-46.0,130.0) 
TCAA       
1.8-4 6 103 1 1 0 0 
4.1-5.7 10 101 1.8 (0.6,5.4) 1.2 (0.5,2.7) -39.7 (-170.1,90.7) -2.4 (-92.0,82.0) 
5.8-9.1 12 98 2.6 (0.9,7.4) 1.3 (0.5,3.5) -43.0 (-173.1,87.0) -3.6 (-99.0,67.0) 
BCAA       
7.0-7.8 6 103 1 1 0 0 
7.9-8.4 11 99 2.2 (0.8,6.3) 1.4 (0.7,3.4) -94.4 (-224.5,35.8) -4.3 (-77.0,44.0) 
8.5-9.9 11 100 2.0 (0.7,5.6) 1.4 (0.6,3.6) -67.2 (-198.3,63.9) -1.1 (-76.0,58.0) 
BDCAA       
6.1-7.8 7 102 1 1 0 0 
7.9-9.4 10 101 1.5 (0.5,4.1) 1.1 (0.4,2.5) 20.4 (-108.2,148.9) 8.8 (-34.0,99.0) 
9.5-11.5 11 99 1.7 (0.6,4.7) 1.4 (0.6,3.9) 34.5 (-97.3,166.3) -4.5 (-78.0,48.0) 
DBCAA       
2.5-4.3 10 99 1 1 0 0 
4.4-5.8 12 99 1.4 (0.5,3.4) 1.2 (0.5,2.9) 21.0 (-108.3,150.3) 0.4 (-64.0,69.0) 
5.9-8.2 6 104 0.5 (0.2,1.6) 1.2 (0.5,3.1) 71.6 (-58.0,201.2) -0.3 (-61.0,71.0) 
BAA       
0.0-0.4 12 99 1 1 0 0 
0.5-1.2 7 102 0.5 (0.2,1.4) 0.9 (0.4,1.8) -39.1 (-169.2,91.1) -3.8 (-77.0,50.0) 
1.3-2.1 9 101 0.7 (0.3,1.7) 1.7 (0.8,5.1) -12.5 (-143.6,118.6) 0.5 (-70.0,70.0) 
DBAA       
2.3-4.4 13 98 1 1 0 0 
4.5-7.2 10 100 0.8 (0.3,1.9) 1.3 (0.6,3.4) 12.3 (-117.7,142.4) 0.2 (-56.0,69.0) 
7.3-11.4 5 104 0.3 (0.1,0.9) 1.1 (0.4,2.6) 62.3 (-69.0,193.6) 2.2 (-57.0,73.0) 
TBAA       
1.5-2.6 8 102 1 1 0 0 
2.7-3 14 97 1.9 (0.7,4.8) 1.7 (0.6,4.8) -57.4 (-186.4,71.6) -8.8 (-86.0,36.0) 
3.1-5.2 6 103 0.7 (0.2,2.0) 1.3 (0.5,3.4) -14.3 (-145.0,116.4) -3.4 (-95.0,51.0) 
* N = 330 for SGA analysis; two births born before 27 weeks’ gestation and 8 births that were < 27 weeks’ in gestation 
when water sampling ended (10 births total)  are not included in third trimester average SGA models 
† N = 297 for term birth weight analysis; eight births that were < 27 weeks’ in gestation when water sampling ended are not 
included in third trimester average term birth weight models 
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‡ Maximum likelihood estimation models were constructed separately for each individual THM and HAA; all models were 
adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity 
and caffeine intake 
§ Fully-Bayesian models specified βj~N(μk,φ2) where k is an indictor for DBP class and bromination (non-brominated 
THM, non-brominated HAA, brominated THM, brominated HAA); models adjusted for other DBPs listed in the table and 
maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and caffeine 
intake.   
Abbreviations: SGA= small-for-gestational-age, MLE = maximum likelihood estimation, OR= odds ratios, CI = confidence 
interval, PI = posterior interval, DBP= disinfection by-product, BDCM= bromodichloromethane, DBCM = 
dibromochloromethane, CAA= chloroacetic acid, DCAA=dichloroacetic acid, TCAA=trichloroacetic acid, BCAA= 
bromochloroacetic acid, BDCAA= bromodichloroacetic acid, DBCAA= dibromochloroacetic acetic acid, BAA= 
bromoacetic acid, DBAA= dibromoacetic acid, TBAA= tribromoacetic acid 
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5.2 Manuscript 2: Drinking water disinfection by-product exposure and duration of 
gestation. 
Abstract 
 Purpose: Recent studies suggest elevated exposure to drinking water disinfection by-
products (DBPs) may be associated with decreased risk of preterm birth. We examined this 
association for exposure to total trihalomethane (TTHM), five haloacetic acids (HAA5) and 
total organic halides (TOX).   Methods: Analysis included 2,039 women in a prospective 
pregnancy study conducted from 2000-2004 in three study sites.  Water samples were 
prospectively collected and analyzed for DBPs. Participant data were collected through 
interviews, an early ultrasound and birth records. The association between DBP and preterm 
birth (< 37 weeks' gestation) was assessed using log-binomial regression. Discrete-time 
hazard analysis was used to model the conditional odds of delivery each week in relation to 
DBP exposure. Results: Average second trimester DBP levels were inversely associated with 
preterm birth. Adjusted risk ratios (95% confidence interval) for TTHM levels of 33.1-55.0, 
55.1-66.3, 66.4-74.8 and 74.9-108.8 versus 2.2-4.6 micrograms/liter were 0.8 (0.5,1.3), 0.9 
(0.6,1.4), 0.7 (0.4,1.1) and 0.5 (0.3,0.9). Risk ratios for HAA5 levels of 17.9-22.0, 22.1-31.5, 
31.6-40.4 and 40.4-52.8 versus 0-0.9 micrograms/liter were 1.1 (0.8, 1.7), 0.8 (0.5, 1.2), 0.5 
(0.3, 0.8), and 0.7 (0.4, 1.1). The conditional odds of delivery each week were decreased for 
the highest TTHM and HAA5 exposure groups versus the low exposure group for gestational 
weeks' 33-40. Conclusions: Results clearly indicate that the probability of preterm birth is 
not increased with high DBP exposure, and suggest that high exposure may be associated 
with delayed birth through the term gestational period. 
 
 191
5.2.1 Introduction 
 
Disinfection of water to control waterborne infectious diseases is clearly an important 
public health measure.  However, the discovery of chloroform and other trihalomethanes 
(THMs) in chlorinated drinking water in the 1970s has prompted concern over the potential 
adverse impacts of exposure to water disinfection by-products (DBPs)1.  While initial interest 
in DBP exposure focused on a possible association with cancer 2-4, more recent research has 
focused on adverse pregnancy outcomes 5,7,8.  Most studies suggest no association with 
preterm birth 92,93,96-98, although more recent studies have provided limited evidence that high 
residential concentrations of total trihalomethane (TTHM) may in fact be associated with 
decreased risk of preterm birth89,90,100.    
Null findings of previous studies may be due to errors in outcome and exposure 
assessment, leading to attenuation of estimated effects.  Multiple factors influence the 
distribution of DBP concentrations within a water distribution system, including source water 
characteristics (e.g., surface versus ground water, temperature and pH), the presence of other 
halides in source water (e.g., bromine), and the type of disinfectant method used (e.g., 
chloramination versus chlorination)9.  Capturing spatial and temporal variability in DBP 
concentrations within a distribution system is essential to accurately assign residential DBP 
concentrations during relevant time windows for exposure119,120.  Furthermore, DBP 
exposure occurs through ingestion of contaminated water as well as inhalation and dermal 
absorption of DBPs during activities such as showering, bathing and swimming12. Failure to 
take individual variation in water use into account also may result in substantial exposure 
assessment error 18,24,121.    
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The purpose of this analysis was to examine the association between DBP exposure 
and duration of gestation as assessed through the proportion of infants born preterm (< 37 
weeks’ gestation) and the conditional odds of delivery each week using improved exposure 
data that allow account inter-individual variability to be estimated more accurately than in 
previous studies.  This study involved the most extensive exposure assessment of any DBP 
study to date, including prospective collection of weekly or bi-weekly DBP measurements 
and incorporation of self-reported water use behaviors to estimate personal exposure.   
 
5.2.2 Materials and methods 
 
Study design and population 
Data for this analysis come from a community-based prospective cohort study 
conducted from 2000-2004 to examine the effect of drinking water disinfection byproduct 
(DBP) exposure on pregnancy health.  Details of the study design and recruitment have been 
published elsewhere 26,124,125.  Briefly, women were recruited early in pregnancy (≤ 12 
weeks’ gestation) or while planning a pregnancy from three study sites within the US.  One 
site had moderate levels of chlorinated DBPs (hereafter referred to as “chlorinated DBP 
site”), one had moderate levels of brominated DBPs (“brominated DBP site”), and one had 
low levels of all DBPs (“low DBP site”).  In addition, the chlorinated and brominated DBP 
sites used chloramination rather than free chlorine for terminal disinfection, which minimized 
spatial variability in DBP concentrations within sites.  Participant data were collected 
through interviews conducted at screening, baseline (completed by 16 weeks’ gestation) and 
follow-up (completed between 20 and 25 weeks’ gestation), a first trimester ultrasound, and 
birth records.  
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A total of 2,766 pregnancies (68% of those screened) were enrolled from all three 
sites. This analysis includes 2,039 singleton live births with a complete baseline interview. 
We excluded 259 (9.4%) pregnancies with no or incomplete baseline interview, 347 (12.5%) 
pregnancies that ended in a loss, 90 (3.3%) pregnancies lost to follow-up, seven (0.2%) 
pregnancies without information on date of birth or birth weight, eight (0.3%) multi-
gestational pregnancies, and 16 (0.6%) repeat live births to a study participant. Women 
retained for analysis were slightly more likely to be White and to have completed ≥ 16 years 
of education than all enrolled participants were, but distributions for maternal age, estimated 
gestational age at enrollment, and parity were similar (data not shown).  
  
Measurement of DBP concentrations 
Weekly water samples were collected from the study sites with moderate DBP levels 
and biweekly in the low exposure site at a single, representative location in the water 
distribution system.  Details of sampling and verification of low spatial variability are 
provided elsewhere26.  When the chlorinated and brominated sites converted to free chlorine 
for system flushing (during one month each year), samples were collected at additional 
locations to capture resultant spatial variability in DBP levels within the system and 
combined to estimate a system-wide weekly average.  Water samples were returned 
overnight to the University of North Carolina and refrigerated at 4oC until analyzed for all 
four individual THMs, all nine haloacetic acids (HAAs), and total organic halide (TOX).  
THM levels were analyzed using a modified version of US Environmental Protection Agency 
(US EPA) Method 551.1 104 and HAAs were analyzed using a method developed by Brophy 
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et al.105 based on standard methods106,107.  Additional information on sample collection, 
shipment and analysis is provided in detail elsewhere26. 
 
Characterization of DBP exposure 
This analysis focuses on exposure to aggregate DBP measures, including total 
trihalomethanes (TTHM), the sum of five haloacetic acids (HAA5), and total organic halides 
(TOX).  TTHM and HAA5 are currently regulated by the US EPA14 and TOX provides an 
estimate of the overall organic halide level in water.  Two exposure metrics were examined: 
residential DBP concentrations, estimated by TTHM, HAA5 and TOX concentration in the 
water distribution system serving a woman’s residence, and personal DBP exposure, 
estimated as uptake through showering and bathing for TTHM and by intake through tap 
water consumption for HAA.  THMs are highly volatile, and a much greater proportion of 
the uptake of THM parent compounds occurs through inhalation and absorption rather than 
tap water consumption126.  Thus, showering and bathing were considered for personal TTHM 
exposure but not tap water consumption.  Conversely, only tap water consumption was 
considered for personal HAA exposure because HAAs are non-volatile and minimal 
exposure occurs from other water use activities12.  
Personal exposure was estimated using algorithms described in previous 
publications26,125.  Briefly, women were asked about their tap water consumption, showering 
and bathing habits in detail during baseline and follow-up interviews.  Personal TTHM 
exposure was estimated by integrating residential THM concentrations and self-reported 
information on average duration and frequency of showering and bathing into an absorbed 
dose (µg/day) using uptake factors derived from toxicokinetic studies126,127.  Personal HAA 
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exposure was estimated in two steps.  Residential HAA concentrations were first adjusted for 
boiling and filtering using correction factors26,109 and then combined with self-reported 
information on the number and size of glasses of cold/hot filtered/unfiltered tap water drinks 
typically consumed per day to calculate average daily intake of HAAs (µg/day).  Self-
reported changes in water use habits (e.g., between baseline and follow-up interviews) were 
accounted for by calculating time-weighted averages over periods with change.     
 
Estimation of gestational age at birth 
Self-reported last menstrual period (LMP) and an early ultrasound, both obtained 
during the first trimester, were combined with infant date of birth to estimate gestational age 
at birth.  Gestational age derived from LMP was used for the majority of subjects (81.4%) 
unless the LMP date differed by more than +/- 7 days from the ultrasound-based estimate of 
gestational age (17.7%) or self-reported LMP was incomplete (0.9%), in which case the 
ultrasound estimate was used. Infant date of birth was obtained from medical records for 
43.0% of live births, vital records for 56.5%, and participant self-report for only 0.5%.    
    
Statistical Analysis 
The association between DBP exposure and preterm birth (defined as delivery before 
37 weeks’ gestation) was examined using log binomial regression. Given no strong 
biological evidence to determine a critical time window for exposure, second trimester 
average DBP exposure was used in all models, as this period was identified as the relevant 
window for preterm birth in a previous study of TTHM100.  Residential DBP concentrations 
were examined initially using restricted quadratic splines to model the dose-response in 
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probability of preterm birth.  Linear models were constructed following visual inspection of 
dose-response curves to confirm the assumption of linearity was not violated.   
To produce more easily interpretable risk ratios (RR) and facilitate comparison with 
previous studies, preterm birth models were also run using categories of residential DBP 
concentrations divided into quartiles of second trimester average concentrations among 
women from the moderate exposure sites, using the low exposure site as the referent, and 
dichotomizing residential TTHM levels at the current US EPA regulatory standard (≥ 80 
micrograms/liter).  Concentrations of HAA5 above the US EPA standard (≥ 60 
micrograms/liter) were too rare for meaningful analysis.  Personal DBP exposure estimates 
were examined using categorical coding only, as the authors believe this exposure metric is 
most useful for roughly separating women into “high”, “moderate” and “low” exposure 
groups when considering the amount of error potentially introduced through use of self-
reported data on water use and consumption. 
Dichotomization of births as preterm versus non-preterm masks variability in the 
severity of prematurity among infants classified as preterm while over-emphasizing 
differences between deliveries occurring shortly before and after 37 weeks’ gestation.  
Furthermore, inferences about the effect of exposure on timing of delivery throughout 
gestation cannot be made.  Therefore, partially constrained continuation odds ratio models 
were constructed to model the effect of DBP exposure on the odds of delivery each week 
conditional on a woman not having delivered in a prior week116, with time interactions 
between DBP exposure and pregnancy intervals of 20-32, 32-36, 37-40, and ≥ 41 weeks’ 
gestation.  Time-to-birth (in weeks) was defined as the time from 20 weeks’ completed 
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gestation until gestational age at birth.  This model is analogous to discrete hazard regression 
using a logit link and time-varying coefficients. 
Time interaction intervals listed above were selected because they approximately 
represent very preterm, moderately preterm, term and post-term periods, respectively, and a 
sufficient number of births occurred during each interval to support statistical analyses.    
Continuation log odds models also can incorporate exposures with time-varying values. 
Therefore, in addition to second-trimester average exposure, two coding schemes allowing 
DBP exposure values to change over pregnancy were considered in separate models: a 6-
week sliding average (i.e., average over the index week plus the five proceeding weeks) and 
a 1-week “current” exposure estimate.   
For both sets of analyses, confounders (listed in table 1) were identified from the 
literature as risk factors for preterm birth that may be independently associated with DBP 
exposure but not on the causal pathway between exposure and disease according to directed 
acyclic graph analysis 115. Effect measure modification by maternal age (< 25, 25-29, 30-35, 
≥ 35 years of age), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic and 
other) and swimming during pregnancy (yes/no) was assessed by constructing DBP-covariate 
interaction terms and were retained in the model if the p- value was < 0.10. 
   
5.2.3 Results 
 
Of the 2,039 births included in this analysis, 185 (9.1%) were born preterm.  The 
proportion of preterm births varied considerably by site (6.1% at the chlorinated DBP site, 
12.6% at the brominated DBP site, and 11.0% at the low DBP site).  Women from the 
brominated DBP site were more likely to be Hispanic and parous, less likely to be employed 
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during pregnancy or married, and tended to be younger, less educated, and have a lower 
income than women from the chlorinated and low DBP sites (table 51).  Although women 
from the chlorinated and low DBP sites were much more similar, women from the 
chlorinated site were still slightly older, more educated, had higher income and were more 
likely to be non-Hispanic White than those from the low DBP site. 
As expected, the low DBP site had much lower concentrations of TTHM, HAA5 and 
TOX than the chlorinated and brominated DBP sites (table 52).  TTHM concentrations were 
similar between the chlorinated and brominated DBP sites, but HAA5 was slightly higher 
and TOX lower at the chlorinated DBP site compared to the brominated DBP site.  A higher 
relative concentration of brominated compounds at the brominated DBP site compared to the 
chlorinated site was also confirmed (results not shown)26.     
 
Preterm birth 
Dose-response modeling of the association between preterm birth and DBPs 
suggested an overall trend of decreasing probability of preterm birth with increasing levels of 
residential TTHM and HAA5 concentrations, particularly at levels ≥ 60 micrograms/liter 
TTHM and  ≥ 18 micrograms/liter HAA5 (figure 18).  Estimated risk ratios (RRs) for 
preterm birth comparing women in the higher quantile categories of exposure to the lowest 
exposure group also indicated an inverse relationship for both residential and personal 
exposure metrics (table 53).  Similar results were found in site-specific analyses, although 
when restricted to the brominated DBP site alone, the dose-response pattern for HAA5 was 
less consistent and RRs for all DBPs were less precise (results not shown).  Effect measure 
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modification by maternal age, maternal race/ethnicity or swimming during pregnancy was 
not found (results not shown). 
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Time to birth 
The odds of delivery each week, conditional on not having delivered in a previous 
week, were decreased for women in the higher categories of average second trimester 
residential TTHM and HAA5 concentrations compared to women in the lowest group for 
gestational weeks 33-40 (figure 19).  Odds ratios (ORs) over this period ranged from 0.5-0.9 
for residential TTHM concentrations and 0.4 to 1.3 for residential HAA5 concentrations.  
ORs for 20-32 weeks and 41-44 weeks were imprecise, as evidenced by wide confidence 
intervals, due to the small number of infants born during these periods.  Results suggest that 
the conditional probability of birth each week was increased with higher DBP exposure over 
the 41-44 weeks period (ORs ranged from 2.1-7.3); however, these findings should be 
interpreted with caution.  In addition to poor precision, the majority of births during the 41-
44 weeks’ period occurred at 41 or 42 weeks’ (98%) and later births (at 43 or 44 weeks’) are 
likely due to errors in gestational age estimation.       
Conditional ORs estimates for personal TTHM and HAA5 exposure showed a pattern 
of association similar to residential concentrations for 37-40 weeks and 41-44 weeks but 
were inconsistent for 33-36 weeks (figure 19).  Estimated ORs from models examining 6-
week sliding average exposure and weekly exposure did not differ substantially from those 
shown in figure 19 (results not shown).  Effect measure modification by maternal age, 
maternal race/ethnicity or swimming during pregnancy was not indicated (results not shown).  
 
5.2.4 Discussion 
 
Results of our study clearly suggest that the risk of preterm birth does not increase 
with exposure to high levels of TTHM or HAA5.  Our study provides additional support to 
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recent findings suggesting that high levels of TTHM exposure during pregnancy may in fact 
be related to decreased risk of preterm birth.  We also found that the delay in timing of birth 
associated with high DBP exposure continues through the term period of gestation (37-40 
weeks’).   
Previous studies examining the association between TTHM and preterm birth have 
generally indicated no association, with estimated relative risks for preterm birth ranging 
between 0.7-1.2 and no notable dose-response trends 90,92,93,96-98.  However, a small inverse 
relationship between TTHM and preterm birth was reported in recent studies by Wright et al. 
(2004)89 and Lewis et al. (2007)100.  The former study examined third trimester average 
residential DBP exposure among births to women residing in Massachusetts from 1995 to 
1998 and estimated ORs of 0.95 (0.91, 0.99) and 0.88 (0.81,0.94) comparing TTHM levels of 
33-74 and 74-163 versus 0-33 micrograms/liter but did not find an association with HAA5.  
Lewis et al. reported hazard ratios for preterm birth of 0.87 (0.77, 0.99) and 0.82 (0.71, 0.94) 
comparing second trimester average residential TTHM levels 40-60 and ≥ 60 versus < 40 
micrograms/liter, respectively, among births between 1999-2001 to women residing in 27 
communities served by a single water utility.    
Exposure assessment in all previous studies was done by linking maternal residence 
at the time of birth with municipal water DBP measurements and only one prior study 
estimated personal water use.  Most investigations only had quarterly measurements of DBP 
concentrations from a limited number of locations within the water distribution systems.  As 
a result, temporal and spatial variability in DBP concentrations may not have been 
adequately captured, resulting in exposure assessment error and attenuation of estimated 
effects. However, much like our study, the Lewis et al. (2007) study obtained weekly 
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monitoring data on TTHM measurements from a utility company that employed water 
treatment regimens to minimize spatial variability in TTHM concentrations100.  In general, 
our study found slightly stronger inverse effects than reported by previous studies.    
Another potentially important finding from our study is that high DBP exposure may 
be associated with delayed birth through the “term” gestational period.  One previous study 
reported increased mean gestational length associated with higher second trimester average 
TTHM exposure90. Because labor is routinely induced at 42 weeks’ gestation, such a delay 
could increase the portion of women requiring labor induction.  However, we did not collect 
information on labor induction and there were too few births born postterm (at ≥ 42 weeks’ 
gestation) to assess this association. A study of the magnitude necessary to accurately study 
this association is probably not warranted.   
The strong relationship between residential location (i.e., study site) and residential 
DBP concentrations in our study is both a strength and a limitation.  By design, we have a 
range of reliable DBP measures (high/literow, chlorinated/brominated) that has never before 
been assembled for a study of DBPs and reproductive health, but there are also substantial 
differences in the population characteristics of the study sites.  Women who participated from 
each site have different demographic profiles and show an overall difference in the 
proportion of births born preterm.  To control for potential confounding between study sites, 
we adjusted for the major risk factors for preterm birth that varied in distribution between 
sites and performed site specific analysis to confirm that the pattern of results between DBPs 
and time of birth were similar across study sites. The point estimates for these analyses were 
similar to the main results but less stable due to small numbers.  For example, RRs (95% 
confidence interval) for the US EPA TTHM regulatory standard (≥ 80 micrograms/liter 
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versus < 80 micrograms/liter) were 0.6 (0.3, 1.2) excluding the low DBP site, 0.5 (0.2, 1.4) 
restricting to the chlorinated DBP site alone, and 0.9 (0.3, 2.5) restricting to the brominated 
DBP site alone, suggesting that the preterm risk associated with DBP exposure was not 
substantially influenced by underlying population differences related to site.  However, there 
may still be other unmeasured factors that influence timing of birth and vary by study site 
(e.g., unknown environmental exposures or social influences) that biased results down and 
away from the null.  
The proportion of preterm births may be higher during late summer and fall compared 
to spring65,66 and DBP concentrations are generally higher during warm seasons compared to 
colder seasons12, which could lead to confounding by season.  We examined whether season 
of birth predicted the proportion of infants born preterm among our study population and 
found no association.  Therefore, we did not control for season to preserve maximum 
temporal variability in DBP levels.  Furthermore, the expected direction of bias due to 
seasonal confounding would be upwards, away from the null, which is counter to the inverse 
association found in this study.   
A major strength of this study is the availability of individual-level information on 
water consumption, bathing and showering to estimate participants’ personal DBP exposure.  
One other study examining preterm birth has incorporated information on individual water 
use to estimate personal DBP exposure, combining residential DBP concentrations with self-
reported consumption of water to estimate “THM dose”92.  However, no previous study of 
preterm birth has had access to such extensive data on individual water use. At the same 
time, it is important to acknowledge that information on water consumption and use was 
collected by interview and is subject to the usual concerns about the accuracy of self-reported 
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information on exposure in a prospective study. Ultimately, we found similar patterns of 
association with duration of gestation for residential and personal DBP measures.  
A major strength of our study is the prospective design with individual follow-up of 
pregnancies to determine pregnancy outcomes.  Previous studies have relied on information 
provided in vital records to estimate gestational age, which is prone to substantial error102.  In 
our study, self-reported LMP was collected from participants during the first trimester of 
pregnancy (when recall is more accurate) and, first trimester ultrasounds were conducted and 
available to adjust LMP dates that were more than seven days discrepant with the ultrasound 
estimate.  Therefore, estimation of gestational age at birth and classification of births as 
preterm is very accurate in our study.   
In conclusion, our study is the most extensive study of DBP exposure and preterm 
birth conducted to date.  Our results clearly demonstrate that high DBP exposure is not 
associated with increased risk of preterm birth.  While concerns persist for other reproductive 
health risks (e.g., fetal growth restriction) 5,7,8, the association between DBP exposure and 
preterm birth risk does not merit further investigation. Our findings also provide evidence 
that DBP exposure may in fact be associated with a decreased risk of preterm birth.  The 
delay in birth was evident throughout most of gestation.  While this may have implications 
for the proportion of births requiring labor induction, a study of the scale necessary to 
address this concern is probably not warranted.     
 
5.2.5 References 
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Table 51. Characteristics of women included in the analysis of exposure to drinking 
water DBPs and duration of gestation, 2000-2004. 
All women in the analysis 
(n=2,039) 
Chlorinated DBP 
site (n=929) 
Brominated DBP 
site (n=349) 
Low DBP site
(n=761) 
Covariate N Col. % % preterm* Col. % Col. % Col. % 
Maternal Age (years)       
< 25 599 29.4 10.9 21.0 47.7 31.1 
25-29 657 32.2 8.2 31.6 33.0 32.7 
30-35 564 27.7 7.3 34.6 13.6 25.6 
≥ 35 219 10.7 11.4 12.8 5.8 10.6 
Maternal Race/ethnicity       
Non-Hispanic White 1169 57.4 7.4 67.1 35.9 55.5 
Non-Hispanic Black 609 29.9 12.5 25.2 22.4 39.1 
Hispanic 185 9.1 8.7 3.1 39.7 2.4 
Other 73 3.6 6.8 4.6 2.0 3.0 
Missing 3      
Highest education level 
obtained       
High school or less 573 28.1 12.7 16.9 53.3 30.3 
Some college 440 21.6 9.5 18.5 27.2 22.8 
College degree or more 1025 50.3 6.8 64.6 19.5 47.0 
Missing 1      
Annual household income ($)       
<30,000 637 32.5 11.9 22.3 60.2 32.5 
30,001-60,000 535 27.3 7.1 29.4 22.0 27.3 
60,001-80,000 321 16.4 5.6 18.1 9.3 17.5 
>80,000 465 23.8 8.0 30.2 8.4 22.7 
Missing 81      
Employed during pregnancy       
Non-employed 608 29.8 9.4 28.2 37.5 28.3 
Employed 1430 70.2 8.9 71.8 62.5 71.7 
Missing 1      
Marital status       
Married 1390 68.2 7.2 74.9 53.2 66.9 
Not married 648 31.8 13.1 25.1 46.8 33.1 
Missing 1      
Pre-pregnancy BMI (kg/m2)       
<19.8 232 11.7 7.8 13.4 8.3 11.1 
19.8-25.9 1016 51.1 8.1 54.7 46.3 48.8 
26.0-29.9 333 16.7 6.6 15.2 18.1 18.1 
>29.9 407 20.5 14.3 16.7 27.3 22.1 
Missing 51      
Daily caffeine intake (mg/day)       
0 519 25.4 9.1 27.6 23.2 23.9 
1-150 468 23.0 8.1 21.3 22.6 25.1 
151-300 387 19.0 10.6 16.6 21.8 20.6 
>300 665 32.6 8.9 34.5 32.4 30.4 
Parity       
Nulliparous 991 48.6 10.2 53.1 42.4 46.0 
Parous 1048 51.4 8.0 46.9 57.6 54.0 
* Percent of births within the covariate born preterm among all births in the study 
Abbreviations: BMI = body mass index, DBP= disinfection by-product 
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Table 52. Second trimester average residential DBP 
concentrations*across study sites among women included in the 
analysis of exposure to drinking water DBPs and duration of 
gestation, 2000-2004.   
DBP   
(μg/liter) 
All sites 
(n=2,039) 
Chlorinated DBP site 
(n=929) 
Brominated DBP site 
(n=349) 
Low DBP site 
(n=761) 
TTHM 42.4 (32.4) 66.4 (15.8) 63.6 (11.8) 3.3 (0.6) 
HAA5 20.0 (17.3) 35.9 (8.6) 21.1 (2.5) 0.08 (0.1) 
TOX 119.2 (79.8) 173.8 (16.3) 195.3 (16.7) 17.7 (2.0) 
* Mean (standard deviation) 
Abbreviations: DBP= disinfection by-product, TTHM = total Trihalomethane, HAA5 = 
sum of five haloacetic acids, TOX= total organic halides. 
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Table 53. Association between average second-trimester DBP exposure and probability of 
preterm birth among included in the analysis of exposure to drinking water DBPs and 
duration of gestation, 2000-2004. 
 n preterm n term 
Unadjusted 
RR (95% CI)* 
Adjusted 
RR (95% CI)† 
Residential TTHM Concentration (μg/liter)     
2.2-4.6 84 677 1. 1. 
33.1-55 27 295 0.8 (0.5,1.1) 0.8 (0.5, 1.3) 
55-66.3 30 288 0.9 (0.6,1.3) 0.9 (0.6, 1.4) 
66.4-74.8 24 294 0.7 (0.4,1.1) 0.7 (0.4, 1.1) 
74.9-108.8 20 300 0.6 (0.4,0.9) 0.5 (0.3, 0.9) 
 per 10 μg/liter   0.94 (0.90, 0.98) 0.95 (0.91, 1.00) 
p for linear trend test‡   0.008 0.03 
≥ 80 vs. <80** 9/176 175/1,679 0.5 (0.3,1.0) 0.5 (0.3,1.1) 
TTHM exposure through showering & bathing  
(μg absorbed /day)     
0.02-0.09 50 458 1. 1. 
0.1-0.8 56 453 1.1 (0.8,1.6) 0.9 (0.6, 1.4) 
0.9-1.5 29 480 0.6 (0.4,0.9) 0.7 (0.4, 1.0) 
1.6-27.1 50 458 1.0 (0.7,1.4) 0.8 (0.5, 1.2) 
Residential HAA5 Concentration (μg/liter)     
0-0.9 84 677 1. 1. 
17.9-22 39 282 1.1 (0.8,1.6) 1.1 (0.8, 1.7) 
22.1-31.5 24 294 0.7 (0.4,1.1) 0.8 (0.5, 1.2) 
31.6-40.4 18 300 0.5 (0.3,0.8) 0.5 (0.3, 0.8) 
40.4-52.8 20 301 0.6 (0.4,0.9) 0.7 (0.4, 1.1) 
per 10 μg/liter   0.87 (0.80, 0.94) 0.89 (0.81, .0.97) 
p for trend test‡   0.001 0.01 
HAA5 exposure through tap-water consumption 
(μg consumed /day)     
0 63 539 1. 1. 
0.01-16.1 56 422 1.1 (0.8,1.6) 0.9 (0.6, 1.4) 
16.2-54.4 40 437 0.8 (0.5,1.2) 0.9 (0.6, 1.4) 
54.7-369.1 26 452 0.5 (0.3,0.8) 0.6 (0.4, 0.9) 
Residential TOX Concentration (μg/liter)     
14.3-22.4 84 677 1. 1. 
136.7-169.6 19 300 0.5 (0.3,0.8) 0.7 (0.4, 1.1) 
169.6-177.7 21 300 0.6 (0.4,0.9) 0.6 (0.4, 1.0) 
177.7-192.6 24 295 0.7 (0.4,1.1) 0.7 (0.4, 1.1) 
192.8-235.2 37 282 1.1 (0.7,1.5) 1.1 (0.8, 1.7) 
per 10 μg/liter   0.98 (0.97, 1.00) 0.99 (0.97, 1.00) 
p for trend test‡   0.05 0.2 
* Unadjusted model 
† Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy 
BMI, parity and caffeine intake 
‡ Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term) 
 ** # preterm and # term are frequency of births with TTHM ≥ 80 μg/liter / frequency of births with TTHM < 80 μg/liter. 
Abbreviations: RR = risk ratio, CI= confidence interval  
 
 
 208
Figure 18. Predicted risk of preterm birth by second trimester average residential 
concentrations of total Trihalomethane (TTHM) and five haloacetic acids (HAA5) among 
women included in the analysis of drinking water disinfection by-product (DBP) exposure 
and duration of gestation, 2000-2004.  
 
Model adjusted for maternal age, race/ethnicity, education level, annual household income, employment status 
during pregnancy, marital status, pre-pregnancy BMI (kg/m2), daily caffeine intake (mg/day) and parity. Solid 
line is the predicted probability of preterm birth and dashed lines are lower and upper pointwise 95% 
confidence interval. 
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Figure 19. Association between second trimester average drinking water disinfection by-
products (DBP) exposure and the conditional odds of delivery each week (gestational weeks’ 
20-44) stratified by gestational period among women included in the analysis of exposure to 
drinking water DBPs and duration of gestation, 2000-2004. 
 
Residential concentrations of total trihalomethane (TTHM), the sum of five haloacetic acids (HAA5) and total 
organic halides presented in μg/liter; personal exposure to TTHM through showering and bathing presented in 
μg absorbed/day and to HAA5 through tap water consumption as μg consumed/day; models adjusted for 
maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity 
and caffeine intake; ** = non-estimable because all infants in exposure category delivered at 41 weeks’ 
gestation.  
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5.3 Manuscript 3: Comparison of gestational age at birth based on last menstrual 
period and ultrasound during the first trimester  
 
Abstract 
 Reported last menstrual period (LMP) is commonly used to estimate gestational age 
(GA) but may be unreliable. Ultrasound in the first trimester is generally considered a highly 
accurate method of pregnancy dating. The authors compared first trimester report of LMP 
and first trimester ultrasound for estimating GA at birth and examined whether disagreement 
between estimates varied by maternal and infant characteristics. Analyses included 1,867 
singleton live births to women enrolled in a prospective pregnancy cohort. Authors computed 
the difference between LMP and ultrasound GA estimates (GA difference) and examined the 
proportion of births within categories of GA difference stratified by maternal and infant 
characteristics. The proportion of births classified as preterm, term and postterm by 
pregnancy dating methods also was examined. LMP-based estimates were 0.8 days (standard 
deviation=8.0, median=0) longer on average than ultrasound estimates. LMP classified more 
births as postterm than ultrasound (4.0% versus 0.7%) but the proportions classified as 
preterm were similar (10.0% versus 8.9%). GA difference was greater among young women, 
non-Hispanic Black and Hispanic women, less educated women, women of non-optimal 
body weight and mothers of low birth weight infants. Results indicate first trimester report of 
LMP is a reliable estimate of GA.  
 
5.3.1 Introduction 
 
Self-report of last menstrual period is often used to estimate gestational age in clinical 
care and epidemiologic research. However, reported LMP may be unreliable 128. Women 
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may not recall the date of LMP accurately 129,130 or misinterpret early pregnancy bleeding as 
normal menses 131. In addition, the convention of assigning a 14-day interval between 
menstruation and ovulation, implicit in calculations of gestational age, will be inaccurate for 
women with irregular menstrual cycles or delayed ovulation 132,133. This presents the 
dilemma of whether reported LMP has acceptable precision for research on pregnancy 
outcomes.  
Ultrasonography before 20 weeks’ gestation is generally viewed as a more accurate 
method of estimating gestational age than menstrual dating 134,135, with ultrasound assessment 
between 5 to 8 weeks’ having the greatest accuracy. In general, ultrasound assessment is 
limited by the implicit assumption that all fetal size variability is due to gestational age 136, 
which can lead to systematic underestimation of gestational age among pregnancies 
exhibiting early growth restriction 137. This is less of a concern for very early ultrasound 
scans given that variation in fetal size is minimal during the first trimester of pregnancy 138. 
In practice, early ultrasounds may only be available for a select group of individuals (i.e., 
those for whom an early ultrasound is medically indicated) 139, and generally have not been 
obtained in large-scale studies.   
Previous studies comparing second trimester ultrasound with LMP found that 
ultrasound, on average, resulted in lower (younger) gestational age estimates than those 
derived from LMP 62,63,134,140 and that the discrepancy between estimates was increased with 
young maternal age, lower education, single marital status, cigarette smoking, nulliparity, 
non-optimal pre-pregnancy weight, and pre-pregnancy or gestational diabetes 62,63. 
Ultrasound also resulted in a higher proportion of preterm births and a lower proportion of 
postterm births relative to LMP dating. Systematic inaccuracy of gestational age dating could 
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distort estimated associations between maternal characteristics and adverse pregnancy 
outcomes derived using gestational age (e.g., preterm birth) and result in outcome 
misclassification. 
We compared estimates of gestational age at birth based on first trimester report of 
LMP and very early ultrasound to determine whether LMP collected early in pregnancy 
could accurately date pregnancies and identify predictors of increased discrepancy between 
gestational age estimates.   
 
5.3.2 Materials and Methods 
 
Study design and population  
Right from the Start (RFTS) is an ongoing, community-based prospective cohort 
study. Women in this analysis were participants in RFTS Phase I, conducted from 2000-
2004. Details of site selection and recruitment are described elsewhere 124. The Institutional 
Review Boards at the University of North Carolina, University of Tennessee, and the 
University of Texas approved study protocols; participants gave informed consent.   
We recruited women who were early in pregnancy (≤ 12 weeks’ gestation) or 
planning to become pregnant. Pregnant women were enrolled after providing an LMP date 
and date of their first positive pregnancy test (n=2,514). Women trying to become pregnant 
were “pre-enrolled” and followed for up to six months with free pregnancy test kits provided; 
those who conceived were formally enrolled (n=252). In all, 2,766 pregnancies (68 percent of 
those screened) were enrolled and available for assessment. This analysis includes 1,867 
singleton live births with complete baseline interview, LMP (month and day of month) and 
ultrasound data. We excluded 347 (12.5 percent) pregnancies that ended in a loss, 90 (3.3 
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percent) pregnancies lost to follow-up, eight (0.3 percent) multi-gestational pregnancies, and 
16 (0.6 percent) repeat live births to a RFTS participant. Additional exclusions were made for 
pregnancies with no or incomplete baseline interview (n=259; 9.4 percent), incomplete LMP 
date (n=18; 0.6 percent), no ultrasound data (n=158; 5.7 percent) and missing infant birth 
date (n=3; 0.07 percent). Women retained for analysis were similar to all enrolled 
participants with respect to maternal age, estimated gestational age at enrollment, and parity, 
but were slightly more likely to be White and to have completed ≥ 16 years of education.  
 
Data Collection 
Self-reported LMP. Information about LMP was obtained during screening and intake 
telephone interviews, typically at eight weeks’ gestation for women pregnant at initial 
screening and five weeks’ gestation for “pre-enrolled” women. Women were informed they 
might need a calendar to answer certain questions and invited to obtain a calendar for the 
interview. Women were asked “What was the first day of your last menstrual period?” If 
necessary, women were prompted to think of an event that happened around the same time as 
their last period (e.g., a holiday, vacation, or weekend) to facilitate recall. Additional 
maternal characteristics also were collected by telephone interview.  
Early ultrasound. First trimester endovaginal ultrasounds were conducted by clinical 
sonographers required to have ARDMS® certification, use state-of-the-art equipment as 
assessed by a study investigator (KH), conduct and document manufacturer recommended 
machine calibration, and have three or more years experience in pelvic and obstetric 
diagnostic sonography. In addition, sonographers participated in study-specific training. 
Measurements of the gestational sac, yolk sac, fetal pole, and fetal heart rate were fully 
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comparable with those required for clinical pregnancy dating. A still image was reviewed by 
trained staff prior to entry of ultrasound data, and a 20% quality sample was reviewed by a 
clinician skilled in first trimester sonography (KH). All ultrasounds were performed at or 
before 13 weeks’ completed gestation (mean= 9, median = 8 weeks).  
Birth outcomes. Multiple data sources were used to obtain and confirm live birth 
outcomes: birth and fetal death records, hospital discharge summaries and prenatal care 
records and participant self-report. For this analysis, pregnancy outcome information was 
documented using medical records for 42.9 percent of live births, vital records for 56.8 
percent and participant self-report for only 0.4 percent.  
 
Statistical analysis 
We compared the distributions of gestational age at birth (in days) from LMP (date of 
birth – date of LMP) and ultrasound (date of birth – [date of ultrasound – clinical age by 
ultrasound at assessment]). Difference in days between LMP and ultrasound estimates was 
calculated (LMP estimate - ultrasound estimate, hereafter referred to as “gestational age 
difference”) and categorized into five groups (<-14, -14 to -8, -7 to +7, +8 to +14 and >+14 
days). Positive values indicate that the LMP-based estimate is “older” than the ultrasound-
based estimate, and negative values indicate that the LMP-based estimate is “younger” than 
the ultrasound-based estimate. Mean and standard deviation values for gestational age 
difference and the proportion of births within categories of gestational age difference were 
calculated within and compared across strata of maternal and infant characteristics. Women 
were also stratified by self-reported certainty in LMP date (“very sure”, “pretty sure”, 
“somewhat uncertain”, or “very uncertain”) and pregnancy status (“trying to conceive” and 
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“already pregnant”) at initial screening. The “already pregnant” women were further 
subdivided into three groups: women who had not used contraceptives in the past year or 
stopped using contraceptives to become pregnant, women who became pregnant during a gap 
or break in contraceptive use, and women who got pregnant while using contraception.  
Kappa statistics and associated 95 percent confidence intervals were calculated to 
assess agreement between dating methods for preterm, term and postterm classification. We 
also calculated the proportion of births discordantly classified as preterm, term or postterm 
by LMP and ultrasound. Analyses were performed using Stata version 9 (College Station, 
TX).  
 
5.3.3 Results 
 
The median estimated gestational age at birth was 276 days (39 weeks’ gestation) for 
both dating methods. Compared to LMP, ultrasound-derived gestational age was slightly 
shorter (mean of 273 versus 274 days), less variable (standard deviation of 14 versus 16 
days), and had a narrower range (214 to 307 days versus 207 to 315 days). A slightly higher 
proportion of births were classified as preterm (<37 weeks’ gestation) by LMP than by 
ultrasound (10.0 versus 8.9 percent). The proportion of births classified as postterm (>41 
week’s gestation) was notably higher by LMP dating (4.0 versus 0.7 percent).  
Gestational age difference was within +/- 7 days for 80.8 percent of women and +/- 
30 days for 98.5 percent (Figure 20). The mean difference was 0.8 days (standard deviation = 
8.0, median = 0 days) and ranged from -70 to 38 days. LMP-based estimates were somewhat 
more likely to be higher than ultrasound-based estimates when discrepant (gestational age 
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difference was zero for 10.5 percent of women, positive for 47.8 percent and negative for 
41.7 percent).  
Women < 20 years old were more likely to have a discrepancy of > +14 days or 
between -14 to -8 days than other age groups (Table 54). Low education level (completed 
high school or less), single marital status, and non-optimal body mass index (BMI) (<18.9 or 
>29.0 kg/m2) were also associated with overall increased discrepancy. Non-Hispanic Black 
women were more likely to have a negative discrepancy (< -8 days) compared to non-
Hispanic White women. Conversely, women of Hispanic and other ethnicity were more 
likely to have a positive discrepancy (≥ +8 days) compared to non-Hispanic White women.  
An overall increase in discrepancy was found as self-reported “certainty” in LMP 
date decreased, particularly for a positive discrepancy > +14 days among women who were 
only “somewhat sure” or “very uncertain” (Table 54). Women who were planning a 
pregnancy at initial screening were more likely to have a positive discrepancy and much less 
likely to have a negative discrepancy than women already pregnant. Among those already 
pregnant, women who became pregnant during a gap in contraceptive use or due to 
contraceptive failure had increased discrepancy in both directions.  
Low birth weight (LBW) infants (<2500 grams at birth) were more likely to have a 
positive discrepancy of +8 to +14 days than larger infants (Table 1). The degree of 
discrepancy between estimates did not vary by maternal smoking, parity, or infant gender.  
Exclusion of women with a gestational age difference > -30 or < 30 days did not affect the 
pattern of associations found (results not shown).   
Maternal and infant characteristics examined in this analysis are correlated. 
Therefore, we constructed multi-variable logistic regression models for the log odds of a 
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gestational age difference ≥ 8 days versus +/- 7 days and a gestational age difference ≤ -8 
days versus +/- 7 days to determine whether associations remained after adjustment for other 
variables. Results of the regression analyses agree with those presented above with the 
exception of marital status, which was no longer associated with gestational age difference 
after adjustment (results not shown). 
Classification of births as preterm, term, and postterm was concordant for 91.2% of 
all births (Figure 21). The Kappa coefficient for classification into these three categories was 
0.59 (95% Confidence Interval [CI]: 0.54, 0.65), indicating moderate agreement 141. 
Agreement for classifying live births as preterm (<37 versus ≥ 37 weeks’) was higher (Kappa 
coefficient = 0.75, 95% CI: 0.70, 0.80). Agreement for classifying live births as postterm (≤ 
41 versus > 41 weeks’) was very low (Kappa coefficient = 0.05, CI:-0.02, 0.13).  
 
5.3.4 Discussion 
 
Findings from this study suggest that early report of LMP results in accurate dating 
for the majority of participants. However, LMP tended to slightly overestimate gestational 
age based upon ultrasound when discrepant (by approximately 1 day, on average) and 
resulted in a higher proportion of births classified as postterm. Proportions for preterm birth 
were comparable. Over ninety percent of women were concordantly classified as preterm, 
term or postterm by LMP and ultrasound.  
The degree of difference between LMP and ultrasound-based estimates was greater 
among young women, non-Hispanic Black and Hispanic women, less educated women, 
women of non-optimal body weight and low birth weight infants. Difference also increased 
as maternal certainty in LMP decreased and was greater among women pregnant at initial 
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screening who became pregnant during a gap in contraceptive use or due to contraceptive 
failure. Gestational age difference did not vary by maternal smoking, parity or infant gender.  
Gestational age misdating can arise from uncertainty in participant recall of LMP, as 
evidenced by less discrepancy in gestational age estimates among women who indicated they 
were “very sure” of their LMP compared to women who were less sure. We also found that 
gestational age difference was lower among women who were planning a pregnancy and 
presumably tracking their menstrual cycles closely, a finding demonstrated previously 62. 
Increased gestational age difference also was found among women of young maternal age, 
lower education, single marital status and non-optimal body weight, consistent with previous 
studies 62,63,142. Women with these characteristics may have greater difficulty recalling LMP 
in general 142, which would contribute to random error in menstrual dating and account for 
increases in both positive and negative discrepancies.  
Gestational age misdating also results from systematic error. Reported LMP 
underestimated ultrasound-based gestational age by 8+ days for a greater proportion of young 
women (< 20 years) compared to other age groups. Early vaginal bleeding, often confused 
with menses, is more prevalent among young mothers 143. This biological phenomenon could 
cause young women to systematically misrepresent their LMP and explain the apparent 
mismatch between the two dating methods. Furthermore, delayed ovulation, which is more 
common than early ovulation 144 and believed to be more prevalent among young women and 
those of non-optimal body weight 145, could explain the systematic overestimation of 
gestational age based on LMP among these women.  
Hispanic women, predominately Mexican American in our study population, were 
more likely to have a positive gestational age difference compared to Non-Hispanic White 
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women, suggesting that menstrual dating could result in underestimation of the proportion of 
Hispanic infants born preterm. In contrast, results of a study examining birth-weight 
distributions within strata of gestational age by LMP suggested that term Mexican American 
infants may be misclassified as preterm more often than non-Hispanic Whites, which could, 
in part, explain the LBW paradox among Mexican American infants 146. The proportion of 
Mexican American infants classified as preterm by LMP and ultrasound was similar in our 
study (11.4 versus 10.8), with moderately high agreement for preterm classification (kappa = 
0.74, 95% CI: 0.58, 0.90), but our findings are based on a very small, non-random sample of 
Mexican American infants (n=176). Additional research is needed to address LMP misdating 
as a potential source of bias.  
Among non-Hispanic Black women, LMP-based gestational age was generally 
younger than the gestational age resulting from early ultrasound. Given the persistent racial 
disparity in all adverse birth outcomes between White and Black non-Hispanic women, this 
could be an important finding from our study. If, on average, Black women’s LMP reports’ 
systematically underestimates their infants’ actual “developmental” age, some portion of the 
racial disparity in birth outcomes may result from misdating. Verification in a representative 
sample is needed.  
We found increased gestational age difference among LBW infants, predominately in 
a positive direction. This is consistent with previous studies based on second trimester 
ultrasound 63,147,148, and may be due to systematic underestimation of gestational age among 
growth restricted fetuses who are later LBW. However, growth restriction at 8 to 9 weeks’ 
gestation, when ultrasounds predominately were conducted for this study, has not been 
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previously reported. Further research is needed to address whether first trimester growth 
restriction is a potential source of bias in very early ultrasound assessment of gestational age.  
Maternal smoking and infant sex were not associated with increased positive 
gestational age difference, unlike previous studies predominantly based on second trimester 
ultrasounds 62,63,136. However, differences in crown-rump length measurements have not been 
found by infant gender at ultrasound assessments conducted during the first trimester of 
pregnancy 149,150. This may explain why we did not find evidence for systematic 
underestimation of gestational age at birth by ultrasound among female fetuses in our study, 
and similarly, among smokers.    
In our study, LMP was collected early in pregnancy (by 12 weeks) and may not 
accurately reflect errors in menstrual dating that occur when LMP is recalled over a longer 
period. Therefore, our results may not be generalizable to studies collecting LMP later in 
pregnancy. Furthermore, participants’ care providers were given a copy of the first trimester 
ultrasound report, which provided them with an earlier (and hence, more accurate) estimate 
of gestational age according to ultrasound than what is usually available. Clinicians may have 
been more willing to believe these ultrasounds and let women “misclassified” as postterm by 
LMP only (i.e., not postterm by ultrasound) continue on in pregnancy. As a result, our study 
may overstate the excess of births classified as postterm by LMP compared to a more general 
setting.   
Participants in the RFTS study represent a group of women who knew they were 
pregnant in the first trimester and volunteered to participate in a prospective pregnancy study, 
and thus, may not be comparable to other study samples or the general population. In a 
previous report, we compared maternal characteristics of pregnancies enrolled in the RFTS 
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study to all births identified from vital records in the same geographic location over the same 
time period 26. RFTS participants were similar to the general population with respect to age 
but where more likely to be highly educated (≥ 16 years of education), non-Hispanic White, 
and nulliparous when compared to the general population.  
Gestational age remains an important measurement in reproductive and perinatal 
research. Findings from our study suggest that menstrual dating, based upon LMP collected 
early in pregnancy, is a reasonably accurate method for estimating gestational age at birth in 
studies when first trimester ultrasound is not available.  However, LMP tends to overestimate 
gestational age, on average, and result in a higher proportion of postterm births. Thus, LMP 
should not be used to date pregnancies in studies directed at examining factors associated 
with postterm birth. The degree of difference between LMP and ultrasound-based estimates 
also varies by important maternal and infant characteristics (e.g., maternal race/ethnicity), 
which should be taken into consideration when designing and interpreting results from a 
study examining the association between these characteristics and pregnancy outcomes 
derived using gestational age. 
 
5.3.5 References 
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Table 54. Difference in LMP and ultrasound-based estimates of gestational age at birth by 
selected maternal and infant characteristics, live births (n=1,867) to participants in the 
RFTS study from 2000-2004. 
   GA difference (in days): LMP – US estimate 
 N Mean (SD) <-14 -14 to -8 ± 7 +8 to +14 >+14 
p-
value* 
All participants 1,867 0.8 (8.0) 2.0 4.5 80.8 8.6 4.1  
Maternal age         
<20 107 1.7 (12.2) 2.8 10.3 65.4 12.2 9.4 
20-24 426 0.5 (9.8) 2.8 5.6 75.6 11.3 4.7 
25-29 610 1.5 (7.4) 1.5 3.8 81.2 8.7 4.9 
30-34 528 0.6 (6.4) 2.3 2.8 85.8 6.6 2.5 
≥ 35 196 -0.6 (6) 1.0 5.6 85.7 6.1 1.5 
<0.001 
Race/ethnicity         
Non-Hispanic White 1,109 1.2 (6.5) 1.3 3.4 84.1 8.3 2.9 
Non-Hispanic Black 520 -0.5 (9.7) 3.3 7.7 76.5 7.7 4.8 
Hispanic 176 1.3 (9.3) 3.4 3.4 75.0 11.9 6.3 
Other 59 2.5 (10.1) 1.7 0 72.9 13.6 11.9 
0.02† 
Missing 3        
Education level         
High school or less 496 0.8 (10.8) 3.2 5.7 73.2 11.9 6.1 
Some college 417 0.6 (7.1) 1.9 4.8 80.6 9.8 2.9 
4+ years of college 954 0.9 (6.5) 1.5 3.8 84.8 6.4 3.6 
<0.001 
Marital status         
Married 1,298 1.1 (6.9) 1.6 3.4 83.4 8.0 3.5 
Not married 568 0.1 (10.1) 3.0 7.0 74.8 9.9 5.3 
<0.001 
Missing 1        
Pre-pregnancy BMI 
(kg/m2)         
<19.8 192 1.5 (7.6) 0.5 6.8 77.1 9.4 6.3 
19.8-25.9 956 0.8 (7.5) 1.4 4.0 84.0 7.2 3.5 
26.0-29.0 253 0.2 (8.0) 3.6 4.0 80.6 8.3 3.6 
> 29.0 418 0.8 (9.0) 2.9 5.0 76.6 10.8 4.8 
0.03 
Missing 48        
Certainty of LMP date         
Very sure 1,275 0.5 (7.2) 1.7 3.7 84.2 7.8 2.6 
Pretty sure 367 0.6 (8.7) 2.7 6.8 76.6 9.3 4.6 
Somewhat sure 137 3.1 (11) 2.9 5.1 66.4 13.1 12.4 
Very uncertain 48 2.1 (12.9) 4.2 8.3 56.3 14.6 16.7 
missing 40       
0.01† 
Pregnancy status at 
screening         
Trying to conceive 153 3 (6.8) 0 0.7 83.7 9.8 5.9 
Pregnant‡ 1,714 0.6 (8.1) 2.2 4.8 80.5 8.5 3.9 
 No birth control use 1,236 -0.3 (8.3) 1.7 3.4 82.6 9.3 3 
 Gap/Break in birth 
control use 323 1.4 (11.4) 4.0 9.3 74.9 6.2 5.6 
 Birth control failure 147 0.6 (8.2) 2.0 6.8 76.2 7.5 7.5 
<0.001 
Missing 8        
Infant birth weight 
(grams)         
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<2500 104 0.9 (10.0) 4.8 2.9 74.0 12.5 5.8 
2500-3499 959 1.0 (8.4) 2.2 5.4 77.9 9.9 4.6 
3500-3999 557 0.6 (7.2) 1.4 4.3 84.2 6.6 3.4 
≥ 4000 245 0.2 (7.2) 1.6 2.0 86.9 6.5 2.9 
0.02 
Missing 2        
* p value corresponds to two-sided Pearson Chi-square test for independence of maternal/infant 
characteristics and categories of gestational age (GA) difference unless otherwise specified. 
† p value corresponds to two-sided Fisher’s Exact test for independence of maternal/infant characteristics and 
categories of GA difference. 
‡ Participants that were pregnant at enrollment were further subdivided into three categories: those who 
reported they had not used contraceptives in the past year or had stopped using contraceptives to become 
pregnant, those who reported they became pregnant during a gap or break in contraceptive use, and those 
who reported they became pregnant due to contraceptive failure. 
Abbreviations: BMI = body mass index, GA= gestational age, LMP= last menstrual period, RFTS= Right 
from the Start, SD= standard deviation, US= ultrasound 
 
 
Figure 20. Distribution of the number of days difference between estimated gestational age at 
birth derived from last menstrual period (LMP) and ultrasound (US) among live births 
(n=1,867) to participants in the Right From the Start study from 2000-2004.  
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Figure 21. Scatter plot of estimated gestational age at birth derived from last menstrual 
period (LMP) by estimated gestational age at birth derived from ultrasound among live births 
(n=1,867) to participants in the Right From the Start study from 2000-2004. Black line, 
preterm cut-point (259 days); striped bars, postterm cut-point (294 days).  
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CHAPTER 6: DISCUSSION 
6.1 Summary of findings 
Findings of this study do not suggest an adverse effect of total trihalomethane 
(TTHM) or the sum of five haloacetic acids (HAA5) on fetal growth at residential 
concentrations below the current regulatory standards.  In addition, no association was found 
with estimated personal exposure to TTHM and HAA5 or with TOX exposure.  An increased 
probability of delivering an SGA infant was found when comparing women with average 
third trimester TTHM residential concentrations ≥ 80 micrograms/liter to women with 
average levels < 80 micrograms/liter, but few women experienced average TTHM levels that 
high.  Findings were similar for site-specific analyses of aggregate DBP measures and fetal 
growth.  
Findings for site-specific analyses of individual trihalomethanes (THMs) and 
haloacetic acids (HAAs) were unclear.  Results from maximum likelihood estimation (MLE) 
analyses restricted to the chlorinated DBP site suggest that brominated TTHMs may be 
associated with increased risk of delivering an SGA infant.  Conversely, MLE results from 
the brominated DBP site suggest that chlorinated HAAs may be associated with both 
increased risk of SGA and decreased mean birth weight among term births.  However, results 
of the Bayesian analyses indicated that a null or protective effect for each of the individual 
DBPs on fetal growth restriction is still probable given our prior assumptions and the data at 
hand, as all 95% credible limits included the null value.  Therefore, study results do not 
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provide strong support that any particular DBP (or set of DBPs) is associated with fetal 
growth restriction. 
Finally, results of our study clearly suggest that the risk of preterm birth is not 
increased with exposure to high levels of TTHM or HAA5.  Our study provides additional 
support to recent findings suggesting that high levels of TTHM exposure during pregnancy 
may in fact be related to decreased risk of preterm birth.  We also found that the delay in 
timing of birth associated with high DBP exposure continues through the “moderately 
preterm” and “term” period of gestation (33-40 weeks’ gestation).  
 
6.2 Strengths and limitations 
6.2.1 Prospective collection of DBP measurements 
 
The greatest strength of this study is the marked improvement in exposure assessment 
compared to previous studies.  The Right from the start (RFTS) study collected information 
on weekly (or biweekly) residential concentrations of a wide variety of individual THMs and 
HAAs, including four HAAs that are not regulated by the US Environmental Protection 
Agency (EPA).  Furthermore, measurements were validated to represent DBP concentrations 
in tap water reaching participants’ home.  No other study to date has had access to such 
detailed and comprehensive information on residential DBP exposure information as that 
provided by the RFTS study.   None-the-less, measured residential DBP concentrations are 
only applicable to locations within study sites.  A small portion of RFTS participants 
(approximately 8%) worked outside of their respective study sight, in which case DBP 
measurements are not available to directly estimate exposure from water consumed at work, 
which could have resulted in exposure misclassification.  Furthermore, despite the relatively 
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high frequency of water sampling in RFTS, there is still the potential for unmeasured 
variability in DBP concentrations within a water system over a week period, which could 
also contribute to exposure misclassification.  
 
6.2.2 Selection of study sites  
 
The inclusion of three different study sites with different exposure profiles is both a 
strength and a limitation of this study.  By design, a range of reliable DBP measures 
(high/low, chlorinated/brominated) was available that has never before been assembled for a 
study of DBPs and reproductive health.  However, there are also substantial differences in the 
underlying population characteristics of the study sites.  Women who participated from each 
site have different demographic profiles and show overall differences in the proportion of 
births born small-for-gestational-age (SGA), the proportion of infants born preterm, and 
mean birth weight.  To control for potential confounding between study sites, major risk 
factors for adverse birth outcomes that varied in distribution between sites were adjusted for 
and site-specific analysis were performed to confirm that the pattern of results between DBPs 
and adverse birth outcomes were similar across study sites.  However, residual confounding 
by unmeasured risk factors (e.g., unknown environmental exposures or social influences) 
cannot be dismissed. 
 
6.2.3 Estimation of personal DBP exposure     
 
A major strength of this study is the combination of data on residential DBP 
concentrations with individual-level information on water consumption, bathing and 
showering to estimate participants’ personal DBP exposure.  No other study of fetal growth 
  228
or duration of gestation to date has had access to such extensive data on individual water use 
and exposure.  At the same time, it is important to acknowledge that information on water 
consumption and use was collected by interview and is subject to the usual concerns about 
the accuracy of self-reported information on exposure in a prospective study.  The potential 
for pregnancy health-related distortion of personal exposure measurement (e.g., whether 
factors related to pregnancy-health, such as nausea, might influence how much tap water a 
woman consumes during the first trimester) must also be considered 151.   
An additional concern is that the method for estimation of personal DBP exposure 
used in this study does not account for exposure that occurs through swimming, washing 
dishes and clothes, bathing children and other activities such as washing hands and flushing 
the toilet, nor does it account for differences in inhalation exposure influenced by home 
ventilation or differential metabolism of DBPs.  Incorporating all of these factors into 
exposure assessment would be extremely difficult, as exposure pathways are very complex, 
and toxicokinetic and toxicodynamic studies of DBP exposure are limited.  Nonetheless, 
failure to incorporate these factors into exposure estimation may result in exposure 
misclassification.  Ultimately, findings for personal DBP metrics were similar to the findings 
for residential DBP concentrations in this study.  This is likely because the drastic contrast in 
residential DBP concentrations between study sites contributed more to personal exposure 
variability than differences in individual water use habits.   
 
6.2.4 Prospective follow-up of participants 
 
A major strength of this study is the prospective design with individual follow-up of 
pregnancies to determine pregnancy outcomes.  Previous studies have relied on information 
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provided in vital records to estimate gestational age and classify infants as SGA.  In this 
study, information on maternal age, race/ethnicity and parity and self-reported last menstrual 
period (LMP) was collected directly from participants early in pregnancy (when recall is 
likely more accurate).  Furthermore, first trimester ultrasounds were conducted and available 
to adjust LMP estimates of gestational age that were more than seven days different from the 
ultrasound estimate.  As a result, estimation of gestational age at delivery and information on 
maternal characteristics for SGA classification should be very accurate in this study.   
The benefits of prospective follow-up did come with some costs.  Unlike previous 
studies which used vital records, and thus are population-based, this study population 
represents a group of women who knew they were pregnant in the first trimester and 
volunteered to participate in a prospective pregnancy study. Maternal characteristics of 
pregnancies enrolled in the RFTS study were compared to all births identified from vital 
records in the same geographic location over the same time period in a previous report.  
RFTS participants were similar to the general population with respect to age but where more 
likely to be highly educated (≥ 16 years of education), non-Hispanic White, and nulliparous 
when compared to the general population26.  In addition, the sample size of our study was 
considerably lower than most previous studies, which ultimately resulted in low precision, 
particularly when stratifying by study site.  Similarly, low power for detecting effect 
estimates of a magnitude within the range found in previous studies was expected given the 
results of preliminary power calculations.  Low power may have contributed to the 
predominately-null findings from analyses of aggregate DBP measures and fetal growth 
outcomes.      
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6.2.5 Assessment of fetal growth restriction  
 
A limitation of this study was the inability to directly identify infants that were 
growth restricted.  Fetal growth restriction describes a decrease in fetal growth rate that 
prevents an infant from reaching his/her growth potential at a given age. We used SGA as a 
surrogate for fetal growth restriction because it is used conventionally to identify more severe 
growth restriction in epidemiological research and has been examined in previous DBP 
studies.  However, not all infants that are “small” at birth are growth restricted and vice 
versa.  Heterogeneity among births identified as SGA could lead to attenuation of estimated 
effects, so researchers often restrict SGA analyses to term infants to obtain a “cleaner” group 
of infants to assess fetal growth restriction.  We found similar results when we restricted 
analyses to infants born at ≥ 37 weeks’ completed gestation.    
 
6.2.6 Use of Bayesian analytical methods 
 
A final strength of this study is the use of Bayesian analytical techniques to examine 
individual DBP exposures simultaneously.  The mechanism by which DBP exposure may 
lead to reduced fetal growth is not well understood 7.   While previous epidemiological 
studies have linked TTHM exposure with adverse pregnancy outcomes, it is unclear whether 
a specific constituent of TTHM (e.g., bromodichloromethane) is biologically active, or 
alternatively, TTHM is simply serving as a marker for another drinking water contaminant 
(e.g., bromoacetic acid).  Because individual THM and HAA levels are highly correlated, 
modeling each exposure in a separate risk model could lead to spurious associations due to 
confounding by other correlated DBPs, but adjustment for multiple DBP exposures in a 
single model using standard maximum likelihood estimation (MLE) may fail to provide 
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plausible results.   By using Bayesian analytic techniques, the highly correlated DBP 
exposures could be modeled simultaneously in a single model, minimizing concern over 
confounding by other DBPs.  In addition, prior distributions were specified to allow 
“borrowing” of information across sets of DBPs of the same class and bromination status.  
Use of this method increases confidence that no strong associations with fetal growth exist in 
this study.  
 
6.3 Public health implications 
In 1974, the Safe Drinking Water Act (SDWA) was passed authorizing the USEPA to 
set and enforce safe drinking water standards.  Chloroform was first discovered in 
chlorinated drinking water that same year.  In 1996, amendments were made to the SDWA 
requiring EPA to develop rules to balance the risks between microbial pathogens and DBPs.  
Clearly, disinfection of drinking water is necessary to control transmission of harmful 
waterborne diseases and plays a vital role in maintaining a healthy population.  However, 
disinfection of drinking water is not without consequence, as evidenced by the established 
association between THMs and bladder cancer as well as toxicological and epidemiological 
data that suggests DBPs may be associated with adverse reproductive outcomes.   
Maximum contaminant level (MCL) values for those DBPs currently regulated by the 
USEPA are derived based upon cancer risk assessments and do not take into account 
potential adverse reproductive outcomes associated with DBP exposure.  There is some 
concern that current regulations may not fully protect against adverse pregnancy outcomes.  
Given the long-term consequences of adverse birth outcomes such as spontaneous abortion, 
birth defects, fetal growth restriction and preterm birth, and the fact that most pregnant 
  232
women are exposed to some amount of DBPs during pregnancy, even a small effect of 
exposure could have a substantial impact on a population level.  To that extent, findings of 
this study suggest that residential concentrations of TTHM and HAA5 below the current 
regulatory standards are not associated with increases in fetal growth restriction or preterm 
birth.  While increased risk of fetal growth restriction was suggested for average TTHM 
residential concentrations above 80 micrograms/liter (the US EPA MCL for annual running 
average TTHM concentrations), very few women experienced TTHM exposure this high.   
 
6.4 Conclusions 
This study is the most extensive study conducted to date examining the effects of 
drinking water DBP exposure during pregnancy on fetal growth and duration of gestation.  
The exposure and outcome assessment methods herein greatly improve upon those used in 
previous research in many ways.  Given these improvements and the ability to better control 
for known confounders, I expected to find stronger estimated effects for TTHM exposure 
than those reported in previous studies given the assumption that TTHM is in fact associated 
with increased risk of fetal growth restriction or preterm birth.  Findings of this study largely 
do not support such associations.         
Taking results from previous studies into consideration, several conclusions about the 
effects of DBP exposure on pregnancy health can be drawn from this study.  The most 
definitive conclusion is that DBP exposure is not associated with increased risk of preterm 
birth.  As such, additional studies of this particular pregnancy outcome are not warranted.  A 
more tentative conclusion is that the current MCLs for TTHM and HAA5 need not be 
lowered to insure that regulatory standards are sufficient to protect against fetal growth 
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restriction and preterm birth, albeit associations with other adverse reproductive outcomes 
(e.g., birth defects) remain unclear 5,7,8.  Finally, with respect to individual THMs and HAAs, 
no particular DBPs have been consistently linked to increased risk of fetal growth restriction 
in this study or prior studies.  Therefore, there is little epidemiological evidence to support 
the hypothesis that HAAs and brominated compounds as a whole are more toxic than THMs 
or non-brominated compounds when considering effects on fetal growth.   
In this study, elevated concentrations of the “uncommon” DBPs at each study site 
were associated with increased risk of fetal growth restriction.  What this particular finding 
implies is unclear.  It is possible that “uncommon” DBPs serve as a marker for other 
unknown DBPs that were not measured.  This highlights perhaps the biggest limitation of 
this study: over 500 DBP subspecies have been reported in the literature 13 but this study was 
only able to examine exposure to the chlorinated and brominated THM and HAA 
compounds.  Future studies of drinking water DBPs should make an effort to collect data on 
newly emerging DBPs (e.g., iodated DBPs, haloacetamides, halonitromethanes), which may 
be considerably more toxic than the DBPs currently regulated.  Along those same lines, TOX 
was not associated with fetal growth restriction or preterm birth, suggesting that this 
aggregate DBP measure does not provide additional information about water quality beyond 
the aggregate DBP measures currently regulated (TTHM and HAA5).   Finally, although the 
ability to estimate personal DBP exposure was a major strength of this study, residential 
concentrations were the predominate determinant in ranking women into those with “high”, 
“moderate”, and “low” personal exposure given the wide range in DBP concentrations across 
study sites.  Future studies should consider the range of residential DBP concentrations their 
proposed study is expected to cover when determining how much effort to put into collecting 
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individual information on water use and consumption versus recruiting a larger, more 
representative group of women and/or conducting a more detailed assessment of water 
quality (e.g., collect data on newly emerging DBP).           
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APPENDIX 1: WATER SAMPLING AND ANALYTIC METHODOLOGY 
 
The following text was abstracted from the AWWARF technical report entitled 
“Drinking Water Disinfection By-Products and Pregnancy loss” prepared by Savitz et al. 
(2005) (Chapter 2, pp. 20-22).  Specific sections abstracted include “Water Sampling 
Methodology” (pp. 20-22) and “Analytic Methodology” (pp. 22-23) and “Quality Assurance 
and Control” (pp. 23-24). 
 
“WATER SAMPLING METHODOLOGY 
 
 Weekly samples were collected at the representative locations for THM, HAA, and 
TOX analysis. Residual chlorine concentrations and temperature were also measured at the 
time of DBP sample collection. Periodically samples were collected at several points in the 
distribution system to verify that the sampling locations had THM, HAA, and TOX 
concentrations that were representative of the system on that day. Additionally, an intensive 
short-term sampling program was carried out at the sampling location on several occasions to 
characterize temporal variability in DBP levels. Samples were collected every 6 hours for 5 
consecutive days and analyzed for THM, HAAs, and TOX. 
 For one month each year (March), the Site 1 utility switched from combined chlorine 
to free chlorine to control potential microbial regrowth and biofilm problems. During the 
one-month conversion, samples for DBP analysis were collected weekly at up to 10 locations 
in the distribution system to account for the anticipated spatial variation in DBP levels. The 
Site 3 utility also converted to free chlorine for a period of several weeks during October 
2003. Again, to account for the anticipated spatial variation in DBP levels, samples were 
collected weekly at a number of locations in the distribution system including the 
representative sample location. 
 Sample collection was performed by field personnel in accordance with a specified 
protocol. Sample collection vials were washed and labeled, and preservatives appropriate for 
the target analyte groups added prior to shipment to each of the three sites. Forty-milliliter 
clear glass VOA screw cap sample vials were used for all THM and HAA sampling events, 
while 250 mL amber glass screw cap bottles were used to collect samples for TOX analysis. 
Specific reagents were added to the clean vials and bottles prior to shipment to the sample 
collection sites. Approximately 20 mg of granular ammonium sulfate (Mallinckrodt, Paris, 
Ky.) was added as a chlorine-quenching agent for both the THM and HAA analyses. 
Approximately 0.7 g of phosphate buffer was also added to the THM vials to standardize the 
pH of all samples to be between 4.8 and 5.5. 50 μL of an 80 mg/liter aqueous solution of 
sodium azide (Aldrich, Milwaukee, Wis.) was added to HAA sample vials to inhibit 
microbial growth. One hundred sixty microliers (160 μL) of a 40 mg/mL aqueous solution of 
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sodium sulfite (Mallinckrodt Baker, Phillipsburg, N.J.) was added to each TOX sample bottle 
as a dechlorinating agent. 
 Identification labels were placed on all sample bottles. The labels were marked with 
the sampling location, target analyte, and reagents added. Spaces were provided on each label 
for the sampler to provide the date, time, and their initials. The vials were packed in ESS 
FoamPac and bubble wrap packing material and placed in the coolers with ice packs. Chain 
of Custody documentation and return overnight shipping labels were also included in each 
cooler. At the University of North Carolina (UNC), records were kept in a status spreadsheet 
which included cells for sampling date, target analyte, outgoing shipment date, date received 
back at UNC, extraction date, instrument analysis date, quantification date, and quality 
control review status. 
 The weekly THM and HAA samples were collected in quadruplicate in order to 
provide duplicate samples for analysis and duplicate samples to be used for matrix spike 
analyses. Additionally, one THM and one HAA field blank was supplied for each weekly 
sampling event at Sites 1 and 3; these vials were prepared with quenching agents and 
preservatives in the same manner as the sample vials. For Site 2, one travel blank was 
prepared for each sampling event to monitor possible contamination of the samples as they 
traveled from the laboratory to the field and back. Single TOX samples were collected 
because of time limitations associated with this analysis and the need to have all samples 
analyzed within a 14-day holding time limit. 
 Samples were collected near mid-day on Thursday at Site 1, Tuesday at Site 2, and 
Wednesday at Site 3, from a cold water tap that had been run for at least five minutes prior to 
sample collection. The vials were filled completely to eliminate headspace. The date and 
time were recorded on each vial and on the separate chain of custody document which was 
also used to record temperature and free and total chlorine residuals which were measured 
with a Hach (Loveland, Colo.) chlorine test kit pocket colorimeter. Sample bottles were re-
packed in the cooler with the same packaging in which they arrived. The samples were 
returned by overnight delivery to the Drinking Water Research Center laboratories of UNC 
where they were inspected and stored in a refrigerator at 4°C.” 
 
 
“ANALYTICAL METHODOLOGY 
 
 THM and TOX samples were analyzed within a 14-day holding time of the sample 
collection date. HAA samples were analyzed within a 21-day holding time. HAA and THM 
extracts were analyzed using a 5890 series II gas chromatograph (Agilent Technologies, Palo 
Alto, Calif.) equipped with an electron capture detector (ECD). For both analyses, ultra high 
purity helium was used as a carrier gas (1.0–1.5 mL/min) and ultra high purity nitrogen (50 
mL/min) was employed as a make-up gas. 
 
THM Analysis 
 
 A modified version of Environmental Protection Agency (EPA) Method 551.1 (U.S. 
EPA 1995a) was utilized to extract each of the THM4 species from the aqueous samples. The 
process employed a liquid-liquid extraction of salted-out and pH-adjusted 20 mL aqueous 
samples with 4 mL of methyl tert-butyl ether (MtBE) containing internal standard (1, 2-
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dibromopropane). Two microliters (2.0 μL) of the THM4 extract were injected into the gas 
chromatograph (GC). The injection port was maintained at 150°C and the detector at 300°C.  
The initial column oven temperature (35°C) was held 10 minutes and then raised from 35 to 
150°C at 10°C/min. The temperature was again ramped from 150°C to 250°C at 25°C/min 
and held for 11 minutes. The total THM run-time was 36.5 minutes. Linear calibration for 
each THM species was in the range 1.0–150 μg/liter. The acceptable relative percent 
difference (RPD) for THM analysis duplicates was < 10% and the matrix spike recovery had 
to be in the range 80–120%. Any samples not meeting these criteria were flagged and 
examined further for analytical or instrumentation errors.  
 
HAA Analysis 
 
 The method used for extraction of all nine HAA species was developed by Brophy et 
al. (2000) and based upon EPA method 552 (US EPA 1995b) and Standard Method 6251B 
(APHA 1998). This method requires acidification to pH < 2 of 20 mL aqueous samples to 
which a surrogate recovery standard (2,3-dibromopropionic acid) was previously added. This 
is followed by liquid-liquid extraction of the protonated acids using MtBE. The HAAs 
partition from the ionized aqueous environment into the organic solvent which, after 
separation, is removed, placed into 2 mL volumetric flasks, and subsequently methylated by 
previously generated diazomethane. After reacting for 15 minutes at 4°C, silicic acid n-
hydrate powder is added to quench the residual diazomethane. The resulting methyl esters are 
transferred in the organic solvent to glass GC autosampler vials and then analyzed by GC-
ECD. One microliter (1.0 μL) of the HAA extract was injected into the GC. The injection 
port was maintained at 180°C and the detector at 300°C. The initial oven temperature (37°C) 
was held 21 minutes and then raised from 37°C to 136°C at 5°C/min and held 3 minutes. The 
temperature was again ramped from 136°C to 250°C at 20°/min and held for 3 minutes. The 
total HAA run-time was 52.5 minutes. 
 The coefficient of variation (%CV) was calculated for the surrogate area counts of all 
analytical samples. The practical quantitation limit for all nine HAAs was 2.0 μg/liter, and 
the maximum calibration standard utilized was 150 μg/liter. Analysis and quantification of 
the calibration standards and aqueous samples was based on replicate precision of duplicate 
samples having a relative percent difference of less than 25%.  
 
TOX Analysis 
 
 TOX analysis was performed using a model AD-2000 Adsorption Module and TOX 
Analyzer (Tekmar Dohrmann, Cincinnati, Ohio). Samples of 250 mL were acidified to pH < 
2 with 2 mL of concentrated sulfuric acid (H2SO4). Samples were then loaded into an 
adsorption module and dispensed through two granular activated carbon columns (top and 
bottom) and subsequently rinsed with 2 mL of potassium nitrate (500 g/liter in laboratory 
grade water) to remove retained inorganic chloride. The carbon was then combusted at 850°C 
to volatilize organic halogens which were then analyzed by micro-coulometric detection. 
Preceding and following each batch of samples, a “nitrate blank” was also analyzed to 
determine the contribution of background organic halogen from the reagents, carbon, and 
carrier gases. Each blank was a single, clean column that was rinsed with 2 mL of potassium 
nitrate. 
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 TOX results and breakthrough percentages are calculated for the combustion of top 
and bottom columns of samples based on sample results and nitrate blank values reported by 
the instrument data output using the following formulae (Equations 1 and 2): 
 
 TOX (μg Cl/liter) = (OX top column + OX bottom column) – 2*OX blank (1) 
    Volume (ml) of sample absorbed 
 
 Breakthrough (%) =  (OX bottom – OX blank)*100             (2) 
   [(OX top + OX bottom) – 2*OX blank] 
 
 OX = organic halogen in μg Cl 
 OX blank = average of analysis of two columns 
 
If breakthrough exceeded 10% the samples were re-analyzed within their 14-day holding 
time. The organic halide analyzer was checked for recovery (cell check) and the combustion 
performance (combustion check) prior to analysis of each sample batch (< 6 samples). If the 
sodium chloride (200 ng/μL) cell check (5 μL) and the 2,4,6-trichlorophenol (500 ng/liter) 
combustion check (5 μL) recoveries obtained ranged between 90–110% the system was 
considered to be effective in the determination of the TOX content of the samples. To further 
evaluate the system performance, a check standard or duplicate sample was analyzed as one 
of the six samples in each batch. 
 
Residual Disinfectants 
 
 Free and total chlorine levels in the water were measured using a colorimetric test kit 
(Hach Chemical, Loveland, Colo.). Before each sample, the colorimeter was zeroed using 
laboratory grade water, and the sample cell rinsed with the sample. The colorimeter reads in 
concentration units (mg/liter). Water with residual chlorine above the range of the 
colorimeter was diluted with laboratory grade water (LGW) and concentrations corrected 
accordingly.” 
 
 
“QUALITY ASSURANCE AND CONTROL 
 
 Calibration standards were prepared in LGW. Seven THM and six HAA working 
dilutions of standard stock solutions were utilized to cover the expected range of 
concentrations in samples. The calibration standards were extracted and analyzed along with 
the samples, using the same batch of MtBE and internal standard. The target THM and HAA 
analyte concentrations were measured as peak area responses on chromatograms relative to 
that of the internal standard. The relative areas from duplicate standards were then plotted 
against the prepared standard concentrations to prepare a calibration which was used to 
calculate sample concentrations (μg/liter) as a function of relative areas. Samples below the 
practical quantitation limits of 2.0 μg/liter for HAA9 and 0.1 μg/liter for THM4 are 
considered below the limit of quantitation and are not reported. Two or three calibration 
points were extracted in triplicate so that the third sample served as an analytical check 
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during GC analysis. The standards were run periodically throughout each analytical batch to 
monitor possible instrument drift or change in sensitivity that might affect calculations. 
 The internal standard and two stock calibration standards were checked for 
contamination and degradation prior to each THM4 extraction. An aliquot of extracting 
solvent, MtBE with internal standard, as well as two calibration point check standards were 
prepared, analyzed, and compared to the original check standard concentrations (made each 
time a stock solution was prepared). The stock solutions were re-made prior to extraction if 
any of the analyte concentrations deviated by more than 20% from the original detector 
responses obtained when the standards had been freshly prepared. 
 Matrix spike samples were used in THM and HAA analyses to document any method 
bias in a given sample matrix. Matrix spikes were created by spiking samples, in duplicate, 
with a known concentration of the target analytes prior to extraction. 
 Travel blanks or field blanks accompanied all samples throughout the sampling 
process in order to monitor possible contamination of the samples as they traveled from the 
laboratory to the sample site and back. Travel blanks were filled, prior to shipping, with 
LGW according to the water collection procedure described above. Field blanks were opened 
at the sample collection site and filled, under the same guidelines, with LGW provided in an 
amber bottle. Travel blanks were left unopened in the cooler. 
 An excel macro was created and utilized for most of the HAA9 and THM4 analyses 
described in this report. The chromatograms were collectively re-processed using revision 
A.06 HP ChemStation (Hewlett-Packard, Palo Alto, Calif.) software and then the retention 
time, area, and height of each analyte’s peak exported into Excel files. Sample concentrations 
were calculated based on Excel-automated linear regression of the calibration curve and 
interpreted under standard operating procedure guidelines. Any duplicate sample relative 
areas that differed by greater than 20% or were not consistent with other observations were 
flagged or eliminated. 
 After the THM, HAA, and TOX concentrations had been measured and interpreted in 
accordance with standard operating procedures, they were submitted to the project supervisor 
for quality assurance and quality control review. This process involved further examination 
of the concentrations detected for feasibility in light of previously detected concentrations at 
each site. Also, at this point, any shifts in speciation were noted for review, as well as any 
inconsistencies among THM and HAA measurements for a given sampling event. The 
flagged results were re-addressed by the analysts for possible errors in the extraction, 
integration, or quantification processes. Unreasonable inconsistencies that could not be 
resolved resulted in the elimination of that particular sampling event from the results 
reported, but this occurred very infrequently in this study. For statistical interpretation of 
data, analytes that were below the quantifiable limit of detection were treated as zero values 
even though on occasion chromatographic peaks were observed for these analytes.” 
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APPENDIX 2: CONVERSION FACTORS TO ADJUST RESIDENTIAL DBP 
CONCENTRATIONS FOR HEATING AND FILTRATION 
 
 
 Thermal treatment (boiling)a Filtrationb 
 Chloraminated 
water 
Chlorinated 
water 
POU filter Pitcher 
Trihalomethanes 
(μg/liter) 
    
chloroform 0.25 0.66 0.00 0.60 
BDCM 0.25 0.19 0.00 0.60 
DBCM 0.30 0.18 0.00 0.60 
Bromoform 0.40 0.24 0.00 0.60 
Haloacetic acids 
(μg/liter) 
    
CAA 0.91c 1.15 0.92 0.87 
BCAA 1.4 1.51 0.41 0.67 
DCAA 0.91 1.59 0.55 0.70 
BAA 0.93c 1.72c 0.58 0.67 
TCAA 0.91 100.0 0.36 0.65 
DBAA 0.93 1.72 0.33 0.66 
BDCAA 0.47 0.43 0.19 0.47 
DBCAA 0.00 0.00 0.16 0.42 
TBAA 0.68 100.0c 0.09 0.35 
aThermal treatment conversion factors were obtained from Krasner & Wright (2005) (107) unless otherwise noted 
bFiltration conversion factors were obtained from Savitz et al. (2005) (25) 
cThermal treatment conversion factor were not available from Krasner and Wright (2005) (107), so the conversion 
factor of the most closely related chemical structure was substituted 
Abbreviations: TTHM=total trihalomethanes, BDCM=bromodichloromethane, DBCM= dibromochloromethane, 
THM-Br = sum of all brominated trihalomethanes, HAA5= sum of five regulated haloacetic acids, HAA9= sum 
of all haloacetic acids, CAA= chloroacetic acid, BCAA= bromochloroacetic acid, DCAA= dichloroacetic acid, 
TCAA= trichloroacetic acid, BAA= bromoacetic acid, DBAA= dibromoacetic acid, BDCAA= 
bromodichloroacetic acid, DBCAA= dibromochloroacetic acid, POU=point-of-use  
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APPENDIX 3: RIGHT FROM THE START BASELINE QUESTIONNAIRE 
 
 
The attached questionnaire sequence (“Section D Water Exposure”, pp. 24-35) was 
abstracted from the “Baseline Questionnaire” prepared by David Savitz and colleagues for 
the Right from the Start (RFTS) study funded by AWWARF (CATI Version 2, October 25, 
2001- text updated to match CATI on December 16, 2002).   
 
 
Section D Water exposure 
The next set of questions is about your use of water for drinking, cooking, showering and 
cleaning. Water use in pregnancy and its affect on pregnancy has not yet been studied 
thoroughly. This is, therefore, an area that we would like to explore in some detail. To do 
this, I’m first going to ask about the places you have lived in the past four months. 
 
D1a. Do you currently live at [address from screening interview]? 
yes? skip to D2.  no  don’t know/refused 
D1b. Please tell me the street address, city and state [where you currently 
live/of your next most recent residence]. [If she doesn’t give us her address, 
we will not be able to mail her check to her.] 
Don’t know 
D1c. Would you tell me the city you currently live in? 
D2. Have you lived at this residence for more than 4 months? 
yes ? to D4 if D1a. is no 
yes ? to D6 if D1a is yes 
no 
D3. When did you move to this address?  
month/day/year 
D4. [Is/was] the source of your tap water at ___________ [street address], that 
is the water that comes out of your faucets, from a private well or from 
the public water supplier [your town or city]? 
If D2=yes, → D6. 
D5. How many addresses other than your current address have you lived at 
since [date 4 months ago]? [only her primary residences ie. where she spends 
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most of her time. No vacation spots unless she spends a part of the year at this 
residence at which time it is her primary residence.] 
_______ # addresses 
 
Ask D1b., D3, and D4 for each additional address where the woman has lived 
in the last 4 months. 
 
 Residence #1 Residence #2 Residence #3 
D1a. yes ?skip to D2. 
no 
  
D1b.  
Address 
 
Street: 
Apt. or lot#. 
City 
State 
Zip code 
Street: 
Apt. or lot#. 
City 
State 
Zip code 
Street: 
Apt. or lot#. 
City 
State 
Zip code 
D2. 
 
Yes ? D4.if D1a. = no 
Yes ? D6. if D1a = yes No 
yes 
no 
yes 
no 
D3. 
 
_ _ /_ _/_ _ 
mm/dy/yr 
_ _ /_ _/_ _ 
mm/dy/yr 
_ _ /_ _/_ _ 
mm/dy/yr 
D4. 
 
private well 
city/town 
private well 
city/town 
private well 
city/town 
 
 
D6. For the following questions about water use, please think about what 
you drank over the past week when answering what you typically drink 
in a day. Was this past week a typical week for you, meaning that you 
weren’t on vacation or there wasn’t anything unusual that would affect 
your water use? [auto fill from Ca., if no just remind respondent to think of a 
typical week and if yes skip this question] 
 
Yes ? For the following questions about water use, please think about what you 
drank over the past week when answering what you typically drink in a day. 
No ? A quick reminder, since last week was not typical for you, for all the following 
questions please think about a different week that you would consider a more typical 
week for you. 
 
Total cold tap water use[home and work] 
Now, I’m going to ask you questions about how much cold tap water you typically drink 
each day. For these questions, include both filtered and unfiltered water, from your home and 
work place [if she works]. Also include all cold drinks made from that tap water such as 
powdered drinks. Do not include bottled or canned drinks. 
[interviewer notes: include water from the tap, refrigerator spigot or refrigerated water 
fountain. Cold drinks include instant iced tea but not brewed, and drinks from concentrate. 
No bottled water, no sodas, no canned or bottled juices. Hot water from the tap or from a hot 
shot should be included in the ‘cold water’ drinks.] 
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D7a. How many glasses of tap water, including cold 
drinks made with tap water, do you usually drink 
per day? 
__ # of glasses per day ? if 
0 skip to D7c. 
____<1 per day ?  D7c. 
Don’t know/refused ? to 
D7c 
D7b. Are those glasses usually small like a juice glass, 
about 4-10oz; medium like a water glass, about 12-
20; or large like a giant size drink at the 
movies/Fast food, about 22-34oz? 
Sm 
Med 
Lg  
Other: __________ 
Don’t know/refused 
D7c. Over the past four months, have you changed the 
amount of tap water that you drink by more than 
two glasses a day? 
Yes 
No ? skip to D8a. 
DK/refused ? to D8a. 
D7d. Before you changed, how many glasses of tap 
water did you usually drink per day? 
_____ # of glasses per day 
D7e. When did you change the amount of tap water you 
drink? 
month: ____ 
day: ______ [if doesn’t 
remember day ask D7f.] 
year: _______ 
 
? doesn’t remember/ 
refused 
D7f. Do you remember what week in [month] that was, 
the first, second, third, fourth or fifth? 
_____1st 
____2nd 
____ 3rd 
______ 4th 
_________5th 
? doesn’t remember/ 
refused 
 
 
Total hot tap water use[home and work] 
Next, I’m going to ask you questions about how many hot drinks made with tap water you 
typically drink each day. For these questions, include drinks made with tap water from your 
home and your work [if she works]. [Hot water means that she boiled the water on the stove 
or in a microwave to get it hot. Hot water from the tap or from a hot shot should be included 
in the ‘cold water’ drinks.] 
 
D8a. How many cups of hot drinks made from tap water, 
such as coffee, tea including brewed iced tea, hot 
chocolate or cup-a-soups, do you usually drink per 
day? 
___ # of cups per day ?if 
0 skip to D8c. 
__<1 per day ? D8c. 
DK/refused ? to D8c. 
D8b. Are those cups usually small like a tea cup, about 4-
10 oz; medium like a coffee mug, about 12-14oz; or 
large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm 
Med 
Lg 
Other: specify _______ 
don’t know/refused 
D8c. Over the past four months, have you changed the 
amount of hot drinks made with tap water that you 
drink by more than two cups a day? 
Yes 
No ? skip to D14a. 
Don’t know/refused ? 
to D14a. 
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D8d. Before you changed, how many cups of hot drinks 
made with tap water did you usually drink per day? 
____ # of cups per day 
D8e. When did you change the amount of hot drinks you 
drink? 
month: ____ 
day: ______ [if doesn’t 
remember day ask D8f.] 
year: _______ 
 
? doesn’t remember/ 
refused 
D8f. Do you remember what week in [month] that was, 
the first, second, third, fourth or fifth? 
_____1st 
____2nd 
____ 3rd 
______ 4th 
_________ 5th 
? doesn’t remember/ 
refused 
? ? after these questions skip to D14a. ? 
 
[If all her current jobs are located in Raleigh (B4b.), do not ask D9-D13. You should ask D6-
D8.] 
D9. For the following questions about water use, please think about what 
you drank over the past week when answering what you typically drink 
in a day. Was this past week a typical week for you, meaning that you 
weren’t on vacation or there wasn’t anything unusual that would affect 
your water use? [auto fill from Ca., if no just remind respondent to think of a 
typical week and if yes skip this question] 
 
Yes ? For the following questions about water use, please think about what you 
drank over the past week when answering what you typically drink in a day. 
No ? A quick reminder, since last week was not typical for you, for all the following 
questions please think about a week that you would consider a typical week for you. 
 
 
Cold tap water use at work 
Now, I’m going to ask you questions about how much cold tap water you typically drink 
each day at work. For these questions, include both filtered and unfiltered water, from work 
place. Also include all cold drinks made from that tap water such as powdered drinks. Do not 
include bottled or canned drinks. 
[interviewer notes: include water from the tap, refrigerator spigot or refrigerated water 
fountain. Cold drinks include instant iced tea but not brewed, and drinks from concentrate. 
No bottled water, no sodas, no canned or bottled juices. Hot water from the tap or from a hot 
shot should be included in the ‘cold water’ drinks.] 
 
D10a. How many glasses of water from your office tap do 
you usually drink per day? 
__ # of glasses per day ? 
if 0 skip to D10c. 
__<1 per day ? D10c. 
DK/refused ? to D10c. 
D10b. Are those glasses usually small like a juice glass, 
about 4-10oz; medium like a water glass, about 12-
Sm 
Med 
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20; or large like a giant size drink at the movies/Fast 
food, about 22-34oz? 
Lg 
Other: specify _____ 
Don’t know/refused 
D10c. Over the past four months, have you changed the 
amount of office tap water that you drink per day by 
more than two glasses? 
Yes 
No ? skip to D11a 
DK/refused ? to D11a. 
D10d. Before you changed, how many glasses of office tap 
water did you usually drink per day? 
_____ # of glasses per 
day 
D10e. When did you change the amount of office tap water 
you drink? 
month: ____ 
day: ______ [if doesn’t 
remember day ask D10f.] 
year: _______ 
 
? doesn’t remember/ 
refused 
D10f. Do you remember what week in [month] that was, 
the first, second, third, fourth or fifth? 
_____1st 
____2nd 
____ 3rd 
______ 4th 
_________ 5th 
? doesn’t remember/ 
refused 
 
 
Hot tap water use at work 
Next I’m going to ask you questions about how many hot drinks made with tap water from 
work you typically drink each day. [Hot water means that she boiled the water on the stove 
or in a microwave to get it hot. Hot water from the tap or from a hot shot should be included 
in the ‘cold water’ drinks.] 
 
 
D11a. How many cups of hot drinks made from office tap 
water, such as coffee, tea including brewed iced tea, 
hot chocolate or cup-a-soups, do you usually drink 
each day? 
___ # of cups per day ? 
if 0 skip to D11c. 
__<1 per day ? D11c. 
DK/refused ? to D11c. 
D11b. Are those cups usually small like a tea cup, about 4-
10 oz; medium like a coffee mug, about 12-14oz; or 
large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm 
Med 
Lg 
Other: specify _______ 
don’t know/refused 
D11c. Over the past four months, have you changed the 
amount of hot drinks made with office tap water that 
you drink by more than two cups a day? 
Yes 
No ? skip to D12a. 
DK/refused ? To D12a. 
D11d. Before you changed, how many cups of hot drinks 
made with tap water did you usually drink each day? 
____ # of cups per day 
D11e. When did you change the amount of hot drinks you 
drink? 
month: ____ 
day: ______ [if doesn’t 
remember day ask D11f.] 
year: _______ 
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? doesn’t remember/ 
refused 
D11f. Do you remember what week in [month] that was, the 
first, second, third, fourth or fifth? 
_____1st 
____2nd 
____ 3rd 
______ 4th 
_________ 5th 
? doesn’t remember/ 
refused 
 
 
Cold tap water use at home 
Now, I’m going to ask you questions about how much cold tap water you typically drink 
each day at home. For these questions, include both filtered and unfiltered water. Also 
include all cold drinks made from that tap water such as powdered drinks. If you bring tap 
water from home to work, or other places, also include that water. Do not include bottled or 
canned drinks. 
[interviewer notes: include water from the tap, refrigerator spigot or refrigerated water 
fountain. Cold drinks include instant iced tea but not brewed, and drinks from concentrate. 
No bottled water, no sodas, no canned or bottled juices. Hot water from the tap or from a hot 
shot should be included in the ‘cold water’ drinks.] 
 
D12a. How many glasses of water from your home tap do 
you usually drink per day? 
__ # of glasses per day ? 
if 0 skip to D12c. 
__<1 per day? D12c. 
DK/refused ? to D12c. 
D12b. Are those glasses usually small like a juice glass, 
about 4-10oz; medium like a water glass, about 12-20; 
or large like a giant size drink at the movies/Fast 
food, about 22-34oz? 
Sm 
Med 
Lg 
Other: specify ______ 
Don’t know/refused 
D12c. Over the past four months, have you changed the 
amount of home tap water that you drink per day by 
more than two glasses? 
Yes 
No ? skip to D13a 
DK/refused ? to D13a. 
D12d. Before you changed, how many glasses of home tap 
water did you usually drink per day? 
_____ # of glasses per 
day 
D12e. When did you change the amount of home tap water 
you drink? 
month: ____ 
day: ______ [if doesn’t 
remember day ask D12f.] 
year: _______ 
 
? doesn’t remember/ 
refused 
D12f. Do you remember what week in [month] that was, the 
first, second, third, fourth or fifth? 
_____1st 
____2nd 
____ 3rd 
______ 4th 
_________ 5th 
? doesn’t remember/ 
refused 
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Hot tap water use at home 
The next questions I’m going to ask are about hot drinks made with home tap water. [Hot 
water means that she boiled the water on the stove or in a microwave to get it hot. Hot water 
from the tap or from a hot shot should be included in the ‘cold water’ drinks.] 
 
 
D13a. How many cups of hot drinks made from home tap 
water, such as coffee, tea including brewed iced tea, 
hot chocolate or cup-a-soups, do you usually drink 
each day? 
___ # of cups per day 
?if 0 skip to D13c 
__<1 per day? D13c 
DK/ refused ? to D13c. 
D13b. Are those cups usually small like a tea cup, about 4-
10 oz; medium like a coffee mug, about 12-14oz; or 
large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm 
Med 
Lg 
Other: specify _______ 
don’t know/refused 
D13c. Over the past four months, have you changed the 
amount of hot drinks made with home tap water that 
you drink by more than two cups a day? 
Yes 
No ? skip to D14a 
DK/refused ? to D14a. 
D13d. Before you changed, how many cups of hot drinks 
made with tap water did you usually drink each day? 
____ # of cups per day 
D13e. When did you change the amount of hot drinks you 
drink? 
month: ____ 
day: ______ [if doesn’t 
remember day ask 
D13f.] 
year: _______ 
DK/ refused 
D13f. Do you remember what week in [month] that was, the 
first, second, third, fourth or fifth? 
_____1st 
____2nd 
____ 3rd 
_____ 4th 
_______  5th 
? doesn’t remember/ 
refused 
 
 
Bottled water 
Now I’m going to ask you some questions about your bottled water use. Try to answer the 
following questions as closely to what you usually or typically drink in a day. Bottled water 
includes water that you purchase in bottles or plastic jugs and that you get from any water 
cooler, but not from a water fountain. Bottled water can include spring water, mineral water, 
distilled water, or sparkling water such as Quibell, Poland Spring, Perrier, Calistoga, some is 
flavored. Do not include tonic water, club soda, soda water, seltzer or caffeinated water about 
which we already asked you earlier.  
 
[She should  include Vitamin water and Fruit flavored water (distilled water with citric acid, 
flavors and electrolytes). Seltzer is different from sparkling water. Sparkling water is usually 
made with spring water whereas seltzer is usually made with tap water] 
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D14a. In the past four months, how much of all the water you drink is bottled 
water, including water used for hot and cold drinks? Is it all or nearly all, 
most, some, very little or none of the water? 
All or nearly all 
Most 
Some ? skip to D15. 
Very little? skip to D15. 
none? skip to D15. 
don’t know/refused ? skip to D15. 
 
[if woman says she drinks bottles of water rather than glasses, in Q14b. ask her the number 
of bottles and in Q14c. ask her the size of the bottle] 
 
D14b. How many glasses/bottles of bottled water 
do you usually drink per day? 
____ # of glasses per day  
? if 0 skip to D15. 
____<1 per day ? skip to D15. 
Don’t know/refused 
D14c. Are those glasses usually small like a juice 
glass, about 4-10oz; medium like a water 
glass, about 12-20; or large like a giant 
size drink at the movies/Fast food, about 
22-34oz? 
OR for Bottles:  
Are those bottles usually small, about 8-12 
ounces; medium, about 14-24 ounces; or 
large, about 26-34 ounces? 
 
Sm 
Med 
Lg 
Other: specify __________ 
 
or  
small bottle [8-12] 
medium [14-24] 
large bottle [26-34] 
Other: specify ____________ 
D14d. What is the primary brand of bottled water 
that you usually drink? [note brand name] 
? Brand name ______ 
? Name of store ____ [if filling 
bottle at store] 
? No specific brand 
? don’t know/refused 
 
 
Filtering 
[Ask D15-D20a. for each residence in which she has lived during the past 4 months, one 
residence at a time] 
D15. In the past four months, have you, in any way, filtered any of your tap 
water at ___________ [street address]? 
yes no ? skip to D21a. don’t know/refused 
 
D16. Is the water filtering system at ___________ [street address], for the entire 
house or at specific locations such as a faucet, showerhead, or a 
pitcher? 
entire house  
Specific locations ? skip to D18a. 
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D17. What is the brand name of the filter you use/used for the entire house? 
______________________ brand name ? skip to D21a. 
 
D18a. Do/did you have a filter on your showerhead? 
yes no ?skip to D19a. don’t know/refused  ?skip to D19a 
 
D18b. What is/was the brand name of the filter on the showerhead? 
__________________________ 
 
D18c. How often do/did you replace the filter? 
____# times per month / year  
 
D19a. In the past four months, how much of the tap water you drink/drank at 
_________ [street address] has been filtered, including water used for 
hot and cold drinks? Was it _________ [read choices]? 
All or nearly all 
Most 
Some ? skip to D20a. 
Very little? skip to D20a. 
none? skip to D20a. 
don’t know/refused ? skip to D20a. 
 
D19b. Is the filter you use/used for the water you drink/drank at home, at the 
faucet, part of the refrigerator, or a filtering pitcher such as Brita or 
PUR? [mark all that apply] 
? Faucet 
? Refrigerator 
? Pitcher 
? Other, Specify 
 
D19c. What brand is/was the filter on the _____________? [check spelling of brand 
name] 
 
D19d. How often do you replace the filter in the __________? [if never code 0] 
 
 brand name replacement 
? faucet 
? refrigerator 
? pitcher 
? other 
? don’t know /refused 
_____________ brand name 
_____________ brand name 
_____________ brand name 
_____________ brand name 
 
____# times per month / 
year 
____# times per month / 
year 
____# times per month / 
year 
____# times per month / 
year 
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D20a. In the past four months, how much of the tap water you use/used for 
cooking at ________ [street address] has been filtered? Was it ______ 
[read choices]? 
All or nearly all 
Most 
Some 
Very little 
none 
don’t know/refused 
 
[Ask D15-D20a. for each of the residences before continuing with D21a.] 
 
D21a. In the past four months, how much of the tap water you drink outside 
your home has been filtered, including water used for hot and cold 
drinks? Was it ___ [read choices]? [interviewer note: ‘outside home’ would 
include any place where she drinks a significant amount of her water such as at work, 
restaurants, friend’s home.] 
? All or nearly all 
? Most 
? Some? skip to D22. if D15 is yes; if D15 is no skip to D23a. 
? Very little? skip to D22. if D15 is yes; if D15 is no skip to D23a. 
? None? skip to D22. if D15 is yes; if D15 is no skip to D23a. 
? don’t know/refused ? skip to D22. if D15 is yes; if D15 is no skip to D23a. 
 
D21b. Is the filter you use for the tap water you drink outside your home, at the 
faucet, part of a refrigerator, or a filtering pitcher such as Brita or PUR? 
[mark all that apply] 
? Faucet 
? Refrigerator 
? Pitcher 
? Other, Specify 
 
D21c. What brand is the filter in the _________? [only ask for pitcher or other] 
 
D21d. How often do you replace the filter in the ______? [only ask for pitcher or 
other] 
 
 brand name replacement 
? faucet 
? refrigerator 
? pitcher 
? other 
? don’t know /refused 
 
 
____________ brand name 
____________ brand name 
 
 
 
____# times per month / 
year 
____# times per month / 
year 
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D22. Thinking about the filters you use both at home and outside your home, 
when replacing any of these filters, how do you decide when to replace 
it? Is it _________ [read choices, mark all that apply]? 
? based on manufacturer recommendations 
? when the water begins to taste bad 
? when you remember 
? other [specify] ______________ 
 
 
Now I’m going to ask you about other uses of water in your home such as for showering, 
bathing, bathing children, and washing dishes and clothes. Again, think about what you 
currently do in a typical week. 
 
 
Showering 
 
D23a. How often do you shower at home? 
___ times per day/week/month [If < 2x per week, skip to D24a. ] 
___ < 1x month ? skip to D24a. 
 
D23b. How many minutes do you usually spend actually in the shower? 
________ # minutes 
 
D23c. How many minutes do you usually spend in the bathroom with the door 
closed while the shower is running before getting in? 
_________ #minutes 
 
D23d. How many minutes do you usually spend in the bathroom with the door 
closed after you’ve showered? 
___________ # minutes  
 
 
Bathing 
D24a. How often do you take a bath at home, not including showers? 
[interviewer note: include if she takes a bath with her children] 
___ times per day/week/month [if < 2x per week, skip to D25a.] 
___ < 1x month? skip to D25a. 
 
D24b. When you take a bath, how full is the tub: ¼, ½, ¾, or completely full? 
[refers to how submerged she is] 
¼  ½  ¾ full 
 
D24c. How many minutes do you usually spend in the tub? 
_____ # minutes 
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D24d. How many minutes do you usually spend in the bathroom with the door 
closed while the bathtub is filling up before getting in? 
_______ #minutes 
 
D24e. How many minutes do you usually spend in the bathroom with the door 
closed after you’ve bathed? 
___________ #minutes 
 
Children 
D25a. At home, how often do you bathe infants or small children, those too 
young to leave alone in the bath tub? [do not include times when she takes a 
bath with her children, this should be included in D24a] 
______ # times per day / per week / per month [if < 2 bath per week skip to D26a.] 
___ < 1x month [if < 2 bath per week skip to D26a.] 
 
D25b. How many minutes per bath do you usually spend bathing children? 
____ minutes per bath 
 
D25c. How many minutes do you usually spend in the bathroom with the door 
closed while the bath is filling before you bathe children? 
________ #minutes 
 
D25d. How many minutes do you usually spend in the bathroom with the door 
closed after you’ve bathed children? 
________ # minutes 
 
Dishes 
D26a. How often do you typically rinse or wash dishes by hand? 
_____ # times per day / week / month [if less than twice per week? Skip to D27a.] 
___ < 1x month [if less than twice per week? Skip to D27a.] 
 
D26b. How much time do you usually spend on each occasion rinsing or 
washing dishes by hand? 
_______ #minutes / hours per occasion 
 
D26c. How often do you use gloves when washing the dishes, all of the time, 
most of the time, some of the time, or very rarely? 
? All the time 
? Most of the time 
? Some of the time 
? Rarely or never 
? Refused/Don’t know 
 
 
Clothes 
D27a. How often do you wash clothing by hand instead of machine? 
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____ # times per week / month /never [if < 2x per week ? skip to Section E] 
___ < 1x month [if < 2x per week ? skip to Section E] 
 
D27b. How much time do you usually spend each time you wash clothes by 
hand?  
____ #minutes / hours per occasion 
 
D27c. How often do you use gloves when washing clothing by hand, all of the 
time, most of the time, some of the time, or very rarely? 
? All the time 
? Most of the time 
? Some of the time 
? Rarely or never 
? Don’t know/refused 
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APPENDIX 4: RIGHT FROM THE START FOLLOW-UP QUESTIONNAIRE 
 
 
 
The attached questionnaire sequence (“Section D Water Exposure”, pp. 13-19) was 
abstracted from the “Still pregnant Follow-up Questionnaire” prepared by David Savitz and 
colleagues for the Right from the Start (RFTS) study funded by AWWARF (CATI Version 
2, October 25, 2001- text updated to match CATI on December 16, 2002).  
 
 
Section D Water exposure 
The next questions are about your use of water for drinking, cooking, showering and 
cleaning. I’m first going to ask about the places you have lived since your first interview on 
______ [date]. 
 
D1a. Do you currently live at _______ [address(es) from D1. or D2. in first 
interview]? 
yes? skip to D2.  no  don’t know/refused 
D1b. Please tell me the street address, city and state [where you currently 
live/of your next most recent residence]. [If she doesn’t give us her address, 
we will not be able to mail her check to her.] 
Don’t know 
D1c. [if she doesn’t answer D1b.] Would you tell me the city you currently live in? 
D2. Have you lived at this residence since your first interview? 
yes ? if D1a is yes, skip to D6. if B4b is only Raleigh or to D9. if B4b. is not only 
Raleigh 
if D1a is not yes, continue with D4. When asking additional addresses that we’re 
listed in the baseline, ask D3-D4. 
no 
D3. When did you move to this address?  
month/day/year 
D4. [Is/was] the source of your tap water at ___________ [street address], that 
is the water that comes out of your faucets, from a private well or from 
the public water supplier [your town or city]? 
D5. How many addresses other than your current address have you lived at 
since ________ [date of the first interview]? [only her primary residences ie. 
where she spends most of her time. No vacation spots unless she spends a part of the 
year at this residence at which time it is her primary residence.] 
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_______ # addresses ? if 1 or more continue with D1b. 
 
Ask D1b., D3, and D4 for each additional address where the woman has lived in since the 
first interview. 
 Residence #1 Residence #2 Residence #3 
D1a. yes ?skip to D2. 
no 
  
D1b.  
Address 
 
Street: 
Apt. or lot#. 
City, State, Zip code 
Street: 
Apt. or lot#. 
City, State, Zip code 
Street: 
Apt. or lot#. 
City, State, Zip 
code 
D2. 
 
Yes ? 
No 
yes 
no 
yes 
no 
D3. 
 
_ _ /_ _/_ _ 
mm/dy/yr 
_ _ /_ _/_ _ 
mm/dy/yr 
_ _ /_ _/_ _ 
mm/dy/yr 
D4. 
 
private well 
city/town 
private well 
city/town 
private well 
city/town 
D6. [auto fill from Ca., if no just remind respondent to think of a typical week and if yes 
skip this question] Was this past week a typical week for you, meaning that 
you weren’t on vacation or there wasn’t anything unusual that would 
affect your water use? 
Yes ? For the following questions about water use, please think about what you 
drank over the past week when answering what you typically drink in a day. 
No ? A quick reminder, since last week was not typical for you, for all the following 
questions please think about a week that you would consider a typical week for you. 
 
 
Total cold tap water use[home and work] 
Now, I’m going to ask you questions about how much cold tap water you typically drink 
each day. For these questions, include both filtered and unfiltered water, from your home and 
work place [if she works]. Also include all cold drinks made from that tap water such as 
powdered drinks. However, do not include bottled or canned drinks. 
[interviewer notes: include water from the tap, refrigerator spigot or refrigerated water 
fountain. Cold drinks include instant iced tea but not brewed, and drinks from concentrate. 
No bottled water, no sodas, no canned or bottled juices. Hot water from the tap or from a hot 
shot should be included in the ‘cold water’ drinks.] 
 
D7a. How many glasses of tap water, including cold 
drinks made with tap water, do you usually drink 
per day? 
__ # of glasses per day ? if 
0 skip to D8a. 
<1 per day ? skip to D8a. 
DK/refused ? to D8a. 
D7b. Are those glasses usually small like a juice glass, 
about 4-10oz; medium like a water glass, about 12-
20; or large like a giant size drink at the 
movies/Fast food, about 22-34oz? 
Sm 
Med 
Lg  
Other: __________ 
Don’t know/refused 
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Total hot tap water use[home and work] 
Next, I’m going to ask you questions about how many hot drinks made with tap water you 
typically drink each day. For these questions, include drinks made with tap water from your 
home and your work [if she works]. [Hot water means that she boiled the water on the stove 
or in a microwave to get it hot. Hot water from the tap or from a hot shot should be included 
in the ‘cold water’ drinks. Water can be filtered and unfiltered.] 
 
D8a. How many cups of hot drinks made from tap water, 
such as coffee, tea including brewed iced tea, hot 
chocolate or cup-a-soups, do you usually drink per 
day? 
___ # of cups per day 
?if 0 skip to 
D14a. 
<1 per day?skip to 
D14a. 
DK/refused ? to D14a. 
D8b. Are those cups usually small like a tea cup, about 4-
10 oz; medium like a coffee mug, about 12-14oz; or 
large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm 
Med 
Lg 
Other: specify 
_______ 
don’t know/refused 
 
D9. [auto fill from Ca., if no just remind respondent to think of a typical week and if yes 
skip this question] Was this past week a typical week for you, meaning that 
you weren’t on vacation or there wasn’t anything unusual that would 
affect your water use? 
Yes ? For the following questions about water use, please think about what you 
drank over the past week when answering what you typically drink in a day. 
No ? A quick reminder, since last week was not typical for you, for all the following 
questions please think about a week that you would consider a typical week for you. 
 
Cold tap water use at work 
Now, I’m going to ask you questions about how much cold tap water you typically drink 
each day at work. For these questions, include both filtered and unfiltered water, from your 
work place. Also include all cold drinks made from that tap water such as powdered drinks. 
Do not include bottled or canned drinks. 
[interviewer notes: include water from the tap, refrigerator spigot or refrigerated water 
fountain. Cold drinks include instant iced tea but not brewed, and drinks from concentrate. 
No bottled water, no sodas, no canned or bottled juices. Hot water from the tap or from a hot 
shot should be included in the ‘cold water’ drinks.] 
 
D10a. How many glasses of water from your office tap, 
including cold drinks made with tap water, do you 
usually drink per day? 
__ # of glasses per day 
? if 0 skip to 
D10c. 
__<1 per day ? 
D10c. 
DK/refused ? to D10c.
D10b. Are those glasses usually small like a juice glass, 
about 4-10oz; medium like a water glass, about 12-20; 
or large like a giant size drink at the movies/Fast 
food, about 22-34oz? 
Sm 
Med 
Lg 
Other: specify _____ 
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Don’t know/refused 
 
 
Hot tap water use at work 
Next I’m going to ask you questions about how many hot drinks made with tap water from 
work you typically drink each day. [Hot water means that she boiled the water on the stove 
or in a microwave to get it hot. Hot water from the tap or from a hot shot should be included 
in the ‘cold water’ drinks.] 
 
D11a. How many cups of hot drinks made from office tap 
water, such as coffee, tea including brewed iced tea, 
hot chocolate or cup-a-soups, do you usually drink 
each day? 
___ # of cups per day 
? if 0 skip to 
D11c. 
__<1 per day ? 
D11c. 
DK/refused ? to 
D11c. 
D11b. Are those cups usually small like a tea cup, about 4-
10 oz; medium like a coffee mug, about 12-14oz; or 
large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm 
Med 
Lg 
Other: specify 
_______ 
don’t know/refused 
 
 
Cold tap water use at home 
Now, I’m going to ask you questions about how much cold tap water you typically drink 
each day at home. For these questions, include both filtered and unfiltered water. Also 
include all cold drinks made from that tap water such as powdered drinks. If you bring tap 
water from home to work, or other places, also include that water. Do not include bottled or 
canned drinks. 
[interviewer notes: include water from the tap, refrigerator spigot or refrigerated water 
fountain. Cold drinks include instant iced tea but not brewed, and drinks from concentrate. 
No bottled water, no sodas, no canned or bottled juices. Hot water from the tap or from a hot 
shot should be included in the ‘cold water’ drinks.] 
 
D12a. How many glasses of water from your home tap, 
including cold drinks made with tap water, do you 
usually drink per day? 
__ # of glasses per day 
? if 0 skip to 
D12c. 
__<1 per day? 
D12c. 
DK/refused ? to D12c.
D12b. Are those glasses usually small like a juice glass, 
about 4-10oz; medium like a water glass, about 12-20; 
or large like a giant size drink at the movies/Fast 
food, about 22-34oz? 
Sm 
Med 
Lg 
Other: specify ______ 
Don’t know/refused 
 
 
Hot tap water use at home 
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The next questions I’m going to ask are about hot drinks made with home tap water. [Hot 
water means that she boiled the water on the stove or in a microwave to get it hot. Hot water 
from the tap or from a hot shot should be included in the ‘cold water’ drinks.] 
 
D13a. How many cups of hot drinks made from home tap 
water, such as coffee, tea including brewed iced tea, 
hot chocolate or cup-a-soups, do you usually drink 
each day? 
___ # of cups per day 
?if 0 skip to 
D13c 
__<1 per day? 
D13c 
DK/ refused ? to 
D13c. 
D13b. Are those cups usually small like a tea cup, about 4-
10 oz; medium like a coffee mug, about 12-14oz; or 
large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm 
Med 
Lg 
Other: specify 
_______ 
don’t know/refused 
 
 
Bottled water 
Now I’m going to ask you some questions about your bottled water use. Try to answer the 
following questions as closely to what you usually or typically drink in a day. Bottled water 
includes water that you purchase in bottles or plastic jugs and that you get from any water 
cooler, but not from a water fountain. Bottled water can include spring water, mineral water, 
distilled water, or sparkling water such as Quibell, Poland Spring, Perrier, Calistoga, some is 
flavored. Do not include tonic water, club soda, soda water, seltzer or caffeinated water.  
 
[She should include Vitamin water and Fruit flavored water (distilled water with citric acid, 
flavors and electrolytes). Seltzer is different from sparkling water. Sparkling water is usually 
made with spring water whereas seltzer is usually made with tap water] 
 
D14a. Currently, how much of all the water you drink is bottled water, 
including water used for hot and cold drinks? Is it all or nearly all, most, 
some, very little or none of the water? 
All or nearly all 
Most 
Some ? skip to D23a. 
Very little? skip to D23a. 
None? skip to D23a. 
don’t know/refused ? skip to D23a. 
 
[if woman says she drinks bottles of water rather than glasses, in Q14b. ask her the number 
of bottles and in Q14c. ask her the size of the bottle] 
 
D14b. How many glasses/bottles of bottled water 
do you usually drink per day? 
____ # of glasses per day  
? if 0 skip to D23a. 
<1 per day ? skip to D23a. 
Don’t know/refused 
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D14c. Are those glasses usually small like a juice 
glass, about 4-10oz; medium like a water 
glass, about 12-20; or large like a giant 
size drink at the movies/Fast food, about 
22-34oz? 
[OR for Bottles:] 
Are those bottles usually small, about 8-12 
ounces; medium, about 14-24 ounces; or 
large, about 26-34 ounces? 
Sm 
Med 
Lg 
Other: specify __________ 
or  
small bottle [8-12] 
medium [14-24] 
large bottle [26-34] 
Other: specify ____________ 
D14d. What is the primary brand of bottled water 
that you usually drink? [note brand name] 
? Brand name ______ 
? Name of store ____ [if fills 
bottle at store] 
? No specific brand 
? don’t know/refused 
 
 
Now I’m going to ask you about other uses of water in your home such as for showering, 
bathing, bathing children, and washing dishes and clothes. Again, think about what you 
currently do in a typical week. 
 
Showering 
D23a. How often do you shower at home? 
___ times per day/week/month [If < 2x per week, skip to D24a. ] 
___ < 1x month ? skip to D24a. 
 
D23b. How many minutes do you usually spend actually in the shower? 
________ # minutes 
 
D23c. How many minutes do you usually spend in the bathroom with the door 
closed while the shower is running before getting in? 
_________ #minutes 
 
D23d. How many minutes do you usually spend in the bathroom with the door 
closed after you’ve showered? 
___________ # minutes  
 
 
Bathing 
D24a. How often do you take a bath at home, not including showers? 
[interviewer note: include if she takes a bath with her children] 
___ times per day/week/month [if < 2x per week, skip to D25a.] 
___ < 1x month? skip to D25a. 
 
D24b. When you take a bath, how full is the tub: ¼, ½, ¾, or completely full? 
[refers to how submerged she is] 
¼  ½  ¾ full 
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D24c. How many minutes do you usually spend in the tub? 
_____ # minutes 
 
D24d. How many minutes do you usually spend in the bathroom with the door 
closed while the bathtub is filling up before getting in? 
_______ #minutes 
 
D24e. How many minutes do you usually spend in the bathroom with the door 
closed after you’ve bathed? 
___________ #minutes 
 
Children 
D25a. At home, how often do you bathe infants or small children, those too 
young to leave alone in the bath tub? [do not include times when she takes a 
bath with her children, this should be included in D24a] 
______ # times per day / per week / per month [if < 2 bath per week skip to D26a.] 
___ < 1x month [if < 2 bath per week skip to D26a.] 
 
D25b. How many minutes per bath do you usually spend bathing children? 
____ minutes per bath 
 
D25c. How many minutes do you usually spend in the bathroom with the door 
closed while the bath is filling before you bathe children? 
________ #minutes 
 
D25d. How many minutes do you usually spend in the bathroom with the door 
closed after you’ve bathed children? 
________ # minutes 
 
Dishes 
D26a. How often do you typically rinse or wash dishes by hand? 
_____ # times per day / week / month [if less than twice per week? Skip to D27a.] 
___ < 1x month [if less than twice per week? Skip to D27a.] 
 
D26b. How much time do you usually spend on each occasion rinsing or 
washing dishes by hand? 
_______ #minutes / hours per occasion 
 
D26c. How often do you use gloves when washing the dishes, all of the time, 
most of the time, some of the time, or very rarely? 
? All the time 
? Most of the time 
? Some of the time 
? Rarely or never 
? Refused/Don’t know 
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Clothes 
D27a. How often do you wash clothing by hand instead of machine? 
____ # times per week / month /never [if < 2x per week ? skip to Section E] 
___ < 1x month [if < 2x per week ? skip to Section E] 
 
D27b. How much time do you usually spend each time you wash clothes by 
hand?  
____ #minutes / hours per occasion 
 
D27c. How often do you use gloves when washing clothing by hand, all of the 
time, most of the time, some of the time, or very rarely? 
? All the time 
? Most of the time 
? Some of the time 
? Rarely or never 
? Don’t know/refused 
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APPENDIX 5.1: ASSOCIATION BETWEEN DBP EXPOSURE AND PRETERM 
BIRTH AMONG WOMEN INCLUDED IN DURATION OF GESTATION 
ANALYSES*, 2000-2004. 
 # preterm # term 
Unadjusted 
RR (95% CI) 
Adjusted 
RR (95% CI)† 
Residential TTHM Concentration (μg/liter)     
2.2-4.6 84 677 1 1 
33.1-55 27 295 0.76 (0.5,1.15) 0.83 (0.54, 1.29) 
55-66.3 30 288 0.85 (0.58,1.27) 0.94 (0.61, 1.43) 
66.4-74.8 24 294 0.68 (0.44,1.06) 0.71 (0.44, 1.15) 
74.9-108.8 20 300 0.57 (0.35,0.91) 0.55 (0.32, 0.93) 
p for trend test‡   0.008 0.03 
≥ 80 vs. <80** 9/176 175/1,679 0.52 (0.27,0.99) 0.54 (0.27,1.09) 
TTHM exposure through showering & bathing 
(μg/day)     
0.02-0.09 50 458 1 1 
0.1-0.8 56 453 1.12 (0.78,1.60) 0.95 (0.64, 1.40) 
0.9-1.5 29 480 0.58 (0.37,0.90) 0.66 (0.42, 1.04) 
1.6-27.1 50 458 1.00 (0.69,1.45) 0.79 (0.52, 1.20) 
Residential HAA5 Concentration (μg/liter)     
0-0.9 84 677 1 1 
17.9-22 39 282 1.10 (0.77,1.57) 1.14 (0.76, 1.72) 
22.1-31.5 24 294 0.68 (0.44,1.06) 0.78 (0.49, 1.22) 
31.6-40.4 18 300 0.51 (0.31,0.84) 0.48 (0.27, 0.84) 
40.4-52.8 20 301 0.56 (0.35,0.90) 0.67 (0.41, 1.09) 
p for trend test‡   0.001 0.01 
HAA5 exposure through tap-water consumption 
(μg/day)     
0 63 539 1 1 
0.01-16.1 56 422 1.12 (0.80,1.57) 0.94 (0.65, 1.37) 
16.2-54.4 40 437 0.80 (0.55,1.17) 0.94 (0.63, 1.39) 
54.7-369.1 26 452 0.52 (0.33,0.81) 0.56 (0.36, 0.89) 
Residential TOX Concentration (μg/liter)     
14.3-22.4 84 677 1 1 
136.7-169.6 19 300 0.54 (0.33,0.87) 0.66 (0.40, 1.07) 
169.6-177.7 21 300 0.59 (0.37,0.94) 0.62 (0.38, 1.02) 
177.7-192.6 24 295 0.68 (0.44,1.05) 0.66 (0.40, 1.08) 
192.8-235.2 37 282 1.05 (0.73,1.51) 1.13 (0.75, 1.69) 
p for trend test‡   0.05 0.2 
TOX exposure through showering and bathing 
(μg/day)     
0-25.8 55 454 1 1 
25.9-75 55 453 1.00 (0.70,1.43) 0.86 (0.59, 1.26) 
75.1-252.9 38 471 0.69 (0.47,1.03) 0.66 (0.43, 1.02) 
253.6-1302.9 37 472 0.67 (0.45,1.00) 0.73 (0.48, 1.09) 
*  2,039 women eligible from the chlorinated DBP site; 5 term births missing information on tap water comsunption and showering and 
bathing needed to assign TTHM, HAA5 and TOX exposure. 
† Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and 
caffeine intake 
‡ Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term). 
** # preterm and # term are No. ≥ 80 μg/liter /No. < 80 μg/liter. 
Abbreviations: RR = risk ratio, CI= confidence interval, TTHM = total trihalomethane, HAA5= sum of five haloacetic acids, TOX = total 
organic halides 
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APPENDIX 5.2: ASSOCIATION BETWEEN DBP EXPOSURE AND PRETERM 
BIRTH WOMEN INCLUDED IN DURATION OF GESTATION ANALYSES FROM 
THE CHLORINATED DBP SITE*, 2000-2004. 
 # preterm # term 
Unadjusted 
RR (95% CI) 
Adjusted 
RR (95% CI)† 
Residential TTHM Concentration (μg/liter)     
33.1-60.3 21 289 1 1 
60.4-74 17 294 0.81 (0.43,1.50) 0.77 (0.41, 1.47) 
74-108.8 19 289 0.91 (0.50,1.66) 0.61 (0.30, 1.23) 
p for trend test‡   0.4 0.2 
≥ 80 vs. <80** 6/51 153/719 0.57 (0.25,1.30) 0.55 (0.22,1.37) 
TTHM exposure through showering & bathing 
(μg/day)     
0.08-0.9 15 294 1 1 
1-1.5 15 294 1.00 (0.50,2.01) 0.86 (0.42, 1.75) 
1.6-27.1 27 283 1.79 (0.97,3.31) 1.38 (0.68, 2.81) 
Residential HAA5 Concentration (μg/liter)     
18.7-32.4 20 288 1 1 
32.5-40.7 17 294 0.84 (0.45,1.58) 0.56 (0.28, 1.13) 
40.7-52.8 20 290 0.99 (0.55,1.81) 0.74 (0.39, 1.40) 
p for trend test‡   0.8 0.4 
HAA5 exposure through tap-water consumption 
(μg/day)     
0-35.3 23 287 1 1 
35.3-69.7 17 291 0.74 (0.41,1.36) 0.99 (0.51, 1.92) 
69.7-369.1 17 293 0.74 (0.4,1.36) 0.87 (0.44, 1.72) 
2nd-trimester Residential TOX Concentration 
(μg/liter)average     
136.7-169.2 19 290 1 1 
169.3-178.4 18 295 0.94 (0.50,1.75) 0.72 (0.36, 1.42) 
178.4-220.6 20 287 1.06 (0.58,1.95) 0.76 (0.39, 1.45) 
p for trend test‡   1.0 0.7 
TOX exposure through tap-water consumption 
(μg/day)     
0-143.9 24 285 1 1 
144.6-306.7 16 294 0.66 (0.36,1.23) 0.86 (0.43, 1.72) 
307-1225.5 17 292 0.71 (0.39,1.29) 0.89 (0.46, 1.73) 
*  929 women eligible from the chlorinated DBP site; 1 term birth missing information on tap water comsunption and showering and 
bathing needed to assign TTHM, HAA5 and TOX exposure.  
† Model adjusted for maternal age, race/ethnicity, income, education, employment status, marital status, pre-pregnancy BMI, parity and 
caffeine intake. 
‡ Chi-square test (H0: βDBP = 0) for a single, continuous residential DBP concentration term (i.e., linear term). 
** # preterm and # term are number ≥ 80 μg/liter /number  < 80 μg/liter. 
Abbreviations: RR = risk ratio, CI= confidence interval, TTHM = total trihalomethane, HAA5= sum of five haloacetic acids, TOX = total 
organic halides  
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